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Abstract 
 
Rheumatoid arthritis (RA) is an autoimmune disease characterised by chronic 
inflammation at multiple joints. Because of the association of the condition with certain 
alleles of the DRB1 gene which encodes the β-chains of human leukocyte antigen 
(HLA)-DR molecules, it has been postulated that auto-reactive CD4
+
 T-cells - specific 
for joint-associated autoantigens presented in the context of these RA-associated HLA-
DR molecules – are involved in the initiation or perpetuation of the disease process. In 
addition, citrullination of autoantigen-derived peptides may enhance their binding 
affinity to RA-associated HLA-DR molecules, implicating citrullinated autoantigens in 
RA pathogenesis. Since RA primarily affects the joints, proteins of articular origin and 
those expressed in the joints such as human cartilage glycoprotein 39 (HCgp39), type II 
collagen (CII), aggrecan, α-enolase, fibrinogen and vimentin are candidate autoantigens 
in RA. However, it has been difficult to consistently detect T-cell responses to these 
candidate RA autoantigens in RA patients. In this project, I hypothesised that T-cell 
responses to candidate autoantigens are heightened in RA patients compared to healthy 
subjects and that the T-cell responses of RA patients are pro-inflammatory while those 
of healthy subjects are not. I first optimised an experimental system for detecting 
autoantigen-specific T-cell responses and applied the protocol to measure proliferative 
and cytokine production responses of peripheral blood mononuclear cells (PBMC) from 
RA patients, healthy subjects and disease controls to unmodified and citrullinated whole 
protein and peptide forms of the candidate RA autoantigens mentioned above. 
Responses to the candidate autoantigens were readily detectable in RA patients, healthy 
subjects and disease controls. Furthermore, I found no evidence of increased 
immunogenicity of citrullinated peptides versus their unmodified counterparts. Thus the 
study failed to provide evidence that T-cell responses to either unmodified or 
citrullinated autoantigens are important in RA pathogenesis. 
 iii 
Acknowledgements 
 
Firstly I would like to thank my supervisors Doctor Wan-Fai Ng and Professor John 
Isaacs for their sound advice, encouragement and many helpful suggestions throughout 
my PhD. I would also like to express my gratitude to Doctor Alexei von Delwig for 
sharing both his research and expertise. Many thanks also to Professors Jaap Van Laar 
and John Robinson, Julie Diboll and the rest of the staff and students in the 
musculoskeletal research group. I am very grateful to Doctors Amit Patel (former PhD 
student of Professor Drew Rowan) and Caroline Wilson (former PhD student of Doctor 
Andrew Knight) for their kind gifts of human type II collagen and bovine aggrecan 
respectively. 
 
My thanks are also extended to Professor Patrick Venables of Imperial College for 
giving me the opportunity to collaborate on his group’s research into immune responses 
to citrullinated enolase and for kindly providing samples of the relevant peptides. Many 
thanks also to Doctor Natalia Wegner, Professor Venables’ former PhD student, for her 
assistance with setting up the experiments described in section 5.2.5. 
 
I would also like to thank Arthritis Research UK for funding this PhD. 
 
Last but not least I would like to express my gratitude to my parents for their support 
and understanding whilst writing this thesis. 
 iv 
List of abbreviations 
 
ACPA = anti-citrullinated peptide antibodies 
ADA = adalimumab 
AICD = activation-induced cell death 
AIRE = autoimmune regulator 
AMLR = autologous mixed lymphocyte reaction 
APECED = autoimmune polyendocrinopathy-candidiasis-ectodermal-dystrophy 
syndrome 
APC = allophycocyanin 
AS = autologous serum 
BSA = bovine serum albumin 
CII = type II collagen 
Ca = calcium 
CCP = cyclic citrullinated peptide (in RA patient clinical details tables, refers to ‘cyclic 
citrullinated peptide antibodies’) 
CD = cluster of differentiation 
CFSE = carboxyfluorescein succinimidyl ester 
CIA = collagen-induced arthritis 
(Cit) = citrulline 
Cit = citrullinated 
COX = cyclooxygenase 
cpm = counts per minute 
CRP = C-reactive protein 
CS = chondroitin sulphate 
CTLA-4 = cytotoxic T lymphocyte-associated antigen 4 
DeglyAgg = deglycosylated aggrecan 
dH2O = de-ionised water 
DisC = disease controls 
DMARDs = disease-modifying anti-rheumatic drugs 
DMSO = dimethyl sulphoxide 
DNA = deoxyribonucleic acid 
DPBS = Dulbecco’s phosphate buffered saline 
ECL = electrochemiluminescence 
EDTA = ethylenedinitrilotetraacetic acid 
 v 
ELISA = enzyme-linked immunosorbent assay 
ESR = erythrocyte sedimentation rate 
ETR = etanercept 
F = female 
FACS = fluorescence-activated cell sorting 
FBS = foetal bovine serum 
Fc = fragment, crystallisable 
FITC = fluorescein isothiocyanate 
FoxP3 = fork-head box P3 
FSC = forward scatter 
GAD = glutamic acid decarboxylase 
GlyAgg = glycosylated aggrecan 
GM-CSF = granulocyte-macrophage colony-stimulating factor 
GPI = glucose-6-phosphate isomerase 
HABS = human AB serum 
HACPG = human adult cartilage proteoglycan 
HBSS = Hank’s balanced salt solution 
HCgp39 = human cartilage glycoprotein 39 
HCQ = hydroxychloroquine 
HFCPG = human foetal cartilage proteoglycan 
HLA = human leukocyte antigen 
H2O2 = hydrogen peroxide 
HRP = horse radish peroxidase 
HS = healthy subjects 
H2SO4 = sulphuric acid 
3HTdR = 
3
H-thymidine 
IBD = inflammatory bowel disease 
IFN-γ = interferon gamma 
IL = interleukin 
IPEX = immunodysregulation, polyendocrinopathy and enteropathy, X-linked 
syndrome 
IQR = inter quartile range 
JIA = juvenile idiopathic arthritis 
KS = keratin sulphate 
LAL = limulus amoebocyte lysate 
 vi 
LEF = leflunomide 
LPS = lipopolysaccharide 
M = male 
MCTD = mixed connective tissue disease 
Mg = magnesium 
MHC = major histocompatibility complex 
Mo-DC = monocyte-derived dendritic cells 
MPL = monophosphoryl lipid A 
MTX = methotrexate 
NaCl = sodium chloride 
NaHCO3 = sodium bicarbonate 
NaH2PO4H2O = sodium dihydrogen phosphate monohydrate 
Na2HPO4 = disodium hydrogen phosphate 
Na2HPO42H2O = disodium hydrogen phosphate dihydrate 
NaN3 = sodium azide 
ND = no data 
Neg = negative 
NSAIDs = non-steroidal anti-inflammatory drugs 
OA = osteoarthritis 
OPD = o-phenylenediamine dihydrochloride 
OPG = osteoprotegerin 
PAD = peptidyl arginine deiminase 
PBMC = peripheral blood mononuclear cells 
PBS = phosphate buffered saline 
PD-1 = programmed cell death 1 
PE = phycoerythrin 
PFA = paraformaldehyde 
PG = proteoglycan 
PHA = phytohaemagglutinin 
PMB = polymyxin B 
PPD = purified protein derivative (tuberculin) 
PsA = psoriatic arthritis  
PTPN22 = protein tyrosine phosphatase non-receptor 22 
RA = rheumatoid arthritis 
RANK = receptor activator of nuclear factor kappa-B 
 vii 
RANKL = receptor activator of nuclear factor kappa-B ligand 
RF = rheumatoid factor 
RTX = rituximab 
SAPHO = synovitis, acne, pustulosis, hyperostosis, osteitis 
SCID = severe combined immunodeficiency 
SE = shared epitope 
SEM = standard error of mean 
SFMC = synovial fluid mononuclear cells 
SI = stimulation index 
SLE = systemic lupus erythematosus 
SSC = side scatter 
SSZ = sulfasalazine 
TCAR = T-cell antigen receptor 
TNF-α = tumour necrosis factor alpha 
 viii 
Table of contents 
 
Chapter 1. Introduction        1 
1.1. Rheumatoid arthritis        1 
1.1.1. Aetiology of rheumatoid arthritis      1 
1.1.2. Treatment of rheumatoid arthritis      2 
1.2. Synovial joints         3 
1.2.1. Articular cartilage        3 
1.2.2. The synovium in health and disease     4 
1.3. The role of T-cells in rheumatoid arthritis     5 
1.3.1. T-cell-implicating genetic factors in rheumatoid arthritis  6 
1.3.2. The role of regulatory T-cells in rheumatoid arthritis   8 
1.3.3. The role of TH17 cells in rheumatoid arthritis   9 
1.3.4. The efficacy of treatments targeting T-cells    9 
1.3.5. T-cell tolerance and autoimmune disease    11 
1.4. The role of B-cells in rheumatoid arthritis     13 
1.4.1. Autoantibodies in rheumatoid arthritis    14 
1.4.2. The efficacy of treatments targeting B-cells    15 
1.5. Candidate autoantigens in rheumatoid arthritis     16 
1.5.1. Human cartilage glycoprotein 39 (HCgp39)    16 
1.5.2. Type II collagen (CII)       18 
1.5.3. Aggrecan        19 
1.5.4. Antigens recognised by antibodies in rheumatoid arthritis sera 22 
1.6. The role of citrullination in rheumatoid arthritis     24 
1.7. The importance of measuring T-cell responses to candidate autoantigens 26 
1.8. Aims of the project        26 
1.8.1. Specific aims of the project      26 
1.9. Hypotheses         27 
 
Chapter 2. Materials and methods       32 
2.1. Study subjects         32 
2.2. Reagents and plastics        32 
2.2.1. Reagents for cell culture, separation and storage   32 
2.2.2. Cell culture stimuli       32 
2.2.3. Reagents for flow cytometry      33 
 ix 
2.2.4. Reagents for measurement of cytokine production in culture supernatant
          33 
2.2.5. Plastics         33 
2.3. Cell culture techniques        34 
2.3.1. Media and conditions       34 
2.3.2. Isolation of peripheral blood mononuclear cells (PBMC)  34 
2.3.3. Serum isolation        35 
2.3.4. Immunomagnetic isolation of CD14
+
 and CD3
+
 PBMC  35 
2.3.5. PBMC cryopreservation      36 
2.3.6. Monocyte-derived dendritic cells (mo-DC)    36 
2.3.7. Cell labelling with carboxyfluorescein succinimidyl ester (CFSE) 37 
2.3.8. Assessment of cellular proliferation using 
3
H-thymidine (3HTdR) 
incorporation         37 
2.3.9. Assessment of cellular proliferation using CFSE dilution  38 
2.4. Flow cytometric analysis        39 
2.5. Quantification of cytokine production in culture supernatant   40 
2.5.1. Electrochemiluminescence (ECL) multiplex analysis   40 
2.5.2. Enzyme-linked immunosorbent assay (ELISA) analysis  41 
2.6. Limulus amoebocyte lysate (LAL) endotoxin detection assay   42 
2.7. Removal of endotoxin from contaminated protein/peptide samples  43 
2.8. Bradford protein assay        44 
2.9. Statistical analysis        44 
 
Chapter 3. Optimisation of a system for detecting autoantigen-specific T-cell 
immune responses         59 
3.1. Introduction         59 
3.1.1. Detecting proliferation and cytokine production: Assays and culture 
media          60 
3.1.2. Aims         62 
3.2. Results          62 
3.2.1. PBMC/CD3
+
 PBMC proliferation with 10% FBS-supplemented, 5% 
HABS-supplemented and 5% AS-supplemented culture media  62 
3.2.2. Background PBMC/CD3
+
 PBMC proliferation with 10% FBS-
supplemented, 5% HABS-supplemented and 5% AS-supplemented culture media
          63 
 x 
3.2.3. PHA-induced and PPD-induced PBMC/CD3
+
 PBMC proliferation with 
10% FBS-supplemented, 5% HABS-supplemented and 5% AS-supplemented 
culture media         64 
3.2.4. SI values of PHA-induced and PPD-induced PBMC/CD3
+
 PBMC 
proliferation with 10% FBS-supplemented, 5% HABS-supplemented and 5% AS-
supplemented culture media       65 
3.2.5. Background cytokine production with 10% FBS-supplemented, 5% HABS-
supplemented and 5% AS-supplemented culture media   68 
3.2.6. Raw values of PHA-induced and PPD-induced cytokine production with 
10% FBS-supplemented, 5% HABS-supplemented and 5% AS-supplemented 
culture media         69 
3.2.7. Absolute values (raw values minus background) of PHA-induced and 
PPD-induced cytokine production with 10% FBS-supplemented, 5% HABS-
supplemented and 5% AS-supplemented culture media   70 
3.3. Discussion         71 
3.4. Summary          75 
 
Chapter 4. T-cell immune responses to whole-protein candidate RA autoantigens 
in health and disease         89 
4.1. Introduction         89 
4.2. Results          89 
4.2.1. HCgp39-induced T-cell proliferation in RA patients   89 
4.2.2. Bulk culture approach; HCgp39-induced, CII-induced and GlyAgg-
induced PBMC proliferation       90 
4.2.3. Triplicate culture approach; HCgp39-induced, CII-induced, GlyAgg-
induced and DeglyAgg-induced PBMC proliferation and cytokine production
          93 
4.2.3.1. PHA-induced and PPD-induced PBMC proliferation and 
background cytokine production     93 
4.2.3.2. HCgp39-induced responses     95 
4.2.3.3. CII-induced responses     96 
4.2.3.4. GlyAgg-induced responses     97 
4.2.3.5. HCgp39-induced, CII-induced and GlyAgg-induced PBMC 
proliferation; triplicate culture 3HTdR incorporation approach versus 
bulk culture 3HTdR incorporation approach    98 
 xi 
4.2.3.6. DeglyAgg-induced responses    99 
4.2.4. Co-culture approach with mo-DC and T-cells    100 
4.2.5. The role of bacterial lipopolysaccharide (LPS) contamination in 
DeglyAgg-induced responses       101 
4.3. Discussion         103 
4.4. Summary          110 
 
Chapter 5. T-cell immune responses to candidate RA autoantigen-derived peptides 
in health and disease         132 
5.1. Introduction         132 
5.1.1. Peptide stimuli versus whole-protein stimuli    132 
5.1.2. Peptides of interest       133 
5.2. Results          134 
5.2.1. Peptide panel #1       134 
5.2.2. Peptide panel #2       136 
5.2.3. Non-citrullinated and citrullinated forms of an α-enolase peptide; REP-1 
and CEP-1         138 
5.2.3.1. Proliferative responses to REP-1 and CEP-1  139 
5.2.3.2. Cytokine production responses to REP-1 and CEP-1 141 
5.2.4. The role of LPS contamination in CEP-1-induced responses  143 
5.2.5. LPS-free REP-1-induced and LPS-free CEP-1-induced PBMC 
proliferation and cytokine production     145 
5.3. Discussion         148 
 
Chapter 6. Discussion        189 
6.1. Introduction         189 
6.1.1. Qualitative and quantitative comparisons of candidate RA autoantigen-
specific T-cell immune responses in RA patients and healthy subjects/disease 
controls         189 
6.1.2. Exploring the role of citrullinated candidate RA autoantigens 190 
6.2. Limitations of the study        193 
6.3. Strengths of the study        196 
6.4. Future work         197 
6.5. Conclusions         198 
 
 xii 
References          202 
 xiii 
List of tables 
 
Chapter 1 
Table 1.1. Summary of previous studies investigating human cartilage glycoprotein 39 
(HCgp39)-induced responses.       28 
Table 1.2. Summary of previous studies investigating type II collagen (CII)-induced 
responses.          29 
Table 1.3. Summary of previous studies investigating aggrecan-induced responses.
           30 
Table 1.4. Summary of previous studies investigating responses to citrullinated RA 
autoantigen-derived peptides.        31 
 
Chapter 2 
Table 2.1. Clinical details of RA patients tested in the HCgp39 and CFSE experiments 
described in 4.2.1.         45 
Table 2.2. Clinical details of RA patients tested in the bulk culture 3HTdR incorporation 
experiments described in 4.2.2.       46 
Table 2.3. Clinical details of RA patients tested in the triplicate culture 3HTdR 
incorporation experiments described in 4.2.3.     47 
Table 2.4. Clinical details of RA patients tested in the peptide panel #1 experiments 
described in 5.2.1.         48 
Table 2.5. Clinical details of RA patients tested in the peptide panel #2 experiments 
described in 5.2.2.         49 
Table 2.6. Clinical details of RA patients tested in the REP-1 and CEP-1 experiments 
described in 5.2.3/5.2.5.        50 
Table 2.7. Clinical details of disease controls tested in the REP-1 and CEP-1 
experiments described in 5.2.3.       51 
Table 2.8. Supplementary reagents used in cell culture.    52 
Table 2.9. Cell culture stimuli.       53 
Table 2.10. Peptide details.        54 
Table 2.11. Flow cytometry antibodies.      55 
Table 2.12. Additional reagents for cytokine detection.    56 
Table 2.13. Cytokine detection antibodies.      57 
 
 
 xiv 
Chapter 4 
Table 4.1. HCgp39-induced proliferation of peripheral blood T cells in RA patients.
           111 
Table 4.2. PBMC proliferation detected in RA patients and healthy subjects when using 
the bulk culture 3HTdR incorporation approach.     112 
Table 4.3. HCgp39-induced PBMC responses identified with the triplicate culture 
approach.          113 
Table 4.4. CII-induced PBMC responses identified with the triplicate culture approach.
           114 
Table 4.5. GlyAgg-induced PBMC responses identified with the triplicate culture 
approach.          115 
Table 4.6. DeglyAgg-induced PBMC responses identified with the triplicate culture 
approach.          116 
Table 4.7. Background cytokine production detected in the RA patients tested for 
candidate RA autoantigen-induced cytokine production in the experiments described in 
4.2.3.           117 
Table 4.8. Background cytokine production detected in the healthy subjects tested for 
candidate RA autoantigen-induced cytokine production in the experiments described in 
4.2.3.           118 
 
Chapter 5 
Table 5.1. Details of peptide stimuli used in chapter 5.    152 
Table 5.2. Peptide 1-induced PBMC proliferation and cytokine production detected in 
RA patients and healthy subjects.       153 
Table 5.3. Peptide 2-induced PBMC proliferation and cytokine production detected in 
RA patients and healthy subjects.       154 
Table 5.4. Peptide 3-induced PBMC proliferation and cytokine production detected in 
RA patients and healthy subjects.       155 
Table 5.5. Peptide 4-induced PBMC proliferation and cytokine production detected in 
RA patients and healthy subjects.       156 
Table 5.6. Peptide 5-induced PBMC proliferation and cytokine production detected in 
RA patients and healthy subjects.       157 
Table 5.7. Peptide 6-induced PBMC proliferation and cytokine production detected in 
RA patients and healthy subjects.       158 
 xv 
Table 5.8. Peptide 7-induced PBMC proliferation and cytokine production detected in 
RA patients and healthy subjects.       159 
Table 5.9. Responders and non-responders; peptide panel #1.   160 
Table 5.10. Peptide 8-induced and peptide 9-induced PBMC proliferation and cytokine 
production detected in RA patients.       161 
Table 5.11. Peptide 8-induced and peptide 9-induced PBMC proliferation and cytokine 
production detected in healthy subjects.      162 
Table 5.12. Peptide 10-induced and peptide 11-induced PBMC proliferation and 
cytokine production detected in RA patients.      163 
Table 5.13. Peptide 10-induced and peptide 11-induced PBMC proliferation and 
cytokine production detected in healthy subjects.     164 
Table 5.14. Peptide 12-induced and peptide 13-induced PBMC proliferation and 
cytokine production detected in RA patients.      165 
Table 5.15. Peptide 12-induced and peptide 13-induced PBMC proliferation and 
cytokine production detected in healthy subjects.     166 
Table 5.16. Peptide 14-induced and peptide 15-induced PBMC proliferation and 
cytokine production detected in RA patients.      167 
Table 5.17. Peptide 14-induced and peptide 15-induced PBMC proliferation and 
cytokine production detected in healthy subjects.     168 
Table 5.18. RA patient responders and non-responders; peptide panel #2.  169 
Table 5.19. Healthy subject responders and non-responders; peptide panel #2. 170 
Table 5.20. REP-1-induced and CEP-1-induced PBMC responses detected in RA 
patients, healthy subjects and disease controls.     171 
Table 5.21. ‘LPS-free’ REP-1-induced and ‘LPS-free’ CEP-1-induced PBMC 
proliferation and cytokine production detected in RA patients.   172 
Table 5.22. ‘LPS-free’ REP-1-induced and ‘LPS-free’ CEP-1-induced PBMC 
proliferation and cytokine production detected in healthy subjects.   173 
Table 5.23. Background cytokine production detected in the RA patients tested for 
candidate RA autoantigen-derived peptide-induced cytokine production in the 
experiments described in chapter 5.       174 
Table 5.24. Background cytokine production detected in the healthy subjects tested for 
candidate RA autoantigen-derived peptide-induced cytokine production in the 
experiments described in chapter 5.       175 
 
 
 xvi 
Chapter 6 
Table 6.1. Numbers of subjects tested with each of the four whole protein candidate 
autoantigens and the approaches and assays used in the experiments described in the 
various sections of Chapter 4.       199 
Table 6.2. Numbers of subjects tested with the various combinations of 2 or more of the 
four whole protein candidate autoantigens in the experiments described in 4.2.3. 
           200 
Table 6.3. Numbers of subjects tested with each of the various candidate autoantigen-
derived peptides in the experiments described in the various sections of Chapter 5. 
           201 
 xvii 
List of figures 
 
Chapter 2 
Figure 2.1. Diagram of a CFSE versus cell-lineage-marker flow cytometry dot plot 
showing dilution of CFSE by cell division.      58 
 
Chapter 3 
Figure 3.1. The experimental systems used to assess the suitability of 10% FBS-
supplemented, 5% HABS-supplemented and 5% AS-supplemented culture media. 
           76 
Figure 3.2. An example of 3HTdR incorporation data showing PBMC proliferation in a 
healthy subject.         77 
Figure 3.3. An example of CFSE dilution data showing proliferation of CD3
+
 PBMC 
from a healthy subject.        78 
Figure 3.4. Background PBMC proliferation with 10% FBS-supplemented, 5% HABS-
supplemented and 5% AS-supplemented culture media.    79 
Figure 3.5. Background CD3
+
 PBMC proliferation versus background PBMC 
proliferation.          80 
Figure 3.6. PHA-induced and PPD-induced PBMC proliferation with 10% FBS-
supplemented, 5% HABS-supplemented and 5% AS-supplemented culture media. 
           81 
Figure 3.7. PHA-induced and PPD-induced PBMC proliferation versus PHA-induced 
and PPD-induced CD3
+
 PBMC proliferation.     82 
Figure 3.8. SI values of PHA-induced and PPD-induced PBMC proliferation with 10% 
FBS-supplemented, 5% HABS-supplemented and 5% AS-supplemented culture media.
           83 
Figure 3.9. SI values of PHA-induced and PPD-induced PBMC proliferation versus SI 
values of PHA-induced and PPD-induced CD3
+
 PBMC proliferation.  84 
Figure 3.10. Background cytokine production with 10% FBS-supplemented, 5% HABS-
supplemented and 5% AS-supplemented culture media.    85 
Figure 3.11. PHA-induced cytokine production with 10% FBS-supplemented, 5% 
HABS-supplemented and 5% AS-supplemented culture media.   86 
Figure 3.12. PPD-induced cytokine production at day 6 with 10% FBS-supplemented, 
5% HABS-supplemented and 5% AS-supplemented culture media.   87 
 xviii 
Figure 3.13. Absolute values of PPD-induced cytokine production at day 6 with 10% 
FBS-supplemented, 5% HABS-supplemented and 5% AS-supplemented culture media.
           88 
 
Chapter 4 
Figure 4.1. PHA-induced and PPD-induced PBMC proliferation in RA patients and 
healthy subjects; bulk culture 3HTdR incorporation approach.   119 
Figure 4.2. Kinetics of the HCgp39-induced, CII-induced and GlyAgg-induced 
proliferative responses; bulk culture 3HTdR incorporation approach.  120 
Figure 4.3. HCgp39-induced, CII-induced and GlyAgg-induced PBMC proliferation in 
RA patients and healthy subjects; bulk culture 3HTdR incorporation approach. 121 
Figure 4.4. PHA-induced PBMC proliferation in RA patients and healthy subjects; 
triplicate culture 3HTdR incorporation approach versus bulk culture 3HTdR 
incorporation approach.        122 
Figure 4.5. PPD-induced PBMC proliferation in RA patients and healthy subjects; 
triplicate culture 3HTdR incorporation approach versus bulk culture 3HTdR 
incorporation approach.        123 
Figure 4.6. Background cytokine production in RA patients and healthy subjects. 
           124 
Figure 4.7. HCgp39-induced PBMC proliferation in RA patients and healthy subjects; 
triplicate culture 3HTdR incorporation approach.     125 
Figure 4.8. CII-induced PBMC proliferation in RA patients and healthy subjects; 
triplicate culture 3HTdR incorporation approach.     126 
Figure 4.9. GlyAgg-induced PBMC proliferation in RA patients and healthy subjects; 
triplicate culture 3HTdR incorporation approach.     127 
Figure 4.10. HCgp39-induced, CII-induced and GlyAgg-induced PBMC proliferation in 
RA patients and healthy subjects; triplicate culture 3HTdR incorporation approach 
versus bulk culture 3HTdR incorporation approach.     128 
Figure 4.11. DeglyAgg-induced PBMC responses in RA patients and healthy subjects; 
triplicate culture approach.        129 
Figure 4.12. PPD-induced and autoantigen-induced T cell proliferation; mo-DC & T 
cell co-culture approach.        130 
Figure 4.13. The effect of polymyxin B on the DeglyAgg response.   131 
 
 
 xix 
Chapter 5 
Figure 5.1. Proportions of positive responses to peptides 1-7 in RA patients versus 
healthy subjects.         176 
Figure 5.2. Proportions of positive responses to peptides 8-15 in RA patients versus 
healthy subjects.         177 
Figure 5.3. Comparing REP-1-induced PBMC proliferation with CEP-1-induced PBMC 
proliferation in RA patients, healthy subjects and disease controls.   178 
Figure 5.4. Comparing REP-1-induced PBMC proliferation and CEP-1-induced PBMC 
proliferation in RA patients (RA), healthy subjects (HS) and disease controls (DisC).
           179 
Figure 5.5. Kinetics of the REP-1-induced and CEP-1-induced proliferative responses.
           180 
Figure 5.6. Comparing REP-1-induced cytokine production with CEP-1-induced 
cytokine production in RA patients.       181 
Figure 5.7. Comparing REP-1-induced cytokine production with CEP-1-induced 
cytokine production in healthy subjects.      182 
Figure 5.8. Comparing REP-1-induced cytokine production with CEP-1-induced 
cytokine production in disease controls.      183 
Figure 5.9. Comparing REP-1-induced cytokine production in RA patients (RA), 
healthy subjects (HS) and disease controls (DisC).     184 
Figure 5.10. Comparing CEP-1-induced cytokine production in RA patients (RA), 
healthy subjects (HS) and disease controls (DisC).     185 
Figure 5.11. LPS-induced PBMC proliferation.     186 
Figure 5.12. The effect of polymyxin B on the CEP-1 response.   187 
Figure 5.13. Comparing the immunogenicities of original CEP-1 and *clean* CEP-1.
           188 
 
 
 1 
Chapter 1. Introduction 
 
1.1. Rheumatoid arthritis 
Rheumatoid arthritis is an autoimmune disease characterised by chronic inflammation 
of multiple joints and affecting around 1% of the western world’s adult population 
(Firestein, 2003). Although RA can develop at any time, disease onset most commonly 
occurs between thirty and fifty years of age and the condition is three times more 
prevalent in females than males (Isaacs & Moreland, 2011). The disease predominantly 
manifests itself in the diarthroidal or synovial joints of the hands, wrists and feet, with 
joints often being affected in a symmetrical fashion. The inflammation, which occurs in 
the synovium of an affected joint (hence synovitis), involves the infiltration of various 
immune cells and causes symptoms of pain, swelling and stiffness which may also be 
accompanied by feelings of malaise, depression and fatigue (Isaacs & Moreland, 2011). 
Production of inflammatory mediators such as TNF-α is thought to have a key role in 
disease pathogenesis. Persistent synovitis results in the destruction of articular cartilage 
and the underlying bone which in turn can lead to deformation and the eventual loss of 
function of the affected joints (Isaacs & Moreland, 2011). Extra-articular or systemic 
manifestations of the disease affecting the heart, lungs, eyes, skin and blood can also 
occur in RA (Isaacs & Moreland, 2011). 
 
1.1.1. Aetiology of rheumatoid arthritis 
While the aetiology of RA remains unclear, certain genetic factors are well known to 
contribute to the condition. For example, the associations with RA of certain 
polymorphisms within the DRB1, PTPN22, CTLA4 and PADI4 genes are well 
established and other loci involved in immune responses such as the IL-1 genes and the 
TNF-α gene have also been implicated. Thus, while a number of genes seem to be 
involved in RA susceptibility, those predisposing to RA can differ between patients, and 
so RA is said to be a polygenic and genetically heterogeneous disease. However, 
various environmental factors are thought to compliment the genetic contribution to the 
aetiology of RA by acting as triggers for disease onset in the genetically predisposed. 
Immune responses to a transient infection could trigger chronic inflammation if they 
cross-react with autologous structures therefore infectious agents are possible 
candidates for environmental triggers. Alternatively, because RA is three times more 
prevalent in females than males, certain sex hormones may be involved in triggering 
disease onset. In addition, smoking increases the risk of developing seropositive RA in 
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individuals with disease-associated DRB1 alleles (Padyukov et al, 2004; Klareskog et 
al, 2006). Indeed, smoking is a proven environmental factor that increases the risk of 
developing anti-CCP-positive RA (Kallberg et al, 2007). 
 
1.1.2. Treatment of rheumatoid arthritis 
As yet there is no cure for RA and once severe bone damage has occurred it is 
irreversible. Therefore, the current aim of RA treatment is to control the pathogenic 
inflammation so that symptoms can be alleviated and damage to articular cartilage and 
bone can be minimised. Non-steroidal anti-inflammatory drugs (NSAIDs) alleviate the 
symptoms of pain, swelling and stiffness by reducing inflammation and can thus restore 
function to affected joints in the short term. NSAIDs work by inhibiting the enzyme 
cyclooxygenase (COX) which exists in two isoforms and is responsible for the 
production of prostaglandins which are involved in inflammation. Non-selective 
NSAIDs such as aspirin, diclofenac, ibuprofen, ketoprofen, naproxen and indometacin 
target both COX-1 and COX-2 and often cause gastrointestinal side-effects such as 
heartburn, indigestion and stomach upsets. In contrast, COX-2-specific NSAIDs such as 
celecoxib and etoricoxib provide the same therapeutic benefits as non-selective NSAIDs 
but have fewer side-effects on the gastrointestinal system. However, NSAIDs can cause 
other side-effects such as rashes, headaches, wheeziness and fluid retention, and their 
use may increase the likelihood of strokes and heart attacks. NSAIDs exert their 
therapeutic effect within a few hours and single doses can remain effective for anything 
from a few hours to a whole day but they ultimately have no long-term effect on the 
disease. Corticosteroids, administered intra-articularly, intra-venously, intra-muscularly 
or orally, act very quickly to potently suppress inflammation and thereby provide relief 
of pain and swelling in the joint and they also improve fatigue symptoms. While 
corticosteroids can have quite severe side-effects, there is evidence to suggest that they 
can reduce the rate of progression of RA if they are administered early on in the disease 
(Kirwan, 1995). 
 
Disease-modifying anti-rheumatic drugs (DMARDs), as their name suggests, treat the 
disease and not the symptoms, although they do alleviate pain, swelling and stiffness 
over a protracted period of time by slowing the progress of the disease. Intramuscular 
gold injections, hydroxychloroquine (HCQ), sulfasalazine (SSZ) and the 
immunosuppressants azathioprine, cyclosporine, leflunomide (LEF) and methotrexate 
(MTX) are fairly well established in their use and are known as conventional DMARDs. 
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More recently there has been a lot of interest in newer types of DMARDs known as 
biological therapies that target specific proteins and cells involved in inflammation and 
joint damage. For example, adalimumab (ADA), etanercept (ETA) and infliximab target 
TNF-α, a pro-inflammatory cytokine involved in RA pathogenesis, while tocilizumab 
targets the IL-6 receptor, thus neutralising the action of IL-6, another pro-inflammatory 
cytokine involved in disease pathogenesis. Abatacept and rituximab (RTX) target T-
cells and B-cells respectively, which both have roles in the pathogenesis of RA. All 
DMARDs take a long time to exert their beneficial effects therefore they do not provide 
immediate relief from the symptoms of RA. Therefore they are often used in 
combination with NSAIDs and/or corticosteroids and indeed combinations of DMARDs 
are also prescribed when single drugs can not effectively control the disease. In the past, 
RA was treated with NSAIDs, rest and corticosteroid injections and DMARDs were 
often used as a last resort. This is no longer the case as recent research has shown that 
administration of DMARDs in the early stages of disease can have a much more drastic 
effect on slowing progression of the disease. However, the search for novel targets of 
RA treatments continues. 
 
1.2. Synovial joints 
Joints are the structures formed where the extremities of two bones come together and 
they can be cartilaginous, fibrous or synovial in nature. Synovial or diarthroidal joints 
are the most common joints in the body, and also the most moveable. The two bones 
involved in a synovial joint are surrounded by a fibrous capsule of tough ligaments 
which provides support to the structure and forms the synovial cavity that distinguishes 
synovial joints from cartilaginous and fibrous joints. The joining ends of each of the 
bones are covered with articular hyaline cartilage, and the interior of the joint capsule is 
lined by a synovial membrane or synovium which also covers any bone within the 
capsule that is not covered with cartilage. The synovium secretes a viscous, lubricating 
and nutrient-rich liquid known as synovial fluid into the joint cavity. The synovial fluid 
provides nutrients to the articular cartilage and keeps the surfaces lubricated with its 
hyaluronic acid content so they can glide over each other.  
 
1.2.1. Articular cartilage 
Articular cartilage is an avascular but well-hydrated structure of chondrocytes 
embedded in a matrix of collagen, proteoglycans and other matrix proteins such as 
fibronectin which are all secreted by the chondrocytes themselves. However, there is 
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actually only a low density of chondrocytes in articular cartilage and it is the collagens 
and proteoglycans that give the structure its tensile strength and compressibility. Type II 
collagen accounts for around 90% of the collagen present in articular cartilage and, like 
all collagens, it displays a triple helical structure which lends the protein great tensile 
strength. The most predominant proteoglycan component of articular cartilage is 
aggrecan and by virtue of its anionic nature it is very effective at trapping water so that 
the aggrecan can be subjected to deformation and compressive stress without being 
damaged. Interestingly, the surface layers of articular cartilage contain substantially 
more collagen than proteoglycan but proteoglycan content increases the nearer the 
cartilage is to the bone. Thus the surface layers of articular cartilage have a high degree 
of tensile strength while the deeper layers have more ability to be deformed and 
compressed. Because articular cartilage is avascular, it derives its nutrients from the 
synovial fluid. 
 
1.2.2. The synovium in health and disease 
The synovial membrane is composed of both a lining layer, known as the intima, which 
borders the synovial cavity, and an underlying, sub-lining layer known as the sub-
intima, which contacts the walls of the joint capsule. The intima is a cellular structure 
composed of macrophage-like, bone marrow-derived type A synoviocytes and 
fibroblast-like type B synoviocytes which are arranged in loosely-packed layers. The 
synoviocytes within the intima are held together by a matrix composed predominantly 
of proteoglycans and glycosaminoglycans such as hyaluronic acid. The sub-intima is a 
body of connective tissue which contains blood vessels, lymphatics and nerve endings 
which are surrounded by a matrix composed of lipids, collagen fibrils and fibrous tissue. 
In a healthy synovial joint, the intima consists of only one or two layers of synoviocytes 
and the sub-intima is largely devoid of cells. 
 
However, RA causes substantial changes in the morphology of the synovium. For 
example, the sub-intima becomes riddled with networks of new blood vessels which 
facilitate the recruitment of T-cells, macrophages, dendritic cells and B-cells. Within the 
intima, an increased influx of type A synoviocytes from the bone marrow and the in-situ 
proliferation of type B synoviocytes cause this layer to dramatically increase in 
thickness (Isaacs & Moreland, 2011). This causes increase in cell numbers (hyperplasia) 
and there is also an increase in cell size (hypertrophy). Furthermore, the cells within the 
RA synovium become activated and produce matrix metalloproteinases such as 
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collagenase and aggrecanase and other tissue-degrading enzymes which accumulate in 
SF and attack exposed articular cartilage. Activated macrophages produce TNF-α and 
IL-1β, and stimulate chondrocytes to produce proteolytic enzymes that degrade cartilage 
matrix. As the disease progresses, the hyperplastic synovium may evolve into a 
migratory pannus which encroaches on the articular cartilage (Isaacs & Moreland, 
2011). Activated macrophages and fibroblasts within the pannus produce matrix 
metalloproteinases such as collagenase and aggrecanase which destroy articular 
cartilage. In addition the volume of synovial fluid within affected joints increases and 
ultimately articular bone is damaged. Bone erosion in RA is thought to be caused by 
osteoclasts, and the generation of such cells (osteoclastogenesis) and their subsequent 
activation requires the cytokine known as receptor activator of nuclear factor kappa-B 
ligand (RANKL) (Boyle et al, 2003). RANKL exerts its osteoclastogenic and 
osteoclast-activating effects through binding with its receptor, receptor activator of 
nuclear factor kappa-B (RANK), which is expressed on myeloid precursor cells and 
osteoclasts (Li, J. et al, 2000). Osteoprotegerin (OPG) is a soluble receptor of RANKL 
which regulates osteoclast generation and function - by preventing RANKL from 
interacting with RANK - and thus osteoclast-mediated bone erosion (Simonet et al, 
1997). Interestingly, RANKL is expressed by synovial fibroblasts and infiltrating T-
cells in the rheumatoid joint where sites of bone erosion are associated with higher 
levels of RANKL expression as opposed to OPG expression (Pettit et al, 2006). 
Synovial B-cells have recently been identified as a major cellular source of RANKL in 
RA (Yeo et al, 2011). 
 
1.3. The role of T-cells in rheumatoid arthritis 
As mentioned, the pathogenesis of RA involves infiltrations of lymphocytes into the 
synovial membranes of affected joints. It has been shown that 70-85% of the 
lymphocytes infiltrating the synovial membranes of RA patients are T-cells (van Boxel 
& Paget, 1975). The majority of these infiltrating T-cells express markers of activation 
such as CD69, which is involved in activation of macrophages, HLA-DR and VLA-1 
yet only a small proportion express the IL-2 receptor CD25 and indeed levels of IL-2 in 
RA synovium are low (Iannone et al, 1994). It was initially thought that IFN-γ produced 
by these T-cells was responsible for the activation of synovial monocytes, many of 
which have an activated phenotype in the synovium (Firestein & Zvaifler, 1987). 
Indeed, macrophage-derived pro-inflammatory cytokines such as IL-1, IL-6, IL-8 and 
TNF-α are highly abundant in the RA synovium, especially at the cartilage-pannus 
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junction where joint damage occurs (Chu et al, 1991 and Chu et al, 1992). However, the 
levels of IFN-γ in the synovial fluid and tissue of RA patients are very low therefore 
activation of synovial monocytes may be independent of IFN-γ (Firestein & Zvaifler, 
1987). In addition, the low levels of IL-2 present in the rheumatoid synovium created 
some speculation as to how the synovial T-cells had activated phenotype (Iannone et al, 
1994). This initially suggested that T-cells are not very important in pathogenesis. IL-15 
produced by macrophages has been found to be chemoattractant for T-cells and it also 
induces T-cell proliferation acting like IL-2 (McInnes et al, 1996). Furthermore, it has 
been shown that T-cells activated by IL-15 can induce macrophages to produce 
substantial levels of TNF-α and activate synoviocytes and osteoclast formation, all in a 
cell contact dependant manner that involves CD69, LFA-1 and ICAM-1 (McInnes et al, 
1997). Thus T-cells appear important for driving pathogenesis. Indeed, the paucity of 
classical T-cell cytokines such as IL-2 and IFN-γ in the RA synovium can be explained 
by the predominant role of TH17 cells in RA pathogenesis (see section 1.3.3). 
 
1.3.1. T-cell-implicating genetic factors in rheumatoid arthritis 
A well established susceptibility locus in RA is DRB1, and several alleles of this gene 
are associated with the disease, namely DRB1*0101, *0102, *0401, *0404, *0405, 
*0408, *0409, *0410, *1001, *1402 and *1406 (Weyand et al, 1995 and Saruhan-
Direskeneli, 1998). DRB1 encodes the β-chains of HLA-DR MHC class II molecules 
(Svendsen et al, 2004) which are each composed of a polymorphic β-chain and an 
invariant α-chain, encoded by the gene DRA1. Thus RA-associated DRB1 allomorphs 
pair with invariant HLA-DR α-chains to produce complete HLA-DR molecules of the 
DR1, DR4, DR10 and DR14 subtypes (Gorman et al, 2004). The β-chains encoded by 
the RA-associated DRB1 alleles all contain a similar amino acid sequence of either 
QKRAA (*0401), QRRAA (*0101, *0102, *0404, *0405, *0408) or RRRAA (*1001) 
at positions 70-74 of the third hypervariable region (Saruhan-Direskeneli, 1998). 
Analysis of this so-called ‘shared epitope’ (SE) has shown that the amino acids at 
positions 70 and 71 have positively-charged side chains (Hammer et al, 1995). DRB1 
alleles such as DRB1*0402 which encode β-chains with negative or neutral charges at 
positions 70 and 71 have been reported to protect against RA therefore the presence of 
positively-charged amino acids at positions 70 and 71 of HLA-DR β-chains may 
predispose to RA (Reviron et al, 2001). Interestingly, positions 67-74 of the β-chain 
border the peptide-binding groove of the resulting HLA-DR molecule (Svendsen et al, 
2004). Therefore, the charges of the side chains on these amino acids will influence 
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which peptides can bind the MHC molecule and indeed which T-cells the MHC 
molecule can present peptides to (Hammer et al, 1995). The association of RA with 
certain HLA-DR molecules suggests that MHC class II-restricted CD4
+
 T-cells are 
important in the pathogenesis of the disease (Svendsen et al, 2004). One hypothesis, 
termed the ‘shared epitope’ hypothesis, is that disease-associated HLA-DR molecules 
bind peptides of articular autoantigens and present them to antigen-specific CD4
+
 T-
cells which in turn initiate or perpetuate the inflammatory process that characterises RA 
(Gregersen et al, 1987). Indeed, it has been shown recently that SE-positive MHC class 
II molecules bind certain citrullinated peptides with high affinity (Hill et al, 2003). 
Alternatively, SE-positive HLA-DR molecules may select a repertoire of T-cells that 
include ones specific for self antigens (Kotzin et al, 2000). 
 
Further evidence implicating T-cells in the pathogenesis of RA is the association of the 
disease with the 1859 C→T polymorphism of the protein tyrosine phosphatase non-
receptor 22 gene, PTPN22 (Bowes & Barton, 2008), and the +49G polymorphism of the 
cytotoxic T lymphocyte-associated antigen-4 gene, CTLA-4 (Lei et al, 2005). PTPN22 
encodes a 110kD, lymphoid-specific intracellular protein tyrosine phosphatase (PTP) 
known as Lyp (Orozco et al, 2005). The mouse homologue of Lyp, PEP, is known to 
function as a down-regulator of T-cell receptor signalling when associated with Csk 
(Begovich et al, 2004). Several studies have shown that the PTPN22 1858T allele which 
arises from the 1859 C→T polymorphism is significantly more prevalent in RA patients 
than in healthy subjects (Begovich et al, 2004; Orozco et al, 2005; Hinks et al, 2005 and 
Michou et al, 2007) and an increased occurrence of this allele has also been observed in 
other autoimmune diseases such as type I diabetes mellitus, systemic lupus 
erythematosus (SLE) and juvenile idiopathic arthritis (JIA) (Bottini et al, 2004; Orozco 
et al, 2005 and Hinks et al, 2005). Interestingly, the PTPN22 1858 C→T polymorphism 
has been shown to prevent Lyp from binding Csk therefore it is postulated that it 
prevents down-regulation of T-cell activation (Bottini et al, 2004). Alternatively, it has 
been reported that this mutation leads to increased phosphatase activity and more potent 
suppression of T-cell receptor signalling (Begovich et al, 2004). It has been postulated 
that this dampening of T-cell signalling allows the survival of autoreactive thymocytes 
during the negative selection process of T-cell development and allows their subsequent 
development into mature T-cells capable of causing autoimmune responses once in the 
periphery (Bottini et al, 2004). CTLA-4 is a co-stimulatory receptor expressed on 
activated T-cells and, like CD28, it binds B7 co-stimulatory molecules expressed on 
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antigen-presenting cells. However, while signalling through ligated CD28 provides a T-
cell with an activating signal, signalling through ligated CTLA-4 provides an inhibitory 
signal. An A/G polymorphism exists at nucleotide 49 in exon 1 of the CTLA-4 gene, and 
the G allele of this polymorphism has been shown to be more prevalent in RA and other 
autoimmune diseases than in healthy subjects in Asian and Far Eastern populations 
(Pratt et al, 2009). It is postulated that the +49G polymorphism of CTLA-4 is involved 
in pathogenesis of RA because it prevents the inhibition of T-cell activation (Pratt et al, 
2009). 
 
1.3.2. The role of regulatory T-cells in rheumatoid arthritis 
Rodent studies originally identified a population of CD4
+
 CD25
+
 T-cells which once 
activated by recognition of their specific antigen can suppress the activation and 
proliferation of other T-cells in vitro. These cells, which account for 10% of peripheral 
CD4
+
 T-cells in healthy rodents, play an important role in the maintenance of self-
tolerance and the prevention of autoimmunity (Sakaguchi et al, 2001). Indeed mice 
deficient in CD4
+
 CD25
+
 T-cells are susceptible to autoimmune diseases which can be 
prevented by adoptive transfer of CD4
+
 CD25
+
 T-cells from healthy, syngeneic mice 
(Asano et al, 1996 and Suri-Payer et al, 1998). Furthermore, depletion of such T-cells 
from mice with experimentally-induced collagen-induced arthritis (CIA), a mouse 
model of RA exacerbates the disease (Morgan et al, 2003). A similar population of 
CD4
+
 CD25
+
 T-cells has also been identified in humans, although it is less clear what 
the role of these regulatory T-cells is in human autoimmunity (Ng et al, 2001; Baecher-
Allan et al, 2001 and Annunziato et al, 2002). In RA patients CD4
+
 CD25
+
 T-cells are 
enriched in synovial fluid compared to peripheral blood and can suppress proliferation 
of T-cells in vitro (Cao et al, 2003; Mottonen et al, 2005 and Lawson et al, 2006). CD4
+
 
CD25
+
 T-cells from RA patients can not suppress production of pro-inflammatory 
cytokines from activated T-cells and monocytes suggesting defective functioning 
(Ehrenstein et al, 2004). Further evidence for the defective functioning of CD4
+
 CD25
+
 
regulatory T-cells in RA comes from the study carried out by van Bilsen et al which 
analysed the responses of T-cells from RA patients and healthy controls to the candidate 
RA autoantigen human cartilage glycoprotein 39 (HCgp39). PBMC from healthy 
controls responded to HCgp39 with production of IL-10 while those from RA patients 
responded with production of IFN-γ. The HCgp39-specific T-cells from the healthy 
controls had phenotypes very similar to those of CD4
+
 CD25
+
 regulatory T-cells and 
appeared to have a regulatory function after stimulation with HCgp39, having the ability 
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to suppress both proliferation of and production of IFN-γ by conventional CD4+ T-cells 
specific for other antigens. However, HCgp39-specific T-cells from RA patients lacked 
this regulatory/suppressive function (van Bilsen et al, 2004). 
 
1.3.3. The role of TH17 cells in rheumatoid arthritis 
It has recently been shown that a certain subset of CD4
+
 T-cells known as TH17 cells 
appear to be of importance in the pathogenesis of animal models which mimic RA 
(Nakae et al #1, 2003; Nakae et al #2, 2003 and Hirota et al #1, 2007). TH17 cells, 
which secrete IL-17 but not IFN-γ and IL-4, are dependant on IL-23 for development 
and IL-23-deficient mice have been shown to be resistant to CIA, a mouse model of 
RA, as well as other experimentally-induced autoimmune diseases (Langrish et al, 
2005). There are substantial levels in the synovial tissue and fluid of RA patients and it 
can activate osteoclasts, therefore it may be involved in the pathogenesis of the disease 
and joint destruction (Kotake et al, 1999). IL-17 induces the production of IL-1β and 
TNF-α by macrophages and the production of IL-6 and IL-8 by synovial fibroblasts 
(Jovanovic et al, 1998 and Fossiez et al, 1996) and therefore induces production of pro-
inflammatory cytokines involved in RA pathogenesis. IL-1, IL-6 and TNF-α stimulate 
synoviocytes, cause inflammation and activate matrix metalloproteinases (Panayi, 
2005). In addition to inducing production of these pro-inflammatory cytokines, IL-17 
also induces metalloproteinases directly (Chabaud et al, 2001). A dominant role for 
TH17 cells in RA pathogenesis (van Hamburg et al, 2011) would explain the low levels 
of the Th1 cytokine IFN-γ in RA synovium. Indeed, IL-17 producing CD4+ T-cells have 
been reported in RA patients in greater proportions than in healthy controls (Shen et al, 
2009 and Colin et al, 2010). Interestingly, TH17 cells express CCR6, and synoviocytes 
from inflamed joints produce CCL20, the ligand for CCR6. Additionally, levels of 
synovial CCL20 correlate with levels of synovial IL-17, and CCL20 production in 
inflamed joints attracts Th17 cells (Hirota et al #2, 2007). High levels of IL-15 in 
synovial fluid of RA patients and the levels of IL-17 in synovial fluid of RA patients 
correlate very well. IL-15 induces PBMC to produce IL-17 and production can be 
reduced by immunosuppressive cyclosporine A (Ziolkowska et al, 2000). 
 
1.3.4. The efficacy of treatments targeting T-cells 
The benefits of T-cell-targeting therapies in RA have been reviewed (Isaacs, 2008). The 
conventional DMARDs cyclosporine, leflunomide and methotrexate all interfere with 
T-cell function. Cyclosporine inhibits production of IL-2 which is essential for T-cell 
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activation and proliferation and reduces symptoms of RA and disease progression. It 
was introduced into RA management in the 1990s although it is relatively toxic to the 
kidneys so is now only used occasionally, and when other DMARDs fail to control 
disease. Leflunomide inhibits proliferation of activated T-cells and slows progression of 
RA, high dosages are associated with gastrointestinal toxicity and blood counts, liver 
function and blood pressure need to be monitored during treatment. Methotrexate also 
inhibits proliferation of activated T-cells but only for a short while after each 
administration therefore it is unclear whether its efficacy relates to this. It is thought that 
methotrexate may exert its effect by causing release of anti-inflammatory adenosine as 
polymorphisms in certain genes involved in the adenosine pathway are associated with 
differing clinical responses to treatment with the drug (Wessels et al, 2006). While 
monoclonal antibodies targeting T-cell surface antigens could reverse autoimmunity in 
animal models, the use of monoclonal antibodies targeting T-cell antigens CD4, CD52 
and CD28 (TGN1412) to treat RA in humans was less successful, these agents only 
providing transient clinical benefit (Strand et al, 2007). Indeed, the monoclonal 
antibody known as TGN1412 which targets the T cell antigen CD28 caused severe side-
effects in healthy controls in its first phase 1 clinical trial (Suntharalingham et al, 2006 
and Stebbings et al, 2007). However, the efficacy of the co-stimulatory signal inhibitor 
abatacept suggests that T-cells are important in the pathogenesis of RA.     
For a T-cell that has recognised a peptide-MHC complex to gain the ability to 
proliferate, produce cytokines and activate other immune cells, it requires an additional 
co-stimulatory signal which is received when CD28 on the T-cell binds CD80 and 
CD86 on an antigen-presenting cell. Blocking of this co-stimulatory signal has been 
shown to slow disease progression in animal models of RA and the autoimmune 
disease, lupus (Finck et al, 1994 and Webb et al, 1996). Abatacept, also known as 
CTLA4Ig, is a soluble recombinant fusion protein which consists of the external domain 
of human CTLA4 fused to the Fc portion of human IgG1. The CTLA4 portion of 
abatacept (CTLA4Ig) enables the protein to out-compete CD28 for binding to CD80 
and CD86 on antigen-presenting cells, thereby preventing delivery of a co-stimulatory 
signal to T-cells, thus preventing activation of T-cells. It is a licensed, efficacious 
treatment for RA. Disease activity/signs/symptoms in RA patients not responding to 
methotrexate were significantly reduced after CTLA4Ig treatment and physical 
function/quality of life improved (Kremer et al, 2003; Kremer et al, 2005; Kremer et al, 
2006 and Kremer et al, 2008). Significant clinical and functional improvements were 
also observed in RA patients with disease activity not responding to anti-TNF treatment 
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and it has proved a safe therapy (Genovese et al, 2005 and Genovese et al, 2008). 
However, it has been reported that while the use of abatacept in combination with 
conventional DMARDs like methotrexate is safe, combining it with biologic DMARDs 
can cause serious adverse effects (Weinblatt et al, 2006). 
 
1.3.5. T-cell tolerance and autoimmune disease 
During T-cell development in the thymus, the random rearrangement of T-cell antigen 
receptor (TCAR) genes generates an extraordinarily diverse repertoire of TCARs. Many 
thymocytes express TCARs that are incapable of recognising self peptide-MHC 
complexes and are consequently of no use to the immune system, while those 
expressing TCARs with low affinity for self peptide-MHC complexes are positively 
selected and allowed to differentiate further into CD4
+
 or CD8
+
 T-cells (Hogquist et al, 
2005). However, thymocytes expressing TCARs highly reactive with self peptide-MHC 
complexes are also created. If these auto-reactive thymocytes are allowed to 
differentiate unchecked they could mount autoimmune reactions once in the periphery 
which may lead to autoimmune diseases, therefore the differentiation of such 
thymocytes must be strictly controlled so that self tolerance is established within the 
mature T-cell population. The induction of T-cell tolerance in the thymus is achieved in 
part by the process of negative selection, in which thymocytes expressing highly self-
reactive TCARs are selected against, mainly by elimination (clonal deletion) but also by 
‘neutralisation’, achieved via both anergy induction and receptor editing (Palmer, 2003; 
Hammerling et al, 1991 and McGargill et al, 2000). Another mechanism inducing 
central T-cell tolerance is the selection of auto-reactive thymocytes for differentiation 
into specific subsets of regulatory T-cells, such as the fork-head box P3 (FoxP3)-
expressing CD4
+
 CD25
+
 population mentioned in 1.3.2 (Sakaguchi, 2005). The 
observation that mutations in the autoimmune regulator gene AIRE which cause a defect 
in clonal deletion lead to the development of autoimmune polyendocrinopathy-
candidiasis-ectodermal-dystrophy syndrome (APECED) and the association of 
immunodysregulation, polyendocrinopathy and enteropathy, X-linked syndrome (IPEX) 
with mutations in the FOXP3 gene which impede the development of CD4
+
 CD25
+
 
regulatory T-cells demonstrate the importance of mechanisms of T-cell central tolerance 
in maintaining self tolerance (Villasenor et al, 2005 and Sakaguchi, 2005). 
 
However, thymocytes expressing TCARs with low affinity for self peptide-MHC 
complexes as well as those with TCARs capable of recognising tissue-specific antigens 
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not expressed in the thymus evade the mechanisms of T-cell central tolerance. 
Therefore, for self tolerance to be maintained, mechanisms for inducing T-cell tolerance 
in the periphery are also necessary (Mueller, 2010). Firstly, autoreactive T-cells may 
remain ignorant of any self-antigens which are expressed in compartments not readily 
accessible to T-cells (Walker & Abbas, 2002). Secondly, when T-cells encounter 
peptide-MHC complexes in conjunction with inhibitory signalling through CTLA-4 or 
the programmed cell death 1 (PD-1) molecule, they become anergic (Walunas et al, 
1996; Greenwald et al, 2001 and Freeman et al, 2000). In addition, even when 
autoreactive T-cells become activated, phenotype skewing may enable tolerance to be 
maintained by altering the ensuing T-cell responses in such a way that pathogenic 
effects are minimised (Walker & Abbas, 2002). Furthermore, repetitive TCAR 
stimulation, which could possibly occur when autoreactive T-cells encounter a 
ubiquitous self-antigen, can trigger activation-induced cell death (AICD), a peripheral 
form of clonal deletion mediated by Fas and Fas Ligand interactions (Walker & Abbas, 
2002). Additionally, regulatory immune cells such as CD4
+
 CD25
+
 regulatory T-cells 
may control the actions of autoreactive T-cells in the periphery (Asano et al, 1996). The 
existence of an additional peripheral tolerance mechanism known as T-cell receptor 
revision in which the autoreactive TCARs of peripheral T-cells may be replaced with 
new ones produced by extrathymic TCAR gene rearrangements has also been discussed 
(Hale & Fink, 2010). The fact that autoreactive T-cells can be found in the peripheries 
of healthy subjects suggests that peripheral tolerance mechanisms are also essential for 
maintaining self tolerance, and that autoimmune diseases can develop when these 
mechanisms fail (Walker & Abbas, 2002). 
 
The K/BxN and SKG mouse models are two examples of genetically manipulated 
spontaneous arthritis which demonstrate how the failure of tolerance inducing 
mechanisms can lead to the development of autoimmune arthritis (Asquith et al, 2009). 
The K/BxN strain of mice develop an erosive arthritis similar to human RA which is 
dependant on self-reactive CD4
+
 T-cells but caused by autoantibodies (Kouskoff et al, 
1996). CD4
+
 T-cells from K/BxN mice are capable of recognising a peptide derived 
from the self-protein glucose-6-phosphate isomerase (GPI) which is expressed in the 
joints but because some of these T-cells escape negative selection, the mice have only 
partial tolerance to GPI (Korganow et al, 1999). The CD4
+
 T-cells recognising GPI-
derived peptide provide help to GPI-specific B-cells to produce GPI-specific IgG 
autoantibodies that in turn form immune complexes with GPI in joints which, through 
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activating complement and interacting with Fc (Fragment, crystallisable) receptors, 
cause the release of the inflammatory mediators IL-1 and TNF-α from mast cells and 
neutrophils (Ditzel, 2004). The SKG strain of mice develop a CD4
+
 T-cell-mediated 
arthritis very similar to human RA which is caused by a mutation in the gene encoding 
the T-cell signalling molecule ZAP-70 (Sakaguchi et al, 2003). The mutation alters 
TCAR signal transduction and affects the development and differentiation of T-cells by 
interfering with the positive and negative selection processes and the generation of 
CD4
+
 CD25
+
 regulatory T-cells. The consequence of this is that SKG mice develop self-
reactive, potentially arthritogenic T-cells and regulatory T-cells with a reduced ability to 
suppress self-reactive T-cells (Sakaguchi et al, 2006). However, development of 
arthritis in SKG mice requires an environmental stimulus in the form of exposure to 
microbial components which may provide danger signals which facilitate the activation 
of self-reactive, arthritogenic CD4
+
 T-cells (Sakaguchi et al, 2006 and Asquith et al, 
2009). 
 
1.4. The role of B-cells in rheumatoid arthritis 
Along with T-cells, macrophages and dendritic cells, B-cells contribute to a proportion 
of the inflammatory infiltrate observed in the synovial membranes of RA joints. While 
the synovial membranes of some RA patients show diffuse infiltrations where there is 
no organisation of the infiltrating cells (diffuse synovitis), in other RA patients the 
infiltrating T-cells and B-cells aggregate into highly organised, follicle-like structures 
(follicular synovitis) which surround follicular dendritic cells (Weyand & Goronzy, 
2003 and Bugatti et al, 2007). While B-cells account for only a small proportion of the 
lymphocyte infiltrate, they do however appear to of be of great importance in disease 
pathogenesis, as demonstrated in a study by Takemura et al (2001). Using severe 
combined immunodeficiency (SCID) mice transplanted with inflamed synovial tissue 
from RA patients, they demonstrated that B-cells are essential for the activation of T-
cells in the RA synovium and the subsequent production of pro-inflammatory cytokines. 
Because the mice lacked their own T-cells and B-cells, they were unable to reject the 
grafts of synovial tissue which were observed to produce substantial amounts of IFN-γ, 
IL-1β and TNF-α. However, when the mice were treated with anti-CD20 monoclonal 
antibodies that depleted the CD20
+
 B-cells in the transplanted synovial tissue, the 
production of IFN-γ, IL-1β and TNF-α decreased dramatically. In addition, B-cells have 
been shown to be essential for the development of type II collagen-induced arthritis, a 
mouse model of rheumatoid arthritis (Svensson et al, 1998). A likely role for B-cells in 
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the pathogenesis of RA is as antigen-presenting cells, presenting self antigens to T-cells 
and providing a co-stimulatory signal so that they can be activated to proliferate and 
activate other immune cells via cytokine production or cell-cell interactions. B-cells 
may also be a source of pro-inflammatory cytokines themselves. Further evidence 
implicating the importance of B-cells in the pathogenesis of RA is the presence of 
autoantibodies in the sera of RA patients and the efficacy of B-cell depleting therapies 
in the treatment of the disease. 
 
1.4.1. Autoantibodies in rheumatoid arthritis 
Rheumatoid factors (RF), autoantibodies specific for the Fc portion of IgG, can be 
detected in the sera of 60-80% of RA patients with established disease (Goldbach-
Mansky et al, 2000 and Steiner et al, 2002). Because of the high sensitivity of these 
autoantibodies for established RA, their presence in serum is one of the American 
College of Rheumatology revised classification criteria for defining disease (Goldbach-
Mansky et al, 2000 and Steiner et al, 2002). Indeed, autoantibodies have an even higher 
‘weighting’ in the more recently updated RA classification criteria (Aletaha et al, 2010). 
Low titres of RF are also detectable in the sera of around 55% of patients with early 
arthritis therefore it may be a useful marker for making an early diagnosis of RA 
(Steiner, 2006). However, low titres of RF are only around 75% specific for RA, as they 
are detectable in the sera of substantial proportions of patients with other rheumatic 
diseases such as Sjŏgren’s syndrome (62%), scleroderma (44%), SLE (27%) and 
osteoarthritis (OA, 25%), and even in 10-15% of healthy controls (Steiner et al, 2002; 
Mewar & Wilson, 2006 and Steiner, 2006). High titre RF is a more specific marker of 
established RA, although this is detected in only 46% of RA patients (Steiner, 2006). 
Interestingly, serum levels of RF correlate well with disease activity in RA, with higher 
titres being associated with more severe joint damage (Knijff-Dutmer et al, 2002). This 
suggests that RF may have a role in the pathogenesis of the disease. Indeed, it is 
postulated that RF form immune complexes which fix complement and that the 
resulting chemotactic factors that are produced recruit inflammatory cells to the affected 
joint which contribute to the articular destruction (Firestein, 2003). 
Anti-citrullinated peptide antibodies (ACPA), autoantibodies specific for citrullinated 
epitopes found within proteins such as α-enolase, fibrin, filaggrin and vimentin, are 
detectable in the sera of up to 75% of patients with established RA (Steiner, 2006). 
Furthermore, ACPA are 95-98% specific for RA and are also detectable in the sera of 
41% of early arthritis patients therefore they are the most specific serological marker of 
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RA to date and are valuable for making a correct diagnosis during the very early stages 
of disease (Steiner, 2006). The presence of citrulline in the epitopes of the self proteins 
appears to be of great importance for their ability to be bound by ACPA (Schellekens et 
al, 1998). Indeed, a synthetic, cyclic citrullinated peptide (CCP) is now used to 
determine the presence of ACPA in sera of early arthritis patients in order to allow early 
diagnosis of RA (Schellekens et al, 2000). The presence of ACPA is associated with 
more joint destruction (Vries-Bouwstra et al, 2008). This suggests that ACPA, like RF, 
may have a role in joint damage in RA. Interestingly, both ACPA and RF can be 
detected several years before the onset of RA (Rantapää-Dahlqvist et al, 2003). 
Anti-A2/RA33 autoantibodies specific for heterogenous nuclear ribonucleoprotein A2 
(hnRNP-A2/RA33) are detectable in the sera of around 35% of RA patients (Hassfeld et 
al, 1995). However, they are also detectable in the sera of around 20% of SLE patients 
and up to 60% of mixed connective tissue disease (MCTD) patients (Hassfeld et al, 
1995 and Skriner et al, 1997), thus are not greatly specific for RA. Like RF and ACPA, 
they can be detected in the early stages of disease but in contrast their presence does not 
appear to predict the severity of the disease (Goldbach-Mansky et al, 2000). However, it 
has been reported that hnRNP-A2/RA33 is over expressed in the synovial tissue of RA 
patients but not in that of OA patients (Fritsch et al, 2002). Furthermore, while humoral 
immunity to the protein is detectable in a substantial proportion of RA patients, it is 
rarely detected in OA patients (Steiner et al, 2002). Therefore anti-A2/RA33 
autoantibodies may have a role in the pathogenesis of RA. 
Anti-BiP autoantibodies specific for the chaperone/stress protein immunoglobulin 
heavy-chain binding protein (BiP) are also detectable in the sera of RA patients and are 
reported to be fairly specific for the disease (Bläss et al, 1995; Bläss et al, 2001 and 
Bodman-Smith et al, 2004). Interestingly, BiP is over expressed in the synovial tissue of 
RA patients compared to those of OA patients or healthy controls (Bläss et al, 2001), 
thus autoimmunity directed at this protein may have a role in the pathogenesis of RA. 
 
1.4.2. The efficacy of treatments targeting B-cells 
CD20 is a B-cell-specific antigen expressed by B-cell precursors and both resting and 
activated mature B-cells, but not by stem cells or plasma cells (Silverman & Weisman, 
2003). Rituximab is a chimeric monoclonal antibody composed of the variable regions 
of a mouse antibody and the constant regions of a human antibody which is specific for 
human CD20. (Silverman & Weisman, 2003), and has been shown to be very effective 
at transiently depleting B-cells in vivo for up to 6 months (Shaw et al, 2003). An early 
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study by Edwards and Cambridge demonstrated the efficacy of rituximab as a treatment 
for RA, providing further evidence that B-cells are important in the pathogenesis of the 
disease (Edwards and Cambridge, 2001), and subsequent studies have supported this. 
RA patients not responding to treatment with methotrexate and cyclosporin A showed 
clinical improvements when treated with rituximab (De Vita et al, 2002). RA patients 
treated with rituximab showed clinical improvements and their serum levels of 
autoantibodies were significantly reduced (Cambridge et al, 2003). Treatment with the 
combination of rituximab and methotrexate improves symptoms of RA patients not 
responding to treatment with methotrexate alone (Edwards et al, 2004). The 
combination has also been shown to have positive effects on disease activity in RA 
patients not responding to anti-TNF treatments (Cohen et al, 2006). Further studies into 
the use of rituximab as a therapy for RA refractory to anti-TNF treatments have 
suggested that treatment with the former may be more effective than treatment with 
alternative anti-TNF agents (Finckh et al, 2007). 
 
1.5. Candidate autoantigens in rheumatoid arthritis 
As mentioned, it has been suggested that auto-reactive CD4
+
 T-cells mediate the 
pathological process in RA. As the disease is characterised by inflammation at the 
joints, proteins of articular origin are popular candidates for autoantigens involved in 
disease pathogenesis. However, because the sera of RA patients often contain antibodies 
specific for certain systemically-expressed antigens, these extra-articular antigens are 
also considered as possible targets for auto-reactive CD4
+
 T-cells. 
 
1.5.1. Human cartilage glycoprotein 39 (HCgp39) 
HCgp39, a 383 amino acid protein also known as YKL-40, is the main secreted product 
of both synoviocytes and articular chondrocytes from OA and RA patients (Nyirkos & 
Golds, 1990 and Hakala et al, 1993). HCgp39-encoding mRNA has been identified in 
abundance in both the synovial fluid and articular cartilage of RA patients yet the 
protein does not appear to be expressed in healthy articular cartilage (Hakala et al, 
1993). Indeed, there is evidence to suggest that it is inflammation and tissue damage 
that induces the secretion of HCgp39, and high serum levels of the protein are 
associated with joint disease (Nyirkos & Golds, 1990; Hakala et al, 1993, and Johansen 
et al, 1993). Interestingly, while increased serum levels of HCgp39 can be detected in 
patients with RA, OA, SLE and inflammatory bowel disease (IBD), the highest serum 
levels of HCgp39 are detected in RA patients and in RA patients increased HCgp39 
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production appears to correlate with the degree of joint destruction and disease activity 
(Vos et al #1, 2000 and Volck et al, 2001). All this suggests that HCgp39 may have 
some role in the joint destruction seen in RA and a common postulation is that HCgp39 
is an autoantigen that is presented to antigen-specific T-cells by RA-associated HLA-
DR molecules. Indeed, there is a wealth of evidence suggesting that this may be the 
case.  
 
Verheijden et al have shown that immunisation of BALB/c mice with HCgp39 in 
Freund’s incomplete adjuvant induces an arthritis manifested in the paws in which 
swelling is observed at symmetrical joints. The incidence of this HCgp39-induced 
arthritis was 100% and while doses of HCgp39 as small as 1µg were capable of 
inducing the disease, more severe symptoms were observed in mice immunised with 
higher doses of the protein. Histological analysis of affected ankle joints of the arthritic 
mice showed that paw swelling was a result of inflammation which involved infiltration 
of mononuclear cells and proliferation of synovial fibroblasts. The group postulated that 
the arthritis was a result of HCgp39-specific T-cells being activated/induced by 
immunisation and then cross-reacting with peptides derived from mouse gp39 and 
thereby initiating autoimmune responses against this endogenous protein. Interestingly, 
the HCgp39-induced arthritis reported in this study was not as severe as proteoglycan-
induced and collagen-induced arthritis in BALB/c and DBA/1 mice respectively. The 
study also showed that intranasal administration of HCgp39 prior to immunisation with 
the protein appears to induce tolerance in HCgp39-specific T-cells. Indeed, 50% of mice 
that were HCgp39-tolerised in this way prior to immunisation did not develop HCgp39-
induced arthritis (Verheijden et al, 1997). 
 
Certain HCgp39-derived peptides have been shown to bind RA-associated HLA-DR 
molecules with high affinity and induce HLA-DR-restricted peripheral blood T-cell 
responses in RA patients but not in healthy controls (Verheijden et al, 1997). In 
addition, HCgp39-derived peptides containing T-cell epitopes identified in HCgp39-
immunised DR4(DRB1*0401) transgenic mice have been shown to induce proliferation 
of peripheral blood T-cells in individuals expressing RA-associated HLA-DR4 
molecules. The immunodominant epitope of HCgp39 identified in the HCgp39-
immunised DR4(DRB1*0401) transgenic mice was residues 263-275 and this was also 
the predominant epitope recognised by DR4 individuals (Cope et al, 1999). Peripheral 
blood T-cell responses to HCgp39-derived peptides have also been identified in 
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apparently healthy individuals, yet they are not detected to the same degree as in RA 
patients (Verheijden et al, 1997 and Vos et al #2, 2000). Furthermore, while peripheral 
blood T-cell responses to HCgp39-derived peptides have also been detected in patients 
with OA, SLE and IBD, to a greater degree than in healthy controls, only in RA do T-
cell responses to HCgp39-derived peptides correlate with disease activity (Vos et al #2, 
2000). One of the immunodominant T-cell epitopes of HCgp39 identified in 
DR4(DRB1*0401) transgenic mice immunised with the protein was a sequence residing 
in residues 263-275 (Cope et al, 1999). Interestingly, Tsark et al showed that when 
HCgp39263-275-specific T-cells from HCgp39263-275-immunised DR4(DRB1*0401) 
transgenic mice were cultured with native HCgp39 in the presence of human DR4+ mo-
DC and macrophages, T-cell responses were detected (Tsark et al, 2002). This 
suggested that human antigen-presenting cells are capable of processing and presenting 
HCgp39 and that the previously identified immunogenic epitopes of the protein can be 
generated in vivo. Indeed, in a study by van Bilsen et al, human PBMC were shown to 
respond to native HCgp39. These HCgp39-specific PBMC responses were identified in 
both RA patients and healthy controls yet whereas RA patient PBMC responded to the 
protein with production of both IL-10 and IFN-γ, PBMC from healthy subjects 
responded with production of IL-10 alone (van Bilsen et al, 2004). 
 
1.5.2. Type II collagen (CII) 
CII is the most abundant protein in articular cartilage. Several studies have reported the 
presence of anti-CII antibodies in the sera of RA patients (Cook et al, 1996 and Terato 
et al, 1990). Indeed, it has been reported that the presence of CII-specific antibodies in 
RA sera is associated with active disease and more severe symptoms (Cook et al, 1996). 
Furthermore, the arthritogenic nature of CII has been demonstrated in several animal 
models (Trentham et al, 1977; Wooley et al, 1981 and Yoo et al, 1988). 
 
Two separate studies by Rosloniec et al using DR1(DRB1*0101) transgenic and 
DR4(DRB1*0401) transgenic B10.M mice (Rosloniec et al, 1997 and Rosloniec et al 
1998) have defined a relationship between the expression of RA-associated HLA-DR 
molecules and immune response to CII by showing that expression of these RA-
associated HLA-DR molecules can allow development of CII-induced CIA due to their 
ability to present CII-derived peptides. The group showed that B10.M mice, normally 
resistant to CIA, could be made susceptible to CII-induced CIA through transgenic 
expression of DR1(DRB1*0101) or DR4(DRB1*0401) molecules. The incidence of 
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CII-induced CIA in the DR1(DRB1*0101) transgenic mice was between 88% and 
100%, and arthritic mice showed T-cell responses to both the immunising human CII as 
well as the endogenous mouse CII. Additionally, T-cell responses to human CII were 
much stronger in the transgenic mice than in wild type B10.M mice that had been 
immunised but were resistant to arthritis. Furthermore, the arthritic mice produced high 
levels of anti-CII antibodies while the non-arthritic wild type B10.M mice only 
produced low levels of anti-CII antibodies. The arthritic mice also produced antibodies 
that recognised mouse CII while the non-arthritic mice did not. The immunodominant 
epitope of CII identified in both the DR1(DRB1*0101) transgenic and 
DR4(DRB1*0401) transgenic B10.M mice was residues 263-270 and CII-derived 
peptides containing this epitope induced strong, DR1(DRB1*0101)-restricted responses 
in T-cells from arthritic mice (Rosloniec et al, 1997). 
 
Several studies have reported CII-specific T-cell responses in RA. Londei et al (1989) 
have reported the persistence of CII-reactive T-cells in the arthritic synovial membrane 
of an individual RA patient over a three year period. Furthermore, another study 
detected reactivity to CII or a peptide composed of residues 255-274 of the protein in 
the synovial fluid mononuclear cells (SFMC) of 62% of RA patients (Kim et al, 1999). 
CII-reactive cells have also been reported in the peripheral blood of RA patients 
(Snowden et al, 1997; Kim et al, 1999 and Park et al, 2001). Indeed, two studies 
showed that significantly higher proportions of RA patients than OA patients or healthy 
controls show CII-specific PBMC reactivity and that the magnitudes of CII-specific 
responses detected in the RA patients were significantly greater than those detected in 
either of the other groups (Kim et al, 1999 and Park et al, 2001). However, Snowden et 
al (1997) reported that while 50% of RA patients with anti-CII antibodies in their sera 
showed positive CII-induced PBMC responses, only 5% of the RA patients lacking 
detectable humoral immunity to CII showed CII-specific PBMC reactivity, as opposed 
to 36% of healthy controls. Interestingly, T-cell responses to CII have been reported as 
being more prevalent and significantly higher in magnitude in the SFMC of RA patients 
compared to PBMC (Kim et al, 1999). 
 
1.5.3. Aggrecan 
Aggrecan is the predominant proteoglycan component of articular cartilage and exists in 
this tissue in large, multi-molecular aggregates of individual aggrecan monomers that 
are each attached to hyaluronan in the extra cellular matrix via non-covalent bonds 
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(Kiani et al, 2002). Individual aggrecan molecules are each composed of two N-
terminal globular domains (G1 and G2) linked by an interglobular domain, which are 
separated from a third, C-terminal globular domain (G3) by a large region of 
glycosaminoglycan (GAG) side chains (Kiani et al, 2002). The GAG region is 
composed of a domain of around 60, 5-15kDa keratin sulphate chains (KS domain) and 
two further domains consisting of a total of around 100, 20kDa chondroitin sulphate 
chains (CS-1 and CS-2), and also contains a number of O- and N-linked 
oligosaccharides (Kiani et al, 2002). Some keratin sulphate chains are also present in 
the G1 and G2 domains as well as in the interglobular domain (Guerassimov et al, 
1998). These trap water due to their anionic nature, and give cartilage its 
compressibility (Kiani et al, 2002). Both the whole molecule of aggrecan as well as the 
G1 domain alone have been shown to be arthritogenic in animal models (Glant et al, 
1987 and Zhang et al, 1998). 
 
Proteoglycan-induced arthritis (PGIA) is an RA-like condition that can be induced in 
BALB/c mice and in certain sub-strains of C3H mice by immunisation with cartilage 
proteoglycan in complete Freund’s adjuvant (Glant et al, 1987). This animal model of 
RA has given great insight into the potential pathogenic mechanisms involved in human 
RA. It is thought that PGIA develops as a result of immune responses being generated 
to the immunising proteoglycan cross-reacting with mouse cartilage proteoglycan and 
attacking structures containing the antigen, such as joints (Glant et al, 1987). This is 
supported by the fact that PGIA can be adoptively transferred to irradiated, non-
immunised BALB/c mice by injecting them with lymphocytes from arthritic mice 
(Mikecz et al, 1990). However, if the lymphocytes are depleted of either T-cells or B-
cells prior to injection, they cannot induce arthritis therefore both T- and B-cells are 
needed for development of arthritis (Mikecz et al, 1990). Development of PGIA is 
related to production of antibodies specific for proteoglycan which suggests that CD4
+
 
(helper) T-cells are important (Glant et al, 1987). Indeed, it has been shown that if PG-
immunised BALB/c mice are depleted of CD4
+
 T-cells, they do not develop PGIA and 
show greatly reduced anti-PG antibody responses compared to arthritic mice (Banerjee 
et al, 1992). Early studies using KS-free human foetal cartilage proteoglycan (HFCPG) 
to induce arthritis in BALB/c mice showed that the removal of the CS chains from the 
proteoglycan drastically increased its arthritogenicity (Leroux et al, 1992). However, 
human adult cartilage proteoglycan (HACPG), which is rich in KS chains, does not 
become more arthritogenic after removal of CS chains therefore glycosylation of 
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proteoglycan may influence arthritogenicity (Leroux et al, 1992). Studies using 
proteoglycan-specific T-cell lines and hybridomas generated from mice with PGIA have 
suggested that the immunodominant epitopes of aggrecan reside in the G1 domain and 
indeed, injection of the G1 domain alone can induce arthritis in BALB/c mice, but only 
after it is depleted of KS (Leroux et al, 1992 and Leroux et al, 1996). Leroux et al 
showed that MHC class II-restricted G1-specific CD4
+
 T-cell hybridomas showed 
enhanced responses to KS-depleted G1 as opposed to native G1. This is because KS-
depleted G1 can be taken up, processed and presented by antigen-presenting cells more 
successfully than native G1 (Leroux et al, 1996). G1-specific T-cell hybridomas 
generated from PG-immunised BALB/c mice were found to respond to two G1-derived 
peptides, aggrecan70-84 and aggrecan150-169, when presented by syngeneic antigen-
presenting cells. Therefore these sequences contain immunodominant epitopes which 
can be naturally processed and presented by antigen-presenting cells. When T-cells 
specific for aggrecan70-84 were injected into mice they developed arthritis. T-cells 
specific for G1 or aggrecan70-84 respond much better to KS-depleted G1 than native G1. 
Enhanced antibody responses were also detected in mice immunised with KS-depleted 
G1 compared to mice immunised with native G1 (Zhang et al, 1998). Therefore, it is 
likely that the presence of KS chains on G1 impedes its ability to induce arthritis by 
inhibiting T- and B-cell responses to epitopes contained within G1. Interestingly, the T-
cells responding to aggrecan70-84 showed reactivity to HFCPG, HACPG, bovine foetal 
cartilage proteoglycan (BFCPG), bovine G1 and bovine link protein, which is similar in 
structure to G1 (Leroux et al, 1992). 
 
Peripheral blood T-cells from a greater proportion of RA patients than healthy controls 
show proliferative responses to DeglyAgg which is free of both KS and CS. Peripheral 
blood T-cells from some RA patients responding to DeglyAgg also proliferated in 
response to peptides from CS1 domain (Goodstone et al, 1996). PBMC from RA 
patients but not healthy controls show G1-specific reactivity, and immunogenicity of 
G1 in RA patients but not healthy controls is greatly enhanced by the removal of the 
keratin sulphate chains (Guerassimov et al, 1998). G1-reactive T-cells have been 
identified in both the peripheral blood and synovium of RA patients although they are 
more frequent in the synovium (Li, N.L. et al, 2000). G1-reactive T-cells have also been 
identified in peripheral blood of healthy controls but are much less frequent than in 
peripheral blood of RA patients (Li, N.L. et al, 2000 and de Jong et al, 2010). It has 
been reported that peripheral blood CD4
+
 T-cells from substantially greater proportions 
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of RA patients than of healthy controls show G1-induced IFN-γ and TNF-α production 
(Zou et al, 2003). PBMC from RA patients produce more pro-inflammatory cytokines 
and chemokines in response to G1-derived peptides than healthy controls (de Jong et al, 
2010). A G1-derived peptide, albeit in citrullinated form, has been shown to induce 
proliferation of PBMC from RA patients but not healthy controls and the responses to 
the peptide were characterised by high levels of IL-17 production and the appearance of 
IL-17
+
 CD4
+
 T-cells (von Delwig et al, 2010). Boots et al have identified eleven 
aggrecan-derived peptides that bind DR4(DRB1*0401) molecules with high affinity and 
one of these eleven also binds both DR4(DRB1*0404) and DR1(DRB1*0101) 
molecules with high affinity. Furthermore, five of the peptides were identified as T-cell 
epitopes in humans although responses to these peptides were more prevalent in healthy 
controls than in RA patients (Boots et al, 1997). 
 
1.5.4. Antigens recognised by antibodies in rheumatoid arthritis sera 
The sera of RA patients often contain antibodies specific for citrulline-containing 
epitopes which can be generated from certain self proteins including α-enolase, 
filaggrin, fibrinogen and vimentin. 
 
While antibodies reacting with placenta-derived α-enolase have been identified in the 
sera of 25% of RA patients, serum reactivity to the recombinant form of the protein was 
less frequently observed (Saulot et al, 2002). Therefore it was suggested that the 
antibodies in the RA sera were recognising a post-translationally modified form of the 
protein. In a study by Kinloch et al, unmodified and citrullinated RA synovial cell 
lysates were probed with the sera of RA patients and a 47 kDa protein from the 
citrullinated lysate, identified as citrullinated α-enolase, was shown to be a target for 
antibodies in RA sera. The group went on to show that while the sera of 46% of RA 
patients showed reactivity to the citrullinated form of α-enolase, only 13% showed 
serum reactivity to the unmodified form of the protein. Sera from 15% of healthy 
controls showed reactivity to both forms of the protein. In addition, they confirmed the 
status as a joint-associated autoantigen by demonstrating that α-enolase was expressed 
in samples of inflamed synovial tissue from 100% of RA patients and provided 
evidence suggesting that the citrullinated form of the protein is present in the joints 
(Kinloch et al, 2005). More recently, the immunodominant epitope of citrullinated α-
enolase recognised by antibodies reacting to the protein has been identified as 
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citrullinated enolase5-21 and has been shown to react with sera of 37% of RA yet only 
3% of DC and 2% of HC (Lundberg et al, 2008). 
 
Anti-perinuclear factor and anti-keratin antibodies, autoantibodies both highly specific 
for RA, recognise citrullinated epitopes from within a 40 kDa protein known as 
filaggrin and have thus been collectively named anti-filaggrin antibodies (Simon et al, 
1993; Sebbag et al, 1995 and Girbal-Neuhauser et al, 1999). In RA patients, 
concentrations of anti-filaggrin antibodies are greater in the synovial membrane 
compared to in the synovial fluid or serum (Masson-Bessiere et al, 2000). Furthermore, 
filaggrin-specific T cell responses have been reported in some RA patients, with both 
the unmodified and citrullinated forms of the protein eliciting responses (Fritsch et al, 
2002). However, as filaggrin is not expressed in the joint, it is unclear how responses to 
this protein could lead to joint damage (Kinloch et al, 2005). Interestingly, citrullinated 
fibrinogen is expressed in the joints of RA patients and it is recognised by anti-filaggrin 
antibodies (Masson-Bessiere et al, 2001). In addition, Auger et al have reported that the 
sera of both shared epitope-negative and shared epitope-positive RA patients contain 
antibodies specific for citrullinated fibrinogen. Furthermore, they demonstrated that 
various RA-associated as well as non-associated HLA-DR molecules bind peptides 
derived from both the α- and β-chains of fibrinogen, and that both unmodified and 
citrullinated forms of the peptides bound equally well. The group also showed that 
peripheral blood T-cells from RA patients responded to a greater number of both 
unmodified and citrullinated fibrinogen-derived peptides than did peripheral blood T-
cells from healthy controls (Auger et al, 2005). Furthermore, citrullinated fibrinogen 
has been shown to be arthritogenic as 35% of DR4(DRB1*0401) transgenic mice 
immunised with the protein developed arthritis, and citrulline-specific, DR4-restricted 
T-cell responses were detected in arthritic mice (Hill et al, 2008). 
 
Various studies have reported the presence of anti-Sa antibodies in the sera of RA 
patients and the mean sensitivity of such antibodies for the disease is around 37% 
(Hueber et al, 1999; El-Gabalawy & Wilkins, 2004 and Vossenaar et al, 2004). 
However, the sensitivity of anti-Sa antibodies for RA varies with disease stage as the 
antibodies are more prevalent in patients with established disease than those with early 
disease (Hueber et al, 1999 and El-Gabalawy & Wilkins, 2004). Anti-Sa antibodies 
have been shown to be very rare in the sera of patients with other rheumatic diseases 
and were reported to be 98% specific for RA (Hueber et al, 1999). Anti-SA antibodies 
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recognise a 50 kDa protein found in human placenta and spleen and the synovial tissue 
of RA patients (Despres et al, 1994). The protein recognised by anti-Sa antibodies has 
been identified as vimentin and it is only recognised by anti-Sa antibodies when 
citrullinated (Vossenaar et al, 2004). A peptide derived from citrullinated vimentin was 
shown to induce DR-restricted T-cell responses in mice transgenic for the RA-
associated DR4(DRB1*0401) molecule (Hill et al, 2003). 
 
1.6. The role of citrullination in rheumatoid arthritis 
As a non-standard amino acid, citrulline is unavailable for incorporation into proteins 
during translation, yet it can be introduced into proteins or peptides by way of a post-
translational modification known as citrullination (Vossenaar, Zendman & van 
Venrooij, 2004). The citrullination reaction is catalysed by Ca
2+
-dependant peptidyl 
arginine deiminase (PAD) enzymes which deiminate protein or peptide-incorporated 
arginine, thus converting it to citrulline (Vossenaar & van Venrooij, 2004). Of the five 
known isotypes of PAD that have been identified in mammals, PAD2 and PAD4 are 
expressed by monocytes and macrophages in the synovial fluid (Vossenaar, Zendman & 
van Venrooij, 2004 and van Gaalen et al, 2005). Interestingly, antibodies specific for 
citrulline-containing epitopes of joint-associated autoantigens such as α-enolase, 
fibrinogen, filaggrin and vimentin are the most disease-specific autoantibodies detected 
in RA and are present in the sera of 60-70% of RA patients (van Gaalen et al, 2005). 
Furthermore, a certain haplotype of the PAD4-encoding PADI4 gene, which appears to 
confer enhanced stability of PADI4 mRNA, is known to be associated with RA in some 
ethnic groups (Vossenaar, Zendman & van Venrooij, 2004). Therefore it is possible that 
citrullination is an important post-translational modification in RA. 
 
When a protein is citrullinated there is a very slight change in its molecular weight and 
the positive charges associated with its arginine residues are substituted for the neutral 
charges of citrulline (van Venrooij & Pruijn, 2000). It is postulated that the 
citrullination-induced change in the charge of a protein may alter the way that it 
interacts with other proteins, either by abolishing existing charge interactions or 
enabling new ones to form (van Venrooij & Pruijn, 2000). Thus it is possible that the 
citrullination of peptides may allow them to bind to MHC molecules that in their 
unmodified form they were unable to bind, and thereby become visible to the immune 
system. Interestingly, residues 70-74 of an HLA-DR β-chain contributing to a complete 
HLA-DR molecule form the P4 peptide binding pocket of the molecule’s peptide 
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binding groove (Hill et al, 2003). Furthermore, the shared epitope sequences found at 
residues 70-74 in RA-associated HLA-DR β-chains possess overall positive charges by 
virtue of the positively-charged side chains on residues 70 and 71 (Hill et al, 2003). 
Therefore, shared epitope-containing HLA-DR molecules are proposed to favour 
peptides that have negative or neutral charges in the positions that anchor in the P4 
binding pocket (van Gaalen et al, 2005). Thus, as citrullination involves the conversion 
of positively-charged arginine to neutrally-charged citrulline, then it is possible that this 
post translational modification may alter the antigenicity and immunogenicity of self 
peptides in shared epitope-positive individuals and thereby initiate autoimmune 
responses (van Gaalen et al, 2005). Possession of the RA-associated PADI4 haplotype 
may be associated with increased expression of PAD4 which could in turn lead to 
increased citrullination of self proteins. Alternatively, smoking may also lead to 
increased citrullination of self proteins. Peptides derived from such citrullinated self 
proteins may then be preferentially bound by SE-positive HLA-DR molecules and may 
thus be presented to citrulline-specific T-cells which become activated and provide help 
for citrulline-specific B-cells so that they can produce ACPA (van Gaalen et al, 2005). 
Indeed, the production of anti-citrulline antibodies has been found to be strongly 
associated with the possession of shared epitope-containing HLA-DR molecules (van 
Gaalen et al, 2004) and citrulline-specific B-cells would require help from citrulline-
specific CD4
+
 T-cells in order to produce these antibodies. This suggests that shared 
epitope-positive HLA-DR molecules may indeed present citrullinated self peptides to 
antigen-specific CD4
+
 T-cells. In addition, several studies have shown how 
citrullination can enhance the antigenicity and immunogenicity of candidate 
autoantigen-derived peptides in shared epitope-positive individuals. Using a vimentin-
derived peptide that was predicted to bind DR4(DRB1*0401) molecules with one of its 
arginine residue anchored in the P4 binding pocket, Hill et al (2003) showed that the 
conversion of this arginine residue to citrulline greatly increased the affinity of the 
peptide for shared epitope-positive but not shared epitope-negative HLA-DR molecules. 
Furthermore, the citrullinated form of the peptide but not the unmodified form was 
shown to elicit DR-restricted T-cell responses in DR4(DRB1*0401) transgenic mice 
(Hill et al, 2003). Further studies by Hill et al (2008) showed that immunisation of 
DR4(DRB1*0401) transgenic mice with citrullinated but not unmodified fibrinogen 
induced an inflammatory arthritis in the mice in which citrulline-specific T-cell 
response were observed. In addition, the citrullinated form but not the unmodified form 
of a fibrinogen-derived peptide predicted to bind DR4(DRB1*0401) molecules with one 
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of its arginine residues anchored in the P4 pocket was shown to elicit DR-restricted T-
cell responses in the mice when citrullinated but not when unmodified (Hill et al, 2008). 
There is also evidence suggesting that the citrullination of two filaggrin-derived 
peptides alters the way in which they interact with MHC molecules as a number of 
human subjects responded to one form but not the other (Fritsch et al, 2002). More 
direct evidence for a role of citrullination in the pathogenesis of RA comes from the 
study of von Delwig et al (2010). Using unmodified and citrullinated forms of 
aggrecan84-103, the peptide identified as the immunodominant T-cell epitope in mice 
with proteoglycan-induced arthritis, the group identified citrulline-specific T-cell 
responses in RA patients but not healthy controls. While PBMC from healthy subjects 
showed no reactivity to either unmodified or citrullinated aggrecan84-103, the 
citrullinated form of the peptide but not the unmodified form induced proliferative 
PBMC responses in 60% of tested RA patients. The response to citrullinated aggrecan84-
103 was characterised by high levels of IL-17 production and an induction of IL-17
+
 
CD4
+
 T-cells (von Delwig et al, 2010). 
 
Recently, a new antibody system recognising proteins altered by another post-
translational modification has been demonstrated in RA by Shi et al (2011). The group 
identified antibodies specific for carbamylated peptides which contain homocitrulline in 
over 45% of RA patients. These so-called anti-CarP antibodies are distinct from ACPA 
and appear to be predictive of a more severe form of ACPA-negative RA. 
 
1.7. The importance of measuring T-cell responses to candidate autoantigens 
At present, the only parameters of RA that are measured in clinics are joint damage, 
measured via X-ray, and the presence of markers of inflammation which are both end 
results of the disease process. Modern RA therapies are aimed at modifying the disease 
process at an early stage and the induction of tolerance to autoantigens thought to be 
involved in disease pathogenesis is a major goal. Thus it is important to be able to 
measure candidate RA autoantigen-specific T-cell responses. 
 
1.8. Aims of project 
1.8.1. Specific aims of the project 
 To optimise an experimental system for the detection of candidate RA 
autoantigen-specific T-cell responses. 
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 To compare, both quantitatively and qualitatively, joint-associated, candidate 
RA autoantigen-specific T-cell responses in RA patients, healthy subjects and 
disease controls. 
 To investigate whether citrullination of candidate RA autoantigens alters their 
immunogenicity in RA patients versus healthy subjects/disease controls. 
 
1.9. Hypotheses 
 Candidate RA autoantigen-specific T-cell responses are significantly more 
prevalent in RA patients than in healthy subjects. 
 Candidate RA autoantigen-specific T-cell responses detected in RA patients are 
qualitatively different from those detected in healthy subjects, the former being 
pro-inflammatory in nature and the latter being immunosuppressive. 
 Immune responses to citrullinated candidate RA autoantigens are detected more 
frequently than immune responses to unmodified candidate RA autoantigens, 
but only in RA patients and not in healthy subjects. 
 The immune responses elicited by citrullinated candidate RA autoantigens are 
qualitatively different from those elicited by their unmodified counterparts, the 
former being more pro-inflammatory in nature and the latter being 
immunosuppressive. 
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 Description of methods 
Prevalence of positive responses / 
Observations 
V
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9
9
7
 PBMC from 18 RA patients and 11 HS were 
cultured in 10% autologous plasma-
supplemented medium with HCgp39-
derived peptides (103-116, 259-271, 263-275 or 326-
338 at 100, 25 or 10µg/ml). 
Proliferation in replicate wells (1.5x10
5
 
cells/well) was assessed after 7 days via 
3HTdR incorporation. 
SI values of 2 or greater were considered to 
represent positive responses. 
HCgp39-induced proliferative 
responses were detected in 56% of 
RA patients and 27% of HS. 
103-116, 263-275 and 326-338 induced 
proliferative responses in RA 
patients alone. 
263-275 was the most immunogenic 
peptide, inducing proliferative 
responses in over 40% of RA 
patients. 
C
o
p
e 
et
 a
l,
 1
9
9
9
 
PBMC from 8 SE 
+
ve RA patients, 6 SE 
+
ve 
HS and 9 SE 
-
ve HS were cultured in 15% 
autologous serum-supplemented medium 
with HCgp39-derived peptides (40-55, 100-115, 
197-211, 256-271, 262-277, 322-337 or 334-349 at 
10µg/ml). 
Proliferation in replicate wells (2x10
5
 
cells/well) was assessed after 6 days via 
3HTdR incorporation. 
SI values greater than 2 were considered to 
represent positive responses. 
Proliferative responses to the 
HCgp39-derived peptides were 
detected in SE 
+
ve individuals from 
both the RA patient and HS groups, 
but not in SE 
–
ve subjects. 
V
o
s 
et
 a
l 
#
2
, 
2
0
0
0
 
PBMC from 50 RA patients and 49 HS were 
cultured in 10% heat-inactivated autologous 
plasma-supplemented medium with 
HCgp39-derived peptides (75-87, 103-116, 259-
271, 263-275 or 362-338 at 10µg/ml). 
Proliferation in replicate wells (1.5x10
5
 
cells/well) was assessed after 7 days via 
3HTdR incorporation. 
SI values of 2 or greater were considered to 
represent positive responses. 
Proliferative responses to 
HCgp39259-271 were detected in 
36% of RA patients and 8% of HS. 
75-87, 263-275 and 326-338 induced 
proliferative responses in RA 
patients alone. 
103-116 induced proliferative 
responses in both RA patients and 
HS. 
Z
o
u
 e
t 
a
l,
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0
0
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 Peripheral blood from 22 RA patients and 20 
HS was stimulated with aggrecan G1 
domain, HCgp39 or CII (20µg/ml). 
After 6 hours, production of IL-10, IL-4, 
TNF-α and IFN-γ by CD4+ T-cells was 
determined via intracellular cytokine 
staining. 
55% of RA patients showed 
production of substantial levels of 
TNF-α and IFN-γ in response to 
aggrecan G1 domain, compared to 
10% of HS. 
HCgp39 and CII failed to induce 
production of substantial levels of 
TNF-α of IFN-γ in both groups. 
 
Table 1.1. Summary of previous studies investigating human cartilage glycoprotein 
39 (HCgp39)-induced responses. Zou et al, 2003 also investigated responses to type II 
collagen (CII) and aggrecan. Abbreviations; PBMC = peripheral blood mononuclear 
cells, SE = shared epitope, RA = rheumatoid arthritis, HS = healthy subjects, 3HTdR = 
3
H-thymidine, SI = stimulation index. 
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 Description of methods 
Prevalence of positive responses / 
Observations 
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9
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PBMC from 56 anti-CII antibody 
–
ve RA 
patients, 10 anti-CII antibody 
+
ve RA 
patients and 28 HS were cultured in 10% 
human AB serum-supplemented medium 
with CII (50µg/ml). 
Proliferation in replicate wells (5x10
5
 
cells/well) was assessed after 4, 6 and 8 
days via 3HTdR incorporation. 
SI values greater than 2 were considered 
to represent positive responses. 
CII-induced proliferative responses 
were observed in 5% of the anti-CII 
antibody 
–
ve RA patients, 50% of the 
anti-CII antibody 
+
ve RA patients and 
36% of the HS. 
The kinetics of the responses observed 
in RA patients were suggestive of 
recall responses while those observed 
in HS were suggestive of primary 
responses. 
K
im
 e
t 
a
l,
 1
9
9
9
 
PBMC from 106 RA patients and 34 HS 
were cultured in 10% foetal bovine 
serum-supplemented medium with 
bovine CII (40µg/ml) and/or a CII-
derived peptide (255-274 at 10µg/ml). 
Proliferation in replicate wells (1x10
5
 
CD3
+
 cells & 1x10
5
 irradiated CD3
-
 
cells/well) was assessed after 5 days via 
3HTdR incorporation. 
SI values of 2 or greater were considered 
to represent positive responses. 
Proliferative responses to bovine CII 
were detected in 35% of RA patients 
and 3% of HS. 
Proliferative responses to CII255-274 
were detected in 38% of RA patients 
and 12% of HS. 
P
a
rk
 e
t 
a
l,
 2
0
0
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PBMC and SFMC from 40 RA patients 
and PBMC from 39 HS were cultured in 
10% FBS-supplemented medium with 
bovine CII (40µg/ml). 
Proliferation in replicate wells (1x10
5
 
CD3
+
 cells & 1x10
5
 irradiated CD3
-
 
cells/well) was assessed after 5 days via 
3HTdR incorporation. 
SI values of 2 or greater were considered 
to represent positive responses. 
CII-induced proliferative responses 
were detected in the peripheral blood 
of 33% of RA patients and 3% of HS. 
CII-induced proliferative responses 
were increased in synovial fluid versus 
peripheral blood in RA patients (62% 
versus 33%). 
 
Table 1.2. Summary of previous studies investigating type II collagen (CII)-
induced responses. Abbreviations; PBMC = peripheral blood mononuclear cells, RA = 
rheumatoid arthritis, HS = healthy subjects, 3HTdR = 
3
H-thymidine, SI = stimulation 
index, SFMC = synovial fluid mononuclear cells. 
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 Description of methods 
Prevalence of positive responses / 
Observations 
G
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 PBMC from 48 RA patients and 32 HS were 
cultured in 10% heat-inactivated autologous 
serum-supplemented medium with 
deglycosylated human aggrecan (10µg/ml). 
Proliferation in replicate wells (1 or 2x10
5
 
cells/well) was assessed after 5 days via 
3HTdR incorporation. SI values greater than 
1.5 were considered to represent positive 
responses. 
Proliferative responses to 
deglycosylated aggrecan were 
observed in 69% of RA patients 
and 37% of HS. SI values of 
deglycosylated aggrecan-induced 
proliferation detected in RA 
patients were significantly greater 
than those detected in HS. 
B
o
o
ts
 e
t 
a
l,
 1
9
9
7
 
PBMC from 9 SE 
+
ve RA patients and 7 SE 
+
ve HS were cultured in 10% human AB 
serum-supplemented medium with a 
selection of human aggrecan-derived 
peptides (107-119, 201-213, 299-311, 623-635, 739-751, 
743-756, 954-966, 1777-1789 or 1805-1819 at 50, 5 or 
0.5µg/ml). Proliferation in replicate wells 
(1.5-2x10
5
 cells/well) was assessed after 7 
days via 3HTdR incorporation. SI values of 
3.5 or greater were considered to represent 
positive responses. 
Proliferative responses to the 
aggrecan-derived peptides were 
observed in both the RA patients 
and HS. The magnitudes of the 
aggrecan-derived peptide-induced 
responses and the numbers of 
aggrecan-derived peptide 
responders were decreased in RA 
patients versus HS (this was not 
due to RA patients being 
hyporesponsive). 
G
u
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v
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 PBMC from 43 RA patients and 13 HS were 
cultured in 10% heat-inactivated human AB 
serum-supplemented medium with either 
native or keratin sulphate-depleted bovine 
aggrecan G1 domain (25µg/ml). 
Proliferation in replicate wells (2-4x10
5
 
cells/well) was assessed after 5 days via 
3HTdR incorporation. 
SI values greater than 2 were considered to 
represent positive responses. 
Proliferation in response to native 
G1 domain was detected in 16% of 
RA patients but was absent in HS. 
Proliferative responses to keratin 
sulphate-depleted G1 domain were 
detected in 51% of RA patients and 
8% of HS. SI values of keratin 
sulphate-depleted G1 domain-
induced proliferation were 
significantly greater in RA patients 
than in HS. 
d
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PBMC from 60 RA patients and 32 HS were 
cultured in 10% human AB serum-
supplemented medium with aggrecan-
derived peptides (50µg/ml). 
Proliferation in replicate wells (2x10
5
 
cells/well) was assessed after 4 days via 
3HTdR incorporation. SI values greater than 
1.8 were considered to represent positive 
responses. Levels of IL-1, IL-2, IL-4, IL-6, 
IL-10, TNF-α and IFN-γ in culture 
supernatants harvested after 3 days were 
determined via electrochemiluminescence 
multiplex assay. 
Proliferative responses to several 
aggrecan-derived peptides were 
increased in the RA patients 
compared to the HS. 
Certain aggrecan-derived peptides 
induced higher levels of IL-1, IL-2, 
IL-6, IL-10 and TNF-α production 
in the RA patients than in the HS. 
 
Table 1.3. Summary of previous studies investigating aggrecan-induced responses. 
Abbreviations; PBMC = peripheral blood mononuclear cells, RA = rheumatoid arthritis, 
HS = healthy subjects, 3HTdR = 
3
H-thymidine, SI = stimulation index, SE = shared 
epitope. 
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 Description of methods 
Prevalence of positive responses / 
Observations 
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PBMC from 19 RA patients and 20 HS 
were cultured in serum-free medium with 
native and citrullinated forms of filaggrin-
derived peptides (2776-2793 or 3005-3022 at 
2.5µg/ml). 
Proliferation in replicate wells (1x10
5
 
cells/well) was assessed after 5 days via 
3HTdR incorporation. 
SI values of 2 or greater were considered 
to represent positive responses. 
Proliferative responses to both native 
and citrullinated forms of the 
peptides were observed in both RA 
patients and HS. 
A
u
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PBMC from 12 RA patients and 10 HS 
were cultured in 10% autologous serum at 
1x10
6
/ml with native and citrullinated 
forms of peptides derived from the α- and 
β-chains of fibrinogen. Proliferation was 
assessed after 7 days via 
bromodeoxyuridine incorporation. 
Optical density readings of 2x background 
or greater were considered to represent 
positive responses. 
Proliferation in response to both 
native and citrullinated forms of the 
fibrinogen-derived peptides was 
more common in RA patients than in 
HS. 18 of the α-chain-derived 
peptides and 27 of the β-chain-
derived peptides induced responses in 
RA patients compared to 2 of the α-
chain-derived peptides and 5 of the β-
chain-derived peptides in HS. 
v
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 PBMC from 28 RA patients and 18 HS 
were cultured in 5% human AB serum-
supplemented medium with either native 
or N terminal citrullinated forms of an 
aggrecan-derived peptide (84-103 at 
10µg/ml). Proliferation in replicate wells 
(2x10
5
 cells/well) was assessed after 9 
days via 3HTdR incorporation. SI values 
greater than 2 were considered to represent 
positive responses. 
Proliferative responses to N terminal 
citrullinated aggrecan84-103 were 
observed in over 60% of RA patients 
but were absent in HS. 
Non-citrullinated aggrecan84-103 failed 
to induce proliferative response in 
both the RA patients and the HS. 
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PBMC from 21 RA patients and 6 SE 
+
ve 
HS were cultured in 10% healthy serum-, 
autologous serum- or allogeneic RA donor 
serum-supplemented medium with either 
native or citrullinated forms of vimentin-, 
CII-, fibrinogen- and aggrecan-derived 
peptides at 3 or 30µg/ml. Proliferation in 
replicate wells (2x10
5
 cells/well) was 
assessed after 5 days via 3HTdR 
incorporation. 
Levels of IL-2, IL-4, IL-6, IL-10, IL-17, 
TNF-α and IFN-γ in culture supernatants 
harvested after 5 days were assessed via 
cytometric bead array. 
SI values of peptide-induced 
proliferation were very low (i.e. 
between 1 and 2) in both the RA 
patients and the HS. 
In the RA patients but not the HS, the 
SI values of citrullinated aggrecan-
derived peptide-induced proliferation 
were significantly greater than those 
of native aggrecan-derived peptide-
induced proliferation. 
The RA patients produced IL-6, IL-
10, IL-17, TNF-α and IFN-γ in 
response to the peptides while the HS 
produced IL-6, IL-17 and TNF-α. 
 
Table 1.4. Summary of previous studies investigating responses to citrullinated RA 
autoantigen-derived peptides. Abbreviations; PBMC = peripheral blood mononuclear 
cells, RA = rheumatoid arthritis, HS = healthy subjects, 3HTdR = 
3
H-thymidine, SI = 
stimulation index, SE = shared epitope, CII = type II collagen. 
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Chapter 2. Materials and methods 
 
2.1. Study subjects 
Subjects used in this study were healthy volunteers recruited from within the 
Musculoskeletal Research Group of the University of Newcastle upon Tyne, and 
patients attending rheumatology clinics at the Freeman Hospital, Newcastle upon Tyne. 
RA patients were identified in accordance with the American College of Rheumatology 
revised classification criteria for RA (1987), while patients with other autoimmune 
inflammatory rheumatic diagnoses served as disease controls. Tables 2.1-2.7 show the 
clinical details of RA patients and disease controls used in the different sections of the 
study. Peripheral venous blood samples were collected from subjects after informed 
consent. Research described in this thesis was approved by the Newcastle and North 
Tyneside Research Ethics Committee. 
 
2.2. Reagents and plastics 
2.2.1. Reagents for cell culture, separation and storage 
The following reagents were used: 
 Calcium (Ca)- and magnesium (Mg)-free Dulbecco’s Phosphate-Buffered Saline 
(DPBS) and Ca- and Mg-free Hank’s Balanced Salt Solution (HBSS) containing 
Phenol Red (Biowhittaker, Lonza, Verviers, Belgium). 
 Lymphoprep (Axis Shield, Oslo, Norway). 
 Dimethyl sulphoxide (DMSO) and RPMI 1640 containing sodium bicarbonate 
(NaHCO3) (Sigma-Aldrich, Gillingham, UK). 
 Foetal bovine serum (FBS) and pooled human AB serum (HABS) (PAA 
Laboratories, Pasching, Austria). 
 CellGro DC medium (CellGenix, Freiburg, Germany). 
Table 2.8 shows the details of other reagents used for cell culture.  
 
2.2.2. Cell culture stimuli 
Tables 2.9 and 2.10 show the details of the various mitogens, antigens and peptides used 
as cell stimuli. Phytohaemagglutinin (PHA) and lipopolysaccharide (LPS) were 
supplied as lyophilised powders and were reconstituted with RPMI 1640 to form stock 
solutions. All peptides were supplied as lyophilised powders and were reconstituted 
with sterile distilled water. DMSO was used as a solvent for certain peptides but at 
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concentrations no greater than 1%. For all stimuli, RPMI 1640 was used as a diluent to 
obtain the desired working dilutions. 
 
2.2.3. Reagents for flow cytometry 
The following reagents were used for flow cytometric analysis:  
Bovine serum albumin (BSA), sodium azide (NaN3) and paraformaldehyde (PFA) were 
all obtained from Sigma-Aldrich. Details of the fluorochrome-conjugated antibodies 
used are shown in Table 2.11. 
 
2.2.4. Reagents for measurement of cytokine production in culture supernatant 
The following reagents were used for the measurement of cytokine production in cell 
culture supernatants:  
(i) For Enzyme-linked Immunosorbent Assays (ELISA): 
Disodium hydrogen phosphate (Na2HPO4), sodium dihydrogen phosphate monohydrate 
(NaH2PO4H2O), sodium chloride (NaCl), Citric acid and disodium hydrogen phosphate 
dihydrate (Na2HPO42H2O) were all obtained from Fisher Scientific, Loughborough, 
UK. Tween-20, hydrogen peroxide (H2O2), o-phenylenediamine dihydrochloride (OPD) 
tablets (15mg substrate/tablet) and concentrated sulphuric acid (H2SO4) were all 
obtained from Sigma-Aldrich.  
(ii) For Electrochemiluminescence (ECL) Multiplex: 
All reagents and materials were supplied by Meso Scale Discovery, Gaithersberg, 
Maryland, USA.  
Table 2.12 shows details of additional cytokine detection reagents while Table 2.13 
shows details of cytokine detection antibodies.   
 
2.2.5. Plastics 
The following were obtained from Greiner Bio-One, Stonehouse, UK: 
 EDTA-containing and gel clot activator-containing specimen tubes. 
 5ml capacity bijou tubes. 
 30ml capacity universal tubes. 
 15ml and 50ml capacity centrifuge tubes. 
 3ml Pasteur pipettes. 
The following were obtained from Corning Costar, Cambridge, Massachusetts, USA: 
 5ml, 10ml and 25ml capacity serological pipettes. 
 1ml capacity cryovials. 
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 Round-bottom 96-well tissue culture plates. 
 Flat-bottom 96-well tissue culture plates. 
 24-well tissue culture plates. 
 48-well tissue culture plates. 
 Flat-bottom high-bind 96-well ELISA plates. 
 
The following were obtained from BD Falcon, Oxford, UK: 
 Fluorescence-activated cell sorting (FACS) tubes. 
 100µm cell strainers. 
 
The following were obtained from Starlab, Milton Keynes, UK: 
 Eppendorf tubes. 
 Repeater pipette tips in various sizes. 
 
0.2µm vacuum filter units were obtained from Millipore, Watford, UK.  
 
2.3. Cell culture techniques 
2.3.1. Media and conditions 
RPMI 1640 supplemented with 2mM L-glutamine, Penicillin-Streptomycin solution 
(100 units/ml & 100µg/ml respectively), 10mM HEPES and 50µM 2-Mercaptoethanol 
was used as culture medium. In addition, autologous serum (AS) at 5% was added to the 
culture medium unless stated otherwise. Cells were cultured at 37ºC in a humidified 
atmosphere containing 95% air and 5% carbon dioxide.  
 
2.3.2. Isolation of peripheral blood mononuclear cells (PBMC) 
Ethylenedinitrilo tetraacetic acid (EDTA)-treated peripheral blood samples were diluted 
1:1 (volume:volume) with DPBS and layered onto lymphoprep and centrifuged at 895g 
with slow acceleration and deceleration for 30 minutes at room temperature. PBMC 
were collected from the interface of the two liquid layers (lymphoprep at the bottom and 
the diluted plasma at the top), washed twice in DPBS and resuspended for counting in 
RPMI 1640 containing 1% FBS. Viable PBMC were counted using a Neubauer 
haemocytometer and non-viable cells were excluded based on positive staining with 
Trypan Blue (Sigma-Aldrich). 
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2.3.3. Serum isolation 
Peripheral blood samples collected into gel-based clot activator-containing tubes were 
subjected to centrifugation at 1800g for 10 minutes at room temperature. At the end of 
the centrifugation, clot (bottom layer) and serum (top layer) were separated by the gel 
layer and the serum was collected. Serum samples were either used immediately as a 
culture medium supplement as described in 2.3.1 or were stored at -20ºC. 
 
2.3.4. Immunomagnetic isolation of CD14
+
 and CD3
+
 PBMC   
CD3 and CD14 MACS® MicroBeads, MACS® LS separation columns and a 
VarioMACS® separator magnet (all obtained from Miltenyi Biotec, Surrey, UK) were 
used for all cell subsets isolations. MACS® buffer solution was prepared by 
supplementing DPBS with 0.5% FBS and 2mM EDTA and was used ice-cold after 
filtration through a 0.2µm membrane. Isolation of CD14
+
 and CD3
+
 PBMC was carried 
out according to manufacturer’s protocol. In brief, suspensions of 5x107-1x108 PBMC 
in 50ml ice-cold 1% FBS/HBSS were filtered through a 100µm cell strainer. PBMC 
were then centrifuged at 400g for 5 minutes and resuspended in 800µl MACS® buffer 
solution. 100µl of human CD14 MicroBeads were added prior to 20 minutes incubation 
on ice with gentle resuspension at 5 minute intervals. Cells were then washed and 
resuspended in 500µl of MACS® buffer solution before being added to a MACS® 
column (pre-rinsed with 3ml MACS® buffer solution) mounted on a MACS® separator 
magnet. Cells bound to the CD14 MicroBeads (CD14
+
 fraction) were retained in the 
column and flow-through cells (CD14
-
 fraction) were collected. The column was 
washed thrice, removed from the separator magnet and placed over a collection tube. 
Column-bound CD14
+
 cells were recovered by flushing the column with 7ml MACS® 
buffer solution under gentle pressure using a plastic plunger. CD14
+
 PBMC were then 
centrifuged at 400g for 5 minutes, resuspended in MACS® buffer solution and kept on 
ice until use. The CD14
-
 flow-through cells were washed in MACS® buffer solution 
and resuspended in 800µl MACS® buffer solution. 100µl human CD3 MicroBeads 
were then added and the cells were incubated on ice for 20 minutes. At the end of the 
incubation period, the cells were washed and resuspended in 500µl MACS® buffer 
solution. CD3
+
 cells (cells bound to the CD3 MicroBeads) were then positively selected 
with a fresh, pre-rinsed MACS® column as described earlier for the isolation of CD14
+
 
cells. The number of viable CD3
+
 PBMC was enumerated using Trypan Blue and a 
Neubauer haemocytometer as described earlier prior to cryopreservation at -80ºC for 7 
days until use in co-culture experiments. Purities of CD14
+
 and CD3
+
 fractions were 
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assessed in 4 separate isolations and the mean percentage purities of these fractions (± 
SEM) were 96 (± 1) and 97 (± 2) respectively. 
 
2.3.5. PBMC cryopreservation 
Un-separated or CD3
+
 PBMC were resuspended in an ice-cold freezing medium 
comprising 10% DMSO/90% FBS (volume:volume) at 2x10
7
 cells/ml. 1ml aliquots 
were transferred to ice-cold cryovials which were then placed in a Mr Frosty 
cryopreserver (Nalgene, Thermo Fisher Scientific, Loughborough, UK) at -80ºC to 
allow controlled lowering of temperature at approximately 1ºC/minute. Cryogenically 
preserved cells were kept at -80ºC for the duration of storage.  
For use in experiments, frozen aliquots of cells were partially thawed by immersion in a 
water bath at 37ºC for 1 minute and diluted immediately with 20ml warm 1% FBS-
supplemented RPMI 1640. Thawed PBMC were washed twice in 1% FBS-
supplemented RPMI 1640 and viable PBMC (counted as described in 2.3.2) were 
resuspended in culture medium at 1x10
6
/ml. The mean percentage (± SEM) of viable 
cells recovered from cryopreserved aliquots of un-separated PBMC (n=6) was 49 (± 3). 
The mean percentage (± SEM) of viable cells recovered from cryopreserved aliquots of 
CD3
+
 PBMC (n=9) was 64 (± 4). 
 
2.3.6. Monocyte-derived dendritic cells (mo-DC) 
Freshly-isolated CD14
+
 PBMC were cultured in CellGro DC medium supplemented 
with Penicillin-Streptomycin solution (100 units/ml & 100µg/ml respectively) in 24-
well plates (0.5x10
6
 cells/well in a volume of 1ml) with IL-4 and granulocyte-
macrophage colony-stimulating factor (GM-CSF) each at 50ng/well. After 3 days, 
450µl of supernatant were removed from each well and replaced with 500µl of 
Penicillin-Streptomycin solution-supplemented CellGro DC medium containing 
100ng/ml IL-4 and GM-CSF. After 6 days, loading of mo-DC with antigen was 
achieved by addition of PPD (1µg/ml) or test antigens (see Table 2.9 for concentrations) 
to appropriate cultures of mo-DC. At the same time-point, maturation of mo-DC, where 
required, was achieved through addition of LPS (0.1µg/ml) to cultures of mo-DC. After 
7 days, mo-DC were harvested. Briefly, plates of mo-DC were incubated on ice for 1 
hour in order to loosen the cells from the plastic, then cells were harvested through 
gentle scraping and pipetting motion and transferred to centrifuge tubes. Each well was 
rinsed with a 1ml volume of ice-cold 1% FBS/HBSS which was then added to the mo-
DC in the centrifuge tubes and cells were washed 4 times at 4ºC in 1% FBS/HBSS then 
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resuspended in 500µl culture medium. Cells were counted using a Neubauer 
haemocytometer and non-viable cells were excluded based on positive staining with 
Trypan Blue. Suspensions of mo-DC were made up to the required concentration by 
addition of culture medium. 
 
2.3.7. Cell labelling with carboxyfluorescein succinimidyl ester (CFSE) 
PBMC were washed once in 0.1% FBS-supplemented DPBS and resuspended in 0.1% 
FBS-supplemented DPBS at 1x10
7 
cells/ml. The cells were then incubated with an equal 
volume of 2µM CFSE in DPBS for 5 minutes at 37ºC. CFSE labelling was terminated 
by adding 5ml of ice-cold 10% FBS-supplemented RPMI 1640 and incubating the cells 
on ice for 5 minutes. The cells were than washed once in 10% FBS-supplemented RPMI 
1640 and resuspended in culture medium at 1x10
6
/ml. 
 
2.3.8. Assessment of cellular proliferation using 
3
H-thymidine (3HTdR) incorporation 
Several different approaches were used in this study. In the first (triplicate culture) 
approach, PBMC at 1x10
6
 cells/ml were cultured in triplicates in round-bottom 96-well 
plates (2x10
5
 cells/well, 200µl) with or without PHA (5µg/ml), tuberculin purified 
protein derivative (PPD, 1µg/ml) or test antigens/peptides (see Table 2.9 for 
concentrations). In the second (bulk culture) approach, PBMC at 1x10
6
 cells/ml were 
cultured in 24-well plates (2x10
6
 cells/well, 2ml) with or without PHA, PPD or test 
antigens as described earlier. At the start of the final 20 hours of the culture period, the 
cells were resuspended in the well with a pipette and transferred in triplicate to round-
bottom 96-well plates (2x10
5
 cells/well, 200µl). Remaining cells were discarded. In the 
third (T-cell:mo-DC co-culture) approach, antigen-loaded mo-DC at varying 
concentrations were co-cultured with CD3
+
 PBMC at 1x10
6
 cells/ml in 5% AS-
supplemented RPMI 1640 in triplicates in round-bottom 96-well plates (200µl/well). 
Mo-DC without antigen-loading were used as negative controls.  
For all 3 approaches, 3HTdR (20µl/well, 11 kBq) was added 20 hours prior to the end 
of the culture period. Cells were harvested using a semi-automated harvester onto filter 
papers which trapped the deoxyribonucleic acid (DNA) of the lysed cells. 3HTdR 
incorporation into the DNA of proliferating cells was quantified using a Microbeta 
TriLux scintillation counter (Perkin Elmer, Emeryville, California, USA). All data are 
expressed as either counts per minute (cpm) readings or as stimulation index (SI) values 
defined as mean cpm reading of the test (mitogen/antigen/peptide-stimulated) culture 
wells divided by the mean cpm value of the negative control (unstimulated) culture 
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wells. SI values of 2 or greater were considered to represent positive proliferative 
responses. Peak SI values of proliferation highlighted in red in data tables represent 
positive responses. 
 
2.3.9. Assessment of cellular proliferation using CFSE dilution 
CFSE-labelled PBMC at 1x10
6
 cells/ml were cultured in 48-well plates (1x10
6
 
cells/well, 1ml) with or without PHA, PPD or test antigens. Unlabelled PBMC cultured 
in the same conditions were used as controls as well as for determination of the 
appropriate compensation settings for flow cytometric analysis. Culture plates were 
wrapped in aluminium foil to protect from light exposure. At the end of the culture 
period, cells were stained with appropriate fluorochrome-conjugated antibodies before 
being analysed with a flow cytometer as described in 2.4. 
For staining with fluorochrome-conjugated antibodies, CFSE-labelled and unlabelled 
PBMC were transferred to FACS tubes, washed in FACS buffer (DPBS supplemented 
with BSA at 1% and NaN3 at 0.05%), and resuspended in 80µl of FACS buffer. 
Fluorochrome-conjugated antibodies at pre-determined optimal dilutions (Table 2.11) 
were added and the cells were incubated on ice for 30 minutes. Cells were then washed 
twice in FACS buffer and resuspended in 200µl of FACS buffer. The cells were fixed 
by adding 200µl of a solution of 2% PFA in DPBS to minimise internalisation of bound 
antibodies and stored at 4ºC until analysis with a flow cytometer. All data are expressed 
as either percentages of CFSE
dim
 cells or as SI values defined as the percentage of 
CFSE
dim
 cells in the test culture well divided by the percentage of CFSE
dim
 cells in the 
negative control culture well. Antigen-induced increases in the percentages of CFSE
dim
 
cells of 0.1% or greater and SI values of 2 or greater were considered to represent 
positive proliferative responses and are highlighted in red in data tables. 
 
The original population of cells labelled with CFSE have a CFSE
bright
 phenotype 
(population ‘0’ in Figure 2.1). When CFSEbright cells undergo division, the CFSE 
contained within them is split evenly between progeny cells therefore division generates 
a population with a CFSE fluorescence intensity 2-fold less than the original population. 
Successive rounds of proliferation produce populations with ever-decreasing CFSE 
fluorescence intensities (populations 1-4 in Figure 2.1). Thus the appearance of CFSE
dim
 
cells signifies proliferation and comparing the percentage/number of CFSE
dim
 cells in an 
antigen-stimulated culture with that in an unstimulated culture with, for example, a 
stimulation index calculation, as described above, allows quantification of antigen-
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specific proliferation. However, the CFSE dilution assay can also provide qualitative 
information about the proliferative response, specifically whether the CFSE
dim
 cells are 
a result of many CFSE
bright
 cells undergoing few rounds of division or of fewer 
CFSE
bright
 cells undergoing a greater number of divisions. Therefore, in comparison 
with 3HTdR incorporation data, expressing the CFSE data as stimulation index values is 
less appropriate. For example, if 50 CFSE
dim
 cells were detected in an unstimulated 
sample of CFSE-labelled cells and 640 CFSE
dim
 cells were detected in the stimulated 
sample, then the SI value of the stimulated cells would be 12.8. However, this SI value 
gives no indication as to the quality of the stimulus-specific proliferative response; 640 
CFSE
dim
 cells could results from 160 CFSE
bright
 cells undergoing 2 rounds of division 
(160 > 320 > 640) or from 10 CFSE
bright
 cells undergoing 6 rounds of division (10 > 20 
> 40 > 80 > 160 > 320 > 640). Indeed, it should technically be possible to determine the 
precursor frequency of antigen-specific cells within a CFSE
bright
 population that 
produced a total population of CFSE
dim
 cells. However, while preliminary work with 
proliferation modelling software showed that this could be achieved to some extent 
when analysing mitogen-induced proliferative responses in which distinct populations 
were observed, it was not possible when measuring antigen-specific responses because 
the number of cells that had undergone cell division were too few for reliable modelling 
using the software. Therefore SI values were used as a simple quantification of 
proliferation. To account for small variations in the numbers of cells analysed from 
different cultures in my CFSE experiments, SI values were calculated based on the 
percentage of CFSE
dim
 cells and not the raw numbers. 
 
2.4. Flow cytometric analysis 
All flow cytometric analyses were performed using a flow cytometer (LSR II, Becton 
Dickinson, New Jersey, USA) equipped with FACSDiva software (Becton Dickinson). 
Acquisition thresholds based on forward scatter (FSC) and side scatter (SSC) 
characteristics were set using samples of unlabelled, unstimulated PBMC. 
Compensation was set prior to acquisition using samples of single-fluorochrome-
labelled PBMC. Further adjustments in compensation were made if necessary using 
FACSDiva software after acquisition of data. For the estimation of the precursor 
frequencies of proliferating cells and other parameters of proliferation kinetics, the data 
were analysed using the Proliferation Platform of FlowJo version 8.7.1 software 
(Treestar Software, San Carlos, California, USA). 
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2.5. Quantification of cytokine production in culture supernatant 
Supernatant samples were collected from cultures of unlabelled cells and stored in 
round-bottom 96-well plates at -20ºC until analysis for cytokine content. When using 
the triplicate culture or T-cell:mo-DC co-culture approaches, 50µl supernatant samples 
were collected from each of the wells in triplicate cultures prior to addition of 3HTdR 
and stored in pooled 150µl volumes. When using the bulk culture approach, 150µl 
supernatant samples were collected from individual bulk cultures prior to resuspension 
of the cells. Frozen supernatant samples were thawed for 1 hour at room temperature 
prior to analysis, and samples were discarded after undergoing 2 freeze/thaw cycles. 
 
My choice of cytokines to quantify production of was based on both previous literature 
and preliminary work. As discussed in chapter 1, the importance of IL-17, IL-6 and 
TNF-α in the pathogenesis of RA is well documented, therefore it was essential that I 
assayed for the production of these cytokines. While IL-2 and IFN-γ are considered 
classical T-cell cytokines, the paucity of these cytokines in the RA synovium - 
discussed in chapter 1 - suggested that they may not be the most useful cytokines to 
assay for. However, a previously mentioned study (van Bilsen et al, 2004) described 
how opposing IFN-γ/IL-10 balances distinguished RA patients from healthy subjects in 
their responses to HCgp39. Therefore I chose to quantify the production of IFN-γ along 
with IL-10, anticipating that production of immunosuppressive IL-10 may be 
characteristic of healthy subjects as opposed to RA patients (Feldman et al, 1996 and 
McInnes & Schett, 2007). Preliminary work showed that IL-4 production was observed 
in response to certain candidate autoantigens so this was another cytokine of interest. 
 
2.5.1. Electrochemiluminescence (ECL) multiplex analysis 
The levels of IL-10, IL-17, IL-4, IL-6 and TNF-α in cell culture supernatants were 
measured via electrochemiluminescence using customized Human MULTI-SPOT 96-
Well–7 Spot kits from Meso Scale Discovery according to the manufacturer’s 
instructions. In brief, all incubations were performed at room temperature with shaking 
at 500rpm. Prior to use, plates were incubated for 30 minutes with 10% FBS-
supplemented RPMI 1640 at 25µl/well. For each plate, six serial dilutions (4-fold) of 
cytokine standards of known concentrations (highest concentration for each cytokine 
was 10,000 pg/ml), and a ‘’blank’’ sample, all in duplicate, were included for the 
construction of cytokine standard curves. 10% FBS-supplemented RPMI 1640 was used 
as diluent. DPBS supplemented with Tween-20 at 0.05% served as a wash buffer and 
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was used at a volume of 200µl/well. Detection antibody mixture at 50µg/ml was diluted 
1/50 with ‘’antibody diluent’’ prior to use. ‘’Read buffer T 4X’’ was diluted 2-fold with 
dH2O before use. For each assay, 25µl/well of test sample were added to the plates. 
After 4 hours of incubation, the plates were washed 3 times, detection antibody mixture 
was added at 25µl/well and the plates were incubated for a further 2 hours. The plates 
were then washed 3 times, ‘’read buffer’’ was added at 150µl/well and plates were read 
using a Sector Imager 2400 (Meso Scale Discovery). Plates were analysed and cytokine 
concentrations in test samples were estimated using MSD Workbench software (Meso 
Scale Discovery). Data were analysed using different approaches; raw pg/ml values, 
absolute ‘pg/ml minus background’ values defined as pg/ml value of supernatant from 
test culture well minus pg/ml value of supernatant from negative control culture well, or 
as SI values defined as pg/ml value of supernatant from test culture well divided by 
pg/ml value of supernatant from negative control culture well. The lower limits of 
detection for IL-10, IL-17, IL-4, IL-6 and TNF-α were defined by Meso Scale 
Discovery as 2.5 standard deviations above ‘’blank’’ well/background value and mean 
(± SEM) values from seventeen assays were 1.5 (± 0.5), 1.8 (± 0.2), 1.4 (± 0.5), 1.4 (± 
0.6) and 1.3 (± 0.4) respectively. Therefore, raw or absolute values of IL-10, IL-17, IL-
4, IL-6 or TNF-α production of 2pg/ml or greater were considered to represent positive 
responses. IL-10, IL-17, IL-4, IL-6 or TNF-α production values highlighted in red in 
data tables represent positive responses. IL-10, IL-17, IL-4, IL-6 or TNF-α production 
values below the threshold level of detection are represented as ‘0’ in data tables. SI 
values of 2 or greater were considered to represent positive responses. 
 
2.5.2. Enzyme-linked immunosorbent assay (ELISA) analysis 
The levels of IFN-γ and IL-6 in cell culture supernatants were measured using ELISA. 
All assays were performed using high-bind 96-well plates. Coating buffer consisted of 
4.35g Na2HPO4 and 5.37g NaH2PO4H2O in 500ml dH2O. 10X PBS consisted of 163.5g 
NaCl, 24.2g Na2HPO4 and 4.4g NaH2PO4H2O in 2L dH2O and was diluted 1/9 in dH2O 
prior to use. Citrate phosphate buffer consisted of 2.55g Citric acid, 3.66g Na2HPO4 and 
4.58g Na2HPO42H2O in 500ml dH2O. PBS containing Tween-20 at 0.1% was used as a 
wash buffer in which plates were washed by submersion. Wash buffer supplemented 
with BSA at 1% was used as both a blocking solution and as a diluent for all dilutions 
unless otherwise stated. For each plate, 9 serial 2-fold dilutions in duplicates of cytokine 
standards of known concentrations (highest concentration for each cytokine was 
2,000pg/ml), and a ‘’blank’’ sample also in duplicate containing diluent only were 
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included for construction of cytokine standard curves. OPD tablets were each dissolved 
in 13ml citrate phosphate buffer to produce substrate solution and 6µl of H2O2 were 
added to each 13ml volume immediately prior to use.  
To all ELISA plates, purified IFN-γ or IL-6 capture antibody (Table 2.13) diluted to 
1µg/ml in coating buffer was added at 50µl/well and incubated overnight at 4ºC. Plates 
were washed once, followed by incubation for 2 hours at room temperature with 
blocking solution at 100µl/well. Plates were washed 4 times prior to addition of 
standards, blanks and test samples, all in duplicates at 50µl/well, and incubated 
overnight at 4ºC. Plates were washed 4 times, corresponding biotinylated detection 
antibody (Table 2.13) diluted to 1µg/ml was then added at 50µl/well and plates were 
incubated for 1 hour at room temperature. Plates were washed 4 times, Streptavidin-
horse radish peroxidase (HRP) solution diluted to 1µg/ml was added at 50µl/well and 
plates were incubated for 30 minutes at room temperature. Plates were washed 5 times 
and substrate solution was added at 50µl/well. Reactions were terminated by addition of 
3M H2SO4 at 50µl/well and the optical density of the solution in each well was read 
spectrophotometrically at 490nm using a Sunrise microplate absorbance reader (Tecan, 
Switzerland). Levels of IFN-γ or IL-6 in test samples were estimated using the linear 
regression function of GraphPad Prism version 5.01 (GraphPad Software, San Diego, 
California, USA) which used the cytokine standard curve to interpolate the 
concentrations of unknown samples. Data were analysed as described in 2.5.1. The 
lower limit of detection for IFN-γ was 5pg/ml. IFN-γ production values highlighted in 
red in data tables represent positive responses. IFN-γ production values below the 
threshold level of detection are represented as ‘0’ in data tables. SI values of 2 or greater 
were considered to represent positive responses. 
 
2.6. Limulus amoebocyte lysate (LAL) endotoxin detection assay 
The levels of bacterial endotoxin in protein or peptide preparations were assessed 
quantitatively using chromogenic LAL assays. All assays were carried out in sterile flat-
bottom 96-well plates pre-warmed to 37ºC and used QCL-1000 LAL kits (Lonza, 
Walkersville, Maryland, USA). All incubations were carried out at 37ºC in a humidified 
environment containing 95% air and 5% CO2. Briefly, vials of lyophilised E. coli 
endotoxin, chromogenic substrate and LAL were reconstituted according to the 
manufacturer’s protocol using LAL reagent water (all reagents were supplied with the 
kit). Solutions containing 1, 0.5, 0.25 and 0.1EU of endotoxin per ml were prepared for 
the construction of the endotoxin standard curve. Test samples and endotoxin standards 
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were added to plates in duplicates at 25µl/well. LAL reagent water was used as a 
negative control. Equal volumes of LAL were added to the wells and the plates were 
incubated for 16 minutes. 50µl chromogenic substrate pre-warmed to 37ºC, were added 
to each of the wells and plates were incubated for a further 6 minutes. Reactions were 
terminated by addition of 50µl/well of a solution of 25% glacial acetic acid (BDH 
Prolabo, VWR, Lutterworth, UK) in dH2O, and the optical density of the solution in 
each well was read at 405nm using a Sunrise microplate absorbance reader (Tecan). 
Levels of endotoxin in test samples were estimated using the linear regression function 
of GraphPad Prism version 5.01 which used the endotoxin standard curve to interpolate 
the endotoxin content of unknown samples. 10EU/ml equates to approximately 1ng/ml 
of endotoxin. 
 
2.7. Removal of endotoxin from contaminated protein/peptide samples 
Bacterial endotoxin was removed from stock preparations of LPS-contaminated 
DeglyAgg/CEP-1 using a Proteospin Endotoxin Removal Micro kit (Norgen, Geneflow, 
Staffordshire, UK) in accordance with the manufacturer’s protocol. The kit included 
spin columns, collection tubes, column activation & wash buffer, binding buffer, 
endotoxin removal solution, neutraliser, elution tubes and elution buffer. Briefly, a 
sample of LPS-contaminated protein or peptide preparation of up to 150µg was made up 
to a volume of 450µl with dH2O and mixed with 20µl of binding buffer. The resulting 
solution was loaded onto one of the provided spin columns (pre-rinsed and centrifuged 
for 1 minute at 14,000g with two 500µl volumes of column activation & wash buffer), 
mixed with a 1% volume of endotoxin removal solution and incubated for 5 minutes at 
room temperature. A 10% volume of isopropanol (Fisher Scientific) was then added to 
the column which was then centrifuged for 1 minute at 14,000g and the flow-through 
was discarded. Column-bound protein/peptide was washed with two 500µl volumes of 
column activation & wash buffer. The column was then inserted into an elution tube 
containing 9.3µl of neutraliser and clean protein/peptide was eluted from the column 
into the elution tube by addition of two 50µl volumes of elution buffer. According to the 
data provided by the manufacturer, 95% of a protein/peptide sample can be recovered 
after the endotoxin removal process. The eluted protein/peptide samples were made up 
to 1mg/ml by further dilution with elution buffer based on a 95% recovery rate. Actual 
concentrations of endotoxin-free protein/peptide samples were determined by the 
Bradford protein assay (see 2.8).   
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2.8. Bradford protein assay  
Bradford reagent (Sigma-Aldrich) was diluted 1:1 (volume:volume) in sterile nanopure 
water prior to use. For creation of standard protein/peptide solutions of 2, 4, 6, 8 and 
10µg/ml, 2, 4, 6, 8 and 10µl volumes of a 1mg/ml BSA solution in sterile Nanopure 
water were added to eppendorf tubes each containing 1ml Bradford reagent and 
solutions were mixed by vortexing. Bradford reagent alone served as a blank. As a 
positive control, 5µl of a 1mg/ml solution of CEP-1 (pre-endotoxin removal hence 5µg) 
were added to a 1ml volume of Bradford reagent and the solution was mixed by 
vortexing. For the test sample, 5µl of a solution of CEP-1 *clean* (post-endotoxin 
removal but concentration adjusted to 1mg/ml) peptide were added to a 1ml volume of 
Bradford reagent and solution was mixed by vortexing. After 10 minutes of incubation 
at room temperature, the standard solutions, the blank and the positive control and test 
sample solutions were added to a flat-bottom 96-well plate in duplicates at 100µl/well 
and absorbance was read at 595nm using a Sunrise microplate absorbance reader 
(Tecan). Levels of protein/peptide in test samples were estimated using the linear 
regression function of GraphPad Prism version 5.01 which used the protein standard 
curve to interpolate the concentrations of unknown samples. 
 
2.9. Statistical analysis 
Statistical analysis, which included descriptive statistics, linear regression, Chi-square 
tests, Mann-Whitney tests and paired t tests, were performed using GraphPad Prism 
version 5.01. P values of less than 0.05 were considered statistically significant. 
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ID Sex Age RF/CCP CRP/ESR 
Year of 
diagnosis 
Medication 
RA 4.1 F 56 Pos/ND 9/34 2000 SSZ 
RA 4.2 M 65 Pos/ND 64/54 
>15 years 
ago 
MTX/ETA 
RA 4.3 F 36 ND/ND ND/8 2001 SSZ 
RA 4.4 F 64 ND/ND 5/40 
>15 years 
ago 
MTX 
RA 4.5 M 60 Neg/ND 6/10 2007 MTX 
RA 4.6 F 45 Pos/Neg 11/38 2008 MTX 
RA 4.7 F 57 Pos/ND ND/20 2001 ADA 
RA 4.8 M 75 ND/ND ND/4 
>15 years 
ago 
Gold 
RA 4.9 F 50 Pos/Pos ND/12 2002 SSZ 
RA 4.10 F 42 Pos/Pos ND/31 2007 MTX 
RA 4.11 F 43 Pos/Pos 8/ND 2008 None 
RA 4.12 F 55 Pos/ND ND/36 
>15 years 
ago 
MTX/ETA 
RA 4.13 M 56 Pos/ND ND/2 2002 MTX 
RA 4.14 M 76 Neg/Neg 5/48 2002 SSZ 
RA 4.15 F 27 Neg/Neg ND/10 2008 MTX 
 
Table 2.1. Clinical details of RA patients tested in the HCgp39 and CFSE 
experiments described in 4.2.1. Abbreviations; F = female, M = male, RF = 
rheumatoid factor, CCP = cyclic citrullinated peptide antibody, Pos = positive, ND = no 
data, Neg = negative, CRP = C-reactive protein, ESR = erythrocyte sedimentation rate, 
Many years ago = pre 1995, ADA = Adalimumab, ETA = Etanercept, MTX = 
Methotrexate, SSZ = Sulfasalazine. 
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ID Sex Age RF/CCP CRP/ESR 
Year of 
diagnosis 
Medication 
RA 4.16 F 68 Pos/Pos <5/10 
>15 years 
ago 
LEF 
RA 4.17 F 73 Pos/ND 14/66 
>15 years 
ago 
MTX 
(previous 
RTX) 
RA 4.18 F 59 ND/ND 11/36 
>15 years 
ago 
MTX+ETA 
RA 4.19 F 49 ND/ND <5/30 2007 MTX 
RA 4.20
1
 F 81 Pos/ND 20/46 2000 LEF 
RA 4.21
2
 F 65 Pos/Pos ND/12 
>10 years 
ago 
SSZ 
RA 4.22
3
 M 64 ND/ND 9/66 
>12 years 
ago 
ETA 
RA 4.23
4
 F 82 Pos/Pos ND/28 2007 MTX 
RA 4.24
5
 F 35 Pos/Pos ND/12 2009 
None, to 
start MTX 
 
Table 2.2. Clinical details of RA patients tested in the bulk culture 3HTdR 
incorporation experiments described in 4.2.2. Abbreviations; F = female, M = male, 
RF = rheumatoid factor, CCP = cyclic citrullinated peptide antibody, Pos = positive, ND 
= no data, CRP = C-reactive protein, ESR = erythrocyte sedimentation rate, Many years 
ago = pre 1995, ETA = Etanercept, LEF = Leflunomide, MTX = Methotrexate, RTX = 
Rituximab, SSZ = Sulfasalazine. Patients with a superscripted number following their 
ID (
1, 2, 3, 4 & 5
) were those also tested in the experiments described in 4.2.3. 
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ID Sex Age RF/CCP CRP/ESR 
Year of 
diagnosis 
Medication 
RA 4.25 F 77 Pos/Pos 20/50 2008 MTX 
RA 4.26 M 47 Pos/Pos 7/34 2007 SSZ+HCQ 
RA 4.27 F 67 ND/ND 11/40 2007 LEF 
RA 4.28 F 46 Pos/Pos ND/22 2008 
None, to 
start MTX 
RA 4.29 M 77 Pos/Pos ND/28 2007 MTX 
RA 4.30 F 60 ND/ND 5/22 
>12 years 
ago 
 anti-TNF 
RA 4.31 F 57 Neg/ND 17/34 2006 MTX+SSZ 
RA 4.32 F 47 Pos/Pos 13/30 2006 SSZ 
RA 4.33 F 52 Pos/Pos 10/56 2007 None 
RA 4.34 F 50 Neg/Neg 34/32 2006 SSZ 
RA 4.35 M 32 Neg/ND 9/6 2003 MTX 
RA 4.36 F 55 ND/ND 5/18 
>12 years 
ago 
MTX 
RA 4.37 F 65 Pos/ND ND/14 2001 MTX 
RA 4.38 F 36 Neg/Pos ND/24 2008 MTX 
RA 4.39 F 64 Pos/Pos ND/52 2008 MTX 
RA 4.40 F 49 Pos/Pos ND/12 2007 MTX 
RA 4.41 F 52 Pos/ND ND/10 2006 ADA+MTX 
RA 4.42
1
 F 81 Pos/ND 20/46 2000 LEF 
RA 4.43
2
 F 65 Pos/Pos ND/12 
>10 years 
ago 
SSZ 
RA 4.44
3
 M 64 ND/ND 9/66 
>12 years 
ago 
ETA 
RA 4.45
4
 F 82 Pos/Pos ND/28 2007 MTX 
RA 4.46
5
 F 35 Pos/Pos ND/12 2009 
None, to 
start MTX 
RA 4.47 F 54 Pos/ND 7/13 2000 MTX 
RA 4.48 M 61 Pos/ND <5/18 
>15 years 
ago 
ETA+MTX 
 
Table 2.3. Clinical details of RA patients tested in the triplicate culture 3HTdR 
incorporation experiments described in 4.2.3. Abbreviations; F = female, M = male, 
RF = rheumatoid factor, CCP = cyclic citrullinated peptide antibody, Pos = positive, ND 
= no data, Neg = negative, CRP = C-reactive protein, ESR = erythrocyte sedimentation 
rate, ADA = Adalimumab, ETA = Etanercept, HCQ = Hydroxychloroquine, LEF = 
Leflunomide, MTX = Methotrexate, SSZ = Sulfasalazine. Patients with a superscripted 
number following their ID (
1, 2, 3, 4 & 5
) were those also tested in the experiments 
described in 4.2.2. 
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ID Sex Age RF/CCP CRP/ESR 
Year of 
diagnosis 
Medication 
RA 5.1 F 50 Pos/ND <5/14 2005 MTX+ETA 
RA 5.2 F 63 Pos/ND 10/36 1998 LEF 
RA 5.3 F 56 Pos/ND 5/60 1998 MTX+ETA 
RA 5.4 F 77 Neg/Neg <5/36 1998 MTX 
RA 5.5 F 51 Pos/ND <5/12 2003 SSZ+LEF 
RA 5.6 F 80 Neg/Neg <5/40 2008 SSZ 
RA 5.7 F 38 ND/ND <5/6 2001 MTX 
RA 5.8
6
 M 62 Pos/ND 25/56 2004 MTX 
RA 5.9
7
 F 48 Pos/Pos <5/6 2009 MTX 
RA 5.10 F 71 Pos/ND 7/28 1998 MTX 
 
Table 2.4. Clinical details of RA patients tested in the peptide panel #1 experiments 
described in 5.2.1. Abbreviations; F = female, M = male, RF = rheumatoid factor, CCP 
= cyclic citrullinated peptide antibody, Pos = positive, ND = no data, Neg = negative, 
CRP = C-reactive protein, ESR = erythrocyte sedimentation rate, ETA = Etanercept, 
LEF = Leflunomide, MTX = Methotrexate, SSZ = Sulfasalazine. Patients with a 
superscripted number following their ID (
6 & 7
) were those also tested in the experiments 
described in 5.2.3/5.2.5. 
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ID Sex Age RF/CCP CRP/ESR 
Year of 
diagnosis 
Medication 
RA 5.11
8
 F 52 Pos/ND 10/60 2005 LEF/MTX 
RA 5.12
9
 M 64 ND/ND 15/66 
>15 years 
ago 
ETA+HCQ 
RA 5.13 F 62 Pos/Neg <5/14 2009 MTX 
RA 5.14 F 64 ND/ND <5/26 1998 MTX 
RA 5.15
10
 F 50 Pos/Pos 11/25 2007 MTX 
RA 5.16
11
 F 61 Pos/Neg 6/15 2009 MTX 
RA 5.17
12
 F 71 Pos/ND <5/9 1998 ETA+MTX 
RA 5.18
13
 M 45 Pos/Pos 11/12 2009 MTX 
RA 5.19
14
 F 73 Pos/ND <5/12 1999 ETA+MTX 
 
Table 2.5. Clinical details of RA patients tested in the peptide panel #2 experiments 
described in 5.2.2. Abbreviations; F = female, M = male, RF = rheumatoid factor, CCP 
= cyclic citrullinated peptide antibody, Pos = positive, ND = no data, Neg = negative, 
CRP = C-reactive protein, ESR = erythrocyte sedimentation rate, ETA = Etanercept, 
HCQ = Hydroxychloroquine, LEF = Leflunomide, MTX = Methotrexate. Patients with 
a superscripted number following their ID (
8, 9, 10, 11, 12, 13 & 14
) were those also tested in 
the experiments described in 5.2.3/5.2.5. 
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ID Sex Age RF/CCP CRP/ESR 
Year of 
diagnosis 
Medication 
RA 5.20 F 67 Pos/ND ND/40 1998 MTX/HCQ 
RA 5.21 F 58 Neg/Pos ND/32 2009 MTX 
RA 5.22 F 38 ND/ND ND/8 2001 SSZ/MTX 
RA 5.23 F 45 Neg/ND <5/16 2003 ETA+MTX 
RA 5.24 F 54 ND/ND 11/6 1999 MTX 
RA 5.25 F 64 Pos/Neg <5/16 1980 MTX 
RA 5.26
8
 F 52 Pos/ND 10/60 2005 LEF/MTX 
RA 5.27
9
 M 64 ND/ND 15/66 
>15 years 
ago 
ETA+HCQ 
RA 5.28 F 48 Pos/ND <5/10 2003 MTX+HCQ 
RA 5.29 F 73 Pos/Pos <5/8 2007 SSZ 
RA 5.30 F 68 ND/ND <5/9 1993 LEF 
RA 5.31 F 64 Pos/ND 79/80 2002 LEF 
RA 5.32 M 53 Neg/Neg <5/12 2007 LEF 
RA 5.33 F 59 Pos/ND <5/16 2001 MTX+ADA 
RA 5.34 F 79 Pos/Pos <5/24 2009 MTX 
RA 5.35 F 59 Neg/Pos <5/40 2009 MTX 
RA 5.36 F 56 Neg/Neg <5/11 2009 SSZ 
RA 5.37 M 72 Neg/Neg <5/6 ND MTX 
RA 5.38
6
 M 62 Pos/ND 25/56 2004 MTX 
RA 5.39
7
 F 48 Pos/Pos <5/6 2009 MTX 
RA 5.40 F 59 Neg/ND 23/36 2005 MTX+SSZ 
RA 5.41 F 44 Pos/Pos <5/12 2009 MTX 
RA 5.42 F 56 ND/ND <5/18 1997 MTX 
RA 5.43
10
 F 50 Pos/Pos 11/25 2007 MTX 
RA 5.44
11
 F 61 Pos/Neg 6/15 2009 MTX 
RA 5.45
12
 F 71 Pos/ND <5/9 1998 ETA+MTX 
RA 5.46
13
 M 45 Pos/Pos 11/12 2009 MTX 
RA 5.47
14
 F 73 Pos/ND <5/12 1999 ETA+MTX 
 
Table 2.6. Clinical details of RA patients tested in the REP-1 and CEP-1 
experiments described in 5.2.3/5.2.5. Abbreviations; F = female, M = male, RF = 
rheumatoid factor, CCP = cyclic citrullinated peptide antibody, Pos = positive, ND = no 
data, Neg = negative, CRP = C-reactive protein, ESR = erythrocyte sedimentation rate, 
ADA = Adalimumab, ETA = Etanercept, HCQ = Hydroxychloroquine, LEF = 
Leflunomide, MTX = Methotrexate, SSZ = Sulfasalazine. Patients with superscripted 
numbers following their ID were those also tested in the experiments described in 5.2.1 
(
6 & 7
) or 5.2.2 (
8, 9, 10, 11, 12, 13 & 14
). 
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ID Sex Diagnosis Age RF/CCP CRP/ESR 
Year of 
diagnosis 
Medication 
DisC 
5.1 
F MCTD 78 Pos/ND <5/30 2005 MTX 
DisC 
5.2 
M PsA 75 Neg/ND 8/43 2009 MTX 
DisC 
5.3 
F SLE 48 Neg/ND 10/80 2008 HCQ+MTX 
DisC 
5.4 
F 
Sweet 
syndrome 
37 Neg/ND 12/12 2009 None 
DisC 
5.5 
F PsA 38 Neg/Neg 6/26 2009 SSZ 
DisC 
5.6 
F PsA 55 Neg/ND <5/18 2002 MTX+SSZ 
DisC 
5.7 
F PsA 45 ND/ND <5/40 2009 SSZ 
DisC 
5.8 
F 
SAPHO 
syndrome 
60 ND/ND <5/40 ND MTX 
DisC 
5.9 
M PsA 48 ND/ND 6/48 1997 MTX 
DisC 
5.10 
M PsA 45 Neg/ND <5/18 2005 MTX 
DisC 
5.11 
F PsA 64 Neg/Neg <5/10 2006 SSZ 
 
Table 2.7. Clinical details of disease controls tested in the REP-1 and CEP-1 
experiments described in 5.2.3. Abbreviations; DisC = disease control, F = female, M 
= male, MCTD = mixed connective tissue disease, PsA = Psoriatic arthritis, SLE = 
systemic lupus erythematosus, SAPHO = synovitis-acne-pustulosis-hyperostosis-
osteitis, RF = rheumatoid factor, CCP = cyclic citrullinated peptide antibody, Pos = 
positive, ND = no data, Neg = negative, CRP = C-reactive protein, ESR = erythrocyte 
sedimentation rate, HCQ = Hydroxychloroquine, MTX = Methotrexate, SSZ = 
Sulfasalazine. 
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Reagent Source 
Stock 
concentration 
Working 
dilution 
Final 
concentration 
L-Glutamine 
Sigma-Aldrich, 
Gillingham, 
UK 
 
200mM Stock 2mM 
Penicillin-
Streptomycin 
10,000 
units/ml & 
10mg/ml 
Stock 
100 units/ml & 
100µg/ml 
HEPES buffer 1M Stock 10mM 
2-
Mercaptoethanol 
14M 1/280 50µM 
CFSE 5mM 
1/100 then 
1/25 
1µM 
PMB 50mg/ml 1/10 25µg/ml 
EDTA 
Fisher 
Scientific, 
Loughborough, 
UK 
0.5M Stock 2mM 
Recombinant 
human IL-4 
ImmunoTools, 
Friesoythe, 
Germany 
250µg/ml 1/50 50ng/ml 
GM-CSF 
Genzyme, 
Oxford, UK 
250µg/ml 1/50 50ng/ml 
3HTdR 
Perkin Elmer, 
Turku, Finland 
37MBq/ml 0.55MBq/ml 
65kBq/ml & 
55kBq/ml 
 
Table 2.8. Supplementary reagents used in cell culture. Abbreviations; CFSE = 
carboxyfluorescein succinimidyl ester, PMB = polymyxin B, EDTA = ethylenedinitrilo 
tetraacetic acid, IL-4 = interleukin 4, GM-CSF = granulocyte-macrophage colony-
stimulating factor, 3HTdR = 
3
H-thymidine. 
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Stimulus Source 
Stock 
concentration 
Working 
dilution 
Final 
concentration 
PHA P-lectin 
from 
phaseolus 
vulgaris 
Sigma-
Aldrich, 
Gillingham, 
UK 
1mg/ml Stock 5µg/ml 
LPS 1mg/ml 1/5 or 1/10 Various 
PPD 
Calbiochem, 
San Diego, 
California, 
USA 
1mg/ml 1/5 1µg/ml 
HCgp39 
A kind gift 
from Organon 
2mg/ml Stock 10µg/ml 
CII 
A kind gift 
from Dr Amit 
Patel (*1) 
0.85mg/ml Stock 10µg/ml 
GlyAgg Kind gifts 
from Dr 
Caroline 
Wilson (*2) 
1.45mg/ml Stock 10µg/ml 
DeglyAgg 1.45mg/ml Stock 10µg/ml 
Peptide 1 
JPT Peptide 
Technologies, 
Berlin, 
Germany 
4mg/ml 1/4 10µg/ml 
Peptide 2 4mg/ml 1/4 10µg/ml 
Peptide 3 4mg/ml 1/4 10µg/ml 
Peptide 4 4mg/ml 1/4 10µg/ml 
Peptide 5 4mg/ml 1/4 10µg/ml 
Peptide 6 4mg/ml 1/4 10µg/ml 
Peptide 7 4mg/ml 1/4 10µg/ml 
Peptide 8 
ProImmune, 
Oxford, UK 
4mg/ml 1/4 10µg/ml 
Peptide 9 4mg/ml 1/4 10µg/ml 
Peptide 10 4mg/ml 1/4 10µg/ml 
Peptide 11 4mg/ml 1/4 10µg/ml 
Peptide 12 4mg/ml 1/4 10µg/ml 
Peptide 13 4mg/ml 1/4 10µg/ml 
Peptide 14 4mg/ml 1/4 10µg/ml 
Peptide 15 4mg/ml 1/4 10µg/ml 
Peptide REP-1 Kind gifts 
from Professor 
Patrick 
Venables 
(Imperial 
College) 
10mg/ml 1/10 10µg/ml 
Peptide CEP-1 10mg/ml 1/10 10µg/ml 
Peptide REP-1 
(2
nd
 batch) 
5mg/ml 1/5 10µg/ml 
Peptide CEP-1 
(2
nd
 batch) 
5mg/ml 1/5 10µg/ml 
 
Table 2.9. Cell culture stimuli. Abbreviations; PHA = phytohaemagglutinin, LPS = 
lipopolysaccharide, PPD = purified protein derivative (tuberculin), HCgp39 = human 
cartilage glycoprotein 39, CII = type II collagen, GlyAgg = glycosylated aggrecan, 
DeglyAgg = deglycosylated aggrecan. *1 = (manufactured in-house from human 
articular cartilage), *2 = (manufactured in-house from bovine nasal cartilage). 
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Peptide ID Sequence Antigen 
1 SAVRA(Cit)SSVPGVR Cit-Vimentin65-77 
2 QDFTN(Cit)INKLKNS 
Cit-Fibrinogen α–
chain80-92 
3 KIHA(Cit)EIFDS(Cit)GNPTVE Cit-Enolase5-21 
4 HSASQDGQDTI(Cit)GHPGSS Cit-Filaggrin2776-2793 
5 DSGH(Cit)GYSGSQASDNEGH Cit-Filaggrin3005-3022 
6 CVLLVATEGRVRVNSAYQDC 
Aggrecan84-103 
with terminal cysteines 
7 CVLLVATEG(Cit)VRVNSAYQDC 
Cit-Aggrecan84-103 
with terminal cysteines 
8 AGWLADQTVRYPI Aggrecan201-213 
9 AGWLADQTV(Cit)YPI Cit-Aggrecan201-213 
10 AGWLADRSVRYPI Aggrecan299-311 
11 AGWLAD(Cit)SVRYPI Cit-Aggrecan299-311 
12 GRSFTLASSETGVGA HCgp39262-276 
13 G(Cit)SFTLASSETGVGA Cit-HCgp39262-276 
14 VVLLVATEG(Cit)VRVNSAYQDK N Cit-Aggrecan84-103 
15 VVLLVATEGRV(Cit)VNSAYQDK C Cit-Aggrecan84-103 
REP-1 CKIHAREIFDSRGNPTVEC 
Enolase5-21 
with terminal cysteines 
CEP-1 CKIHA(Cit)EIFDS(Cit)GNPTVEC 
Cit-Enolase5-21 
with terminal cysteines 
 
Table 2.10. Peptide details. Abbreviations; (Cit) = citrulline, Cit- = citrullinated. The 
purities of peptides 1-15 were >80%. The purities of the REP-1 and CEP-1 peptides 
were >95%. 
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Antibody Source Clone Isotype Final dilution 
Pacific Blue 
anti-human 
CD3 
eBioscience, 
Hatfield, UK 
OKT3 Mouse IgG2a 1/9 
APC anti-
human CD4 
ImmunoTools, 
Friesoythe, 
Germany 
MEM-241 Mouse IgG1 1/9 
PE anti-human 
CD19 
LT19 Mouse IgG1 1/9 
APC anti-
human CD80 
MEM-233 Mouse IgG1 1/9 
FITC anti-
human CD86 
BU63 Mouse IgG1 1/9 
PE anti-human 
HLA-DR 
MEM-12 Mouse IgG1κ 1/9 
 
Table 2.11. Flow cytometry antibodies. Abbreviations; CD = cluster of differentiation, 
APC = allophycocyanin, PE = phycoerythrin, FITC = fluorescein isothiocyanate, HLA 
= human leukocyte antigen. 
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Reagent Source 
Stock 
concentration 
Working dilution 
IL-10 
Meso Scale 
Discovery, 
Gaithersberg, 
Maryland, USA 
50µg/ml 1/5 
IL-17 50µg/ml 1/5 
IL-4 50µg/ml 1/5 
IL-6 50µg/ml 1/5 
TNF-α 50µg/ml 1/5 
Recombinant 
human IFN-γ 
BD Pharmingen, 
San Diego, 
California, USA 
2µg/ml 1/1000 
Recombinant 
human IL-6 
2µg/ml 1/1000 
Streptavidin-HRP 
Dako, Stockport, 
UK 
1mg/ml 1/1000 
 
Table 2.12. Additional reagents for cytokine detection. Abbreviations; IL = 
interleukin, TNF-α = tumour necrosis factor alpha, IFN-γ = interferon gamma, HRP = 
horse radish peroxidase. 
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Antibody Source Clone Isotype 
Stock 
concentration 
Working 
dilution 
SULFO-
TAG 
human IL-
10, IL-17, 
IL-4, IL-6 
& TNF-α 
detection 
antibody 
mix 
Meso Scale 
Discovery, 
Gaithersberg, 
Maryland, 
USA 
Data not available from 
manufacturer 
50µg/ml 1/50 
Purified 
anti-human 
IFN-γ 
BD 
Pharmingen, 
San Diego, 
California, 
USA 
NIB42 
Mouse 
IgG1κ 
1mg/ml 1/1000 
Purified 
anti-human 
IL-6 
MQ2-13A5 Rat IgG1 0.5mg/ml 1/500 
Biotinylated 
anti-human 
IFN-γ 
4S.B3 
Mouse 
IgG1κ 
0.5mg/ml 1/500 
Biotinylated 
anti-human 
IL-6 
MQ2-39C3 Rat IgG2a 0.5mg/ml 1/500 
 
Table 2.13. Cytokine detection antibodies. Abbreviations; IL = interleukin, TNF-α = 
tumour necrosis factor alpha, IFN-γ = interferon gamma. 
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Figure 2.1. Diagram of a CFSE versus cell-lineage-marker flow cytometry dot plot 
showing dilution of CFSE by cell division. ‘0’ represents an initially labelled 
population of ‘parent’ cells with CFSEbright phenotypes. ‘1’, ‘2’, ‘3’ & ‘4’ represent 
populations of ‘progeny’ cells which have ever-decreasing CFSE fluorescence 
intensities and arise from subsequent rounds of cell division. 
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Chapter 3. Optimisation of a system for detecting autoantigen-specific 
T-cell immune responses 
 
3.1. Introduction 
Although the pathogenesis of RA is thought to involve autoimmune T-cell responses, 
the autoantigens against which these T-cell responses are directed have not been fully 
defined. Furthermore, the mechanisms that regulate immune responses to candidate 
autoantigens are poorly understood. Thus the role of autoantigen-specific T-cell 
responses in RA remains under debate. A major argument against the role of 
autoimmune T-cell responses in RA is that such responses have proved difficult to be 
consistently identified within RA patients. There are several explanations as to why this 
might be the case, the simplest being that RA is in fact not driven by autoimmune T-
cells. However, there are a number of other explanations that do not rule out a role for 
autoantigen-specific T-cells in RA pathogenesis.  
 
Firstly, the paucity of detectable T-cell responses to putative RA autoantigens in 
previous studies could be related to the study design. For example, it may be the case 
that previous studies have focussed on inappropriate autoantigens. Furthermore, studies 
investigating more than one candidate autoantigen (Kotzin et al, 2000; Fritsch et al, 
2002 and Zou et al, 2003) are small in number, with the vast majority of previous 
studies having focussed on single candidate autoantigens, and it is possible that different 
autoantigens are involved in different individuals. It is also possible that T-cells specific 
for many different autoantigens exist in RA patients but that their responses to single 
autoantigens are too weak to be detected in peripheral blood. Another possibility is that 
the protocols used in previous studies may have been sub-optimal. For example, 
subjects tested in previous studies have usually had long-standing RA and/or a history 
of immunomodulatory therapy. If the T-cell responses responsible for initiating the 
disease are short-lived, rare or subtle, then the use of such patients may bias against the 
detection of responses. Perhaps more importantly, it is possible that the methods used to 
detect autoantigen-specific T-cell responses in previous studies were not sufficiently 
sensitive. A study of autoantigen-specific immune responses is only as robust as the 
assays used to detect the responses. Thus, in order to achieve our overall aims, we first 
needed to optimise an experimental system for the detection of such autoantigen-
specific T-cell responses. 
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3.1.1. Detecting proliferation and cytokine production: Assays and culture media 
In the majority of previous studies measuring proliferation of whole PBMC in response 
to candidate RA autoantigens, proliferation has been assessed using the 3HTdR 
incorporation assay (Goodstone et al, 1996; Verheijden et al, 1997; Snowden et al, 
1997; Boots et al, 1997; Guerassimov et al, 1998; Cope et al, 1999; Kim et al, 1999; 
Vos et al #2, 2000; Park et al, 2001; Ria et al, 2008 and de Jong et al, 2010). 
Furthermore, this approach has been considered a method of detecting T-cell 
proliferation, yet when measuring proliferation in a mixed PBMC population using this 
method it is not possible to determine the cellular subsets that have undergone cell 
division. Nevertheless, it is a well-validated technique, is easy to perform, and has been 
utilised in many previous studies in this area of work. Therefore, I considered it 
important to include this assay in this part of my project. In addition, I evaluated the use 
of the CFSE dilution assay as a means of measuring proliferation. This is because in 
combination with specific cell surface molecule immunofluorescence staining, this 
assay is not only able to detect proliferation, but also allows the determination of the 
cellular subset(s) within the whole PBMC population that have proliferated. In addition, 
a study by Mannering et al (2003) demonstrated the superior sensitivity of the CFSE 
dilution assay to that of the 3HTdR incorporation assay in measuring autoantigen-
induced proliferation. The group tested PBMC from eight healthy subjects for 
proliferation in response to the type 1 diabetes autoantigen glutamic acid decarboxylase 
(GAD) using both the CFSE dilution and 3HTdR incorporation assays and found that 
while the former assay detected GAD-induced proliferation in all subjects, the latter did 
so in only 50% of the subjects. Furthermore, the responses detected with the CFSE 
dilution assay were significantly stronger than those detected with the 3HTdR 
incorporation assay. The group also demonstrated the CFSE dilution assay’s ability to 
detect autoantigen-induced T-cell proliferation at 10-fold lower antigen concentrations 
than the 3HTdR incorporation assay. Since I am interested in T-cell responses, I used 
the CFSE dilution approach to look at proliferation within the CD3
+
 PBMC subset so 
that I could compare data from this assay with that from the 3HTdR incorporation assay 
to determine whether what is seen with whole PBMC is representative of what is seen 
within the CD3
+
 subset. 
 
However, cell proliferation is only one of several possible manifestations of T-cell 
responses to antigen-specific stimulation. Therefore, if T-cells from RA patients and 
healthy controls show similar levels of proliferation in response to a candidate RA 
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autoantigen, it does not necessarily mean that their responses to the stimulus are 
identical. For example, cytokine production is another important functional 
manifestation of a T-cell response which can occur in tandem with or independent of 
proliferation, and it is possible that the cytokine profiles of candidate RA autoantigen-
induced T-cell responses differ between RA patients and healthy controls, despite 
similar levels of proliferative responses. Indeed, it has been suggested that the cytokine 
responses of RA patients are biased towards a pro-inflammatory phenotype while those 
of healthy controls are more immunosuppressive in nature (Feldman et al, 1996 and 
McInnes & Schett, 2007). Thus, given the importance of cytokines in RA pathogenesis, 
measuring cytokine profiles may be of crucial importance when investigating T-cell 
responses to candidate RA autoantigens. However, many of the previous studies of 
candidate RA autoantigen-specific T-cell responses have measured only cellular 
proliferation (Goodstone et al, 1996; Verheijden et al, 1997; Snowden et al, 1997; 
Boots et al, 1997; Guerassimov et al, 1998; Cope et al, 1999; Kim et al, 1999; Vos et al 
#2, 2000 and Ria et al, 2008), while fewer studies have measured both proliferation and 
cytokine production (Li, N.L. et al, 2000; Park et al, 2001 and de Jong et al, 2010). 
Furthermore, when cytokine production has been measured, often only a few cytokines 
have been assayed for (Li, N.L. et al, 2000; Park et al, 2001 and van Bilsen et al, 2004), 
although a more recent study by de Jong et al (2010) investigated the production of a 
larger panel of cytokines. Therefore, in addition to measuring the proliferation of RA 
patient and healthy control T-cells in response to candidate RA autoantigen stimulation, 
I also quantified the production of a broad range of cytokines. 
 
In addition to comparing different methods of detecting T-cell responses, I also 
compared the use of different types of sera as supplement to the culture media in our 
experimental system. This is because in previous studies examining candidate 
autoantigen-specific T-cell responses in PBMC, different sera were used to supplement 
culture media. For example, some studies utilised FBS-supplemented medium (Kim et 
al, 1999 and Park et al, 2001), while others cultured PBMC in HABS-supplemented 
medium (Boots et al, 1997; Snowden et al 1997; Guerassimov et al, 1998 and Ria et al, 
2008). AS-supplemented culture medium was used by other groups (Goodstone et al, 
1996; Cope et al, 1999 and Li, N.L. et al, 2000). Autologous plasma has also been used 
as a culture medium supplement in some of the previous studies (Verheijden et al, 1997 
and Vos et al #2, 2000). Thus I compared the use of FBS-supplemented, HABS-
supplemented and AS-supplemented culture media. My aim was to determine to what 
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extent the type of serum used would influence the responses of the PBMC to mitogens 
and protein antigens.  
 
3.1.2. Aims 
 To compare the 3HTdR incorporation assay measuring proliferation of whole 
PBMC culture with the CFSE dilution assay measuring proliferation within the 
CD3
+
 subset of PBMC culture. 
 To compare 10% FBS-supplemented, 5% HABS-supplemented and 5% AS-
supplemented culture media in my experimental system in order to determine 
which is the most suitable. 
 
3.2. Results 
10% FBS-supplemented, 5% HABS-supplemented and 5% AS-supplemented culture 
media were compared in an experimental system that comprised the 3HTdR 
incorporation assay measuring proliferation within triplicate cultures of whole PBMC, 
the CFSE dilution assay measuring proliferation within the CD3
+
 subset of CFSE 
labelled PBMC cultures and ECL and ELISA assays measuring cytokine production by 
whole PBMC (Figure 3.1). 
 
3.2.1. PBMC/CD3
+
 PBMC proliferation with 10% FBS-supplemented, 5% HABS-
supplemented and 5% AS-supplemented culture media 
With both proliferation assays I measured background, PHA-induced and PPD-induced 
proliferation. I generated both 3HTdR incorporation and CFSE dilution data from each 
of 6 subjects allowing a direct comparison of PBMC proliferation measured via 3HTdR 
incorporation and CD3
+
 PBMC proliferation measured via CFSE dilution. 
Representative data of PBMC proliferation assessed using the 3HTdR incorporation 
assay and CD3
+
 PBMC proliferation assessed using the CFSE dilution assay are shown 
in Figure 3.2 and Figure 3.3 respectively. 
 
Figure 3.2 A and B show that when PBMC are cultured in 10% FBS-supplemented 
medium alone, they show increasing levels of proliferation as the culture period 
progresses which reach highly detectable peak levels by day 6, yet when they are 
cultured in 5% AS-supplemented medium alone, they show very little proliferation 
throughout the culture period. Regardless of which media the PBMC are cultured in,  
PHA-stimulated PBMC show high levels of proliferation which peak at day 2 (Figure 
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3.2A), while PPD-stimulated cells show more moderate but still highly detectable levels 
of proliferation which peak at day 6 (Figure 3.2B). However, the level of proliferation 
shown at day 6 by the unstimulated PBMC cultured in 10% FBS-supplemented medium 
is very similar to the peak levels of proliferation shown by the PPD-stimulated PBMC 
cultured in either of the two media. Due to the increasingly high levels of background 
PBMC proliferation associated with the use of 10% FBS-supplemented medium, the SI 
values of PHA-induced and PPD-induced proliferation are low when PBMC are 
cultured in this medium. In contrast, highly robust SI values are obtained when PBMC 
are cultured in 5% AS-supplemented medium as it induces very little background 
proliferation. 
 
Figure 3.3 A and B show that regardless of whether the PBMC are cultured in 10% 
FBS-supplemented medium or 5% AS-supplemented medium, very little CD3
+
 PBMC 
proliferation is detected at days 2 or 4 when the cells are cultured with medium alone, 
yet over the same two time-points, increasingly high levels of CD3
+
 PBMC 
proliferation are detected in populations stimulated with PHA. By day 6, substantial 
levels of CD3
+
 PBMC proliferation are detectable in PPD-stimulated cell populations 
cultured in both 10% FBS-supplemented or 5% AS-supplemented media. However, at 
this same time-point, highly detectable levels of CD3
+
 PBMC proliferation are also 
observed in the unstimulated population of PBMC cultured in 10% FBS-supplemented 
medium (Figure 3.3A) although not in the corresponding population of PBMC cultured 
in 5% AS-supplemented medium alone (Figure 3.3B). 
 
3.2.2. Background PBMC/CD3
+
 PBMC proliferation with 10% FBS-supplemented, 
5% HABS-supplemented and 5% AS-supplemented culture media 
The above data suggests that cells undergo a certain amount of background proliferation 
when cultured in 10% FBS-supplemented medium. Figure 3.4 confirms this finding, 
representing PBMC cultured for 7 days without a specific stimulus but with various 
serum supplementations. When PBMC are cultured in 10% FBS-supplemented medium 
alone, they initially show very low levels of background proliferation (mean cpm value 
± SEM of 2061 ± 354 at day 2). However, as the culture period progresses, the levels of 
background proliferation increase, and reach high levels by day 6 (mean cpm value ± 
SEM of 42661 ± 7915). Conversely, when PBMC are cultured in 5% HABS-
supplemented or 5% AS-supplemented medium alone, they show very little background 
proliferation throughout the entire culture period. Figure 3.5A shows that when CFSE 
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labelled PBMC are cultured in 10% FBS-supplemented medium alone, there is initially 
very little background proliferation seen within the CD3
+
 PBMC subset, but as the 
culture period increases, so does the level of background proliferation occurring within 
the CD3
+
 PBMC subset. In contrast, when CFSE labelled PBMC are cultured in 5% 
AS-supplemented medium alone, the levels of background proliferation within the 
CD3
+
 PBMC subset remain low throughout the entire culture period. This correlates 
very well with what is seen with these two media with the corresponding 3HTdR 
incorporation assay data shown in Figure 3.5B. 
 
3.2.3. PHA-induced and PPD-induced PBMC/CD3
+
 PBMC proliferation with 10% 
FBS-supplemented, 5% HABS-supplemented and 5% AS-supplemented culture 
media 
Figure 3.6 shows 3HTdR incorporation data showing the levels of PHA-induced and 
PPD-induced PBMC proliferation with 10% FBS-supplemented, 5% HABS-
supplemented and 5% AS-supplemented culture media. As shown in Figure 3.6A, PHA-
stimulated PBMC show very high levels of proliferation, regardless of which media 
they are cultured in. PBMC cultured in 10% FBS-supplemented medium show 
remarkably similar levels of PHA-induced proliferation to those shown by PBMC 
cultured in 5% AS-supplemented medium at all time-points. With each of these two 
media, the highest levels of PHA-induced proliferation are seen at day 2, and as the 
culture period progresses, the amount of PHA-induced proliferation gradually 
decreases, consistent with the kinetics of responses to mitogenic stimuli. However, 
PBMC cultured in 5% HABS-supplemented medium show somewhat different levels of 
PHA-induced proliferation compared to those of PBMC cultured in the other two media 
at all time-points. PBMC cultured 5% HABS-supplemented medium show the highest 
levels of PHA-induced proliferation at days 3 and 4, and reach higher peak cpm values 
compared to the PBMC cultured in 10% FBS-supplemented and 5% AS-supplemented 
media. 
 
With regard to PPD-induced responses (Figure 3.6B), PBMC that are cultured in 10% 
FBS-supplemented or 5% AS-supplemented medium show high levels of proliferation 
by day 6 (mean cpm values ± SEM of 58852 ± 8100 and 53995 ± 12715 respectively). 
PPD-stimulated PBMC cultured in 10% FBS-supplemented medium show slightly 
higher levels of proliferation then those cultured in 5% AS-supplemented medium at all 
time-points. However, this could be due to the high levels of background proliferation 
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observed in cultures using 10% FBS-supplemented medium. With both of these media, 
the magnitude and kinetics of the PPD-induced response is consistent with recalled (or 
memory) antigen-specific T-cell proliferation. However, PBMC cultured in 5% HABS-
supplemented medium fail to show any substantial amount of proliferation in response 
to PPD at any of the four time-points. 
 
Figure 3.7 shows 3HTdR incorporation data and corresponding CFSE dilution data 
showing PHA-induced and PPD-induced PBMC and CD3
+
 PBMC proliferation. The 
levels of CD3
+
 PBMC proliferation in PHA-stimulated cultures are very high regardless 
of the type of serum used as culture medium supplement, with peak levels of CD3
+
 
PBMC proliferation (80% CFSE
dim
) at day 3 (Figure 3.7A). As mentioned above, the 
magnitude and kinetics of the response are typical of PHA-induced T-cell proliferation. 
The levels of PHA-induced CD3
+
 PBMC proliferation observed in cultures using 10% 
FBS-supplemented and 5% AS-supplemented media are similar. These data mirror 
those observed in the 3HTdR incorporation assay (Figure 3.7B). 
The levels of CD3
+
 PBMC proliferation in PPD-stimulated cultures of CFSE-labelled 
PBMC are high with both 10% FBS-supplemented and 5% AS-supplemented culture 
media (Figure 3.7C). Of the three time-points that I have taken measurements, the 
highest levels of PPD-induced CD3
+
 PBMC proliferation are observed on day 6, 
regardless of the media used. At all time-points, the levels of PPD-induced CD3
+
 
PBMC proliferation seen when the PBMC are cultured in 10% FBS-supplemented 
medium are very similar to those seen when PBMC are cultured in 5% AS-
supplemented medium. Similarly, the percentages of CD3
+
 PBMC that have undergone 
proliferation are slightly higher when PBMC are cultured in 10% FBS-supplemented 
medium as opposed to 5% AS-supplemented medium. This could again be due to the 
high levels of background proliferation in cultures using 10% FBS-supplemented 
medium. As in the case of PHA-induced proliferation, the patterns of PPD-induced 
CD3
+
 PBMC proliferation observed with the CFSE dilution assay are very similar to 
those observed with the 3HTdR incorporation assay (Figure 3.7D). 
 
3.2.4. SI values of PHA-induced and PPD-induced PBMC/CD3
+
 PBMC proliferation 
with 10% FBS-supplemented, 5% HABS-supplemented and 5% AS-supplemented 
culture media 
When the levels of PHA-induced and PPD-induced proliferation seen in the two assays 
are expressed as stimulation indices, the differences between the three different media 
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become clear and the merits of culture media that induce little background proliferation 
become apparent. 
 
Figure 3.8 shows SI values of PHA-induced and PPD-induced PBMC proliferation 
using the 3HTdR incorporation assay. The highest peak SI values of PHA-induced 
PBMC proliferation (mean ± SEM = 361.1 ± 100.7 [mean ± SEM cpm value of 128813 
± 16237 divided by mean ± SEM cpm value of 654 ± 161]) are seen when PBMC are 
cultured in 5% AS-supplemented medium. This is because 5% AS-supplemented 
culture medium induces very little background PBMC proliferation yet supports very 
high levels of PHA-induced PBMC proliferation (Figure 3.8A). Comparable although 
more variable peak SI values of PHA-induced PBMC proliferation (mean ± SEM = 
314.0 ± 224.2 [mean ± SEM cpm value of 166648 ± 15183 divided by mean ± SEM 
cpm value of 1236 ± 502]) are also observed when PBMC are cultured in 5% HABS-
supplemented medium as this too induces very little background PBMC proliferation 
yet is capable of supporting the high levels of PBMC proliferation in response to PHA. 
With both of these media, peak SI values of PHA-induced PBMC proliferation are seen 
at day 3. While SI values in cultures using 5% AS-supplemented medium decrease 
rapidly after the peak, the decrease in SI values observed with 5% HABS-supplemented 
medium is more gradual. Compared to the peak SI values of PHA-induced PBMC 
proliferation seen with the other two culture media, the peak SI values of PHA-induced 
PBMC proliferation seen with 10% FBS-supplemented culture medium are much lower 
(mean ± SEM = 81.8 ± 16.5 [mean ± SEM cpm value of 132274 ± 7241 divided by 
mean ± SEM cpm value of 2061 ± 354]). Even though the cpm values of PHA-
stimulated PBMC cultured in 10% FBS-supplemented medium were very similar to 
those of PHA-stimulated PBMC cultured in 5% AS-supplemented medium, the high 
levels of background proliferation in cultures using the former culture medium mean 
that the proliferative response, when expressed as SI values, is significantly reduced. 
Peak SI values of PHA-induced PBMC proliferation seen with 10% FBS-supplemented 
culture medium are reached at day 2. 
 
The SI values of PPD-induced PBMC proliferation are very low at all time-points when 
PBMC are cultured in 10% FBS supplemented medium (mean ± SEM of 2.7 ± 0.5, 2.2 
± 0.4, 1.6 ± 0.3 and 1.0 ± 0.2 at days 4, 5, 6 and 7 respectively [mean ± SEM cpm 
values of 30328 ± 4913, 48884 ± 8033, 58852 ± 8100 and 46184 ± 8313 divided by 
mean ± SEM cpm values of 12112 ± 1758, 23909 ± 4060, 42661 ± 7915 and 50425 ± 
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8626 at days 4, 5, 6 and 7 respectively]) because the levels of PPD-induced PBMC 
proliferation seen with this medium at days 5, 6 & 7, although very substantial, are only 
slightly greater than the levels of background PBMC proliferation seen with this 
medium at the same time-points. This suggests that the PPD-specific PBMC 
proliferation could have been masked by the high background proliferative response. 
The SI values of PPD-induced PBMC proliferation seen with 5% HABS-supplemented 
medium are also low at all time-points (mean ± SEM of 2.1 ± 1.1, 2.4 ± 1.1, 2.3 ± 0.3 
and 1.1 ± 0.3 at days 4, 5, 6 and 7 respectively [mean ± SEM cpm values of 1835 ± 
1084, 2087 ± 1177, 1653 ± 450 and 1337 ± 540 divided by mean ± SEM cpm values of 
814 ± 216, 786 ± 209, 694 ± 101 and 1130 ± 264 at days 4, 5, 6 and 7 respectively]) 
because although PBMC cultured in this medium had low background proliferation, the 
proliferative response of PBMC to PPD was poor. In contrast, when PBMC are cultured 
in 5% AS-supplemented medium, the SI values of PPD-induced PBMC proliferation are 
highly significant at all time-points, with the peak value observed at day 5 (mean ± 
SEM = 36.2 ± 12.7 [mean ± SEM cpm value of 36395 ± 7506 divided by mean ± SEM 
cpm value of 2179 ± 592]). This is a result of the high levels of PPD-induced 
proliferation and the very low levels of background proliferation that are seen when 
PBMC are cultured in this type of medium (Figure 3.8B). 
 
Figure 3.9 shows 3HTdR incorporation data (Figures 3.9A and 3.9B) and corresponding 
CFSE dilution data (Figures 3.9C and 3.9D) showing the SI values of PHA-induced 
(Figures 3.9A and 3.9C) and PPD-induced (Figures 3.9B and 3.9D) proliferation. 
Because of the higher levels of background proliferation in cells cultured in 10% FBS-
supplemented medium, the SI values of PHA-induced CD3
+
 PBMC proliferation 
observed when PBMC are cultured in this medium (mean ± SEM of 150.6 ± 47.4 at 
peak [mean ± SEM % CFSE
dim
 CD3
+
 PBMC value of 81.8 ± 3.1 divided by mean ± 
SEM % CFSE
dim
 CD3
+
 PBMC value of 1.4 ± 0.8]) are substantially lower than those 
seen when PBMC are cultured in 5% AS-supplemented medium (mean ± SEM of 250.7 
± 53.0 at peak [mean ± SEM % CFSE
dim
 CD3
+
 PBMC value of 83.7 ± 2.9 divided by 
mean ± SEM % CFSE
dim
 CD3
+
 PBMC value of 0.5 ± 0.1], Figure 3.9C). This is a 
similar pattern to that observed in the 3HTdR incorporation data that shows the SI 
values of PHA-induced PBMC proliferation (Figure 3.9A). 
 
SI values of the PPD-induced CD3
+
 PBMC proliferation seen when PBMC are cultured 
in 10% FBS-supplemented medium (mean ± SEM of 9.9 ± 4.3 at peak [mean ± SEM % 
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CFSE
dim
 CD3
+
 PBMC value of 20.5 ± 4.8 divided by mean ± SEM % CFSE
dim
 CD3
+
 
PBMC value of 2.7 ± 0.7]) are substantially less than those seen when PBMC are 
cultured in 5% AS-supplemented medium (mean ± SEM of 57.4 ± 31.6 at peak [mean ± 
SEM % CFSE
dim
 CD3
+
 PBMC value of 15.6 ± 6.1 divided by mean ± SEM % CFSE
dim
 
CD3
+
 PBMC value of 0.3 ± 0.1], Figure 3.9D) because of the higher levels of 
background CD3
+
 PBMC proliferation that are seen when cells are cultured in FBS-
supplemented medium. This is a similar pattern to that observed in the 3HTdR 
incorporation data that shows the SI values of PPD-induced PBMC proliferation (Figure 
3.9B). Peak SI values for PPD-induced CD3
+
 PBMC proliferation were observed at day 
6 with both media. The peak SI values of PPD-induced CD3
+
 PBMC proliferation 
detected with the CFSE dilution assay when using 10% FBS-supplemented culture 
medium are substantial (mean ± SEM peak SI value of 9.9 ± 4.3). On the other hand, 
the peak SI values of PPD-induced PBMC proliferation detected with the 3HTdR 
incorporation assay when using 10% FBS-supplemented culture medium are low and 
were lower than the predefined criteria of a positive responses (mean ± SEM peak SI 
value of 1.7 ± 0.4). 
 
3.2.5. Background cytokine production with 10% FBS-supplemented, 5% HABS-
supplemented and 5% AS-supplemented culture media 
There is currently no standardised method to report cytokine production data. Some 
investigators report raw values of cytokine production while others apply some form of 
adjustment to take into account the levels of background cytokine production. The 
commonest approaches are the calculation of ‘absolute values’, usually defined as raw 
values minus background values, or SI values, defined as raw values divided by 
background values. In this thesis, I first report the raw values and then the absolute 
values of the data obtained. 
 
Figure 3.10 shows the levels of background cytokine production detected in cell culture 
supernatant of PBMC cultured in the different culture media. Levels of background 
production of both IL-10 and IL-4 were very low at all three time-points, regardless of 
the type of culture media used (note scales on y axis). The levels of background 
production of IL-17, IL-6, TNF-α and IFN-γ were more variable and can be very 
substantial when PBMC are cultured in different media. For example, substantial 
background production of IL-17, TNF-α and IFN-γ was observed at day 6 when PBMC 
were cultured in 10% FBS-supplemented medium (mean ± SEM = 31 ± 17, 512 ± 99 
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and 144 ± 81 respectively), while equally detectable levels of background production of 
IL-6 were seen at day 4 when PBMC were cultured in 5% HABS-supplemented 
medium (mean ± SEM = 1025 ± 918). PBMC cultured in 5% AS-supplemented 
medium show low levels of background production of all cytokines, while by day 6, 
PBMC cultured in 10% FBS-supplemented medium show the highest levels of 
background production of all cytokines except IL-6. Indeed, when PBMC are cultured 
in 10% FBS-supplemented medium, background production of IL-10, IL-17, IL-4, 
TNF-α and IFN-γ increases as the culture period progresses, although it is only by day 6 
that the levels of background production of these five cytokines with this medium 
become substantially higher than those seen with the other two media. 
 
3.2.6. Raw values of PHA-induced and PPD-induced cytokine production with 10% 
FBS-supplemented, 5% HABS-supplemented and 5% AS-supplemented culture 
media 
Figure 3.11 shows PHA-induced cytokine production with each of the three different 
culture media. PHA-stimulated PBMC show much higher levels of production of all 
cytokines than unstimulated PBMC regardless of the media that the PBMC are cultured 
in. The levels of PHA-induced IL-10, IL-17, IL-4, IL-6, TNF-α and IFN-γ production 
shown by PBMC cultured in 10% FBS-supplemented medium were similar to those 
shown by PBMC cultured in 5% AS-supplemented medium, although for PBMC 
cultured in 5% HABS-supplemented medium, PHA-induced production of IL-10, IL-17 
and IL-6 is lower compared to that seen with the other two media, while the production 
of IL-4 and IFN-γ are comparable and the production of TNF-α is higher. 
 
Figure 3.12 shows PPD-induced cytokine production with each of the different types of 
culture media. While PBMC cultured in 10% FBS-supplemented medium showed 
higher levels of PPD-induced production of both IL-10 and IL-17 than PBMC cultured 
in 5% HABS-supplemented or 5% AS-supplemented media, these differences failed to 
reach statistical significance and indeed the levels of PPD-induced IL-4 production were 
comparable between all three culture media. However, PBMC cultured in 5% HABS-
supplemented medium showed higher levels of PPD-induced IL-6 production than 
PBMC cultured in either of the other two media (mean ± SEM pg/ml values of PPD-
induced IL-6 production in 5% HABS-supplemented versus 10% FBS-supplemented 
versus 5% AS-supplemented medium = 6915 ± 2008 versus 3418 ± 1074 versus 1675 ± 
467 respectively), although only the difference between 5% HABS-supplemented 
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medium and 5% AS-supplemented medium reached statistical significance (P value = 
0.02, Mann Whitney, Figure 3.12D). PBMC cultured in 10% FBS-supplemented 
medium also showed higher levels of PPD-induced TNF-α production than PBMC 
cultured in either of the other two media (mean ± SEM pg/ml values of PPD-induced 
TNF-α production in 10% FBS-supplemented versus 5% AS-supplemented versus 5% 
HABS-supplemented medium = 1634 ± 430 versus 504 ± 100 versus 190 ± 77 
respectively) although only the difference between 10% FBS-supplemented medium 
and 5% HABS-supplemented medium reached statistical significance (P value = 0.04, 
Mann Whitney, Figure 3.12E). While PBMC cultured in 5% HABS-supplemented 
medium failed to show any PPD-induced IFN-γ production, PBMC cultured in 10% 
FBS-supplemented and 5% AS-supplemented media showed comparable levels of PPD-
induced IFN-γ production (mean ± SEM pg/ml values of 1027 ± 270 and 725 ± 163 
respectively). Thus, cytokine production with 5% AS-supplemented medium is the most 
representative of the expected TH1 response provoked by PPD stimulation. 
 
3.2.7. Absolute values (raw values minus background) of PHA-induced and PPD-
induced cytokine production with 10% FBS-supplemented, 5% HABS-supplemented 
and 5% AS-supplemented culture media 
Essentially, when the PHA-induced cytokine production data are expressed as absolute 
values, they show an almost identical pattern to that observed when they are expressed 
as raw values (absolute value data not shown due to extreme similarity with data shown 
in Figure 3.11). 
 
Figure 3.13 shows the absolute levels of PPD-induced cytokine production with the 
different types of culture media. While the absolute levels of PPD-induced production 
of IL-10, IL-17 and IL-4 were comparable between all three culture media, PBMC 
cultured in 5% HABS-supplemented medium showed higher absolute levels of PPD-
induced IL-6 production than PBMC cultured in either of the other two media (mean ± 
SEM absolute values of PPD-induced IL-6 production in 5% HABS-supplemented 
versus 10% FBS-supplemented versus 5% AS-supplemented culture medium = 6866 ± 
1999 versus 2949 ± 1105 versus 1632 ± 460 respectively), although only the difference 
between 5% HABS-supplemented medium and 5% AS-supplemented medium reached 
statistical significance (P value = 0.02, Mann Whitney, Figure 3.13D). PBMC cultured 
in 10% FBS-supplemented medium showed the highest absolute levels of PPD-induced 
TNF-α production while those cultured in 5% HABS-supplemented medium showed the 
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lowest, although the differences between the different types of culture media failed to 
reach statistical significance. While PBMC cultured in 5% HABS-supplemented 
medium failed to show any PPD-induced IFN-γ production, the absolute levels of PPD-
induced IFN-γ production shown by PBMC cultured in 10% FBS-supplemented and 5% 
AS-supplemented media were comparable and very robust (mean ± SEM absolute 
levels of 882 ± 243 and 715 ± 165 respectively). Thus, when the PPD-induced cytokine 
production data are expressed as absolute values, the patterns of IL-4, IL-6 and IFN-γ 
production are similar to those observed when the data are expressed as raw values, 
while the patterns of IL-10, IL-17 and TNF-α production are slightly different. 
 
3.3. Discussion 
These data show that the type of sera used to supplement the culture medium influences 
the responses of T-cells to specific stimuli and the sensitivities of different assays for 
detecting antigen-specific responses. The serum affects the assays in two main ways;  
 
(i) the level of background (i.e. unstimulated/negative control) responses. 
(ii) the ability of the cell culture to support antigen-specific responses.  
 
PBMC cultured in 10% FBS-supplemented culture medium show progressively higher 
levels of background proliferation (Figures 3.4 and 3.5) and cytokine production (Figure 
3.10A, B, C, E and F) over time, suggesting that FBS contains factor(s) that stimulate 
the PBMC. This background stimulation could perhaps be attributed to the presence of 
xenogeneic antigens within the FBS which are immunogenic to the human PBMC. It is 
also possible that FBS contains soluble molecules that non-specifically stimulate PBMC 
responses by acting directly on T-cells or indirectly via effects on antigen-presenting 
cells. Regardless of the underlying biological mechanisms of the background responses, 
such responses interfere with the determination of proliferative and cytokine production 
responses to the mitogenic (PHA) as well as antigenic (PPD) stimuli. It is, however, not 
possible to determine whether the effects are simply additive or synergistic or both. 
Suffice to say, from my data, both the raw data as well as SI values were affected to 
different degrees. Firstly, for raw data (i.e. 3HTdR cpm readings, CFSE dilution % 
CFSE
dim
 CD3
+
 PBMC values or cytokine production), high levels of background 
proliferation and cytokine production may heighten the proliferative and cytokine 
production responses to specific stimuli, thus making them appear to be of a greater 
magnitude than they really are. PHA-induced proliferative or cytokine production 
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responses are only moderately affected by the high levels of background response, as 
PHA-induced responses seen with 10% FBS-supplemented culture medium are no 
greater than those seen with either of the other two culture media (Figures 3.6A, 3.7A, 
3.7B and 3.11). There are two possible explanations as to why PHA-induced responses 
are less susceptible to the effects of the high levels of background proliferation and 
cytokine production seen with 10% FBS-supplemented culture medium. Firstly, PHA-
induced responses are manifested and measured quite early on in the culture period. At 
these time-points, the levels of background proliferation seen with 10% FBS-
supplemented culture medium, while higher than those seen with the other two media, 
are relatively modest (Figures 3.2A and 3.3A), and background cytokine production is 
similarly low with all three media (Figure 3.10). Secondly, the ratio of the PHA-induced 
responses to background responses are very high, and therefore only very high levels of 
background proliferation or cytokine production will interfere with the measurement of 
such responses. 
 
In contrast, the PPD-induced responses are affected to a greater extent by the high levels 
of background proliferation and cytokine production seen with 10% FBS-supplemented 
culture medium. Indeed, the highest PPD-induced responses are measured when PBMC 
are cultured in this medium (Figures 3.6B, 3.7C, 3.7D and 3.12A, B, E and F). Again, 
there are two factors contributing to this. Firstly, PPD-induced responses are manifested 
and measured later on in the culture period, when the background levels of proliferation 
and cytokine production seen with 10% FBS-supplemented culture medium have 
reached high levels (Figures 3.2B, 3.3A and 3.10A, B, C, E and F). Secondly, PPD-
induced responses are more modest in their magnitude than PHA-induced responses, 
and are therefore more susceptible to interference by the background responses. 
 
Unsurprisingly, the impact of high levels of background proliferation seen with 10% 
FBS-supplemented culture medium on the detection of stimuli specific responses are 
most apparent when the data are expressed as SI values. Because SI calculate the fold 
changes in the levels of proliferation in response to a specific stimulus relative to 
background responses, the high levels of background proliferation seen with 10% FBS-
supplemented medium will reduce the SI values of responses to specific stimuli. Indeed, 
even strong T-cell responses such as PHA-induced responses are affected. Thus, 
proliferation data show that the SI values of PHA-induced proliferation seen with 10% 
FBS-supplemented culture medium are substantially lower than those seen with either 
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of the other two culture media (Figures 3.8A, 3.9A and 3.9C). However, while SI values 
of PHA-induced proliferation are greatly reduced with 10% FBS-supplemented culture 
medium, they remain high. This is again due to a combination of the facts that at the 
early time-points at which PHA-induced responses are measured, background 
proliferation with 10% FBS-supplemented medium has not reached high levels, and that 
the PHA-induced responses are very great in magnitude. In contrast, the high levels of 
background proliferation seen with 10% FBS-supplemented culture medium reduce the 
SI values of the PPD-induced response much more dramatically (Figures 3.8B, 3.9B 
and 3.9D). Indeed, the SI values of PPD-induced PBMC proliferation detected with the 
3HTdR incorporation assay when using 10% FBS-supplemented culture medium are 
below the threshold of a positive response as defined in the protocol (Figure 3.9B). 
 
Taken together, the high levels of background proliferation associated with the use of 
10% FBS-supplemented medium make this culture medium unsuitable for use in an 
experimental system for detecting autoantigen-specific immune responses. 
 
5% HABS-supplemented culture medium induces very little background proliferation 
(Figure 3.4) and cytokine production (Figure 3.10A, B, C, E and F) but does not support 
antigen-specific responses as well as the other two sera (Figures 3.6B and 3.8B), so is 
therefore also unsuitable. It should be noted that the HABS used in the experiments 
described in this chapter was all derived from the same batch, and it is possible that 
HABS from another batch may have proved to be a suitable culture medium 
supplement. However, the favourable results obtained when using AS lead me to 
discard the idea of testing HABS from a different batch and instead use AS as the 
culture medium supplement. 
 
5% AS-supplemented culture medium is associated with very little background 
proliferation (Figures 3.4 and 3.5) and cytokine production (Figure 3.10), yet supports 
both mitogen and antigen-specific responses very well (Figures 3.6, 3.7, 3.8, 3.9), and 
thus allows the most sensitive and specific detection of antigen-specific responses 
among the three types of sera tested. While it is possible that sera from different 
subjects may differ in their ability to support T-cell responses, this was not apparent in 
any of the experiments utilising AS-supplemented culture medium described in this 
chapter. 
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As mentioned previously, when measuring proliferation within an un-separated 
population of PBMC, the 3HTdR incorporation assay can not allow the identification of 
the subset(s) of the PBMC that are responsible for the detected ‘proliferation’, whereas 
the CFSE dilution assay, when used in combination with immunofluorescence staining 
for specific cell surface molecules, allows the detection of cellular subset-specific 
proliferation within an un-separated PBMC population. The availability of 
contemporaneous 3HTdR incorporation data from whole PBMC as well as CFSE 
dilution data showing proliferation of CD3
+
 PBMC from 6 healthy subjects allowed me 
to determine whether the proliferation seen within the whole PBMC population was 
representative of that seen within the CD3
+
 subset of the PBMC. When looking at the 
levels of background proliferation with 10% FBS-supplemented and 5% AS-
supplemented culture medium, both sets of data show a similar pattern in that with 5% 
AS-supplemented culture medium, the levels of background proliferation remain very 
low for the duration of the 6 day culture period, yet the levels of background 
proliferation seen with 10% FBS-supplemented culture medium start to differ from 
those seen with 5% AS-supplemented culture medium after 4 days of culture and reach 
very substantial levels by day 6 (Figure 3.5). Further similarities are seen between the 
two assays when looking at the levels of PHA and PPD-induced proliferation. The 
kinetic of the PHA-induced proliferative response of whole PBMC (Figure 3.7B) 
mirrors that of the CD3
+
 PBMC (Figure 3.7A). The kinetics of the PPD-induced 
proliferative responses of whole PBMC and CD3
+
 PBMC are also quite similar (Figures 
3.7C and 3.7D). The fact that the levels of PPD-induced PBMC/CD3
+
 PBMC 
proliferation seen with 10% FBS-supplemented culture medium are slightly higher than 
those seen with 5% AS-supplemented culture medium suggests that both assays are 
susceptible to the high levels of background proliferation shown by 10% FBS-
supplemented culture medium (Figures 3.7C and 3.7D). The data showing the SI values 
of PHA and PPD-induced PBMC/CD3
+
 PBMC proliferation is further evidence of this 
susceptibility to high levels of background proliferation that both of the assays have in 
common (Figure 3.9). All this suggests that when the 3HTdR incorporation assay is 
used to measure proliferation within un-separated PBMC population, it does reflect T-
cell proliferation. Because the 3HTdR incorporation assay is easier to perform, requires 
less cells and is less expensive compared to the CFSE dilution assay, using the former 
as a means of measuring ‘T-cell’ proliferation may be more appropriate. However, the 
fact that SI values of PPD-induced proliferation suggestive of positive responses were 
detected with the CFSE dilution assay but not the 3HTdR incorporation assay when 
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using 10% FBS-supplemented culture medium (Figure 3.9D versus Figure 3.9B) 
suggests that the former is more sensitive. Therefore, I have decided to compare these 
two approaches further in their ability to detect autoantigen-specific T-cell responses. 
 
Finally, although the type of serum has a significant impact on the measurements of 
proliferative responses, the impact on cytokine production appears to be more modest. 
The reasons for this discrepancy are not clear but it further highlights the differences 
between proliferative and cytokine responses. It should also be mentioned that the 
cellular source of the cytokine production in these assays has not been specifically 
determined. 
 
3.4. Summary 
Proliferation seen in un-separated PBMC with the 3HTdR incorporation assay is 
representative of that seen in the CD3
+
 subset with the CFSE dilution assay. 10% FBS-
supplemented culture medium is associated with substantial levels of background 
stimulation which cause background proliferation and cytokine production that increase 
with the length of the culture period and reach highly substantial levels after 6 days of 
culture. The high levels of background proliferation and cytokine production seen with 
10% FBS-supplemented culture medium interfere with the interpretation of proliferative 
and cytokine production responses to specific stimuli. When proliferative responses are 
expressed as SI values, the SI values of antigen-specific responses are masked by the 
high levels of background proliferation. 5% HABS-supplemented culture medium 
induces very little background proliferation and cytokine production but does not allow 
antigen-induced responses to be detected, which may be a consequence of its relative 
inability to support longer term cell culture. 5% AS-supplemented culture medium 
induces very little background proliferation and cytokine production and supports 
mitogen and antigen-induced responses. Therefore, I have chosen to use exclusively 5% 
AS-supplemented culture medium for my subsequent experiments. 
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Figure 3.1. The experimental systems used to assess the suitability of 10% FBS-
supplemented, 5% HABS-supplemented and 5% AS-supplemented culture media. 
Unlabelled PBMC from each of 3 healthy subjects were cultured in A) 10% FBS-
supplemented, B) 5% HABS-supplemented and C) 5% AS-supplemented media with 1) 
medium alone, 2) 5µg/ml PHA or 3) 1µg/ml PPD (left half of figure). CFSE-labelled 
PBMC from an additional 6 healthy subjects were cultured in A) 10% FBS-
supplemented and C) 5% AS-supplemented media with 1) medium alone, 2) 5µg/ml 
PHA or 3) 1µg/ml PPD (right half of figure). After 2, 3, 4, 5, 6 & 7 days, proliferation 
of unlabelled PBMC in triplicate cultures on round-bottom 96-well plates was assessed 
via 3HTdR incorporation. At corresponding time-points, CFSE-labelled PBMC in 
individual cultures on flat-bottom 48-well plates were stained for CD3 expression and 
proliferation within the CD3
+
 subset was assessed via CFSE dilution. Supernatant 
samples taken from cultures of unlabelled PBMC after 2, 4 & 6 days were analysed for 
cytokine content via ECL and ELISA. 
Individual cultures of CFSE-
labelled PBMC in A) & C) 
CD3 staining & 
flow cytometry 
CD3+ PBMC 
proliferation 
1) 
2) 
3) 
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ECL multiplex 
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PBMC 
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1) 
2) 
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Figure 3.2. An example of 3HTdR incorporation data showing PBMC proliferation 
in a healthy subject. A, the mean cpm readings of triplicate wells of both unstimulated 
and PHA-stimulated PBMC after 2, 3, 4 & 5 days of culture in both 10% FBS-
supplemented medium and 5% AS-supplemented medium. The vertical bars on each 
data point represent SEM. B, the mean cpm readings of triplicate wells of both 
unstimulated and PPD-stimulated PBMC after 4, 5, 6 & 7 days of culture in both 10% 
FBS-supplemented medium and 5% AS-supplemented medium. The vertical bars on 
each data point represent SEM. C, the SI values of PHA-stimulated PBMC after 2, 3, 4 
& 5 days of culture in both 10% FBS-supplemented medium and 5% AS-supplemented 
medium. The dotted horizontal line represents the threshold level for a positive 
response. D, the SI values of PPD-stimulated PBMC after 4, 5, 6 & 7 days of culture in 
both 10% FBS-supplemented medium and 5% AS-supplemented medium. The dotted 
horizontal line represents the threshold for a positive response. 
A) B) 
C) D) 
PHA response PPD response 
PHA SI PPD SI 
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Figure 3.3. An example of CFSE dilution data showing proliferation of CD3
+
 
PBMC from a healthy subject. A, CFSE versus CD3 flow cytometry dot plots of 
unstimulated, PHA-stimulated and PPD-stimulated CFSE-labelled PBMC after 2, 4 & 6 
days of culture in 10% FBS-supplemented culture medium. B, CFSE versus CD3 flow 
cytometry dot plots of unstimulated, PHA-stimulated and PPD-stimulated CFSE-
labelled PBMC after 2, 4 & 6 days of culture in 5% AS-supplemented culture medium. 
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Figure 3.4. Background PBMC proliferation with 10% FBS-supplemented, 5% 
HABS-supplemented and 5% AS-supplemented culture media. 3HTdR 
incorporation data showing the mean cpm readings of unstimulated PBMC from each of 
the 9 healthy subjects after 2, 3, 4, 5, 6 & 7 days of culture in 10% FBS-supplemented 
medium (n=9), 5% HABS-supplemented medium (n=3) and 5% AS-supplemented 
medium (n=9). In each data set, each point represents the overall mean cpm reading i.e. 
the sum of the mean cpm readings from individual subjects divided by n. The vertical 
bars on each data point represent SEM. 
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Figure 3.5. Background CD3
+
 PBMC proliferation versus background PBMC 
proliferation. A, CFSE dilution data showing the mean % CFSE
dim
 CD3
+
 PBMC in 
unstimulated cultures of CFSE-labelled PBMC from each of 6 healthy subjects after 2, 
3, 4, 5 & 6 days of culture in 10% FBS-supplemented medium and 5% AS-
supplemented medium. In each data set, each point represents the mean value, and the 
vertical bars on each data point represent SEM. B, 3HTdR incorporation data showing 
the mean cpm readings of unstimulated PBMC from each of the same 6 healthy subjects 
represented in A after 2, 3, 4, 5 & 6 days of culture in 10% FBS-supplemented medium 
and 5% AS-supplemented medium. In each data set, each point represents the overall 
mean cpm reading i.e. the sum of the mean cpm readings from individual subjects 
divided by 6. The vertical bars represent SEM. 
A) 
B) 
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Figure 3.6. PHA-induced and PPD-induced PBMC proliferation with 10% FBS-
supplemented, 5% HABS-supplemented and 5% AS-supplemented culture media. 
A, 3HTdR incorporation data showing the mean cpm readings of PHA-stimulated 
PBMC from each of 9 healthy subjects after 2, 3, 4 & 5 days of culture in 10% FBS-
supplemented medium (n=9), 5% HABS-supplemented medium (n=3) and 5% AS-
supplemented medium (n=9). Each point in each data set represents the overall mean 
cpm reading i.e. the sum of the mean cpm readings from individual subjects divided by 
n. The vertical bars on each data point represent SEM. B, 3HTdR incorporation data 
showing the mean cpm readings of PPD-stimulated PBMC from each of 9 healthy 
subjects after 4, 5, 6 & 7 days of culture in 10% FBS-supplemented medium (n=9), 5% 
HABS-supplemented medium (n=3) and 5% AS-supplemented medium (n=9). Each 
point in each data set represents the overall mean cpm reading i.e. the sum of the mean 
cpm readings from individual subjects divided by n. The vertical bars on each data point 
represent SEM. 
A) 
B) 
PHA-induced responses 
PPD-induced responses 
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Figure 3.7. PHA-induced and PPD-induced PBMC proliferation versus PHA-
induced and PPD-induced CD3
+
 PBMC proliferation. A & C, CFSE dilution data 
showing the mean % CFSE
dim
 CD3
+
 PBMC in PHA-stimulated (A) and PPD-stimulated 
(C) cultures of CFSE-labelled PBMC from each of 6 healthy subjects after 2, 3, 4, 5 & 6 
days of culture in 10% FBS-supplemented medium and 5% AS-supplemented medium. 
For both graphs, each point in each data set represents the mean value, and the vertical 
bars on each data point represent SEM. B & D, 3HTdR incorporation data showing the 
mean cpm readings of PHA-stimulated (B) and PPD-stimulated (D) PBMC from each 
of the same 6 healthy subjects represented in A & C after 2, 3, 4, 5 & 6 days of culture 
in 10% FBS-supplemented medium and 5% AS-supplemented medium. For both 
graphs, each point in each data set represents the overall mean cpm reading i.e. the sum 
of the mean cpm readings from individual subjects divided by 6. The vertical bars on 
each data point represent SEM. 
A) B) 
C) D) 
PHA-induced responses 
PPD-induced responses 
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Figure 3.8. SI values of PHA-induced and PPD-induced PBMC proliferation with 
10% FBS-supplemented, 5% HABS-supplemented and 5% AS-supplemented 
culture media. A, 3HTdR incorporation data showing the SI values of PHA-induced 
PBMC proliferation detected in each of 9 healthy subjects after 2, 3, 4 & 5 days when 
PBMC are cultured in 10% FBS-supplemented medium (n=9), 5% HABS-
supplemented medium (n=3) and 5% AS-supplemented medium (n=9). Each point in 
each data set represents the mean SI value i.e. the sum of SI values from individual 
subjects divided by n. The vertical bars on each data point represent SEM, while the 
dotted horizontal line represents the threshold level for a positive response. B, 3HTdR 
incorporation data showing the SI values of PPD-induced PBMC proliferation detected 
in each of 9 healthy subjects after 4, 5, 6 & 7 days when PBMC are cultured in 10% 
FBS-supplemented medium (n=9), 5% HABS-supplemented medium (n=3) and 5% 
AS-supplemented medium (n=9). Each point in each data set represents the mean SI 
value i.e. the sum of SI values from individual subjects divided by n. The vertical bars 
on each data point represent SEM, while the dotted horizontal line represents the 
threshold for a positive response. 
A) 
B) 
PHA-induced responses 
PPD-induced responses 
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Figure 3.9. SI values of PHA-induced and PPD-induced PBMC proliferation 
versus SI values of PHA-induced and PPD-induced CD3
+
 PBMC proliferation. A 
& B, 3HTdR incorporation data showing the SI values of PHA-induced and PPD-
induced PBMC proliferation respectively that are detected in each of 6 healthy subjects 
after 2, 3, 4, 5 & 6 days when PBMC are cultured in 10% FBS-supplemented medium 
and 5% AS-supplemented medium. For both graphs, each point in each data set 
represents the mean SI value i.e. the sum of the SI values from individual subjects 
divided by 6. The vertical bars on each data point represent SEM, while the dotted 
horizontal line represents the threshold level for a positive response. C & D, CFSE 
dilution data showing the SI values of PHA-induced and PPD-induced CD3
+
 PBMC 
proliferation respectively that are detected in each of the same 6 healthy subjects 
represented in A & B after 2, 3, 4, 5 & 6 days when PBMC are cultured in 10% FBS-
supplemented medium and 5% AS-supplemented medium. For both graphs, each point 
in each data set represents the mean SI value i.e. the sum of the SI values from 
individual subjects divided by 6. The vertical bars on each data point represent SEM, 
while the dotted horizontal line represents the threshold for a positive response. 
A) B) 
D) C) 
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Figure 3.10. Background cytokine production with 10% FBS-supplemented, 5% 
HABS-supplemented and 5% AS-supplemented culture media. Graphs show in 
pg/ml the mean levels of production of A) IL-10, B) IL-17, C) IL-4, D) IL-6, E) TNF-α 
& F) IFN-γ by unstimulated PBMC after 2, 4 and 6 days of culture in 10% FBS-
supplemented medium (n=9), 5% HABS-supplemented medium (n=3) and 5% AS-
supplemented medium (n=9). For all graphs, each point in each data set represents the 
mean value i.e. the sum of the pg/ml values from individual subjects divided by n. The 
vertical bars on each data point represent SEM. 
A) B) 
C) D) 
E) F) 
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Figure 3.11. PHA-induced cytokine production with 10% FBS-supplemented, 5% 
HABS-supplemented and 5% AS-supplemented culture media. Graphs show in 
pg/ml the mean levels of production of A) IL-10, B) IL-17, C) IL-4, D) IL-6, E) TNF-α 
& F) IFN-γ by PHA-stimulated PBMC after 2 and 4 days of culture in 10% FBS-
supplemented medium (n=9), 5% HABS-supplemented medium (n=3) and 5% AS-
supplemented medium (n=9). For all graphs, each point in each data set represents the 
mean value i.e. the sum of the pg/ml values from individual subjects divided by n. The 
vertical bars on each data point represent SEM. 
A) B) 
C) D) 
E) F) 
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Figure 3.12. PPD-induced cytokine production at day 6 with 10% FBS-
supplemented, 5% HABS-supplemented and 5% AS-supplemented culture media. 
Graphs show in pg/ml the levels of production of A) IL-10, B) IL-17, C) IL-4, D) IL-6, 
E) TNF-α & F) IFN-γ by PPD-stimulated PBMC after 6 days of culture in 10% FBS-
supplemented medium (n=9), 5% HABS-supplemented medium (n=3) and 5% AS-
supplemented medium (n=9). For all graphs, each point in each data set represents a 
pg/ml value from an individual subject, and the bold horizontal line in each data set 
represents the median value. 
A) B) 
C) D) 
E) F) 
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Figure 3.13. Absolute values of PPD-induced cytokine production at day 6 with 
10% FBS-supplemented, 5% HABS-supplemented and 5% AS-supplemented 
culture media. Graphs show the absolute values of PPD-induced production of A) IL-
10, B) IL-17, C) IL-4, D) IL-6, E) TNF-α & F) IFN-γ at day 6 when using 10% FBS-
supplemented medium (n=9), 5% HABS-supplemented medium (n=3) and 5% AS-
supplemented medium (n=9). For all graphs, each point in each data set represents an 
absolute value from an individual subject, while the bold horizontal line in each data set 
represents the median absolute value. 
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Chapter 4. T-cell immune responses to whole-protein candidate RA 
autoantigens in health and disease 
 
4.1. Introduction 
In chapter 3, I examined different protocols for detecting antigen-specific proliferation 
and cytokine production responses in cultures of PBMC. The results suggested that 
using 5% AS-supplemented culture medium is the most reliable approach, whether 
using 3HTdR incorporation or CFSE dilution proliferation assays, and either ECL 
multiplex or ELISA cytokine production assays. Ultimately, I am interested in 
autoantigen-specific T-cell responses, and an additional question was whether, when the 
3HTdR incorporation assay is used to detect proliferation within whole PBMC cultures, 
the results could be used as a measure of CD3
+
 T-cell proliferation. My data suggested 
that 3HTdR incorporation assays did reflect the data obtained from the CFSE dilution 
assays, suggesting that the former could be used as an estimate of T-cell proliferation. 
However, each assay had its own advantages and disadvantages. The 3HTdR 
incorporation assay requires fewer cells than the CFSE dilution assay and is easier to 
perform. In contrast, the CFSE dilution assay is more technically demanding, but can 
provide insights into subset-specific responses (e.g. CD3
+
 CD4
+
 T-cells). Consequently, 
I decided to further explore the relative merits of both assays in the study of T-cell 
responses to candidate RA autoantigens, the choice of assay reflecting the specific 
question to be addressed. 
 
4.2. Results 
4.2.1. HCgp39-induced T-cell proliferation in RA patients 
For my first set of experiments involving a candidate RA autoantigen, I cultured CFSE-
labelled PBMC from RA patients with 10µg/ml HCgp39 for 7 days prior to harvesting, 
staining for expression of CD3 and CD4 and measuring proliferation via CFSE dilution. 
PHA was used as a positive control in all experiments and proliferation was measured 
both as an increase in the % CFSE
dim
 cells in response to stimulation (i.e. % CFSE
dim
 
cells in PHA/HCgp39-stimulated culture minus % CFSE
dim
 cells in unstimulated 
culture) and as a CFSE dilution stimulation index (i.e. number of CFSE
dim
 cells in 
PHA/HCgp39-stimulated culture divided by number of CFSE
dim
 cells in unstimulated 
culture). Proliferation was measured in both the CD3
+
 CD4
+
 and CD3
+
 CD4
-
 subsets of 
peripheral blood T-cells. For this set of experiments, a total of 15 RA patients were 
studied (see Table 2.1 in chapter 2 for RA patient clinical details). 
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All 15 patients showed good PHA-induced proliferative responses (mean ± SEM SI 
value of 116.6 ± 48.6, CD3
+
 CD4
+
 subset [lowest individual SI value was 60.2]; data 
not shown). The data in Table 4.1 shows that of the 15 RA patients tested with HCgp39, 
5 showed HCgp39-induced increases in the % of CFSE
dim
 CD3
+
 CD4
+
 T-cells (mean ± 
SEM HCgp39-induced increase in the % of CFSE
dim
 CD3
+
 CD4
+
 T-cells of 1.17 ± 
0.75), and the CD3
+
 CD4
+
 subset of T-cells from of one of these 10 patients (RA 4.5) 
showed a very substantial HCgp39-induced increase in the % CFSE
dim
 cells which 
measured 4.17%. Four of the RA patients showed HCgp39-induced increases in the % 
of CFSE
dim
 CD3
+
 CD4
-
 T-cells (mean ± SEM HCgp39-induced increase in the % of 
CFSE
dim
 CD3
+
 CD4
-
 T-cells of 0.28 ± 0.08). Two of the patients showed HCgp39-
induced proliferation in both subsets, and the HCgp39-induced increases in the % of 
CFSE
dim
 cells detected in the CD4
+
 T-cell subsets of these patients (0.41 and 4.17) were 
greater than those detected in the CD4
-
 T-cell subsets (0.10 and 0.43). Interestingly, 
when the HCgp39-induced proliferation was expressed as SI values, only 1 of the 15 
patients (RA 4.5) showed a positive proliferative response, yet this was visible in both 
the CD3
+
 CD4
+
 and CD3
+
 CD4
-
 subsets of T-cells (SI values of 4.0 and 3.3 
respectively). However, overall the SI values of HCgp39-induced proliferation detected 
within the CD3
+
 CD4
+
 T-cell subset were significantly greater than those of HCgp39-
induced proliferation detected within the CD3
+
 CD4
-
 T-cell subset (mean ± SEM SI 
values of 1.3 ± 0.2 versus 1.1 ± 0.2 respectively, P value = 0.02, paired t test). As the 
response to HCgp39 is MHC class II-restricted, the proliferation observed in the CD3
+
 
CD4
-
 subset of the PBMC upon stimulation with HCgp39 could be explained as 
antigen-independent proliferation induced by IL-2 produced by CD3
+
 CD4
+
 cells 
recognising HCgp39 peptide-MHC class II complexes (Wong & Pamer, 2001). 
 
4.2.2. Bulk culture approach; HCgp39-induced, CII-induced and GlyAgg-induced 
PBMC proliferation 
In my previous set of experiments that used the CFSE dilution assay to measure the 
proliferation of RA patient peripheral blood T-cells in response to HCgp39 stimulation, 
only 1 of the 15 patients tested appeared to show a positive HCgp39-induced 
proliferative response when the data were expressed as SI values. Several previous 
studies had reported higher incidences of HCgp39-induced proliferative responses in 
RA patients (Verheijden et al, 1997 and Vos et al #2, 2000) therefore I performed some 
further experiments measuring HCgp39-induced responses in RA patients using a 
different approach. Since these previous studies had used the 3HTdR incorporation 
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assay to measure proliferation in cultures of PBMC, I decided to attempt to replicate the 
findings of these previous HCgp39 studies and to focus on the 3HTdR incorporation 
assay as a means of measuring HCgp39-induced responses in PBMC as a whole. 
However, instead of using the triplicate/multiple culture approach with a maximum of 
2x10
5
 cells/well which had been employed by these previous studies and additional 
published studies on candidate RA autoantigens (Goodstone et al, 1996; Boots et al, 
1997; Cope et al, 1999; Kim et al, 1999 and de Jong et al, 2009), I wanted to explore 
the use of a bulk culture approach similar to that used in my CFSE dilution experiments 
in which the PBMC were cultured with higher cell numbers per well. My rationale was 
that increasing the cell number may improve the chance of detecting low precursor 
frequency T-cell responses. In addition, I was also able to test the responses to CII and 
GlyAgg at the same time, as samples of these other candidate autoantigens had become 
available. For these bulk culture experiments, a total of 9 RA patients and 8 healthy 
subjects were used (see Table 2.2 in chapter 2 for RA patient clinical details). The data 
in Table 4.2 shows the SI values for PHA-induced, PPD-induced, HCgp39-induced, 
CII-induced and GlyAgg-induced PBMC proliferation detected in each of the RA 
patients and healthy subjects, as determined by 3HTdR incorporation.  
 
Figure 4.1 shows the comparison between the levels of PHA-induced (A) and PPD-
induced (B) PBMC proliferation detected in RA patients and healthy subjects when 
using the bulk culture approach. While the median SI value of PHA-induced PBMC 
proliferation detected in the RA patients (median = 89.8, IQR: 41.3-170.4) was greater 
than that of PHA-induced PBMC proliferation detected in the healthy subjects (median 
= 37.8, IQR: 30.9-59.5), the difference between the two groups was not statistically 
significant (P value = 0.09, Mann Whitney). As shown in Table 4.2, only 63% of the 
RA patients showed positive PPD-induced PBMC proliferative responses compared to 
100% of the healthy subjects. However, this difference was not statistically significant 
(P value = 0.45, Chi-square). Furthermore, the peak SI values of PPD-induced PBMC 
proliferation detected in both the RA patients and healthy subjects (median = 3.1, IQR: 
1.8-22.0 and median = 5.4, IQR: 2.8-9.1 respectively) were statistically similar (P value 
= 0.28, Mann Whitney). 
 
Figure 4.2 shows the kinetics of the HCgp39-induced, CII-induced and GlyAgg-induced 
proliferative responses detected in both RA patients and healthy subjects when using the 
bulk culture approach. In the RA patients that showed positive HCgp39-induced PBMC 
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proliferative responses, peak levels of proliferation were detected at days 9 and 11 (n=1 
and 3 respectively, Figure 4.2A). In the healthy subjects that showed positive HCgp39-
induced PBMC proliferative responses, peak levels of proliferation were also detected at 
days 9 and 11 (n=2 and 1 respectively, Figure 4.2B). In the RA patients that showed 
positive CII-induced PBMC proliferative responses, peak levels of proliferation were 
detected at days 7, 9 and 11, Figure 4.2C). In the healthy subjects that showed positive 
CII-induced PBMC proliferative responses, peak levels of proliferation were detected at 
days 7 and 9 (n=2 and 1 respectively, Figure 4.2D). None of either the RA patients or 
healthy subjects showed positive GlyAgg-induced PBMC proliferative responses 
(Figures 4.2E and 4.2F respectively). 
 
As shown in Table 4.2, similar proportions of RA patients and healthy subjects (44% 
and 38% respectively) showed positive HCgp39-induced PBMC proliferative responses. 
Furthermore, the peak SI values of HCgp39-induced PBMC proliferation detected in the 
RA patients (median = 1.7, IQR: 1.2-3.2) and those of HCgp39-induced PBMC 
proliferation detected in the healthy subjects (median = 1.9, IQR: 1.3-3.3) were similar 
(P value = 0.70, Mann Whitney, Figure 4.3A). Positive CII-induced PBMC proliferative 
responses were detected in a similar proportion of the healthy subjects as the RA 
patients (38% and 33%, healthy subjects and RA patients, Table 4.2). The median peak 
SI value of CII-induced PBMC proliferation detected in the healthy subjects (median = 
1.9, IQR: 1.5-9.9) was slightly greater than that of CII-induced PBMC proliferation 
detected in the RA patients (median = 1.4, IQR: 1.2-3.7), although the difference 
between the 2 groups was not statistically significant (P value = 0.18, Mann Whitney, 
Figure 4.3B). None of the RA patients or healthy subjects showed positive GlyAgg-
induced PBMC proliferative responses (Table 4.2), and the peak SI values of GlyAgg-
induced PBMC proliferation detected in the RA patients versus the healthy subjects 
were almost identical (median = 0.8, IQR: 0.7-1.0 versus median = 0.8, IQR: 0.6-1.3 
respectively, Figure 4.3C). 
 
Of the four RA patients that showed positive HCgp39-induced PBMC proliferative 
responses, three (RA 4.16, RA 4.23 and RA 4.24) were both RF and CCP positive, 
while RF and CCP levels in the fourth (RA 4.19) were not known. All four HCgp39 
responders showed CRP levels of less than 5. Interestingly, two of the HCgp39 
responders (RA 4.19 and RA 4.24) also showed positive CII-induced PBMC 
proliferative responses. The third CII responder (RA 4.20) was RF positive but CCP 
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levels were unknown and CRP levels were more substantial compared to those in other 
autoantigen responders (20 versus <5). However, while this suggested that positive 
HCgp39-induced or CII-induced PBMC proliferative responses were associated with 
RF and CCP positivity and CRP levels of less than 5, such clinical traits were also 
observed in patients that failed to show positive HCgp39-induced or CII-induced PBMC 
proliferative responses (RA 4.17 and RA 4.21). Of the six patients showing positive 
responses to HCgp39 and/or CII, three (RA 4.19, RA 4.23 and RA 4.24) had been only 
recently diagnosed with RA (i.e. within 2 years of the time of testing) while the other 
two (RA 4.16 and RA 4.20) had longer standing disease. As was seen with the RA 
patients, two of the healthy subjects that showed positive HCgp39-induced PBMC 
proliferative responses also showed positive CII-induced PBMC proliferative responses 
(HS 4.6 and HS 4.7). In both of these subjects, the CII-induced responses (SI values of 
10.6 and 13.1) were more potent than the HCgp39-induced responses (SI values of 2.5 
and 3.5). 
 
4.2.3. Triplicate culture approach; HCgp39-induced, CII-induced, GlyAgg-induced 
and DeglyAgg-induced PBMC proliferation and cytokine production  
When using the bulk culture approach to detect proliferation of RA patient and healthy 
subject PBMC in response to HCgp39, CII and GlyAgg, only HCgp39 and CII appeared 
to be capable of eliciting positive proliferative responses. However, the numbers of 
subjects from each of the two cohorts showing positive proliferative responses to these 
stimuli were low, and the responses were similar between RA patients and healthy 
subjects in terms of both the prevalence and the magnitudes. I therefore decided to 
repeat these experiments using the triplicate culture approach so that I could compare 
similar data from each of the two approaches. I had also obtained some DeglyAgg so 
this was added to my panel of autoantigens. For these triplicate culture experiments, a 
total of 24 RA patients and 16 healthy subjects were studied (see Table 2.3 in chapter 2 
for RA patient clinical details). 
 
4.2.3.1. PHA-induced and PPD-induced PBMC proliferation and background 
cytokine production 
When using the triplicate culture approach, the median SI value of PHA-induced PBMC 
proliferation detected in RA patients (median = 232.8, IQR: 162.9-463.1) was slightly 
greater than that of PHA-induced PBMC proliferation detected in healthy subjects 
(median = 186.4, IQR: 113.1-321.3), but the difference between the two groups was not 
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statistically significant (P value = 0.26, Mann Whitney, Figure 4.4A). This is similar to 
what was seen with the bulk culture approach. However, Figures 4.4B and 4.4C show 
that for both RA patients and healthy subjects respectively, the SI values of PHA-
induced PBMC proliferation detected with the triplicate culture approach were 
significantly greater than those detected with the bulk culture approach (P values = 
0.0039 and 0.0011 respectively, Mann Whitney). Of the 23 RA patients that were tested 
for PPD-specific PBMC proliferation with the triplicate culture approach, 20 (87%) 
showed positive responses, while all 16 of the healthy subjects showed positive PPD-
induced PBMC proliferative responses. The median peak SI value of PPD-induced 
PBMC proliferation detected in RA patients (median = 14.9, IQR: 3.6-31.1) was less 
than that of PPD-induced PBMC proliferation detected in healthy subjects (median = 
19.1, IQR: 10.2-31.8) but, as was seen with the bulk culture approach, the difference 
between the 2 groups was not statistically significant (P value = 0.34, Mann Whitney, 
Figure 4.5A). Although this is a similar pattern to that seen with the bulk culture 
approach, it is worth noting that with the RA patients, a higher incidence of ‘positive’ 
PPD-specific proliferative responses was detected when using the triplicate culture 
approach as opposed to the bulk culture approach, although this trend failed to reach 
statistical significance (87% versus 63% respectively, P value = 0.69, Chi-square). 
Nevertheless, Figure 4.5B shows that for RA patients, the peak SI values of PPD-
induced PBMC proliferation detected with the triplicate culture approach were 
statistically similar to those detected with the bulk culture approach (P value = 0.16, 
Mann Whitney). However, for healthy subjects, the peak SI values of PPD-induced 
PBMC proliferation detected with the triplicate culture approach were significantly 
greater than those detected with the bulk culture approach (P value = 0.02, Mann 
Whitney, Figure 4.5C). Therefore, while both the bulk culture and triplicate culture 
approaches showed similar incidences of positive PPD-specific proliferative responses, 
the magnitudes of these responses were greatest when using the triplicate culture 
approach. 
 
Levels of background production of IL-10, IL-17, IL-4, IL-6, TNF-α and IFN-γ by both 
RA patient and healthy subject PBMC from the triplicate culture experiments were 
measured after 5 and 11 days of culture. I hypothesised that RA patients would have 
higher levels of background production of pro-inflammatory cytokines compared to 
healthy subjects. Figure 4.6A shows that at day 5, the levels of background PBMC 
cytokine production detected in both RA patients and healthy subjects were very 
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similar. Background IL-6 production was high in both RA patients and healthy subjects, 
with mean ± SEM levels measuring 1276 ± 1152 and 893 ± 541 respectively. Day 11 
data shows a similar finding but with less pronounced IL-6 production in both groups 
(Figure 4.6B). 
 
4.2.3.2. HCgp39-induced responses 
The 3HTdR incorporation data in Table 4.3 shows that only 40% of RA patients showed 
positive HCgp39-induced PBMC proliferative responses compared to 75% of healthy 
subjects (this compares to the 44% of RA patients and 38% of healthy subjects seen 
with the bulk culture approach), although this difference failed to reach statistical 
significance (P value = 0.70, Chi-square). The median peak SI value of HCgp39-
induced PBMC proliferation detected in RA patients (median = 1.9, IQR: 1.6-2.8) was 
slightly less than that of HCgp39-induced PBMC proliferation detected in healthy 
subjects (median = 2.7, IQR: 1.9-3.6) but this difference was not statistically significant 
(P value = 0.18, Mann Whitney, Figure 4.7A). In the RA patients that showed positive 
HCgp39-induced PBMC proliferative responses, peak levels of proliferation were 
detected at days 5, 9 and 11 (n=2, 1 and 1 respectively, Figure 4.7B). In the healthy 
subjects that showed positive HCgp39-induced PBMC proliferative responses, peak 
levels of proliferation were detected at days 5, 7, 9 and 11 (n=2, 1, 1 and 2 respectively, 
Figure 4.7C). 
 
The cytokine production data in Table 4.3 shows that of the six RA patients and six 
healthy subjects tested for HCgp39-induced cytokine production, equal proportions of 
subjects from both groups (67%) showed cytokine production in response to the 
stimulus. However, this may be an underestimate as some of the RA patients and 
healthy subjects that were not tested for cytokine production did show HCgp39-induced 
proliferation. Of the four RA patients that showed HCgp39-induced cytokine 
production, all showed up-regulation of IL-6 in response to the stimulus (191pg/ml, 
86pg/ml, 2649pg/ml and 673pg/ml), while three also showed up-regulation of TNF-α 
(4pg/ml, 90pg/ml and 64pg/ml). One of the RA patients that showed HCgp39-induced 
up-regulation of both IL-6 and TNF-α also showed up-regulation of IL-4 in response to 
the stimulus (10pg/ml). Of the four healthy subjects that showed HCgp39-induced 
cytokine production, three showed up-regulation of IL-6 in response to the stimulus 
(4890pg/ml, 58pg/ml and 10pg/ml) and one of these subjects also showed up-regulation 
of both TNF-α and IL-4 (46pg/ml and 3pg/ml respectively) while another also showed 
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up-regulation of TNF-α alone (9pg/ml). The fourth healthy subject that showed 
HCgp39-induced cytokine production up-regulated production of IFN-γ alone in 
response to the stimulus (14pg/ml). In both the RA patients and healthy subjects, 
HCgp39-induced cytokine production was detected both in conjunction with and 
independent of HCgp39-induced proliferative responses. Interestingly, HCgp39 failed 
to induce production of detectable levels of IL-10 or IL-17 in either RA patients or 
healthy subjects. Furthermore, only in healthy subjects did HCgp39 induce production 
of detectable levels of IFN-γ. The levels of HCgp39-induced IL-4, IL-6 and TNF-α 
production did not differ significantly between the RA patients and the healthy subjects 
(P values = 1.00, 0.46 and 0.35 for IL-4, IL-6 and TNF-α respectively, Mann Whitney). 
 
4.2.3.3. CII-induced responses 
The 3HTdR incorporation data shown in Table 4.4 shows that only 57% of RA patients 
showed positive CII-induced PBMC proliferative responses compared to 88% of 
healthy subjects (this compares to the 33% of RA patients and 38% of healthy subjects 
seen with the bulk culture approach), although this difference failed to reach statistical 
significance (P value = 0.78, Chi-square). In addition, the median peak SI value of CII-
induced PBMC proliferation detected in RA patients (median = 2.1, IQR: 1.2-3.8) was 
less than that of CII-induced PBMC proliferation detected in healthy subjects (median = 
2.7, IQR: 2.3-4.1), yet once again the difference between the 2 groups failed to reach 
statistical significance (P value = 0.34, Mann Whitney, Figure 4.8A). In the RA patients 
that showed positive CII-induced PBMC proliferative responses, peak levels of 
proliferation were detected at days 3, 9 and 11 (n=1, 1 and 2 respectively, Figure 4.8B). 
In the healthy subjects that showed positive CII-induced PBMC proliferative responses, 
peak levels of proliferation were detected at days 3, 5, 7, 9 and 11 (n=1, 1, 2, 1 and 2 
respectively, Figure 4.8C). 
 
The cytokine production data in Table 4.4 shows that all four of the RA patients and all 
six of the healthy subjects that were tested for CII-induced cytokine production showed 
cytokine production in response to the stimulus. All four of the RA patients showed CII-
induced up-regulation of IL-6 (3326pg/ml, 462pg/ml, 79pg/ml and 1817pg/ml) and in 
three of the patients this was accompanied by an up-regulation of both IL-17 and TNF-α 
(3pg/ml and 99pg/ml respectively), TNF-α alone (84pg/ml) or IFN-γ alone (8pg/ml). 
Five of the six healthy subjects showed CII-induced up-regulation of IL-4 (14pg/ml, 
3pg/ml, 6pg/ml, 13pg/ml and 18pg/ml), IL-6 (5768pg/ml, 3788pg/ml, 4679pg/ml, 
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3775pg/ml and 12633pg/ml) and TNF-α (14pg/ml, 68pg/ml, 426pg/ml, 31pg/ml and 
61pg/ml). Four of these subjects also showed CII-induced up-regulation of two or three 
other cytokines, namely IL-17 and IFN-γ (7pg/ml and 12pg/ml respectively), IL-10 and 
IFN-γ (7pg/ml and 31pg/ml respectively), IL-10 and IL-17 (8pg/ml and 6pg/ml 
respectively) and IL-10, IL-17 and IFN-γ (3pg/ml, 15pg/ml and 8pg/ml respectively). 
The sixth healthy subject showing CII-induced cytokine production showed an up-
regulation of TNF-α alone in response to the stimulus (10pg/ml). In the RA patients, 
CII-induced cytokine production was detected both in conjunction with and independent 
of CII-induced PBMC proliferation, while in the healthy subjects, all subjects that 
showed CII-induced cytokine production also showed positive CII-induced PBMC 
proliferative responses. Interestingly, CII-induced production of detectable levels of IL-
10 and IL-4 was observed only in the healthy subjects. The levels of CII-induced IL-17, 
IL-6, TNF-α and IFN-γ production did not differ significantly between the RA patients 
and the healthy subjects (P values = 0.24, 0.11, 0.75 and 0.57 for IL-17, IL-6, TNF-α 
and IFN-γ respectively, Mann Whitney). 
 
4.2.3.4. GlyAgg-induced responses 
The 3HTdR incorporation data in Table 4.5 shows that the proportions of RA patients 
and healthy subjects that showed positive GlyAgg-induced PBMC proliferative 
responses were very similar (44% and 40% respectively). The median peak SI value of 
GlyAgg-induced PBMC proliferation detected in RA patients was similar to that of 
GlyAgg-induced PBMC proliferation detected in healthy subjects (median = 1.6, IQR: 
1.0-2.8 and median = 1.5, IQR: 1.1-2.7 respectively, P value = 0.90, Mann Whitney, 
Figure 4.9A). In the RA patients that showed positive GlyAgg-induced PBMC 
proliferative responses, peak levels of proliferation were detected at days 3 and 5 (n=1 
and 3 respectively, Figure 4.9B). In the healthy subjects that showed positive GlyAgg-
induced PBMC proliferative responses, peak levels of proliferation were detected at 
days 5, 9 and 11 (n=1, 2 and 1 respectively, Figure 4.9C).  
 
The cytokine production data in Table 4.5 shows that of the five RA patients tested for 
GlyAgg-induced cytokine production, 80% showed cytokine production in response to 
the stimulus, compared to 63% of the tested healthy subjects. However, this difference 
was not significant (P value = 0.98, Chi-square). The cytokines produced by RA 
patients in response to GlyAgg stimulation were IL-10 (2pg/ml), IL-17 (3pg/ml), IL-4 
(6pg/ml and 3pg/ml), IL-6 (24pg/ml, 209pg/ml, 1640pg/ml and 3037pg/ml) and TNF-α 
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(4pg/ml, 3pg/ml and 34pg/ml). Healthy subjects only showed production of IL-6 
(25pg/ml, 146pg/ml, 116pg/ml, 393pg/ml and 430pg/ml) and TNF-α (4pg/ml) in 
response to the stimulus. All four of the RA patients that showed GlyAgg-induced 
cytokine production also showed GlyAgg-induced proliferation while in the healthy 
subjects GlyAgg-induced cytokine production was detected both in conjunction with 
and independent of GlyAgg-induced proliferation. The levels of GlyAgg-induced IL-6 
and TNF-α production did not differ significantly between the RA patients and the 
healthy subjects (P values = 0.37 and 0.13 for IL-6 and TNF-α respectively, Mann 
Whitney). 
 
4.2.3.5. HCgp39-induced, CII-induced and GlyAgg-induced PBMC proliferation; 
triplicate culture 3HTdR incorporation approach versus bulk culture 3HTdR 
incorporation approach 
The proportions of HCgp39-specific proliferative responses detected in the RA patients 
are comparable with both the triplicate culture approach and the bulk culture approach 
(40% and 44% respectively). However, in the healthy subjects, a greater proportion of 
HCgp39-specific proliferative responses were detected when using the triplicate culture 
approach as opposed to the bulk culture approach (75% versus 38% respectively), 
although this difference was not statistically significant (P value of 0.68, Chi-square). 
Greater proportions of CII-specific proliferative responses were detected in both the RA 
patients and the healthy subjects when using the triplicate culture approach (57% and 
88% respectively) as opposed to the bulk culture approach (33% and 38% respectively). 
However, these differences failed to reach statistical significance (P values of 0.92 and 
0.37 for RA patients and healthy subjects respectively, Chi-square). When using the 
triplicate culture approach, GlyAgg-specific proliferative responses were detected in 
both the RA patients and the healthy subjects but were not detected in either cohort 
when using the bulk culture approach. 
 
Figure 4.10 compares the peak SI values of HCgp39-induced, CII-induced and GlyAgg-
induced PBMC proliferation detected with the triplicate culture approach with those of 
HCgp39-induced, CII-induced and GlyAgg-induced PBMC proliferation detected with 
the bulk culture approach. Figure 4.10(A) and (B) shows that in both RA patients and 
healthy subjects respectively, the peak SI values of HCgp39-induced PBMC 
proliferation detected with the triplicate culture approach were statistically similar to 
those detected with the bulk culture approach (P values = 0.68 for RA patients and 0.29 
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for healthy subjects, Mann Whitney). Figure 4.10(C) and (D) shows that in both RA 
patients and healthy subjects respectively, the peak SI values of CII-induced PBMC 
proliferation detected with the triplicate culture approach were statistically similar to 
those detected with the bulk culture approach (P values = 0.63 for RA patients and 0.80 
for healthy subjects, Mann Whitney). Figure 4.10(E) and (F) shows that in both RA 
patients and healthy subjects respectively, the peak SI values of GlyAgg-induced 
PBMC proliferation detected with the triplicate culture approach were statistically 
similar to those detected with the bulk culture approach (P values = 0.06 for RA patients 
and 0.14 for healthy subjects, Mann Whitney). 
 
4.2.3.6. DeglyAgg-induced responses 
The 3HTdR incorporation data in Table 4.6 shows that all RA patients and all healthy 
subjects showed positive DeglyAgg-induced PBMC proliferative responses. The 
median peak SI value of DeglyAgg-induced PBMC proliferation detected in RA 
patients (median = 17.9, IQR: 11.4-30.7) was slightly less than that of DeglyAgg-
induced PBMC proliferation detected in healthy subjects (median = 19.1, IQR: 11.9-
30.2), although the difference between the 2 groups was not statistically significant (P 
value = 0.81, Mann Whitney, Figure 4.11A). In the RA patients, peak levels of 
DeglyAgg-induced PBMC proliferation were detected at days 7, 9 and 11 (n=1, 7 and 4 
respectively), and at days 3, 7, 9 and 11 (n=1, 4, 1 and 7 respectively) in the healthy 
subjects (Figure 4.11(B) and (C) respectively). 
 
The cytokine production data in Table 4.6 shows that all eight of the RA patients and all 
eight of the healthy subjects tested for DeglyAgg-induced cytokine production showed 
increased production of IL-10, IL-17, IL-4, IL-6 and TNF-α in response to the stimulus. 
Four of the RA patients and six of the healthy subjects also showed DeglyAgg-induced 
up-regulation of IFN-γ production. Both the RA patients and the healthy subjects 
showed very high levels of DeglyAgg-induced IL-6 production (median absolute values 
of median = 13245, IQR: 12872-20974 and median = 13589, IQR: 12966-22126 
respectively), and highly detectable levels of DeglyAgg-induced TNF-α production 
(median absolute values of median = 862, IQR: 425-972 and median = 782, IQR: 490-
1135 respectively). The levels of DeglyAgg-induced cytokine production did not differ 
significantly between the RA patients and the healthy subjects (P values = 0.51, 0.24, 
0.65, 0.72, 0.96 and 0.06 for IL-10, IL-17, IL-4, IL-6, TNF-α and IFN-γ respectively, 
Mann Whitney). However, when the cytokine data are expressed as SI values as 
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opposed to absolute values, the SI values of DeglyAgg-induced IL-6 production of the 
RA patient group were significantly greater than those of the healthy subject group 
(median SI values of median = 2366, IQR: 115.4-15944 versus median = 54.8, IQR: 
7.9-392.1 respectively, P value = 0.04, Mann Whitney, Figure 4.11D). 
 
Nineteen of the twenty four RA patients and fourteen of the sixteen healthy subjects 
showed proliferation and/or cytokine production responses to at least one of the four 
autoantigens. Furthermore, subjects that showed proliferative and/or cytokine 
production responses to more than one autoantigen were not rare in either of the groups. 
In the RA patient group, RA 3.30, RA 4.32, RA 4.33 and RA 4.34 all showed positive 
proliferative and cytokine production responses to both GlyAgg and DeglyAgg and RA 
4.34 also showed a positive proliferative response to CII. RA 4.35 and RA 4.38 each 
showed positive responses to both HCgp39 and CII. Of the 20 RA patients that showed 
positive responses to at least one of the autoantigens, at least 9 were both RF and CCP 
positive (a further 3 were not tested for both RF and CCP levels and 4 more were 
positive for RF but untested for CCP levels). However, 2 of the 4 non-responders were 
also both RF and CCP positive and indeed one of the responders was negative for both 
RF and CCP. No trends were visible in either the CRP levels or ESR values of 
responders or in the duration of the disease. In the healthy subject group, HS 4.13, HS 
4.15, HS 4.16 and HS 4.17 all showed positive responses to all four of the autoantigens, 
while HS 4.12 and HS 4.23 both showed positive response to HCgp39, CII and 
DeglyAgg. HS 4.10 and HS 4.22 showed positive responses to both GlyAgg and 
DeglyAgg and HCgp39 and DeglyAgg respectively. 
 
4.2.4. Co-culture approach with mo-DC and T-cells 
With the bulk culture and triplicate culture PBMC approaches, proliferative responses 
to HCgp39, CII and GlyAgg, when detected, were very weak in magnitude. 
Furthermore, the magnitude of proliferative responses detected to these autoantigens in 
RA patients was not significantly different to that detected in healthy subjects. I 
hypothesised that the magnitude of the HCgp39-induced, CII-induced and GlyAgg-
induced responses detected with these two whole PBMC approaches were low due to 
the fact that the presentation of the candidate autoantigens by un-separated PBMC was 
sub-optimal due to the lack of professional antigen-presenting cells. Therefore, I 
investigated the use of mo-DC as antigen-presenting cells. 
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As an initial step I set up a co-culture system that would allow me to detect antigen-
specific T-cell proliferation, using PPD as the test antigen. I co-cultured CD3
+
 PBMC 
(T-cells) with both immature and mature mo-DC, each either unloaded or PPD-loaded, 
at three different mo-DC: T-cell ratios; 5:1, 10:1 and 50:1. This would allow me to 
determine which type of mo-DC and which ratio of mo-DC:T-cells would allow for the 
best antigen presentation. Data from these experiments is shown in Figure 4.12A. At all 
three ratios, PPD-loaded, immature mo-DC failed to induce T-cell proliferation. When 
using PPD-loaded, LPS-matured mo-DC, positive T-cell proliferative responses were 
only detected consistently with a mo-DC:T-cell ratio of 50:1. However, the mean SI 
value of PPD-induced T-cell proliferation was only 5, and while this is a clear positive 
response, it was lower than the mean SI values of PPD-induced PBMC proliferation 
detected with either the triplicate culture or bulk culture approaches. 
 
Having established that LPS-matured mo-DC were the most efficient at presenting 
antigen to autologous T-cells, and that a mo-DC: T-cell ratio of 50:1 would elicit the 
greatest T-cell response, these parameters were used in another set of experiments in 
which HCgp39-loaded, CII-loaded, GlyAgg-loaded and DeglyAgg-loaded, LPS-
matured mo-DC were employed to elicit responses in autologous T-cells. Data from 
these experiments are shown in Figure 4.12B. PPD-loaded, LPS-matured mo-DC mixed 
with autologous T-cells served as a positive control. Of the 2 RA patients and 3 healthy 
subjects tested, all showed SI values of PPD-induced T-cell proliferation of 2 or greater, 
although surprisingly the SI values of PPD-induced proliferation seen with the whole 
PBMC triplicate culture approach were significantly greater than those seen with the 
mo-DC and T-cell co-culture approach (median = 16.0, IQR: 5.5-31.1 versus median = 
4.8, IQR: 2.4-6.1 respectively, P value = 0.04, Mann Whitney). Most importantly no T-
cell proliferation was shown by any of the 5 subjects in response to HCgp39, CII, 
GlyAgg or DeglyAgg when using the mo-DC and T-cell co-culture approach. 
 
4.2.5. The role of bacterial lipopolysaccharide (LPS) contamination in DeglyAgg-
induced responses 
Because of the nature of the DeglyAgg-induced responses (i.e. the universal nature of 
eliciting T-cell responses in RA patients and healthy subjects as well as the predominant 
production of IL-6), it was possible that the DeglyAgg preparation was contaminated 
with LPS and that the PBMC were responding to this and not the DeglyAgg antigen. In 
order to first determine whether the DeglyAgg preparation contained any LPS, a LAL 
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assay was performed on samples of the DeglyAgg preparation. At a concentration of 
1mg/ml in RPMI 1640, the DeglyAgg preparation was found to contain 1.7 EU/ml of 
endotoxin. According to the LAL kit manufacturers, 10EU equals 1ng of endotoxin, 
meaning that 1ml of a 1mg/ml solution of the DeglyAgg contained 170pg of endotoxin. 
However, previous studies have suggested that such concentrations of LPS are 
insufficient to induce T-cell proliferation (Tough et al, 1997 and Tulic et al, 2002). To 
determine to what extent this level of LPS was influencing the DeglyAgg response, I 
stimulated PBMC from 5 healthy volunteers with 10µg/ml DeglyAgg with and without 
the presence of PMB, a compound that neutralises LPS (Cardoso et al, 2007). PBMC 
proliferation and IL-6 production in response to the stimulus were assessed after 5, 7, 9 
and 11 days of culture via 3HTdR incorporation and ELISA respectively. Figure 4.13A 
shows the mean SI values of DeglyAgg-induced PBMC proliferation seen with or 
without the presence of PMB at each of the time-points. When no PMB was present in 
the cell cultures, DeglyAgg-induced PBMC proliferation was detectable at all 4 time-
points (mean ± SEM SI values of 2.8 ± 0.6, 8.3 ± 2.9, 11.6 ± 5.5 and 10.9 ± 5.1 at days 
5, 7, 9 and 11 respectively), and peak levels of DeglyAgg-induced PBMC proliferation 
were detected at day 9. However, when PMB was present in the cell cultures, no 
DeglyAgg-induced PBMC proliferation was detected at days 5, 7 and 9 (mean ± SEM 
SI values of 1.2 ± 0.5, 1.5 ± 0.2 and 1.9 ± 0.8 respectively). Only at day 11 was any 
PBMC proliferation in response to the DeglyAgg detected (mean ± SEM SI value of 6.4 
± 2.1). Therefore, while the PMB was certainly reducing the magnitude of the 
DeglyAgg-induced proliferative response, it did not completely abrogate it. Importantly, 
data from three separate experiments showed that PMB treatment of PBMC cultures did 
not reduce the magnitude of the PHA-induced proliferative response (mean ± SEM SI 
value of PHA-induced PBMC proliferation without PMB versus mean ± SEM SI value 
of PHA-induced PBMC proliferation with PMB = 185.6 ± 62.8 versus 240.9 ± 116.8 
respectively, P value of 0.4, paired t test). Figure 4.13B shows the mean absolute levels 
of DeglyAgg-induced IL-6 production seen with or without PMB at each of the 4 time-
points. When PMB was not present in the cultures, high levels of DeglyAgg-induced 
IL-6 production were detected at all 4 time-points. The peak levels of DeglyAgg-
induced IL-6 production were detected at day 5 (mean ± SEM absolute value of 27464 
± 1281), and the levels decreased steadily over the subsequent 2 time-points (mean ± 
SEM absolute values of 26421 ± 1038 and 22914 ± 4125 at days 7 and 9 respectively). 
However, by day 11, the levels of IL-6 production detected in response to the DeglyAgg 
increased again (mean ± SEM absolute value of 25258 ± 974). The kinetic of the 
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DeglyAgg-induced IL-6 production response detected when PMB was present in the 
cultures was very similar, although the presence of the PMB clearly reduced the levels 
of IL-6 production detected in response to the DeglyAgg at all time-points (mean ± 
SEM absolute values of 20578 ± 1247, 17866 ± 1438, 14516 ± 3697 and 17256 ± 1300 
at days 5, 7, 9 and 11 respectively). Indeed, this reduction reached significant levels at 
days 5, 7 and 11 (P values = 0.02, 0.0079 and 0.0079 respectively, Mann Whitney). 
 
4.3. Discussion 
The experiments described in this chapter failed to provide evidence suggesting that 
HCgp39, CII or aggrecan are RA autoantigens involved in disease pathogenesis. In the 
experiments described in 4.2.1, I measured HCgp39-induced proliferation of peripheral 
blood T-cells in each of 15 RA patients using the CFSE dilution assay and assessed 
proliferation within both the CD4
-
 and CD4
+
 subsets as both an increase in the % of 
CFSE
dim
 cells and as a stimulation index. When proliferation was assessed as an 
increase in the % of CFSE
dim
 cells, 7 of the 15 RA patients showed HCgp39-induced T-
cell proliferation (Table 4.1). Proliferation was more frequently seen in the CD4
+
 subset 
than the CD4
-
 subset (5 subjects versus 4 subjects). In 50% of cases, proliferation within 
the CD4
-
 subset occurred in conjunction with proliferation in the CD4
+
 subset. 
However, with one exception (RA 4.5), the percentages of these HCgp39-induced T-cell 
responses were very low and indeed when they were expressed as SI values, none 
exceeded the threshold for a positive response (Table 4.1). As previously mentioned, 
many of the studies measuring proliferation of immune cells in response to candidate 
autoantigens have used the 3HTdR incorporation assay to measure proliferation within 
un-separated populations of PBMC and the data were often expressed as SI values with 
an SI value of 2 or more being used as the threshold for a positive response (Verheijden 
et al, 1997; Snowden et al, 1997; Guerassimov et al, 1998; Cope et al, 1999; Kim et al, 
1999; Vos et al #2, 2000 and Ria et al, 2008). However, it could be the case that 
expressing CFSE dilution data measuring proliferation in a specific subset of PBMC as 
an SI value is not appropriate. Because CFSE dilution assays measure cell division 
whereas 3HTdR incorporation assays measure indirectly DNA incorporation over a 
period of time, then the magnitude of ‘responses’ relative to unstimulated culture may 
not be comparable. Furthermore, in 3HTdR incorporation assays, other subsets of cells 
may also contribute to the proliferative response, although in chapter 3 I found that 
3HTdR incorporation data mirrors that of CFSE dilution assays for CD3
+
 T-cells. 
Although the precursor frequencies of the antigen-specific T-cell responses were not 
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formally enumerated, the data from these experiments suggest that the precursor 
frequencies of autoantigen-specific T-cell responses are likely to be low. The fact that 
good PHA-induced proliferative responses were observed in all 15 of the RA patients 
suggests that the serum from each patient was capable of supporting T-cell proliferation, 
therefore it is unlikely that the observed lack of HCgp39-induced T-cell proliferation 
was due to any problems associated with the use of AS as a culture medium 
supplement. 
 
In the 3HTdR incorporation experiments described in 4.2.2, I chose the bulk culture 
approach as opposed to a triplicate culture approach as I anticipated that the former 
would be more sensitive in the detection of low precursor-frequency autoantigen-
specific T-cell responses. My rationale was that the higher numbers of cells per well 
achieved with the bulk culture approach would increase the likelihood of autoantigen-
specific T-cells encountering antigen-presenting cells presenting the autoantigens. 
While substantial numbers of both HCgp39-induced and CII-induced proliferative 
responses were detected using the bulk culture approach, no GlyAgg-specific 
proliferative responses were detected (Table 4.2). However, similar proportions of RA 
patients and healthy subjects showed positive PBMC proliferative responses to HCgp39 
and CII (Table 4.2). Furthermore, the magnitudes of the proliferative responses to 
HCgp39 and CII were comparable between the RA patients and the healthy subjects 
(Figure 4.3(A) and (B)). 
 
In the 3HTdR incorporation experiments described in 4.2.3, I revisited the triplicate 
culture approach with 2x10
5
 cells/well as used in many previous RA autoantigen 
studies. I also compared the data obtained using the triplicate culture approach with that 
obtained using the bulk culture approach but because the 2 different approaches were 
not tested with PBMC from the same subjects (in part due to the number of cells 
required for such assays) and compared in parallel, observations made from this 
comparison should be interpreted with caution. Nevertheless, I found that triplicate 
culture 3HTdR incorporation assays are at least as sensitive as the bulk culture 
approach. 
 
While there was a general trend suggesting that greater proportions of HCgp39-specific, 
CII-specific and GlyAgg-specific proliferative responses were detected when using the 
triplicate culture approach as opposed to the bulk culture approach in both the RA 
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patients and the healthy subjects, the differences between the 2 approaches were not 
statistically significant. Indeed, the magnitudes of HCgp39-specific, CII-specific and 
GlyAgg-specific proliferative responses detected with the 2 approaches were similar 
(Figure 4.10). Ultimately, as seen with the bulk culture approach, HCgp39-specific, CII-
specific and GlyAgg-specific proliferative responses were no more prevalent in RA 
patients than in healthy subjects (Tables 4.3, 4.4 and 4.5) and the magnitudes of the 
responses were similar in both subject groups (Figures 4.7A, 4.8A and 4.9A). 
 
Of course, proliferation is only one of several immune responses that are made by T-
cells therefore I also examined cytokine production in response to the candidate RA 
autoantigens. I had collected supernatant samples from all of the bulk culture and 
triplicate culture experiments but because the triplicate culture approach was associated 
with greater proportions of candidate RA autoantigen-specific responses, I decided to 
use the supernatant samples from only the triplicate culture experiments to investigate 
candidate RA autoantigen-specific cytokine production. However, as previously 
mentioned, the comparison of the triplicate culture and bulk culture approaches was not 
an optimal comparison. In addition, and as alluded to in my previous chapter and 
demonstrated by the data in this chapter, cytokine production may occur independently 
of proliferation, although it is possible that the optimal conditions for the detection of 
cytokine production responses may be identical to the conditions that are optimal for the 
detection of proliferative responses. Nevertheless, the cytokine production data obtained 
from the triplicate culture experiments showed that the HCgp39-specific, CII-specific 
and GlyAgg-specific cytokine production responses of the RA patients did not differ 
significantly from those of the healthy subjects. 
 
The levels of background cytokine production detected in each of the RA patients and 
healthy subjects tested for candidate autoantigen-induced cytokine production in the 
experiments described in 4.2.3 are shown in Table 4.7 and Table 4.8 respectively. As 
can be seen, many of the subjects from both the RA patient and healthy subject groups 
showed highly detectable levels of background production of both IL-6 and TNF-α. 
When candidate autoantigen-induced increases in IL-6 and TNF-α production were 
observed, they were in the majority of cases highly substantial (see the absolute values 
of HCgp39-induced, CII-induced, GlyAgg-induced and DeglyAgg-induced IL-6 and 
TNF-α production in Table 4.3, Table 4.4, Table 4.5 and Table 4.6 respectively), and 
highly likely to be representative of positive responses. However, occasional subjects 
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showed substantial levels of background production of IL-10, IL-17, IL-4 and IFN-γ, 
and candidate autoantigen-induced increases in production of these cytokines were more 
subtle, thus care must be taken when interpreting such data. For example, when PBMC 
from RA 4.38 were cultured with medium alone, the supernatant was shown to contain 
IL-17 at a concentration of 56pg/ml (Table 4.7), yet the absolute value of CII-induced 
IL-17 production for RA 4.38 was 3pg/ml (Table 4.4A), as the supernatant from the 
CII-stimulated culture of PBMC from this subject was shown to contain IL-17 at a 
concentration of 59pg/ml. However, because background production of IL-17 by the 
PBMC from RA 4.38 was so substantial, it is debatable whether an absolute value of 
CII-induced IL-17 production of 3pg/ml in this patient can really be classed as a 
positive response, despite the fact that it exceeds the detection threshold of a positive 
response. 
 
DeglyAgg-induced proliferative responses were observed in all subjects tested and the 
magnitudes of these responses were similar between RA patients and healthy subjects 
(Table 4.6 and Figure 4.11A). DeglyAgg-induced cytokine production responses of the 
RA patients and the healthy subjects were also comparable (Table 4.6). However, the 
DeglyAgg-specific proliferative responses were more prominent than those induced by 
HCgp39, CII and GlyAgg. In addition, while all subjects produced detectable levels of 
IL-10, IL-17, IL-4, IL-6 and TNF-α in response to DeglyAgg, in both cohorts, IL-6 and 
TNF-α were the most abundantly produced cytokines. This raised the possibility of LPS 
contamination of the DeglyAgg which was confirmed by LAL assay. In experiments 
using PMB to determine to what extent the LPS was influencing the DeglyAgg-specific 
response, I demonstrated that PMB could reduce the DeglyAgg-induced proliferation 
and IL-6 production responses but could not completely abrogate them (Figure 4.13). 
One possible explanation of this observation is that the LPS acts by amplifying the 
response to the DeglyAgg through acting as an adjuvant, perhaps through activating 
antigen-presenting cells and up-regulating antigen processing and presentation among 
this cell population. 
 
The kinetics of the candidate RA autoantigen-induced proliferative responses varied 
between individual subjects, and no clear differences were observed between RA 
patients and healthy subjects on the basis of response kinetics. In both groups, some 
subjects showed peak levels of proliferation early on in the culture period suggestive of 
memory responses, while many showed peak proliferation at the later time-points 
 107 
associated with primary responses of naïve T-cells (Croft et al, 1994). This suggests that 
T-cell memory to HCgp39, CII and aggrecan is no more common in RA patients than in 
healthy subjects. 
 
While it is indeed possible that HCgp39-specific, CII-specific and aggrecan-specific T-
cell responses do not differ between RA patients and healthy subjects in vivo, another 
explanation as to why I was not seeing differences between the HCgp39-specific, CII-
specific and aggrecan-specific T-cell responses of the RA patients and the healthy 
subjects with the bulk culture and triplicate culture approaches could have been that the 
responses were sub-optimal when using in vitro cultures of whole PBMC. Indeed, the 
magnitudes of the HCgp39, CII and GlyAgg-induced proliferation and cytokine 
production responses were in general very moderate, especially when compared to those 
seen in response to DeglyAgg. One explanation as to why the magnitudes of HCgp39-
specific, CII-specific and GlyAgg-specific responses seen in these experiments were 
very moderate could have been that antigen presentation in the whole PBMC cultures 
was not optimal. Enhanced antigen presentation may amplify the T-cell responses and 
enable any differences between the responses of RA patients and healthy subjects to be 
observed more easily. To investigate whether sub-optimal presentation of the antigens 
was a reason for the weak responses seen, I repeated the experiments using a co-culture 
approach using autoantigen-loaded mo-DC and T-cells, anticipating that the presence of 
specialised antigen-presenting cells would solve the potential problem of sub-optimal 
antigen presentation. However, no HCgp39, CII, GlyAgg or even DeglyAgg-specific 
proliferation was seen with this mo-DC and T-cell co-culture approach (Figure 4.12B). 
Furthermore, the magnitudes of the PPD-specific proliferative responses seen with the 
mo-DC and T-cell co-culture approach were significantly less than those seen with the 
triplicate culture approach using un-separated PBMC. However, the comparison of data 
from the mo-DC:T-cell co-culture approach with that from the triplicate culture 
approach was not a direct comparison due to the cell numbers required. In any case, if 
the mo-DC were impairing the PPD-induced proliferative responses, then it would 
suggest that the mo-DC preparation was toxic in some way. 
 
The experiments described in 4.2.2 and 4.2.3.2 showed that HCgp39-specific PBMC 
proliferation was detected in both RA patients and healthy subjects, similar to what has 
been described in previous studies (Verheijden et al, 1997; Cope et al, 1999 and Vos et 
al #2, 2000). However, Verheijden et al (1997) demonstrated that a substantially greater 
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proportion of RA patients than healthy subjects showed HCgp39-specific PBMC 
proliferation, while a subsequent study showed a significantly greater proportion of RA 
patients than healthy subjects showed HCgp39-specific PBMC proliferation (Vos et al 
#2, 2000). However, data from my experiments do not support these observations. In 
the experiments described in 4.2.2, HCgp39-specific PBMC proliferation was detected 
in a very similar proportion of RA patients as healthy subjects (44% and 38% 
respectively, Table 4.2). The difference between my data and those from the Verheijden 
et al and Vos et al #2 studies could be due to the fact that my data were obtained using 
whole protein HCgp39 while the others used HCgp39-derived peptides. Indeed, in these 
studies one or two of the peptides induced the majority of the responses. Perhaps these 
peptides were not being generated in abundance in my in vitro cultures and were not 
readily available for presentation. In the experiments described in 4.2.3.2, HCgp39-
specific PBMC proliferation was detected in a substantially greater proportion of 
healthy subjects than RA patients (75% versus 40%, Table 4.3). It has been previously 
reported that the HCgp39-specific PBMC reactivity of healthy subjects is characterised 
by production of IL-10 while that of RA patients is associated with significantly greater 
levels of IFN-γ production (van Bilsen et al, 2004). However, the experiments described 
in 4.2.3.2 showed that of the four healthy subjects that showed HCgp39-induced 
cytokine production, none showed any up-regulation of IL-10 in response to the 
stimulus (Table 4.3B). Furthermore, of the four RA patients that showed HCgp39-
induced cytokine production, none showed any up-regulation of IFN-γ or IL-10 in 
response to the stimulus (Table 4.3A). This lack of detectable HCgp39-induced IFN-γ 
production by RA patients is similar to what was described by Zou et al (2003). 
However, while Zou et al also reported a lack of detectable HCgp39-induced TNF-α 
production in both RA patients and healthy subjects, my experiments showed that 
HCgp39 induced production of detectable levels of TNF-α production in three of the 
RA patients and two of the healthy subjects (Table 4.3). 
 
The experiments described in 4.2.2 showed that CII-induced proliferative responses 
were detected in 33% of RA patients (Table 4.2), and this is similar to what was 
observed in previous studies that used whole protein CII to stimulate RA patient and 
healthy subject PBMC (Kim et al, 1999 and Park et al, 2001). However, these previous 
studies also demonstrated that CII-specific proliferative responses were significantly 
more prevalent in RA patients than in healthy subjects. In contrast, the data from my 
experiments showed that the proportions of subjects showing CII-induced proliferative 
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responses were comparable between RA patient and healthy subject groups (Table 4.2 
and Table 4.4), and this is similar to what was reported by Snowden et al (1997) who 
also used whole protein CII to stimulate RA patient and healthy subject PBMC. The 
experiments described in 4.2.3.3 detected CII-induced proliferative responses in an even 
greater proportion of RA patients, similar to that described by Snowden et al (1997). It 
has been shown that RA patients show significantly greater levels of CII-induced IFN-γ 
than healthy subjects (Park et al, 2001), although the data from my experiments did not 
support this finding. Indeed, while comparable levels of CII-induced IFN-γ production 
were detected in both RA patients and healthy subjects, a greater proportion of healthy 
subjects than RA patients showed CII-induced IFN-γ production (Figure 4.8A and 
Table 4.4). In addition, while Zou et al (2003) reported that neither RA patients nor 
healthy subjects showed any CII-induced TNF-α production, my data showed that of the 
four RA patients and six healthy subjects that showed CII-induced cytokine production, 
two of the former and all of the latter up-regulated production of TNF-α in response to 
the stimulus (Table 4.4). 
 
In the experiments described in 4.2.3.4, GlyAgg-induced proliferative responses were 
detected in similar proportions of RA patients and healthy subjects and the SI values of 
GlyAgg-induced proliferation were comparable between both groups (Table 4.5 and 
Figure 4.9A). This finding is consistent with the study published by Guerassimov et al 
(1998) which showed that the G1 domain of aggrecan in its native, glycosylated form, is 
no more immunogenic to RA patient PBMC than it is to healthy subject PBMC. 
However, a further observation of the Guerassimov study was that keratin sulphate-
depleted G1 induced proliferative responses in a greater proportion of RA patients than 
healthy subjects and that the SI values of keratin sulphate-depleted G1 were 
significantly greater in RA patients than in healthy subjects. In addition, using whole 
protein DeglyAgg to stimulate RA patient and healthy subject PBMC, Goodstone et al 
(1996) observed that a significantly greater proportion of RA patients than healthy 
subjects showed positive proliferative responses to the stimulus, and that the SI values 
of DeglyAgg-induced PBMC proliferation observed in the former were significantly 
greater than those observed in the latter. However, while the experiments described in 
4.2.3.6 showed that deglycosylation did enhance the immunogenicity of the aggrecan, 
this effect was observed in both the RA patient and healthy subject groups, and the SI 
values of DeglyAgg-induced proliferation were similar in both cohorts (Table 4.6 and 
Figure 4.11A). In terms of cytokine production, it has been reported that certain 
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aggrecan-derived peptides induce significantly higher levels of pro-inflammatory 
cytokines such as IL-6 and TNF-α from RA patient PBMC than from healthy subject 
PBMC but induce very little detectable IL-4 and IFN-γ (de Jong et al, 2009). As shown 
in Table 4.5, I observed an absence of detectable IFN-γ in response to GlyAgg in both 
RA patients and healthy subjects, while detectable GlyAgg-induced IL-4 production 
was absent in the healthy subject group but observed in two subjects from the RA 
patient group. GlyAgg-induced IL-6 and TNF-α production was observed in both 
groups and while IL-6 production by the RA patients tended to be greater than IL-6 
production by the healthy subjects and more RA patients than healthy subjects showed 
TNF-α production, no significant differences were observed between the two groups 
(Table 4.5). The high levels of DeglyAgg-induced IL-6 and TNF-α production observed 
in the RA patients was matched by similar levels in the healthy subjects, and detectable 
levels of IL-4 and IFN-γ production in response to the stimulus were observed in both 
groups (Table 4.6). 
 
4.4. Summary 
Positive proliferative and/or cytokine production responses to the whole protein 
candidate RA autoantigens HCgp39, CII, GlyAgg and DeglyAgg were readily 
detectable in both RA patients and healthy subjects. However, the responses were 
generally weak and both the proportions of subjects showing positive responses to any 
of the autoantigens as well as the magnitudes of these responses did not differ 
significantly between the two groups. Furthermore, the candidate RA autoantigen-
induced cytokine production responses of RA patients were similar to those of healthy 
subjects. 
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ID 
Increase in % CFSE
dim
 cells CFSE dilution SI value 
CD4
-
 CD4
+
 CD4
-
 CD4
+
 
RA 4.1 
1.45-1.60 = 
0 
1.22-1.40 = 
0 
1.45/1.60 =  
0.9 
1.22/1.40 =  
0.9 
RA 4.2 
0.26-0.66 = 
0 
1.20-1.64 = 
0 
0.26/0.66 =  
0.4 
1.20/1.64 =  
0.7 
RA 4.3 
0.27-0.17 = 
0.10 
1.04-0.63 = 
0.41 
0.27/0.17 =  
1.6 
1.04/0.63 =  
1.7 
RA 4.4 
0.17-0.22 = 
0 
1.51-0.93 = 
0.58 
0.17/0.22 =  
0.8 
1.51/0.93 =  
1.6 
RA 4.5 
0.62-0.19 = 
0.43 
5.58-1.41 = 
4.17 
0.62/0.19 =  
3.3 
5.58/1.41 =  
4.0 
RA 4.6 
0.31-0.30 = 
0.01 
0.43-0.32 = 
0.11 
0.31/0.30 =  
1.0 
0.43/0.32 =  
1.3 
RA 4.7 
0.64-0.62 = 
0.02 
1.70-1.10 = 
0.60 
0.64/0.62 =  
1.0 
1.70/1.10 =  
1.6 
RA 4.8 
0.15-0.13 = 
0.02 
0.77-0.71 = 
0.06 
0.15/0.13 =  
1.2 
0.77/0.71 =  
1.1 
RA 4.9 
0.71-0.72 = 
0 
0.52-0.47 = 
0.05 
0.71/0.72 =  
1.0 
0.52/0.47 =  
1.1 
RA 4.10 
0.40-1.13 = 
0 
0.95-1.09 = 
0 
0.40/1.13 =  
0.4 
0.95/1.09 =  
0.9 
RA 4.11 
0.95-0.98 = 
0 
1.40-1.61 = 
0 
0.95/0.98 =  
1.0 
1.40/1.61 =  
0.9 
RA 4.12 
0.62-0.70 = 
0 
1.54-1.46 = 
0.08 
0.62/0.70 =  
0.9 
1.54/1.46 =  
1.1 
RA 4.13 
0.10-0.11 = 
0 
0.16-0.14 = 
0.02 
0.10/0.11 =  
0.9 
0.16/0.14 =  
1.1 
RA 4.14 
1.26-1.06 = 
0.20 
1.29-1.21 = 
0.08 
1.26/1.06 =  
1.2 
1.29/1.21 =  
1.1 
RA 4.15 
2.89-2.51 = 
0.38 
1.23-1.42 = 
0 
2.89/2.51 =  
1.2 
1.23/1.42 =  
0.9 
 
Table 4.1. HCgp39-induced proliferation of peripheral blood T-cells in RA 
patients. CFSE-labelled PBMC from 15 RA patients were cultured with either medium 
alone, 5µg/ml PHA or 10µg/ml HCgp39. After 7 days, cells were harvested, stained for 
expression of CD3 and CD4 and analysed for proliferation via CFSE dilution. 
Proliferation within the CD4
-
 and CD4
+
 subsets of CD3
+
 lymphocytic PBMC was 
measured as both an increase in the % CFSE
dim
 cells in response to the stimulus (i.e. % 
CFSE
dim
 cells in PHA/HCgp39-stimulated culture minus % CFSE
dim
 cells in 
unstimulated culture) and as a CFSE dilution stimulation index (i.e. percentage of 
CFSE
dim
 cells in PHA/HCgp39-stimulated culture divided by percentage of CFSE
dim
 
cells in unstimulated culture). 
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A) RA patients 
ID 
3HTdR incorporation SI value (peak) 
PHA PPD HCgp39 CII GlyAgg 
RA 4.16 34.6 2.2 5 1.7 - 
RA 4.17 44.8 1.9 1 1.4 - 
RA 4.18 288.7 27.7 1.4 1.1 - 
RA 4.19 37.8 4.7 3.7 3.3 - 
RA 4.20 120.9 4 1.7 4 1.1 
RA 4.21 89.8 79 1.6 1.4 0.8 
RA 4.22 168.8 1.7 0.9 1.2 0.8 
RA 4.23 60.1 0.8 2.1 0.9 0.6 
RA 4.24 171.9 - 2.7 8.1 - 
 
B) Healthy subjects 
ID 
3HTdR incorporation SI value (peak) 
PHA PPD HCgp39 CII GlyAgg 
HS 4.1 29.2 9.8 1.9 1.9 - 
HS 4.2 36.1 4.9 1.7 1.4 - 
HS 4.3 38 18.7 7.9 1.9 - 
HS 4.4 4.8 2.4 1.9 1.2 - 
HS 4.5 40.7 7 1.1 7.6 0.9 
HS 4.6 37.5 2.4 2.5 10.6 0.7 
HS 4.7 65.7 5.8 3.5 13.1 1.4 
HS 4.8 175.6 4.1 1.1 1.9 0.6 
 
Table 4.2. PBMC proliferation detected in RA patients and healthy subjects when 
using the bulk culture 3HTdR incorporation approach. PBMC from 9 RA patients 
and 8 healthy subjects were cultured with either medium alone, 5µg/ml PHA, 1µg/ml 
PPD, 10µg/ml HCgp39, 10µg/ml CII or 10µg/ml GlyAgg. Proliferation was assessed 
after 5, 7, 9 & 11 days via 3HTdR incorporation. A, the peak SI values of PHA-induced, 
PPD-induced, HCgp39-induced, CII-induced and GlyAgg-induced PBMC proliferation 
detected in RA patients. B, the peak SI values of PHA-induced, PPD-induced, HCgp39-
induced, CII-induced and GlyAgg-induced PBMC proliferation detected in healthy 
subjects. In both tables, a dash (-) represents an untested value. 
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A) RA patients 
ID 
HCgp39-induced PBMC responses 
3HTdR incorporation 
SI value (peak) 
Cytokine production (day 5) 
IL-10 IL-17 IL-4 IL-6 TNF-α IFN-γ 
RA 4.25 4.4 0 0 0 191 4 0 
RA 4.26 1.8 0 0 0 86 0 0 
RA 4.35 2 0 0 10 2649 90 0 
RA 4.36 1.7 0 0 0 0 0 ˗ 
RA 4.37 1.4 0 0 0 0 0 0 
RA 4.38 1.6 0 0 0 673 64 0 
RA 4.40 1.9 - - - - - - 
RA 4.41 12 - - - - - - 
RA 4.42 1.1 - - - - - - 
RA 4.46 2.3 - - - - - - 
 
B) Healthy subjects 
ID 
HCgp39-induced PBMC responses 
3HTdR incorporation 
SI value (peak) 
Cytokine production (day 5) 
IL-10 IL-17 IL-4 IL-6 TNF-α IFN-γ 
HS 4.12 2 0 0 0 0 0 0 
HS 4.13 3.1 0 0 3 4890 46 0 
HS 4.14 1.7 0 0 0 58 0 0 
HS 4.15 3.6 0 0 0 0 0 0 
HS 4.16 4.4 0 0 0 10 9 0 
HS 4.17 1.9 0 0 0 0 0 14 
HS 4.22 3.4 - - - - - - 
HS 4.23 2.3 - - - - - - 
 
Table 4.3. HCgp39-induced PBMC responses identified with the triplicate culture 
approach. PBMC from 10 RA patients and 8 healthy subjects were cultured with either 
medium alone, 5µg/ml PHA, 1µg/ml PPD or 10µg/ml HCgp39. Proliferation was 
assessed after 3, 5, 7, 9 & 11 days via 3HTdR incorporation and cytokine levels in cell 
culture supernatant samples harvested at day 5 were assessed via ECL multiplex and 
ELISA. A, the peak SI values of HCgp39-induced PBMC proliferation and the day 5 
absolute values of HCgp39-induced cytokine production detected in the RA patients. B, 
the peak SI values of HCgp39-induced PBMC proliferation and the day 5 absolute 
values of HCgp39-induced cytokine production detected in the healthy subjects. In both 
tables, a dash (-) represents an untested value. 
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A) RA patients 
ID 
CII-induced PBMC responses 
3HTdR incorporation 
SI value (peak) 
Cytokine production (day 5) 
IL-10 IL-17 IL-4 IL-6 TNF-α IFN-γ 
RA 4.34 4.5 - - - - - - 
RA 4.35 2.1 0 0 0 3326 84 0 
RA 4.36 2.5 0 0 0 462 0 ˗ 
RA 4.37 3.8 0 0 0 79 0 8 
RA 4.38 1.9 0 3 0 1817 99 0 
RA 4.43 1 - - - - - - 
RA 4.46 1.2 - - - - - - 
 
B) Healthy subjects 
ID 
CII-induced PBMC responses 
3HTdR incorporation 
SI value (peak) 
Cytokine production (day 5) 
IL-10 IL-17 IL-4 IL-6 TNF-α IFN-γ 
HS 4.12 2.6 0 0 0 0 10 0 
HS 4.13 7.4 0 7 14 5768 14 12 
HS 4.14 2.8 0 0 3 3788 68 0 
HS 4.15 2.2 7 0 6 4679 426 31 
HS 4.16 4.4 8 6 13 3775 31 0 
HS 4.17 3.1 3 15 18 12633 61 8 
HS 4.22 1.1 - - - - - - 
HS 4.23 2.4 - - - - - - 
 
Table 4.4. CII-induced PBMC responses identified with the triplicate culture 
approach. PBMC from 7 RA patients and 8 healthy subjects were cultured with either 
medium alone, 5µg/ml, 1µg/ml PPD or 10µg/ml CII. Proliferation was assessed after 3, 
5, 7, 9 & 11 days via 3HTdR incorporation and cytokine levels in cell culture 
supernatant samples harvested at day 5 were assessed via ECL multiplex and ELISA. A, 
the peak SI values of CII-induced PBMC proliferation and the day 5 absolute values of 
CII-induced cytokine production detected in the RA patients. B, the peak SI values of 
CII-induced PBMC proliferation and the day 5 absolute values of CII-induced cytokine 
production detected in the healthy subjects. In both tables, a dash (-) represents an 
untested value. 
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A) RA patients 
ID 
GlyAgg-induced PBMC responses 
3HTdR incorporation 
SI value (peak) 
Cytokine production (day 5) 
IL-10 IL-17 IL-4 IL-6 TNF-α IFN-γ 
RA 4.30 3.5 0 0 0 24 0 0 
RA 4.31 1.6 0 0 0 0 0 0 
RA 4.32 2.1 0 0 0 209 4 0 
RA 4.33 2 0 3 6 1640 3 0 
RA 4.34 3.7 2 0 3 3037 34 0 
RA 4.40 1.1 - - - - - - 
RA 4.41 0.9 - - - - - - 
RA 4.44 0.3 - - - - - - 
RA 4.45 1.2 - - - - - - 
 
B) Healthy subjects 
ID 
GlyAgg-induced PBMC responses 
3HTdR incorporation 
SI value (peak) 
Cytokine production (day 5) 
IL-10 IL-17 IL-4 IL-6 TNF-α IFN-γ 
HS 4.9 1.2 0 0 0 0 0 0 
HS 4.10 4 0 0 0 0 0 0 
HS 4.11 1.3 0 0 0 25 0 0 
HS 4.12 1.7 0 0 0 0 0 0 
HS 4.13 2.3 0 0 0 146 0 0 
HS 4.15 2.7 0 0 0 116 0 0 
HS 4.16 2.7 0 0 0 393 4 0 
HS 4.17 1.2 0 0 0 430 0 0 
HS 4.20 0.8 - - - - - - 
HS 4.21 0.2 - - - - - - 
 
Table 4.5. GlyAgg-induced PBMC responses identified with the triplicate culture 
approach. PBMC from 9 RA patients and 10 healthy subjects were cultured with either 
medium alone, 5µg/ml PHA, 1µg/ml PPD or 10µg/ml GlyAgg. Proliferation was 
assessed after 3, 5, 7, 9 & 11 days via 3HTdR incorporation and cytokine levels in cell 
culture supernatant samples harvested at day 5 were assessed via ECL multiplex and 
ELISA. A, the peak SI values of GlyAgg-induced PBMC proliferation and the day 5 
absolute values of GlyAgg-induced cytokine production detected in the RA patients. B, 
the peak SI values of GlyAgg-induced PBMC proliferation and the day 5 absolute 
values of GlyAgg-induced cytokine production detected in the healthy subjects. In both 
tables, a dash (-) represents an untested value. 
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A) RA patients 
ID 
DeglyAgg-induced PBMC responses 
3HTdR incorporation 
SI value (peak) 
Cytokine production (day 5) 
IL-10 IL-17 IL-4 IL-6 TNF-α IFN-γ 
RA 4.27 17.9 121 36 55 13674 1103 16 
RA 4.28 17.8 18 11 67 13040 914 16 
RA 4.29 9.3 26 37 70 12835 385 0 
RA 4.30 92.4 449 58 819 33570 206 0 
RA 4.31 10.5 28 13 35 11754 938 0 
RA 4.32 14.1 144 13 94 23408 810 0 
RA 4.33 10.5 30 30 46 12982 983 55 
RA 4.34 23.9 18 24 68 13449 544 0 
RA 4.39 16 - - - - - - 
RA 4.46 66.2 - - - - - - 
RA 4.47 26.9 - - - - - - 
RA 4.48 31.9 - - - - - - 
 
B) Healthy subjects 
ID 
DeglyAgg-induced PBMC responses 
3HTdR incorporation 
SI value (peak) 
Cytokine production (day 5) 
IL-10 IL-17 IL-4 IL-6 TNF-α IFN-γ 
HS 4.9 20 173 105 118 33485 531 0 
HS 4.10 30.4 133 46 239 19284 357 0 
HS 4.11 16.7 73 13 92 23073 477 144 
HS 4.12 30 26 47 94 12934 927 27 
HS 4.13 40.2 84 45 64 13695 739 70 
HS 4.15 22.4 25 11 48 9712 1205 505 
HS 4.16 35.4 151 25 33 13063 824 34 
HS 4.17 13 64 44 92 13483 2276 89 
HS 4.18 11.2 - - - - - - 
HS 4.19 12.5 - - - - - - 
HS 4.22 4.5 - - - - - - 
HS 4.23 6.6 - - - - - - 
HS 4.24 19.1 - - - - - - 
 
Table 4.6. DeglyAgg-induced PBMC responses identified with the triplicate culture 
approach. PBMC from 12 RA patients and 13 healthy subjects were cultured with 
either medium alone, 5µg/ml PHA, 1µg/ml PPD or 10µg/ml DeglyAgg. Proliferation 
was assessed after 3, 5, 7, 9 & 11 days via 3HTdR incorporation and cytokine levels in 
cell culture supernatant samples harvested at day 5 were assessed via ECL multiplex 
and ELISA. A, the peak SI values of DeglyAgg-induced PBMC proliferation and the 
day 5 absolute values of DeglyAgg-induced cytokine production detected in the RA 
patients. B, the peak SI values of DeglyAgg-induced PBMC proliferation and the day 5 
absolute values of DeglyAgg-induced cytokine production detected in the healthy 
subjects. In both tables, a dash (-) represents an untested value. 
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ID 
Background cytokine production in pg/ml (day 5) 
IL-10 IL-17 IL-4 IL-6 TNF-α IFN-γ 
RA 4.25 0 8 0 181 6 9 
RA 4.26 0 0 0 45 3 394 
RA 4.27 0 0 0 0 4 12 
RA 4.28 0 0 0 55 53 5 
RA 4.29 2 0 0 439 55 0 
RA 4.30 0 0 0 176 13 0 
RA 4.31 0 0 0 0 0 0 
RA 4.32 0 0 0 463 95 21 
RA 4.33 0 0 0 47 28 0 
RA 4.34 0 0 0 50 2 5 
RA 4.35 0 0 0 3 26 0 
RA 4.36 0 0 0 5 0 0 
RA 4.37 0 0 0 148 11 0 
RA 4.38 5 56 18 16247 94 15 
RA 4.39 - - - - - - 
RA 4.40 - - - - - - 
RA 4.41 - - - - - - 
RA 4.42 - - - - - - 
RA 4.43 - - - - - - 
RA 4.44 - - - - - - 
RA 4.45 - - - - - - 
RA 4.46 - - - - - - 
RA 4.47 - - - - - - 
RA 4.48 - - - - - - 
 
Table 4.7. Background cytokine production detected in the RA patients tested for 
candidate RA autoantigen-induced cytokine production in the experiments 
described in 4.2.3. A dash (-) represents an untested value. 
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ID 
Background cytokine production in pg/ml (day 5) 
IL-10 IL-17 IL-4 IL-6 TNF-α IFN-γ 
HS 4.9 0 0 0 331 33 5 
HS 4.10 0 0 0 200 5 0 
HS 4.11 0 0 0 76 90 0 
HS 4.12 0 0 0 23 84 0 
HS 4.13 0 0 0 0 0 0 
HS 4.14 0 0 0 44 4 0 
HS 4.15 7 5 31 4426 58 23 
HS 4.16 0 0 10 2909 46 9 
HS 4.17 0 0 0 30 6 0 
HS 4.18 - - - - - - 
HS 4.19 - - - - - - 
HS 4.20 - - - - - - 
HS 4.21 - - - - - - 
HS 4.22 - - - - - - 
HS 4.23 - - - - - - 
HS 4.24 - - - - - - 
 
Table 4.8. Background cytokine production detected in the healthy subjects tested 
for candidate RA autoantigen-induced cytokine production in the experiments 
described in 4.2.3. A dash (-) represents an untested value. 
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Figure 4.1. PHA-induced and PPD-induced PBMC proliferation in RA patients 
and healthy subjects; bulk culture 3HTdR incorporation approach. A, the SI values 
of PHA-induced PBMC proliferation detected in both RA patients (RA, n=9) and 
healthy subjects (HS, n=8). B, the peak SI values of PPD-induced PBMC proliferation 
detected in both RA patients (RA, n=8) and healthy subjects (HS, n=8). In each graph, 
the dotted horizontal line represents the threshold for a positive response, while the bold 
horizontal line in each data set represents the median value. 
A) 
B) 
P
H
A
 
P
P
D
 
 120 
 
 
Figure 4.2. Kinetics of the HCgp39-induced, CII-induced and GlyAgg-induced 
proliferative responses; bulk culture 3HTdR incorporation approach. A & B, the 
kinetics of the HCgp39-induced PBMC proliferation detected in RA patients (n=9) and 
healthy subjects (n=8) respectively. C & D, the kinetics of the CII-induced PBMC 
proliferation detected in RA patients (n=9) and healthy subjects (n=8) respectively. E & 
F, the kinetics of the GlyAgg-induced PBMC proliferation detected in RA patients 
(n=4) and healthy subjects (n=4) respectively. In each graph, the dotted horizontal line 
represents the threshold for a positive response, and each data point represents an 
individual SI value. 
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Figure 4.3. HCgp39-induced, CII-induced and GlyAgg-induced PBMC 
proliferation in RA patients and healthy subjects; bulk culture 3HTdR 
incorporation approach. A, the peak SI values of HCgp39-induced PBMC 
proliferation detected in both RA patients (RA, n=9) and healthy subjects (HS, n=8). B, 
the peak SI values of CII-induced PBMC proliferation detected in both RA patients 
(RA, n=9) and healthy subjects (HS, n=8). C, the peak SI values of GlyAgg-induced 
PBMC proliferation detected in both RA patients (RA, n=4) and healthy subjects (HS, 
n=4). In each graph, the dotted horizontal line represents the threshold for a positive 
response, while the bold horizontal line in each data set represents the median value. 
A) 
B) 
C) 
H
C
g
p
3
9
 
C
II
 
G
ly
A
g
g
 
 122 
 
Figure 4.4. PHA-induced PBMC proliferation in RA patients and healthy subjects; 
triplicate culture 3HTdR incorporation approach versus bulk culture 3HTdR 
incorporation approach. A, the SI values of PHA-induced PBMC proliferation 
detected in both RA patients (RA, n=24) and healthy subjects (HS, n=16) when using 
the triplicate culture approach. B, the SI values of PHA-induced PBMC proliferation 
detected in RA patients with both the triplicate culture (TC) approach (n=24) and the 
bulk culture (BC) approach (n=9). C, the SI values of PHA-induced PBMC 
proliferation detected in healthy subjects with both the triplicate culture (TC) approach 
(n=16) and the bulk culture (BC) approach (n=8). In each graph, the dotted horizontal 
line represents the threshold for a positive response, while the bold horizontal line in 
each data set represents the median value. 
A) 
B) 
C) 
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Figure 4.5. PPD-induced PBMC proliferation in RA patients and healthy subjects; 
triplicate culture 3HTdR incorporation approach versus bulk culture 3HTdR 
incorporation approach. A, the peak SI values of PPD-induced PBMC proliferation 
detected in both RA patients (RA, n=23) and healthy subjects (HS, n=16) when using 
the triplicate culture approach. B, the peak SI values of PPD-induced PBMC 
proliferation detected in RA patients with both the triplicate culture (TC) approach 
(n=23) and the bulk culture (BC) approach (n=8). C, the peak SI values of PPD-induced 
PBMC proliferation detected in healthy subjects with both the triplicate culture (TC) 
approach (n=16) and the bulk culture (BC) approach (n=8). In each graph, the dotted 
horizontal line represents the threshold for a positive response, while the bold horizontal 
line in each data set represents the median value. 
A) 
B) 
C) 
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Figure 4.6. Background cytokine production in RA patients and healthy subjects. 
A, the mean levels of cytokine production detected in unstimulated cultures of PBMC 
from RA patients (n=14) and healthy subjects (n=9) after 5 days of culture. B, the mean 
levels of cytokine production detected in unstimulated cultures of PBMC from the same 
RA patients and healthy subjects represented in A after 11 days of culture. For both 
graphs, vertical bars in each data set represent SEM. 
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Figure 4.7. HCgp39-induced PBMC proliferation in RA patients and healthy 
subjects; triplicate culture 3HTdR incorporation approach. A, the peak SI values of 
HCgp39-induced PBMC proliferation detected in both RA patients (RA, n=10) and 
healthy subjects (HS, n=8) when using the triplicate culture approach. The bold 
horizontal line in each data set represents the median value. B & C, the kinetics of the 
HCgp39-induced PBMC proliferation detected in the RA patients and the healthy 
subjects respectively. In all graphs, the dotted horizontal line represents the threshold 
for a positive response. 
A) 
B) 
C) 
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Figure 4.8. CII-induced PBMC proliferation in RA patients and healthy subjects; 
triplicate culture 3HTdR incorporation approach. A, the peak SI values of CII-
induced PBMC proliferation detected in both RA patients (RA, n=7) and healthy 
subjects (HS, n=8) when using the triplicate culture approach. The bold horizontal line 
in each data set represents the median value. B & C, the kinetics of the CII-induced 
PBMC proliferation detected in the RA patients and the healthy subjects respectively. In 
all graphs, the dotted horizontal line represents the threshold for a positive response. 
A) 
B) 
C) 
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Figure 4.9. GlyAgg-induced PBMC proliferation in RA patients and healthy 
subjects; triplicate culture 3HTdR incorporation approach. A, the peak SI values of 
GlyAgg-induced PBMC proliferation detected in both RA patients (RA, n=9) and 
healthy subjects (HS, n=10) when using the triplicate culture approach. The bold 
horizontal line in each data set represents the median value. B & C, the kinetics of the 
GlyAgg-induced PBMC proliferation detected in the RA patients and the healthy 
subjects respectively. In all graphs, the dotted horizontal line represents the threshold 
for a positive response. 
A) 
B) 
C) 
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Figure 4.10. HCgp39-induced, CII-induced and GlyAgg-induced PBMC 
proliferation in RA patients and healthy subjects; triplicate culture 3HTdR 
incorporation approach versus bulk culture 3HTdR incorporation approach. A & 
B, the peak SI values of HCgp39-induced PBMC proliferation detected in RA patients 
and healthy subjects respectively with both the triplicate culture (TC) approach and the 
bulk culture (BC) approach. C & D, the peak SI values of CII-induced PBMC 
proliferation detected in RA patients and healthy subjects respectively with both the 
triplicate culture (TC) approach and the bulk culture (BC) approach. E & F, the peak SI 
values of GlyAgg-induced PBMC proliferation detected in RA patients and healthy 
subjects respectively with both the triplicate culture (TC) approach and bulk culture 
(BC) approach. In all graphs, the dotted horizontal line represents the threshold for a 
positive response, while the bold horizontal line in each data set represents the median 
value. 
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Figure 4.11. DeglyAgg-induced PBMC responses in RA patients and healthy 
subjects; triplicate culture approach. A, the peak SI values of DeglyAgg-induced 
PBMC proliferation detected in both RA patients (RA, n=12) and healthy subjects (HS, 
n=13). The bold horizontal line in each data set represents the median value. B & C, the 
kinetics of the DeglyAgg-induced PBMC proliferation detected in the RA patients and 
the healthy subjects respectively. D, the SI values of DeglyAgg-induced IL-6 
production detected in RA patients (RA, n=8) and healthy subjects (HS, n=8) at day 5. 
The bold horizontal line in each data set represents the median value. In all graphs, the 
dotted horizontal line represents the threshold for a positive response. 
A) 
B) C) 
D) 
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Figure 4.12. PPD-induced and autoantigen-induced T cell proliferation; mo-DC & 
T cell co-culture approach. CD3
+
 PBMC from 4 healthy subjects were co-cultured 
with either unloaded or 1µg/ml PPD-loaded, immature or LPS-matured, autologous mo-
DC at mo-DC:T cell ratios of 5:1, 10:1 or 50:1. Proliferation was assessed at day 5 via 
3HTdR incorporation. The mean SI values of PPD-induced T cell proliferation detected 
with the different mo-DC at the different mo-DC:T cell ratios are shown in A (the 
vertical bars in each data set represent SEM, while the dotted horizontal line represents 
the threshold for a positive response). CD3
+
 PBMC from 2 RA patients and 3 healthy 
subjects were co-cultured with either unloaded, 1µg/ml PPD-loaded, 10µg/ml HCgp39-
loaded, 10µg/ml CII-loaded, 10µg/ml GlyAgg-loaded or 10µg/ml DeglyAgg-loaded, 
LPS-matured, autologous mo-DC at a mo-DC:T cell ratio of 50:1. Proliferation was 
assessed after 3, 5, 7, 9 & 11 days via 3HTdR incorporation. The peak SI values of T 
cell proliferation detected in the RA patients (red data points) and the healthy subjects 
(blue data points) with the different mo-DC are shown in B (the bold horizontal line in 
each data set represents the median value, while the dotted horizontal line represents the 
threshold for a positive response). 
A) 
B) 
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Figure 4.13. The effect of polymyxin B on the DeglyAgg response. PBMC from 5 
subjects were cultured with either medium alone or 10µg/ml DeglyAgg, with or without 
the presence of PMB. After 5, 7, 9 & 11 days, proliferation was assessed via 3HTdR 
incorporation and IL-6 levels in cell culture supernatant samples were assessed via 
ELISA. A, the mean SI values of DeglyAgg-induced PBMC proliferation detected at 
the different time-points when PBMC are cultured with and without the presence of 
PMB. B, the mean absolute values of DeglyAgg-induced IL-6 production detected at 
the different time-points when PBMC are cultured with and without the presence of 
PMB. In each graph, the vertical bars at each data point represent SEM. 
A) 
B) 
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Chapter 5. T-cell Immune responses to candidate RA autoantigen-
derived peptides in health and disease. 
 
5.1. Introduction 
In the experiments described in chapter 4 I measured T-cell proliferation and cytokine 
production in response to several whole protein candidate RA autoantigens. Using both 
the CFSE dilution assay and the 3HTdR incorporation assay to detect proliferation and 
ECL multiplex assays and ELISAs to detect cytokine production, I measured responses 
to HCgp39, CII, GlyAgg and DeglyAgg in bulk and triplicate cultures of whole PBMC 
from RA patients and healthy subjects. Positive responses to these candidate 
autoantigens were frequently detected in both RA patients and healthy subjects, yet with 
the exception of the responses to DeglyAgg, they were generally weak. Furthermore, 
the proportions, natures and magnitudes of the responses detected did not differ 
significantly between the two groups. Hypothesising that the weak responses could have 
resulted from sub-optimal antigen presentation in the whole PBMC cultures, I tried an 
alternative mo-DC and T-cell co-culture approach. However, the magnitude of 
candidate RA autoantigen-specific T-cell proliferative responses detected with this 
approach was no better. This led me to postulate that the magnitude of the responses to 
the whole protein HCgp39, CII and GlyAgg could have been low due to sub-optimal 
antigen processing in the in-vitro cultures. Therefore, I proposed to use candidate RA 
autoantigen-derived peptides in my subsequent studies. 
 
5.1.1. Peptide stimuli versus whole-protein stimuli 
As alluded to in the previous section, my main reason for choosing to use peptide 
stimuli in my subsequent experiments was in an attempt to elicit more substantial T-cell 
responses in my assays. Because T-cells can only recognise their specific antigens when 
they are presented as peptides in the context of MHC molecules, the generation of T-
cell responses to any given antigen is only possible after the antigen molecules have 
been processed into peptide fragments by antigen presenting cells. For example, when 
an exogenous antigen is processed by a professional antigen presenting cell, the 
resulting peptides bind to specific MHC class II molecules and form the MHC class 
II:peptide complexes that antigen-specific CD4
+
 T-cells recognise. Thus the likelihood 
of any T-cell responses being generated relies heavily on the efficiency of the antigen 
processing pathway within the professional antigen presenting cells. The use of peptides 
as stimuli may overcome the potential problem of sub-optimal antigen processing in our 
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assay system. The use of peptides also has further benefits. When a whole protein 
molecule containing potentially autoantigenic epitopes is processed, large numbers of 
peptides will be generated, and so the peptides in which the potentially autoantigenic 
epitopes are found will have to compete with many other peptides for binding to MHC 
molecules. If the potentially autoantigenic peptides are not very abundant and/or have 
low affinities for MHC molecules, then it is possible that they will be out-competed for 
binding to the peptide binding grooves of MHC molecules, and may therefore not be 
presented to antigen-specific T-cells (Adorini & Nagy, 1990). In contrast, if I use 
peptide epitopes as stimuli in my assays, then much higher molar concentrations of the 
peptides of interest can be added to the cell cultures. As a result, peptide competition 
will not be a rate-limiting factor in whether responses to these epitopes are detected. 
 
5.1.2. Peptides of interest 
The peptides tested in this part of the project were chosen based on the findings of 
previous studies (Table 5.1). For example, Hill et al (2003 and 2008) have demonstrated 
that the citrullinated forms but not the un-modified forms of both vimentin65-77 and 
fibrinogen α-chain79-91 elicit HLA-DR-restricted T-cell recall responses characterised by 
proliferation and IFN-γ production in DR4(DRB1*0401) transgenic mice. Furthermore, 
the group’s earlier study also showed that while the unmodified form of the vimentin 
peptide displayed only low affinity for a number of both SE-positive and SE-negative 
HLA-DR molecules, the citrullinated form displayed high affinity for the RA-associated 
HLA-DR molecules DR1(DRB1*0101), DR4(DRB1*0401) and DR4(DRB1*0404). 
These studies suggest that citrullination of autoantigen-derived peptides may enhance 
their antigenicity in SE-positive RA patients. While the study by Fritsch et al (2002) 
demonstrated that citrullination of filaggrin2776-2793 and filaggrin3005-3022 had varying 
effects on the immunogenicities of the peptides, studies by Lundberg et al (2008) and 
von Delwig et al (2010) provide evidence that citrullination of both α-enolase5-21 and 
aggrecan84-103 respectively enhances their immunogenicity in RA patients. In addition, 
aggrecan201-213 and aggrecan299-311 have both been shown to bind with high affinity to the 
RA-associated DR4(DRB1*0401) molecule (Boots et al, 1997), while it was observed 
that the HCgp39262-276 binds with high affinity to the RA-associated HLA-DR molecules 
DR1(DRB1*0101), DR4(DRB1*0401) and DR4(DRB1*0404), and elicits peripheral 
blood T-cell proliferation in RA patients but not healthy subjects (Verheijden et al, 
1997). 
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5.2. Results 
In the experiments covered in this chapter, PBMC from RA patients, healthy subjects 
and disease controls were tested for reactivity to various candidate RA autoantigen-
derived peptides; peptide panel #1 (peptides 1-7, Table 5.1), peptide panel #2 (peptides 
8-15, Table 5.1) and REP-1 and CEP-1 (Table 5.1). Based on my data reported in 
chapter 4, all experiments utilised the triplicate culture approach and proliferation was 
measured via 3HTdR incorporation while cytokine levels in cell culture supernatant 
samples were assessed via ECL multiplex and ELISA. Preliminary work had suggested 
that assessing cytokine production at day 5 would increase the chances of responses 
being detected (data not shown). 
 
5.2.1. Peptide panel #1 
PBMC from 10 RA patients and 10 healthy subjects were tested for proliferation and 
cytokine production in response to the 7 peptides comprising peptide panel #1 (see 
Table 2.4 in chapter 2 for RA patient clinical details). Proliferation was assessed after 5, 
7, 9 & 11 days via 3HTdR incorporation, while cytokine levels in cell culture 
supernatant samples harvested at day 5 were assessed via ECL multiplex and ELISA. 
Figure 5.1 shows the proportions of RA patients and healthy subjects showing positive 
proliferative and/or cytokine production responses to each of the 7 peptides. The peak 
SI values of PBMC proliferation and the absolute values of day 5 cytokine production 
detected in response to peptides 1-7 in both the RA patients and the healthy subjects are 
displayed in Tables 5.2-5.8. Similar proportions of RA patients and healthy subjects 
showed positive proliferative and/or cytokine production responses to peptides 1-7 (RA 
versus HS for peptides 1-7 = 56% versus 40%, 67% versus 60%, 78% versus 60%, 78% 
versus 80%, 67% versus 80%, 67% versus 80% and 78% versus 90% respectively). 
Ultimately, the peak SI values of PBMC proliferation and the absolute values of day 5 
IL-10, IL-17, IL-4, IL-6, TNF-α and IFN-γ production detected in response to each of 
the peptides in panel #1 were comparable between the RA patients and the healthy 
subjects. 
 
While RA 5.8 failed to show a positive PBMC proliferative and/or cytokine production 
response to any of the 7 peptides, all of the other RA patients showed positive PBMC 
proliferative and/or cytokine production responses to two or more of the peptides (table 
5.9A). For example, RA 5.9 showed positive responses to all 7 peptides while RA 5.2, 
RA 5.3 and RA 5.7 all showed positive responses to all peptides except peptides 5, 2 
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and 1 respectively. Based on clinical details, the non-responder RA 5.8 differed from 
the other nine patients by sex (male as opposed to female) and by having a substantially 
higher CRP value. The ESR value of RA 5.8 was also substantially higher than that of 
the majority of the other patients although one of the responders displayed a similar 
ESR value. Complete data on the RF and/or CCP status of the majority of the patients 
was un-available, yet based on the clinical details that were available, the patients 
responding to multiple peptides did not differ from those responding to just one or two 
of the peptides. Of the healthy subjects, all ten showed positive responses to at least two 
of the 7 peptides, and only HS 5.8 and HS 5.9 showed positive responses to less than 
four of the peptides (Table 5.9B). Indeed, HS 5.5 and HS 5.7 showed positive responses 
to all 7 peptides. 
 
Peptides 6 and 7 respectively were non-citrullinated and citrullinated versions of the 
same peptide. In both the RA patient group and the healthy subject group, similar 
proportions of subjects showed positive responses to peptide 7 as to peptide 6 (peptide 7 
versus peptide 6 in RA and HS = 78% versus 67% and 90% versus 80% respectively). 
While two of the seven RA patients that showed positive responses to peptide 7 did not 
show positive responses to peptide 6, the other five peptide 7-responding RA patients 
showed positive proliferation and/or cytokine production responses to both peptides 6 
and 7. RA 5.5 showed a positive response to peptide 6 but not peptide 7. RA 5.2 
responded to peptide 6 with production of IL-17 alone (6pg/ml), yet responded to 
peptide 7 with production of TNF-α and IFN-γ (2pg/ml and 12pg/ml respectively) as 
well as IL-17 (5pg/ml). RA 5.3 responded to both peptides 6 and 7 with both 
proliferation (SI values of 2.2 and 2.4 respectively) and IL-17 production, although 
peptide 7 induced more IL-17 production than peptide 6 (14pg/ml versus 3pg/ml). RA 
5.7 responded to both peptides 6 and 7 with IL-6 production alone, although peptide 7 
induced a slightly more potent response (5pg/ml versus 3pg/ml). RA 5.9 responded to 
peptide 6 with proliferation (SI value of 3.0) and production of IL-17, IL-6 and TNF-α 
(7pg/ml, 13pg/ml and 2pg/ml), yet responded to peptide 7 with IL-17 production alone 
(5pg/ml). RA 5.10 responded to both peptides 6 and 7 with similar levels of 
proliferation and IL-6 and IFN-γ production. No patterns were visible in the CRP level 
or ESR values or the disease duration of patients showing positive responses to the 
citrullinated peptide. Moreover, the CRP level and ESR values and disease duration of 
patients that did show positive responses to the citrullinated peptide did not differ from 
those of patients that did not show positive responses to the citrullinated peptide. Of the 
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three peptide 7-responders with known CCP status, one was positive and two negative. 
Of the nine healthy subjects that showed positive responses to peptide 7, seven also 
showed positive responses to peptide 6. HS 5.4 showed a positive response to peptide 6 
but not peptide 7. HS 5.1 responded to peptide 6 with IFN-γ production alone 
(37pg/ml), yet responded to peptide 7 with both proliferation (SI value of 2.3) as well as 
with more robust IFN-γ production (45pg/ml). While HS 5.2 responded to both peptides 
6 and 7 with production of IL-17, IL-6 and IFN-γ, peptide 7 induced a more robust 
response than peptide 6 and also induced production of TNF-α. HS 5.3 responded to 
peptide 6 with production of IL-6, TNF-α and IFN-γ (11pg/ml, 5pg/ml and 37pg/ml 
respectively), yet responded to peptide 7 with production of only IL-6 and IFN-γ at 
reduced levels (2pg/ml and 31pg/ml respectively). HS 5.5 responded to both peptides 6 
and 7 with both proliferation and IFN-γ production, although peptide 7 induced a more 
robust proliferative response than peptide 6 (SI values of 4.4 versus 3.4) while the latter 
induced a more robust IFN-γ response than the former (60pg/ml versus 31pg/ml). HS 
5.6 responded to peptide 6 with production of IL-17, IL-6 and TNF-α (87pg/ml, 
21pg/ml and 14pg/ml respectively), yet responded to peptide 7 with production of IL-6 
alone (4pg/ml). HS 5.7 responded to peptide 6 with production of IL-6 and TNF-α 
(34pg/ml and 2pg/ml respectively), yet responded to peptide 7 with IL-10 and IL-17 
production (2pg/ml and 12pg/ml respectively) and much more robust IL-6 production 
(960pg/ml). HS 5.9 responded to peptide 6 with production of IL-17 and IL-6 (12pg/ml 
and 133pg/ml respectively), yet responded to peptide 7 with IL-10 production alone 
(3pg/ml). 
 
5.2.2. Peptide panel #2 
PBMC from 9 RA patients and 9 healthy subjects were tested for proliferation and 
cytokine production in response to the 8 peptides comprising peptide panel #2 (see 
Table 2.5 in chapter 2 for RA patient clinical details). Proliferation was assessed after 5, 
7, 9 & 11 days via 3HTdR incorporation, while cytokine levels in cell culture 
supernatant samples harvested at day 5 were assessed via ECL multiplex and ELISA. 
Figure 5.2 shows the proportions of RA patients and healthy subjects showing positive 
proliferative and/or cytokine production responses to each of the 8 peptides. The peak 
SI values of PBMC proliferation and the absolute values of day 5 cytokine production 
detected in response to peptides 8-15 in both the RA patients and the healthy subjects 
are displayed in Tables 5.10-5.17. Similar proportions of RA patients and healthy 
subjects showed positive proliferative and/or cytokine production responses to peptides 
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8-15 (RA versus HS for peptides 8-15 = 75% versus 50%, 89% versus 56%, 75% versus 
50%, 67% versus 56%, 67% versus 83%, 43% versus 78%, 56% versus 78% and 67% 
versus 67% respectively). Ultimately, the peak SI values of PBMC proliferation and the 
absolute values of day 5 IL-10, IL-17, IL-4, IL-6, TNF-α and IFN-γ production detected 
in response to each of the peptides in panel #2 were comparable between the RA 
patients and the healthy subjects. 
 
RA 5.13 failed to show positive responses to any of the peptides from peptide panel #2 
and while RA 5.15 and RA 5.16 both showed positive responses only to peptide 9, the 
rest of the RA patients all responded to four or more of the peptides that they were 
tested against (Table 5.18). Indeed, RA 5.12 showed positive responses to all of the 
peptides in panel #2, while RA 5.11 showed positive responses to all except for peptide 
13. Based on the RA patient clinical details that were available, the non-responder did 
not differ from the responders and those patients showing positive responses to multiple 
peptides did not differ from those showing positive responses to only one of the 
peptides. While HS 5.19 showed a positive response to peptide 14 alone and HS 5.15 to 
peptides 8 and 15, the rest of the healthy subjects showed positive responses to at least 
three of the peptides that they were tested with (Table 5.19). For example, HS 5.12 and 
HS 5.16 both showed positive responses to all of the 8 peptides in panel #2 except for 
peptide 8, while HS 5.14 showed positive responses to all. 
 
In the RA patients group, citrullinated peptide 9 elicited a similar proportion of positive 
responses as its non-citrullinated counterpart, peptide 8 (89% versus 75%), while 
citrullinated peptide 11 elicited a similar proportion of positive responses as its non-
citrullinated counterpart, peptide 10 (67% versus 75%). Furthermore, citrullinated 
peptide 13 elicited a similar proportion of positive responses as its non-citrullinated 
counterpart, peptide 12 (43% versus 67%). In addition, the alternatively citrullinated 
peptides 14 and 15 elicited responses in comparable proportions of patients (56% and 
67% respectively). In the healthy subject group, citrullinated peptides 9, 11 and 13 
elicited comparable proportions of positive responses as their non-citrullinated 
counterparts, peptides 8, 10 and 12 respectively (50% versus 56%, 50% versus 56% and 
83% versus 78% for peptides 8 versus 9, 10 versus 11 and 12 versus 13 respectively). 
The alternatively citrullinated peptides 14 and 15 elicited responses in comparable 
proportions of subjects (78% and 67% respectively). No clear trends or statistical 
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differences were visible between the responses to non-citrullinated versus citrullinated 
peptides within the two groups. 
 
Some of the RA patients and healthy subjects showed positive responses to the non-
citrullinated versions of certain peptides but not to the corresponding citrullinated 
versions (RA 5.11, peptide 12 but not peptide 13; HS 5.13, peptide 8 but not peptide 9; 
HS 5.15, peptide 8 but not peptide 9). Other healthy subjects, although none of the RA 
patients, failed to show positive responses to the non-citrullinated versions of certain 
peptides yet did show positive responses to the corresponding citrullinated versions (HS 
5.12, not peptide 8 but peptide 9; HS 5.13, not peptide 10 but peptide 11; HS 5.16, not 
peptide 8 but peptide 9). When positive responses to both non-citrullinated peptides and 
the corresponding citrullinated peptides were detected in individual subjects (RA 5.11, 
peptides 8 and 9 and peptides 10 and 11; RA 5.12, peptides 8 and 9, peptides 10 and 11 
and peptides 12 and 13; RA 5.14, peptides 8 and 9 and peptides 10 and 11; HS 5.11, 
peptides 12 and 13; HS 5.12, peptides 10 and 11 and peptides 12 and 13; HS 5.13, 
peptides 12 and 13; HS 5.14, peptides 8 and 9, peptides 10 and 11 and peptides 12 and 
13; HS 5.16, peptides 10 and 11 and peptides 12 and 13), they were often different. 
However, responses to citrullinated peptides in individual subjects varied and there 
were no patterns observed in citrullinated responders versus non-responders.  
 
For five of the nine RA patients, data on the CCP status was unfortunately not available 
so it was not possible to determine whether there was any correlation between CCP 
positivity and responses to citrullinated peptides. None of the other clinical 
characteristics distinguished patients responding to citrullinated versions of the peptides 
from those patients not responding to the citrullinated versions. 
 
5.2.3. Non-citrullinated and citrullinated forms of an α-enolase peptide; REP-1 and 
CEP-1 
Citrullinated enolase has recently emerged as a target of ACPA in RA and anti-
citrullinated enolase antibodies have been found to be highly specific for RA (Kinloch 
et al, 2005 and Lundberg et al, 2008). Since such autoantibodies are often of IgG 
subtypes, this suggests that T-cell help may be important, therefore I postulated that T-
cell responses to citrullinated enolase peptides might be heightened in RA patients. 
Citrullinated enolase5-21 is the immunodominant epitope recognised by antibodies 
reacting with citrullinated enolase (Lundberg et al, 2008) therefore I reasoned that the 
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same peptide may also contain a candidate T-cell epitope. Thus, I measured 
proliferation and cytokine production responses of PBMC stimulated with citrullinated 
α-enolase5-21 and its non-citrullinated analogue (peptides CEP-1 and REP-1 
respectively, Table 5.1). A total of 20 RA patients, 9 healthy subjects and 11 disease 
controls were tested (the clinical details of the RA patients - RA 5.20 to RA 5.39 - and 
disease controls are summarised in Tables 2.6 and 2.7 respectively in chapter 2). 
 
5.2.3.1. Proliferative responses to REP-1 and CEP-1 
The peak SI values of REP-1-induced and CEP-1-induced PBMC proliferation detected 
in each of the 20 RA patients, 9 healthy subjects and 11 disease controls are displayed 
in Table 5.20. 
 
Firstly I compared REP-1-induced PBMC proliferation with CEP-1-induced PBMC 
proliferation within each of the 3 groups. In the RA patient group, CEP-1 induced a 
significantly greater proportion of positive PBMC proliferative responses than REP-1 
(95% versus 33%, P value = 0.0030, Chi-square). However, in both the healthy subject 
and disease control groups, CEP-1 and REP-1 induced comparable proportions of 
positive PBMC proliferative responses (CEP-1 versus REP-1 in healthy subject group 
and disease control group = 67% versus 56% and 100% versus 55% respectively, P 
values = 0.99 and 0.17 respectively, Chi-square). 
 
In all 3 groups, the peak SI values of CEP-1-induced PBMC proliferation were 
significantly greater than those of REP-1-induced PBMC proliferation (mean ± SEM 
peak SI values of CEP-1 versus REP-1 of 10.2 ± 1.9 versus 2.1 ± 0.3 in RA patients, 4.9 
± 1.2 versus ± 2.8 ± 0.6 in healthy subjects and 21.4 ± 4.0 versus 2.1 ± 0.2 in disease 
controls, P values of 0.0015, 0.0440 and 0.0007 respectively, paired t test, Figure 5.3A, 
5.3B & 5.3C respectively). 
 
Secondly, I compared REP-1-induced and CEP-1-induced PBMC proliferation between 
the 3 groups, in terms of both the proportions of responders and the magnitudes of the 
responses. Although both the healthy subject and disease control groups showed greater 
proportions of positive REP-1-induced PBMC proliferative responses than the RA 
patient group (56% and 55% versus 33%), the differences were not statistically 
significant (P values of healthy subjects versus RA patients and disease controls versus 
RA patients were 0.87 and 0.87 respectively, Chi-square). In addition, the peak SI 
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values of REP-1-induced PBMC proliferation detected in the RA patient group were 
statistically similar to those detected in both the healthy subject group and the disease 
control group (median peak SI values of REP-1-induced PBMC proliferation were 
median = 1.6, IQR: 1.1-2.9 in RA patients, median = 2.0, IQR: 1.6-3.9 in healthy 
subjects and median = 2.0, IQR: 1.3-2.6 in disease controls, P values of RA patients 
versus healthy subjects and RA patients versus disease controls were 0.17 and 0.42 
respectively, Mann Whitney, Figure 5.4A). 
 
Figure 5.4B shows the peak SI values of CEP-1-induced PBMC proliferation for the 
three groups. Although the RA patient group showed a greater proportion of positive 
CEP-1-induced proliferative responses than the healthy subject group (95% versus 
67%), the difference was not statistically significant (P value of RA patients versus 
healthy subjects = 0.38, Chi-square). Similarly, while there was a tend suggesting that 
the peak SI values of CEP-1-induced PBMC proliferation detected in the RA patients 
were higher than those detected in the healthy subjects (median peak SI values were 
median = 9.0, IQR: 3.6-13.3 in RA patients versus median = 5.7, IQR: 1.0-7.8 in 
healthy subjects), it did not reach statistical significance (P value = 0.06, Mann 
Whitney). However, the peak SI values of CEP-1-induced PBMC proliferation detected 
in the disease controls (median = 17.8, IQR: 9.6-33.7) were significantly greater than 
those of CEP-1-induced PBMC proliferation detected in the RA patients (P value = 
0.01, Mann Whitney). 
 
After analysing the proportions and the magnitudes of the proliferative responses to 
REP-1 and CEP-1 in the 3 subjects groups, I also explored whether the kinetics of the 
responses differed between the groups. Figure 5.5 shows the kinetics of the REP-1-
induced and CEP-1-induced proliferative responses detected in the RA patients, healthy 
subjects and disease controls. In the RA patient group, peak levels of REP-1-induced 
proliferation were detected at days 7, 9 and 11 (n=2, 3 and 1 respectively, Figure 5.5A), 
while peak levels of CEP-1-induced proliferation were also detected at days 7, 9 and 11 
(n=2, 8 and 9 respectively, Figure 5.5B). In the healthy subject group, peak levels of 
REP-1-induced proliferation were detected at days 5, 9 and 11 (n=1, 2 and 2 
respectively, Figure 5.5C), while peak levels of CEP-1-induced proliferation were 
detected at days 9 and 11 (n=5 and 1, Figure 5.5D). In the disease control group, peak 
levels of REP-1-induced proliferation were detected at day 11 (n=6, Figure 5.5E), while 
peak levels of CEP-1-induced proliferation were detected at day 11 (Figure 5.5F). Thus, 
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while there were no clear differences between the kinetics of the proliferative responses 
to these peptides between RA patients and healthy subjects, the kinetics of CEP-1-
induced proliferative responses in disease controls appeared to be delayed compared to 
RA patients. 
 
5.2.3.2. Cytokine production responses to REP-1 and CEP-1 
I first compared the levels of REP-1-induced cytokine production with those of CEP-1-
induced cytokine production within each of the 3 subject groups. In the RA patient 
group, CEP-1 induced significantly higher levels of production of IL-10, IL-4, IL-6, 
TNF-α and IFN-γ from the PBMC than did REP-1 (mean ± SEM absolute pg/ml values 
of cytokine production induced by CEP-1 versus REP-1 were 30 ± 5 versus 2 ± 1 for 
IL-10, 25 ± 3 versus 3 ± 1 for IL-4, 10378 ± 666 versus 1514 ± 775 for IL-6, 838 ± 329 
versus 44 ± 18 for TNF-α and 690 ± 269 versus 5 ± 5 for IFN-γ, P values of <0.0001, 
<0.0001, <0.0001, 0.04 and 0.03 respectively, paired t test, Figure 5.6A, 5.6C, 5.6D, 
5.6E & 5.6F respectively). However, the levels of REP-1-induced and CEP-1-induced 
IL-17 production were comparable (mean ± SEM absolute pg/ml values of 32 ± 13 
versus 1755 ± 1207 respectively, P value = 0.20, paired t test, Figure 5.6B). 
 
In the healthy subject group, REP-1 and CEP-1 induced similar levels of IL-10, IL-17, 
IL-4, TNF-α and IFN-γ production (mean ± SEM absolute pg/ml values of cytokine 
production induced by REP-1 versus CEP-1 were 4 ± 3 versus 14 ± 3 for IL-10, 837 ± 
666 versus 3141 ± 2142 for IL-17, 6 ± 4 versus 16 ± 4 for IL-4, 51 ± 43 versus 111 ± 45 
for TNF-α and 62 ± 38 versus 155 ± 85 for IFN-γ, P values of 0.05, 0.36, 0.08, 0.37 and 
0.30 respectively, paired t test, Figure 5.7A, 5.7B, 5.7C, 5.7E & 5.7F respectively). 
However, CEP-1 induced significantly higher levels of IL-6 production than did REP-1 
(mean ± SEM absolute pg/ml values of 6978 ± 1569 versus 2456 ± 1593 respectively, P 
value = 0.03, paired t test, Figure 5.7D). 
 
In the disease control group, CEP-1 induced significantly higher levels of production of 
IL-10, IL-4, IL-6 and IFN-γ than did REP-1 (mean ± SEM absolute pg/ml values of 
cytokine production induced by CEP-1 versus REP-1 were 22 ± 2 versus 3 ± 2 for IL-
10, 31 ± 3 versus 7 ± 4 for IL-4, 9017 ± 849 versus 1920 ± 1111 for IL-6 and 307 ± 104 
versus 4 ± 3 for IFN-γ, P values of 0.0002, 0.0007, 0.0011 and 0.02 respectively, paired 
t test, Figure 5.8A, 5.8C, 5.8D & 5.8F respectively). However, REP-1 and CEP-1 
induced similar levels of IL-17 and TNF-α production (mean ± SEM absolute pg/ml 
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values of cytokine production induced by REP-1 versus CEP-1 were 621 ± 578 versus 
1590 ± 1018 for IL-17 and 30 ± 18 versus 260 ± 106 for TNF-α, P values of 0.44 and 
0.07 respectively, paired t test, Figure 5.8B & 5.8E respectively). 
 
I also compared the levels of both REP-1 and CEP-1-induced cytokine production 
between each of the three subject groups. Figure 5.9 shows the levels of REP-1-induced 
IL-10, IL-17, IL-4, IL-6, TNF-α and IFN-γ production detected in the RA patients, 
healthy subjects and disease controls. While REP-1 induced similar levels of IL-10, IL-
17, IL-4, IL-6 and TNF-α production in the RA patients as in the healthy subjects and 
disease controls (Figure 5.9A, 5.9B, 5.9C, 5.9D & 5.9E respectively), the levels of 
REP-1-induced IFN-γ production detected in the healthy subjects were significantly 
higher than those detected in the RA patients (median absolute pg/ml values in healthy 
subjects versus RA patients were median = 6, IQR: 0-162 versus median = 0, IQR: 0-0, 
P value = 0.02, Mann Whitney, Figure 5.9F). 
 
Figure 5.10 shows the levels of CEP-1-induced IL-10, IL-17, IL-4, IL-6, TNF-α and 
IFN-γ production detected in the RA patients, healthy subjects and disease controls. The 
RA patients showed significantly higher levels of CEP-1-induced IL-10 production than 
the healthy subjects (median absolute pg/ml values in RA patients versus healthy 
subjects were median = 23, IQR: 16-40 versus median = 11, IQR: 8-18, P value = 0.01, 
Mann Whitney, Figure 5.10A). The RA patients showed significantly higher levels of 
CEP-1-induced IL-6 production than both the healthy subjects and the disease controls 
(median absolute pg/ml values were median = 10588, IQR: 10097-11474 in RA 
patients, median = 9348, IQR: 1939-9991 in healthy subjects and median = 9751, IQR: 
9320-9902 in disease controls, P values of RA patients versus healthy subjects and RA 
patients versus disease controls were 0.01 and 0.01 respectively, Mann Whitney, Figure 
5.10D). The RA patients also showed significantly higher levels of CEP-1-induced 
TNF-α production than both the healthy subjects and the disease controls (median 
absolute pg/ml values were median = 475, IQR: 387-685 in RA patients, median = 86, 
IQR: 18-122 in healthy subjects and median = 162, IQR: 92-270 in disease controls, P 
values of RA patients versus healthy subjects and RA patients versus disease controls 
were 0.0020 and 0.03 respectively, Mann Whitney, Figure 5.10E). The levels of CEP-1-
induced IL-17, IL-4 and IFN-γ production detected in RA patients were comparable to 
those detected in both the healthy subjects and the disease controls (Figure 5.10B, 
5.10C & 5.10F respectively). 
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5.2.4. The role of LPS contamination in CEP-1-induced responses 
The experiments described in 5.2.3 showed that there were differences between the 
CEP-1-induced responses shown by each of the three subject groups. Firstly, the 
percentages of subjects in which positive CEP-1-induced PBMC proliferative responses 
were detected differed between the three subject groups, although these inter-group 
differences were not statistically significant. Secondly, the disease control group 
showed significantly higher levels of CEP-1-induced PBMC proliferation than the RA 
patient group. Thirdly, the RA patient group showed significantly higher levels of CEP-
1-induced IL-10 production than the healthy subject group. Furthermore, the RA patient 
group showed significantly higher levels of CEP-1-induced IL-6 and TNF-α production 
than both the healthy subject and disease control groups. However, despite these 
differences, I had some concerns about the robustness of the CEP-1 data. 
 
Of the first five healthy subjects that were tested with CEP-1, only two had shown 
positive CEP-1-induced PBMC proliferative responses (SI values of 4.3 and 5.7). In 
contrast, the initial six RA patients tested with CEP-1 had all shown positive CEP-1-
induced PBMC proliferative responses (mean ± SEM SI value of CEP-1-induced 
PBMC proliferation was 15.6 ± 5.1). At this stage, the data strongly suggested that the 
frequency and magnitude of positive proliferative responses to CEP-1 were greater in 
the RA patients than in the healthy subjects. This prompted me to measure CEP-1-
induced PBMC responses in disease controls to see how they would compare with those 
detected in RA patients and healthy subjects. I also continued testing more PBMC 
samples from RA patients and healthy subjects with CEP-1.  
 
As was shown in Figure 5.3C, all eleven of the disease controls tested showed positive 
CEP-1-induced PBMC proliferative responses (mean ± SEM SI value of CEP-1-induced 
PBMC proliferation measuring 21.4 ± 4.0.) However, while further experiments with 
RA patient PBMC continued to show a very high incidence of CEP-1 responses in RA, 
a subsequent four healthy subjects tested all showed positive CEP-1-induced PBMC 
proliferative responses (mean ± SEM SI value of CEP-1-induced PBMC proliferation 
measuring 7.8 ± 1.1). 
 
The observation of unusually high proportions of positive CEP-1-induced PBMC 
proliferative responses accompanied by high levels of IL-6 production in both RA 
patients and healthy subjects was similar to that observed when using DeglyAgg as an 
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antigenic stimulus. Therefore, I was concerned that the CEP-1 solution could be 
contaminated with LPS and indeed, when a LAL assay was performed on samples of 
the peptide solution bacterial endotoxin was detected (samples of REP-1 tested negative 
for endotoxin contamination, data not shown). At a concentration of 1mg/ml in RPMI 
1640, the CEP-1 was shown to contain 1.6 EU/ml, while at a concentration of 10µg/ml 
it was found to contain 0.7EU/ml (data representative of two separate LAL assays). 
According to the literature accompanying the LAL assay kit, 10EU equate to 1ng of 
endotoxin, meaning that the 1mg/ml solution of CEP-1 contained 160pg/ml of 
endotoxin while the 10µg/ml solution of CEP-1 contained 70pg/ml of endotoxin. To 
determine whether 70pg/ml of LPS is sufficient to induce PBMC proliferation, I 
stimulated PBMC from a healthy volunteer with a range of concentrations of LPS (from 
1µg/ml to 0.001pg/ml in serial 10-fold dilutions) and measured the resulting 
proliferation via 3HTdR incorporation. Interestingly, PBMC proliferation was only 
observed when using the top four concentrations of LPS (1µg/ml, 100ng/ml, 10ng/ml 
and 1ng/ml) while the other concentrations were insufficient to induce detectable 
proliferation (Figure 5.11). This observation suggested that the CEP-1 response was not 
driven by LPS directly.  
 
However, it remains possible that LPS contamination was affecting the CEP-1 response 
indirectly. Therefore, I stimulated PBMC from a healthy subject with CEP-1, both with 
and without the presence of PMB, a compound that neutralises LPS (Cardoso et al, 
2007). While the PBMC cultured with CEP-1 alone showed good proliferation, those 
cultured with CEP-1 and PMB did not (Figure 5.12A). In addition, cytokine production 
in response to CEP-1 was markedly reduced when PMB was present in the culture 
(Figure 5.12B). These data suggested that the CEP-1 response measured in my earlier 
experiments could have been influenced by LPS contamination. However, I also found 
that PMB could abrogate the responses to other stimuli in which LPS could not be 
detected via LAL assay (data not shown). Therefore, to further investigate the effect of 
LPS contamination on T-cell responses, I removed the contaminating LPS from the 
CEP-1 preparation to generate a ‘clean’ sample of CEP-1 using an endotoxin removal 
kit. Once I had obtained my sample of ‘clean’ CEP-1 solution (LAL assay confirmed 
that the ‘clean’ preparation contained 0EU/ml endotoxin), I performed an experiment in 
which PBMC from two subjects were stimulated with both the original and ‘clean’ 
CEP-1 samples, each at 10µg/ml. Figure 5.13A shows that in both cases, original CEP-1 
preparation induced good proliferative responses (peak SI values of 4.6 and 15.2) yet 
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the corresponding ‘clean’ CEP-1 preparation did not (peak SI values of only 1.0 and 
0.8). In both subjects, the levels of IL-17, IL-4 and TNF-α production detected in 
response to the ‘clean’ CEP-1 were also substantially lower than those detected in 
response to the original CEP-1 and indeed no IL-10, IL-6 or IFN-γ was detected in 
response to the ‘clean’ CEP-1 (Figure 5.13B). Taken together, these observations 
suggested that the CEP-1 response detected in my earlier experiments was substantially 
influenced by LPS contamination.  
 
However, it was also possible that the LPS removal procedure had removed a 
substantial amount of the peptide. The manufacturers of the LPS removal kit stated that 
5% of the protein/peptide would be lost during the endotoxin removal steps, and 
although I had adjusted the concentration of the ‘clean’ CEP-1 preparation accordingly 
for the PBMC assay, the removal process may actually have removed a greater 
proportion of the peptide. Indeed, when I performed a Bradford assay to measure the 
concentration of ‘clean’ CEP-1 preparation, I found that over 60% of the peptides was 
lost after the LPS removal procedure (a ‘clean’ sample that was expected to contain 
5µg/ml of peptide was shown to contain only 1.9µg peptide). Therefore, the lack of 
responses to the ‘clean’ CEP-1 preparation could be a consequence of the use of 
suboptimal concentrations of the peptides, rather than the removal of contaminating 
LPS alone. 
 
5.2.5. LPS-free REP-1-induced and LPS-free CEP-1-induced PBMC proliferation 
and cytokine production 
In order to further explore the role that LPS contamination may have played in the CEP-
1-induced proliferation and cytokine production responses described in 5.2.3, I obtained 
new, LPS-free preparations of REP-1 and CEP-1 and repeated some further REP-1 and 
CEP-1 experiments using these peptide preparations. Prior to use, samples of the new 
peptide preparations were tested with a LAL assay and both were found to be 
endotoxin-free. Thus, for my final set of experiments, I measured LPS-free REP-1-
induced and LPS-free CEP-1-induced PBMC proliferation and cytokine production in 
eight RA patients and six healthy subjects (clinical details of the RA patients - RA 5.40 
to RA 5.47 - are summarised in Table 2.6 in chapter 2). Tables 5.21 and 5.22 show the 
peak SI values of LPS-free REP-1-induced and LPS-free CEP-1-induced PBMC 
proliferation and the day 5, pg/ml minus background cytokine production values that 
were detected in the RA patients and healthy subjects respectively. 
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Firstly, I compared LPS-free REP-1-induced responses with LPS-free CEP-1-induced 
responses in each of the two subject groups. While only three of the eight RA patients 
showed positive proliferative or cytokine production responses to LPS-free REP-1 
(Table 5.21A), five showed positive responses to LPS-free CEP-1 (Table 5.21B) 
although this difference was not significant (P value of 0.91, Chi-square). RA 5.41 
responded to both peptides with PBMC proliferation alone, yet the magnitude of the 
response to LPS-free REP-1 was slightly greater than that of the response to LPS-free 
CEP-1 (SI values of 3.2 versus 2.1). RA 5.42 responded to LPS-free REP-1 with 
production of IL-17, IL-6 and TNF-α (9pg/ml, 756pg/ml and 50pg/ml respectively), yet 
responded to LPS-free CEP-1 with production of only IL-6 and TNF-α at reduced levels 
(24pg/ml and 3pg/ml respectively). RA 5.46 responded to LPS-free REP-1 with 
production of IL-6 alone (277pg/ml), yet responded to LPS-free CEP-1 with more 
potent IL-6 production (403pg/ml) as well as production of IL-10, IL-17, IL-4 and TNF-
α (23pg/ml, 29pg/ml, 7pg/ml and 3022pg/ml). RA 5.45 and RA 5.47 only responded to 
LPS-free CEP-1, showing production of both IL-17 and IL-6 (5pg/ml and 8pg/ml 
respectively) or IL-6 alone (22pg/ml) respectively. Interestingly, no detectable IFN-γ 
production was observed in response to either LPS-free REP-1 or LPS-free CEP-1 in 
any of the RA patients and none showed detectable IL-10 or IL-4 production in 
response to LPS-free REP-1. Ultimately, the peak SI values of LPS-free REP-1-induced 
PBMC proliferation were comparable to those of LPS-free CEP-1-induced PBMC 
proliferation (mean ± SEM peak SI values of 1.5 ± 0.3 versus 1.2 ± 0.1 respectively, P 
value of 0.09, paired t test). Furthermore, the absolute values of LPS-free REP-1-
induced IL-17, IL-6 and TNF-α production were comparable to those of LPS-free CEP-
1-induced IL-17, IL-6 and TNF-α production (mean ± SEM absolute values of 1 ± 1 
versus 4 ± 4 for IL-17, 129 ± 96 versus 57 ± 50 for IL-6 and 6 ± 6 versus 378 ± 378 for 
TNF-α, P values of 0.44, 0.48 and 0.36 respectively, paired t test). 
 
Two of the six healthy subjects showed positive proliferative and/or cytokine 
production responses to LPS-free REP-1 (Table 5.22A), while four showed positive 
responses to LPS-free CEP-1 (Table 5.22B) although this difference was not significant 
(P value of 0.86, Chi-square). HS 5.30 responded to LPS-free REP-1 with PBMC 
proliferation (SI value of 2.9) and production of both IL-17 and IL-6 (16pg/ml and 
52pg/ml respectively), yet responded to LPS-free CEP-1 with PBMC proliferation alone 
(SI value of 2.8). HS 5.32 responded to LPS-free REP-1 with production of IL-6 alone 
(13pg/ml), yet responded to LPS-free CEP-1 with more potent IL-6 production 
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(135pg/ml) as well as production of IL-17 and TNF-α (3pg/ml and 10pg/ml 
respectively). HS 5.31 and HS 5.34 only responded to LPS-free CEP-1, producing both 
IL-6 and TNF-α (9pg/ml and 3pg/ml respectively) or IL-6 alone (8pg/ml) respectively. 
Interestingly, no detectable IL-10, IL-4 or IFN-γ production was observed in response to 
either LPS-free REP-1 or LPS-free CEP-1 in any of the healthy subjects and none 
showed detectable TNF-α production in response to LPS-free REP-1. Ultimately, the 
peak SI values of LPS-free REP-1-induced PBMC proliferation were comparable to 
those of LPS-free CEP-1-induced PBMC proliferation (mean ± SEM peak SI values of 
1.6 ± 0.3 versus 1.5 ± 0.3 respectively, P value of 0.06, paired t test). In addition, the 
absolute values of LPS-free REP-1-induced IL-17 and IL-6 production were comparable 
to those of LPS-free CEP-1-induced IL-17 and IL-6 production (mean ± SEM absolute 
values of 3 ± 3 versus 1 ± 1 for IL-17 and 11 ± 8 versus 25 ± 22 for IL-6, P values of 
0.44 and 0.57 respectively, paired t test). 
 
Secondly, I compared LPS-free REP-1-induced responses and LPS-free CEP-1-induced 
responses between each of the two subject groups. The proportions of subjects showing 
positive LPS-free REP-1-induced responses were comparable in both the RA patient 
group and the healthy subject group, as were the proportions of subjects showing 
positive LPS-free CEP-1-induced responses. In addition, the peak SI values of LPS-free 
REP-1-induced PBMC proliferation detected in both subject groups were comparable 
(median = 1.3, IQR: 1.1-1.5 in RA patients, median = 1.4, IQR: 1.2-2.0 in healthy 
subjects, P value of 0.60, Mann Whitney), as were the peak SI values of LPS-free CEP-
1-induced PBMC proliferation (median = 1.2, IQR: 1.1-1.3 in RA patients, median = 
1.2, IQR: 1.1-1.8 in healthy subjects, P value of 0.79, Mann Whitney). While none of 
the RA patients or healthy subjects showed detectable IL-10, IL-4 or IFN-γ production 
in response to LPS-free REP-1, detectable levels of IL-17 and IL-6 production were 
observed in both cohorts in response to this stimulus. However, while none of the 
healthy subjects showed detectable levels of REP-1-induced TNF-α production, one of 
the RA patients did. The median absolute values of LPS-free REP-1-induced IL-17 and 
IL-6 production were comparable between the RA patients and the healthy subjects 
(median = 0, IQR: 0-0 versus median = 0, IQR: 0-5 for IL-17 and median = 0, IQR: 0-
208 versus median = 1, IQR: 0-23 for IL-6, P values of 0.69 and 0.89 respectively, 
Mann Whitney). While none of the RA patients or healthy subjects showed detectable 
IFN-γ production in response to LPS-free CEP-1, detectable levels of IL-17, IL-6 and 
TNF-α were observed in both cohorts in response to this stimulus. However, while none 
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of the healthy subjects showed any detectable levels of LPS-free CEP-1-induced IL-10 
or IL-4 production, one of the RA patients did. The median absolute values of LPS-free 
CEP-1-induced IL-17, IL-6 and TNF-α production were comparable between the RA 
patients and the healthy subjects (median = 0, IQR: 0-4 versus median = 0, IQR: 0-1 for 
IL-17, median = 4, IQR: 0-23 versus median = 4, IQR: 0-40 for IL-6 and median = 0, 
IQR: 0-2 versus median = 0, IQR: 0-5 for TNF-α, P values of 0.42, 0.95 and 0.50 
respectively, Mann Whitney). 
 
5.3. Discussion 
As discussed in chapter 4, care must be taken when interpreting data showing cytokine 
production in response to test stimuli. Some of the subjects tested in the experiments 
described in chapter 5 showed substantial levels of background production of IL-10, IL-
17, IL-4 and IFN-γ (see Table 5.23 and Table 5.24 for RA patients and healthy subjects 
respectively), yet the absolute values of production of these cytokines in response to test 
peptides were generally very low (see Table 5.2-Table 5.8, Table 5.10-Table 5.17 and 
Table 5.21 and Table 5.22), therefore peptide-induced production of IL-10, IL-17, IL-4 
and IFN-γ could potentially be over-interpreted. As mentioned in the previous chapter, 
if in a given subject the absolute value of test peptide-induced production of a particular 
cytokine is considerably less than the level of background production of the same 
cytokine, it is open to debate whether the absolute value of peptide-induced cytokine 
production is representative of a positive response, regardless of whether it exceeds the 
threshold level of detection for a positive response. 
 
The experiments described in 5.2.1 and 5.2.2 showed that the peptides comprising 
peptide panels #1 and #2 respectively induced similar proportions of positive 
proliferative and/or cytokine production responses in both the RA patient groups and 
the healthy subject groups. Furthermore, for all 15 of the peptides tested in the 
experiments described in 5.2.1 and 5.2.2, there were no significant differences between 
the magnitudes of the proliferative and cytokine production responses that were elicited 
in the RA patient groups and those that were elicited in the healthy subject groups. In 
addition, the citrullinated peptides induced similar proportions of positive proliferative 
and or cytokine production responses as their non-citrullinated counterparts, and the 
magnitudes of the responses elicited by citrullinated peptides were comparable to those 
elicited by their corresponding non-citrullinated peptides. While responses were 
generally weak, the vast majority of the subjects did show positive responses to at least 
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one of the peptides in the panels. Indeed, substantial numbers of both RA patients and 
healthy subjects showed positive responses to three or more of the peptides in these 
peptide panels. However, the peptides that elicited responses and those that failed to 
elicit responses often varied between individuals. Interestingly, the phenotypes of the 
positive responses also differed between individuals but no clear trends were visible and 
the two subject groups could not be distinguished from each other on this basis, nor 
could responses to citrullinated peptides versus non-citrullinated peptides.  
 
The data from the initial experiments described in 5.2.3 showed that in the RA patient 
group but not in the healthy subject or disease control groups, the citrullinated peptide 
CEP-1 induced a greater proportion of positive proliferative responses than its non-
citrullinated counterpart REP-1. However, CEP-1 had induced positive responses in a 
substantial proportion of the healthy subjects and all of the disease controls and indeed 
the magnitudes of the CEP-1-induced proliferative and IL-17, IL-4 and IFN-γ 
production responses detected in the RA patient group did not differ significantly from 
those detected in the healthy subject group. Thus it was evident that CEP-1 was eliciting 
responses in large numbers of subjects, regardless of whether they were RA patients, 
healthy subjects or disease controls. Subsequent experiments indicated that the 
responses to CEP-1 detected in the initial experiments were likely to be the results of 
LPS contamination. Firstly, the CEP-1 preparation was found to contain LPS, and data 
from further experiments showed that neutralising the LPS in the CEP-1 using PMB as 
well as the removal of the LPS from the CEP-1 could abrogate or substantially dampen 
the CEP-1- responses. Additionally, when PBMC from a further eight RA patients and 
six healthy subjects were tested with new LPS-free REP-1 and CEP-1 preparations, I 
found no significant differences in the T-cell responses to CEP-1 or REP-1 between RA 
patients and healthy subjects with regards to the proportion of positive responses, the 
magnitude of the proliferative responses and also cytokine production. Such findings 
were in contrast to those when using the original, LPS-contaminated CEP-1 
preparations. 
 
However, different RA patients and healthy subjects were tested for T-cell responses to 
the new LPS-free preparation of CEP-1 therefore I could not completely exclude the 
possibility that the differences in the responses to the new batch of LPS-free CEP-1 
versus the original LPS-contaminated batch were a consequence of different subjects 
having been tested. Nevertheless, taken collectively, the data from the experiments 
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described in 5.2.4 and 5.2.5 suggested that LPS contamination contributed substantially 
to the CEP-1 responses that were detected in the experiments described in 5.2.3. 
However, the precise role that the LPS had been playing in the CEP-1 responses was 
unclear. 
 
It is possible that the CEP-1 responses detected in the experiments described in 5.2.3 
could simply have been responses to contaminating LPS, which could have been 
inducing T-cell proliferation via two mechanisms. Firstly, the LPS could have been 
acting directly on T-cells via TLR4, as it has been reported that the recognition of LPS 
by human CD8
+
 T-cells via TLR4 can elicit T-cell responses (Komai-Koma et al, 
2009). Secondly, the LPS could have been acting on T-cells indirectly, activating 
antigen presenting cells via TLR4 ligation and causing them to secrete cytokines and/or 
express co-stimulatory molecules which in turn induce T-cell proliferation, as has been 
previously described (Tough et al, 1997 and Mattern et al, 1998). However, there are 
two arguments against these explanations. Firstly, the data from the LPS titration 
experiments described in 5.2.4 suggested that the level of LPS added to the cell cultures 
in the assays described in 5.2.3 was not sufficient to induce a detectable proliferative 
response. The 1mg/ml working solution of CEP-1 was also found to contain LPS at a 
concentration of 160pg/ml. When 10µl of the 1mg/ml working solution of CEP-1 were 
diluted in 1ml RPMI to produce the final concentration of 10µg/ml CEP-1 that was used 
in the assays, this solution was found to contain LPS at a concentration of 70pg/ml. 
Data from my LPS titration experiments showed that even a 100pg/ml concentration of 
LPS was incapable of inducing detectable proliferation, and this observation is similar 
to what has previously been reported (Tough et al, 1997 and Tulic et al, 2002). 
Secondly, there were significant differences between the magnitudes of the CEP-1-
induced responses detected in each of the three subject groups. For example, the 
magnitudes of the CEP-1-induced proliferative responses detected in the disease control 
group were significantly greater than those detected in the RA patient and healthy 
subject groups. In addition, the magnitude of CEP-1-induced IL-10 production in both 
the RA patient and disease control groups was significantly greater than CEP-1-induced 
IL-10 production in the healthy subject group, while the magnitude of CEP-1-induced 
IL-4 production in the disease control group was significantly greater than CEP-1-
induced IL-4 production in the healthy subject group. Furthermore, the magnitudes of 
CEP-1-induced IL-6 and TNF-α production in the RA patient group were significantly 
greater than CEP-1-induced IL-6 and TNF-α production in both the healthy subject and 
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disease control groups. If the CEP-1 response was purely a response to the LPS 
contaminant within the CEP-1 preparation, then all subjects should respond similarly 
with no significant differences between the three subject groups in the way that they 
respond to CEP-1, assuming equivalent sensitivities to LPS between the groups. One 
would not expect an LPS-specific response to differ between the different subject 
groups. However, there is evidence to suggest that the synovial macrophages of RA 
patients express more TLR4 than control macrophages and are therefore more sensitive 
to microbial products like LPS (Huang et al, 2007). Thus RA patient macrophages may 
produce more T-cell-activating cytokines in response to LPS stimulation than their 
healthy subject/disease control counterparts. 
 
However, it is also possible that the LPS was acting as an adjuvant, enhancing the 
responses to the CEP-1 peptide by activating antigen-presenting cells and inducing 
expression of certain cytokines and co-stimulatory molecules which could in turn could 
have provided additional activation signals to CD4
+
 T-cells recognising MHC class 
II:CEP-1 peptide complexes presented by the antigen-presenting cells. Thus the LPS 
may have simply been amplifying CEP-1 peptide-specific proliferative and cytokine 
production responses. It is possible that the addition of an adjuvant like LPS to the 
autoantigen-stimulated cultures is required for autoantigen-specific responses to be 
detected. 
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Peptide ID Sequence Antigen Reference 
1 SAVRA(Cit)SSVPGVR 
Cit-Vimentin65-
77 
1* 
2 QDFTN(Cit)INKLKNS 
Cit-Fibrinogen 
α–chain80-92 
2* 
3 KIHA(Cit)EIFDS(Cit)GNPTVE Cit-Enolase5-21 3* 
4 HSASQDGQDTI(Cit)GHPGSS 
Cit-Filaggrin2776-
2793 
4* 
5 DSGH(Cit)GYSGSQASDNEGH 
Cit-Filaggrin3005-
3022 
6 CVLLVATEGRVRVNSAYQDC 
Aggrecan84-103 
with terminal 
cysteines 
5* 
7 CVLLVATEG(Cit)VRVNSAYQDC 
Cit-Aggrecan84-
103 with terminal 
cysteines 
8 AGWLADQTVRYPI Aggrecan201-213 
6* (non-cit 
peptides 
only) 
9 AGWLADQTV(Cit)YPI 
Cit-Aggrecan201-
213 
10 AGWLADRSVRYPI Aggrecan299-311 
11 AGWLAD(Cit)SVRYPI 
Cit-Aggrecan299-
311 
12 GRSFTLASSETGVGA HCgp39262-276 7* (non-cit 
peptide 
only) 
13 G(Cit)SFTLASSETGVGA 
Cit-HCgp39262-
276 
14 VVLLVATEG(Cit)VRVNSAYQDK 
N Cit-
Aggrecan84-103 
5* 
15 VVLLVATEGRV(Cit)VNSAYQDK 
C Cit-
Aggrecan84-103 
REP-1 CKIHAREIFDSRGNPTVEC 
Enolase5-21 
with terminal 
cysteines 
3* 
CEP-1 CKIHA(Cit)EIFDS(Cit)GNPTVEC 
Cit-Enolase5-21 
with terminal 
cysteines 
 
Table 5.1. Details of peptide stimuli used in chapter 5. Peptides 1-7 comprised 
peptide panel #1, while peptides 8-15 comprised peptide panel #2. (Cit) = citrulline. Cit- 
= citrullinated. 1* = Hill et al, 2003, 2* = Hill et al, 2008, 3* = Lundberg et al, 2008, 4* 
= Fritsch et al, 2002, 5* = von Delwig et al, 2010, 6* = Boots et al, 1997, 7* = 
Verheijden et al, 1997. Peptide 14 (N citrullinated Aggrecan84-103) was the citrullinated 
peptide tested in the experiments described by von Delwig et al, 2010. 
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A) RA patients 
ID 
Peptide 1-induced PBMC responses 
3HTdR incorporation 
SI value (peak) 
Cytokine production (day 5) 
IL-10 IL-17 IL-4 IL-6 TNF-α IFN-γ 
RA 5.1 1.2 0 26 0 203 18 0 
RA 5.2 13.4 0 0 0 164 31 29 
RA 5.3 1.4 0 31 0 306 18 0 
RA 5.4 - - - - - - - 
RA 5.5 1.2 0 0 0 0 0 0 
RA 5.6 1.2 0 0 0 0 0 9 
RA 5.7 1.0 0 0 0 0 0 0 
RA 5.8 1.0 0 0 0 0 0 0 
RA 5.9 1.5 0 0 0 12 0 0 
RA 5.10 1.6 0 0 0 0 0 0 
 
B) Healthy subjects 
ID 
Peptide 1-induced PBMC responses 
3HTdR incorporation 
SI value (peak) 
Cytokine production (day 5) 
IL-10 IL-17 IL-4 IL-6 TNF-α IFN-γ 
HS 5.1 1.2 0 0 0 0 0 0 
HS 5.2 1.6 0 0 0 0 0 10 
HS 5.3 1.5 0 0 0 0 0 0 
HS 5.4 3.8 0 0 0 0 0 0 
HS 5.5 3.0 0 246 0 698 35 7 
HS 5.6 0.9 0 0 0 0 0 0 
HS 5.7 1.2 9 15 0 1322 25 0 
HS 5.8 1.6 0 0 0 0 0 0 
HS 5.9 1.6 0 0 0 0 0 0 
HS 5.10 1.3 0 0 0 0 0 0 
 
Table 5.2. Peptide 1-induced PBMC proliferation and cytokine production 
detected in RA patients and healthy subjects. A & B, the peak SI values of peptide 1-
induced PBMC proliferation and the day 5 absolute values of peptide 1-induced 
cytokine production detected in the RA patients and healthy subjects respectively. A 
dash (-) represents an untested value. 
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A) RA patients 
ID 
Peptide 2-induced PBMC responses 
3HTdR incorporation 
SI value (peak) 
Cytokine production (day 5) 
IL-10 IL-17 IL-4 IL-6 TNF-α IFN-γ 
RA 5.1 1.1 0 0 0 0 0 10 
RA 5.2 0.7 0 7 0 39 0 0 
RA 5.3 1.5 0 0 0 0 0 0 
RA 5.4 - - - - - - - 
RA 5.5 1.2 0 0 0 14 3 0 
RA 5.6 0.9 0 0 0 0 0 15 
RA 5.7 0.9 0 0 0 0 0 8 
RA 5.8 1.0 0 0 0 0 0 0 
RA 5.9 1.3 0 358 0 4 0 0 
RA 5.10 1.6 0 0 0 0 0 0 
 
B) Healthy subjects 
ID 
Peptide 2-induced PBMC responses 
3HTdR incorporation 
SI value (peak) 
Cytokine production (day 5) 
IL-10 IL-17 IL-4 IL-6 TNF-α IFN-γ 
HS 5.1 1.9 0 0 0 0 0 45 
HS 5.2 1.2 0 0 0 0 0 0 
HS 5.3 1.8 0 0 0 0 0 0 
HS 5.4 5.7 0 359 0 0 4 0 
HS 5.5 4.4 0 0 0 690 49 57 
HS 5.6 0.8 0 0 0 3 0 0 
HS 5.7 1.0 0 3 0 90 10 0 
HS 5.8 1.5 0 0 0 0 0 0 
HS 5.9 1.6 0 0 0 0 0 0 
HS 5.10 1.3 0 27 0 88 3 0 
 
Table 5.3. Peptide 2-induced PBMC proliferation and cytokine production 
detected in RA patients and healthy subjects. A & B, the peak SI values of peptide 2-
induced PBMC proliferation and the day 5 absolute values of peptide 2-induced 
cytokine production detected in the RA patients and healthy subjects respectively. A 
dash (-) represents an untested value. 
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A) RA patients 
ID 
Peptide 3-induced PBMC responses 
3HTdR incorporation 
SI value (peak) 
Cytokine production (day 5) 
IL-10 IL-17 IL-4 IL-6 TNF-α IFN-γ 
RA 5.1 1.1 0 31 0 0 0 14 
RA 5.2 1.1 0 8 0 0 0 0 
RA 5.3 2.0 0 0 0 0 0 0 
RA 5.4 - - - - - - - 
RA 5.5 1.1 0 0 0 0 0 0 
RA 5.6 1.0 0 0 0 17 0 0 
RA 5.7 1.0 0 0 0 4 0 0 
RA 5.8 1.0 0 0 0 0 0 0 
RA 5.9 1.5 3 163 0 5 0 0 
RA 5.10 1.3 0 0 0 0 0 0 
 
B) Healthy subjects 
ID 
Peptide 3-induced PBMC responses 
3HTdR incorporation 
SI value (peak) 
Cytokine production (day 5) 
IL-10 IL-17 IL-4 IL-6 TNF-α IFN-γ 
HS 5.1 0.9 0 0 0 0 0 35 
HS 5.2 1.2 0 0 0 0 0 0 
HS 5.3 1.5 0 0 0 30 6 16 
HS 5.4 2.2 0 0 0 0 0 0 
HS 5.5 9.6 0 0 0 0 3 10 
HS 5.6 0.7 0 0 0 9 0 0 
HS 5.7 0.8 3 5 0 254 8 0 
HS 5.8 1.8 0 0 0 0 0 0 
HS 5.9 0.9 0 0 0 0 0 0 
HS 5.10 1.2 0 0 0 0 0 0 
 
Table 5.4. Peptide 3-induced PBMC proliferation and cytokine production 
detected in RA patients and healthy subjects. A & B, the peak SI values of peptide 3-
induced PBMC proliferation and the day 5 absolute values of peptide 3-induced 
cytokine production detected in the RA patients and healthy subjects respectively. A 
dash (-) represents an untested value. 
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A) RA patients 
ID 
Peptide 4-induced PBMC responses 
3HTdR incorporation 
SI value (peak) 
Cytokine production (day 5) 
IL-10 IL-17 IL-4 IL-6 TNF-α IFN-γ 
RA 5.1 - - - - - - - 
RA 5.2 1.3 0 0 0 13 4 0 
RA 5.3 1.3 0 4 0 12 12 0 
RA 5.4 1.3 0 0 0 0 0 0 
RA 5.5 1.0 0 0 0 0 0 11 
RA 5.6 1.1 0 0 0 3 0 0 
RA 5.7 0.9 0 0 0 0 0 16 
RA 5.8 1.1 0 0 0 0 0 0 
RA 5.9 1.2 0 0 0 46 10 0 
RA 5.10 1.5 0 0 0 3 2 0 
 
B) Healthy subjects 
ID 
Peptide 4-induced PBMC responses 
3HTdR incorporation 
SI value (peak) 
Cytokine production (day 5) 
IL-10 IL-17 IL-4 IL-6 TNF-α IFN-γ 
HS 5.1 1.0 0 104 0 0 0 49 
HS 5.2 1.1 0 0 0 0 0 31 
HS 5.3 1.4 0 25 0 40 18 51 
HS 5.4 3.6 4 1220 5 1817 31 57 
HS 5.5 5.6 0 0 0 0 4 0 
HS 5.6 0.7 0 0 0 0 0 0 
HS 5.7 0.9 4 21 2 1310 20 0 
HS 5.8 1.4 0 0 0 0 0 0 
HS 5.9 2.1 0 0 0 0 0 0 
HS 5.10 1.8 0 77 0 6 0 0 
 
Table 5.5. Peptide 4-induced PBMC proliferation and cytokine production 
detected in RA patients and healthy subjects. A & B, the peak SI values of peptide 4-
induced PBMC proliferation and the day 5 absolute values of peptide 4-induced 
cytokine production detected in the RA patients and healthy subjects respectively. A 
dash (-) represents an untested value. 
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A) RA patients 
ID 
Peptide 5-induced PBMC responses 
3HTdR incorporation 
SI value (peak) 
Cytokine production (day 5) 
IL-10 IL-17 IL-4 IL-6 TNF-α IFN-γ 
RA 5.1 - - - - - - - 
RA 5.2 0.8 0 0 0 0 0 0 
RA 5.3 1.7 16 272 27 9692 297 0 
RA 5.4 3.3 0 0 0 0 0 0 
RA 5.5 1.2 0 0 0 0 0 19 
RA 5.6 1.1 0 0 0 0 0 0 
RA 5.7 1.0 0 0 0 0 0 22 
RA 5.8 1.1 0 0 0 0 0 0 
RA 5.9 1.2 0 3 0 0 0 0 
RA 5.10 2.0 0 0 0 4 2 20 
 
B) Healthy subjects 
ID 
Peptide 5-induced PBMC responses 
3HTdR incorporation 
SI value (peak) 
Cytokine production (day 5) 
IL-10 IL-17 IL-4 IL-6 TNF-α IFN-γ 
HS 5.1 1.4 0 0 0 0 0 39 
HS 5.2 1.3 0 0 0 5 3 33 
HS 5.3 1.2 2 0 0 63 29 39 
HS 5.4 1.5 0 0 0 0 0 0 
HS 5.5 5.3 0 0 0 106 21 79 
HS 5.6 0.7 0 0 0 0 3 0 
HS 5.7 0.8 0 0 0 3 0 0 
HS 5.8 2.0 0 0 0 0 0 0 
HS 5.9 1.2 0 0 0 0 0 0 
HS 5.10 1.3 0 0 0 3 0 0 
 
Table 5.6. Peptide 5-induced PBMC proliferation and cytokine production 
detected in RA patients and healthy subjects. A & B, the peak SI values of peptide 5-
induced PBMC proliferation and the day 5 absolute values of peptide 5-induced 
cytokine production detected in the RA patients and healthy subjects respectively. A 
dash (-) represents an untested value. 
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A) RA patients 
ID 
Peptide 6-induced PBMC responses 
3HTdR incorporation 
SI value (peak) 
Cytokine production (day 5) 
IL-10 IL-17 IL-4 IL-6 TNF-α IFN-γ 
RA 5.1 - - - - - - - 
RA 5.2 1.2 0 6 0 0 0 0 
RA 5.3 2.2 0 3 0 0 0 0 
RA 5.4 1.1 0 0 0 0 0 0 
RA 5.5 1.2 0 0 0 0 0 9 
RA 5.6 1.0 0 0 0 0 0 0 
RA 5.7 0.8 0 0 0 3 0 0 
RA 5.8 1.1 0 0 0 0 0 0 
RA 5.9 3.0 0 7 0 13 2 0 
RA 5.10 2.2 0 0 0 4 0 15 
 
B) Healthy subjects 
ID 
Peptide 6-induced PBMC responses 
3HTdR incorporation 
SI value (peak) 
Cytokine production (day 5) 
IL-10 IL-17 IL-4 IL-6 TNF-α IFN-γ 
HS 5.1 1.6 0 0 0 0 0 37 
HS 5.2 1.6 0 3 0 20 0 29 
HS 5.3 1.2 0 0 0 11 5 37 
HS 5.4 5.1 0 0 0 0 0 0 
HS 5.5 3.4 0 0 0 0 0 60 
HS 5.6 1.5 0 87 0 21 14 0 
HS 5.7 1.4 0 0 0 34 2 0 
HS 5.8 1.4 0 0 0 0 0 0 
HS 5.9 1.6 0 12 0 133 0 0 
HS 5.10 1.4 0 0 0 0 0 0 
 
Table 5.7. Peptide 6-induced PBMC proliferation and cytokine production 
detected in RA patients and healthy subjects. A & B, the peak SI values of peptide 6-
induced PBMC proliferation and the day 5 absolute values of peptide 6-induced 
cytokine production detected in the RA patients and healthy subjects respectively. A 
dash (-) represents an untested value. 
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A) RA patients 
ID 
Peptide 7-induced PBMC responses 
3HTdR incorporation 
SI value (peak) 
Cytokine production (day 5) 
IL-10 IL-17 IL-4 IL-6 TNF-α IFN-γ 
RA 5.1 - - - - - - - 
RA 5.2 1.7 0 5 0 0 2 12 
RA 5.3 2.4 0 14 0 0 0 0 
RA 5.4 1.7 0 0 0 11 0 0 
RA 5.5 1.1 0 0 0 0 0 0 
RA 5.6 0.9 0 0 0 5 0 0 
RA 5.7 0.7 0 0 0 5 0 0 
RA 5.8 0.9 0 0 0 0 0 0 
RA 5.9 1.4 0 5 0 0 0 0 
RA 5.10 3.0 0 0 0 5 0 9 
 
B) Healthy subjects 
ID 
Peptide 7-induced PBMC responses 
3HTdR incorporation 
SI value (peak) 
Cytokine production (day 5) 
IL-10 IL-17 IL-4 IL-6 TNF-α IFN-γ 
HS 5.1 2.3 0 0 0 0 0 45 
HS 5.2 1.3 0 11 0 468 3 44 
HS 5.3 1.0 0 0 0 2 0 31 
HS 5.4 1.4 0 0 0 0 0 0 
HS 5.5 4.4 0 0 0 0 0 31 
HS 5.6 1.0 0 0 0 4 0 0 
HS 5.7 1.3 2 12 0 960 0 0 
HS 5.8 2.0 0 5 0 31 0 0 
HS 5.9 1.0 3 0 0 0 0 0 
HS 5.10 4.6 5 3 0 41 0 0 
 
Table 5.8. Peptide 7-induced PBMC proliferation and cytokine production 
detected in RA patients and healthy subjects. A & B, the peak SI values of peptide 7-
induced PBMC proliferation and the day 5 absolute values of peptide 7-induced 
cytokine production detected in the RA patients and healthy subjects respectively. A 
dash (-) represents an untested value. 
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A) RA patients 
ID 
Positive PBMC proliferative and/or cytokine production response 
(Yes/No) 
Peptide 
1 
Peptide 
2 
Peptide 
3 
Peptide 
4 
Peptide 
5 
Peptide 
6 
Peptide 
7 
RA 5.1 Yes Yes Yes - - - - 
RA 5.2 Yes Yes Yes Yes No Yes Yes 
RA 5.3 Yes No Yes Yes Yes Yes Yes 
RA 5.4 - - - No Yes No Yes 
RA 5.5 No Yes No Yes Yes Yes No 
RA 5.6 Yes Yes Yes Yes No No Yes 
RA 5.7 No Yes Yes Yes Yes Yes Yes 
RA 5.8 No No No No No No No 
RA 5.9 Yes Yes Yes Yes Yes Yes Yes 
RA 5.10 No No No Yes Yes Yes Yes 
 
B) Healthy subjects 
ID 
Positive PBMC proliferative and/or cytokine production response 
(Yes/No) 
Peptide 
1 
Peptide 
2 
Peptide 
3 
Peptide 
4 
Peptide 
5 
Peptide 
6 
Peptide 
7 
HS 5.1 No Yes Yes Yes Yes Yes Yes 
HS 5.2 Yes No No Yes Yes Yes Yes 
HS 5.3 No No Yes Yes Yes Yes Yes 
HS 5.4 Yes Yes Yes Yes No Yes No 
HS 5.5 Yes Yes Yes Yes Yes Yes Yes 
HS 5.6 No Yes Yes No Yes Yes Yes 
HS 5.7 Yes Yes Yes Yes Yes Yes Yes 
HS 5.8 No No No No Yes No Yes 
HS 5.9 No No No Yes No Yes Yes 
HS 5.10 No Yes No Yes Yes No Yes 
 
Table 5.9. Responders and non-responders; peptide panel #1. A, how each of the 
RA patients responded to the peptides. A dash (-) represents an untested value. B, how 
each of the healthy subjects responded to the peptides. 
 161 
A) 
ID 
Peptide 8-induced PBMC responses 
3HTdR incorporation 
SI value (peak) 
Cytokine production (day 5) 
IL-10 IL-17 IL-4 IL-6 TNF-α IFN-γ 
RA 5.11 1.0 0 3 0 55 0 0 
RA 5.12 1.5 0 0 0 0 0 75 
RA 5.13 1.3 - - - - - - 
RA 5.14 1.3 0 7 0 0 0 0 
RA 5.15 - - - - - - - 
RA 5.16 - - - - - - - 
RA 5.17 - - - - - - - 
RA 5.18 - - - - - - - 
RA 5.19 - - - - - - - 
 
B) 
ID 
Peptide 9-induced PBMC responses 
3HTdR incorporation 
SI value (peak) 
Cytokine production (day 5) 
IL-10 IL-17 IL-4 IL-6 TNF-α IFN-γ 
RA 5.11 1.0 0 29 0 1433 23 0 
RA 5.12 1.2 0 0 0 0 0 5 
RA 5.13 1.4 - - - - - - 
RA 5.14 1.2 2 135 5 5343 26 0 
RA 5.15 1.1 0 2 0 0 0 0 
RA 5.16 2.1 0 0 0 0 0 0 
RA 5.17 0.9 0 0 0 0 39 11 
RA 5.18 1.2 45 41 17 642 4599 0 
RA 5.19 1.4 4 29 4 0 11 0 
 
Table 5.10. Peptide 8-induced and peptide 9-induced PBMC proliferation and 
cytokine production detected in RA patients. A, the peak SI values of peptide 8-
induced PBMC proliferation and the day 5 absolute values of peptide 8-induced 
cytokine production detected in the RA patients. B, the peak SI values of peptide 9-
induced PBMC proliferation and the day 5 absolute values of peptide 9-induced 
cytokine production detected in the RA patients. In both tables, a dash (-) represents an 
untested value. 
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A) 
ID 
Peptide 8-induced PBMC responses 
3HTdR incorporation 
SI value (peak) 
Cytokine production (day 5) 
IL-10 IL-17 IL-4 IL-6 TNF-α IFN-γ 
HS 5.11 0.9 0 0 0 0 0 0 
HS 5.12 1.5 0 0 0 0 0 0 
HS 5.13 3.2 0 0 0 0 0 0 
HS 5.14 2.2 0 0 0 0 0 459 
HS 5.15 1.1 0 0 0 0 2 0 
HS 5.16 1.1 0 0 0 0 0 0 
HS 5.17 - - - - - - - 
HS 5.18 - - - - - - - 
HS 5.19 - - - - - - - 
 
B) 
ID 
Peptide 9-induced PBMC responses 
3HTdR incorporation 
SI value (peak) 
Cytokine production (day 5) 
IL-10 IL-17 IL-4 IL-6 TNF-α IFN-γ 
HS 5.11 0.8 0 0 0 0 0 0 
HS 5.12 1.2 0 0 0 11 0 0 
HS 5.13 1.5 0 0 0 0 0 0 
HS 5.14 5.4 0 943 0 1665 100 12 
HS 5.15 0.8 0 0 0 0 0 0 
HS 5.16 1.4 0 0 0 20 0 0 
HS 5.17 2.9 0 0 0 3 0 5 
HS 5.18 0.8 0 0 0 13 0 0 
HS 5.19 1.6 0 0 0 0 0 0 
 
Table 5.11. Peptide 8-induced and peptide 9-induced PBMC proliferation and 
cytokine production detected in healthy subjects. A, the peak SI values of peptide 8-
induced PBMC proliferation and the day 5 absolute values of peptide 8-induced 
cytokine production detected in the healthy subjects. A dash (-) represents an untested 
value. B, the peak SI values of peptide 9-induced PBMC proliferation and the day 5 
absolute values of peptide 9-induced cytokine production detected in the healthy 
subjects. 
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A) 
ID 
Peptide 10-induced PBMC responses 
3HTdR incorporation 
SI value (peak) 
Cytokine production (day 5) 
IL-10 IL-17 IL-4 IL-6 TNF-α IFN-γ 
RA 5.11 2.6 0 0 0 22 0 0 
RA 5.12 1.5 0 0 0 31 11 99 
RA 5.13 1.4 - - - - - - 
RA 5.14 1.2 0 0 0 733 0 0 
RA 5.15 - - - - - - - 
RA 5.16 - - - - - - - 
RA 5.17 - - - - - - - 
RA 5.18 - - - - - - - 
RA 5.19 - - - - - - - 
 
B) 
ID 
Peptide 11-induced PBMC responses 
3HTdRincorporation 
SI value (peak) 
Cytokine production (day 5) 
IL-10 IL-17 IL-4 IL-6 TNF-α IFN-γ 
RA 5.11 0.8 0 59 0 0 0 0 
RA 5.12 1.2 0 0 0 0 0 87 
RA 5.13 1.2 - - - - - - 
RA 5.14 1.2 0 0 0 509 9 0 
RA 5.15 1.5 0 0 0 0 0 0 
RA 5.16 1.5 0 0 0 0 0 0 
RA 5.17 1.0 0 0 0 0 60 11 
RA 5.18 1.6 33 3 13 0 2752 0 
RA 5.19 1.3 3 22 3 0 0 7 
 
Table 5.12. Peptide 10-induced and peptide 11-induced PBMC proliferation and 
cytokine production detected in RA patients. A, the peak SI values of peptide 10-
induced PBMC proliferation and the day 5 absolute values of peptide 10-induced 
cytokine production detected in the RA patients. B, the peak SI values of peptide 11-
induced PBMC proliferation and the day 5 absolute values of peptide 11-induced 
cytokine production detected in the RA patients. In both tables, a dash (-) represents an 
untested value. 
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A) 
ID 
Peptide 10-induced PBMC responses 
3HTdR incorporation 
SI value (peak) 
Cytokine production (day 5) 
IL-10 IL-17 IL-4 IL-6 TNF-α IFN-γ 
HS 5.11 1.0 0 0 0 0 0 0 
HS 5.12 1.2 0 14 0 484 7 0 
HS 5.13 1.2 0 0 0 0 0 0 
HS 5.14 4.1 17 0 3 0 23 130 
HS 5.15 1.1 0 0 0 0 0 0 
HS 5.16 2.6 0 2 0 271 0 0 
HS 5.17 - - - - - - - 
HS 5.18 - - - - - - - 
HS 5.19 - - - - - - - 
 
B) 
ID 
Peptide 11-induced PBMC responses 
3HTdR incorporation 
SI value (peak) 
Cytokine production (day 5) 
IL-10 IL-17 IL-4 IL-6 TNF-α IFN-γ 
HS 5.11 0.9 0 0 0 0 0 0 
HS 5.12 2.3 0 0 0 46 0 0 
HS 5.13 3.3 0 0 0 0 0 0 
HS 5.14 1.6 0 0 0 0 3 261 
HS 5.15 1.1 0 0 0 0 0 0 
HS 5.16 1.4 5 17 0 1057 33 0 
HS 5.17 2.1 0 0 0 0 0 0 
HS 5.18 1.0 0 0 0 0 0 0 
HS 5.19 1.9 0 0 0 0 0 0 
 
Table 5.13. Peptide 10-induced and peptide 11-induced PBMC proliferation and 
cytokine production detected in healthy subjects. A, the peak SI values of peptide 
10-induced PBMC proliferation and the day 5 absolute values of peptide 10-induced 
cytokine production detected in the healthy subjects. A dash (-) represents an untested 
value. B, the peak SI values of peptide 11-induced PBMC proliferation and the day 5 
absolute values of peptide 11-induced cytokine production detected in the healthy 
subjects. 
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A) 
ID 
Peptide 12-induced PBMC responses 
3HTdR incorporation 
SI value (peak) 
Cytokine production (day 5) 
IL-10 IL-17 IL-4 IL-6 TNF-α IFN-γ 
RA 5.11 1.3 0 0 0 11 0 0 
RA 5.12 1.0 0 0 0 0 13 99 
RA 5.13 1.1 - - - - - - 
RA 5.14 - - - - - - - 
RA 5.15 - - - - - - - 
RA 5.16 - - - - - - - 
RA 5.17 - - - - - - - 
RA 5.18 - - - - - - - 
RA 5.19 - - - - - - - 
 
B) 
ID 
Peptide 13-induced PBMC responses 
3HTdR incorporation 
SI value (peak) 
Cytokine production (day 5) 
IL-10 IL-17 IL-4 IL-6 TNF-α IFN-γ 
RA 5.11 1.0 0 0 0 0 0 0 
RA 5.12 1.0 0 0 0 10 6 105 
RA 5.13 1.2 0 0 0 0 0 0 
RA 5.14 - - - - - - - 
RA 5.15 1.4 0 0 0 0 0 0 
RA 5.16 1.5 0 0 0 0 0 0 
RA 5.17 - - - - - - - 
RA 5.18 1.2 16 0 8 222 1117 0 
RA 5.19 1.2 2 23 3 0 0 6 
 
Table 5.14. Peptide 12-induced and peptide 13-induced PBMC proliferation and 
cytokine production detected in RA patients. A, the peak SI values of peptide 12-
induced PBMC proliferation and the day 5 absolute values of peptide 12-induced 
cytokine production detected in the RA patients. B, the peak SI values of peptide 13-
induced PBMC proliferation and the day 5 absolute values of peptide 13-induced 
cytokine production detected in the RA patients. In both tables, a dash (-) represents an 
untested value. 
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A) 
ID 
Peptide 12-induced PBMC responses 
3HTdR incorporation 
SI value (peak) 
Cytokine production (day 5) 
IL-10 IL-17 IL-4 IL-6 TNF-α IFN-γ 
HS 5.11 0.8 0 0 0 0 0 6 
HS 5.12 0.9 0 7 0 0 0 0 
HS 5.13 1.5 0 0 0 0 0 20 
HS 5.14 1.5 3 0 0 44 25 11 
HS 5.15 0.9 0 0 0 0 0 0 
HS 5.16 0.9 0 0 0 9 0 0 
HS 5.17 - - - - - - - 
HS 5.18 - - - - - - - 
HS 5.19 - - - - - - - 
 
B) 
ID 
Peptide 13-induced PBMC responses 
3HTdR incorporation 
SI value (peak) 
Cytokine production (day 5) 
IL-10 IL-17 IL-4 IL-6 TNF-α IFN-γ 
HS 5.11 0.9 0 0 0 0 0 10 
HS 5.12 1.4 0 6 0 0 0 0 
HS 5.13 2.6 0 0 0 0 0 0 
HS 5.14 1.8 0 0 0 0 0 7 
HS 5.15 0.9 0 0 0 0 0 0 
HS 5.16 1.2 3 4 0 681 13 0 
HS 5.17 1.8 0 6 0 0 0 5 
HS 5.18 1.1 3 0 0 6 0 0 
HS 5.19 1.1 0 0 0 0 0 0 
 
Table 5.15. Peptide 12-induced and peptide 13-induced PBMC proliferation and 
cytokine production detected in healthy subjects. A, the peak SI values of peptide 
12-induced PBMC proliferation and the day 5 absolute values of peptide 12-induced 
cytokine production detected in the healthy subjects. A dash (-) represents an untested 
value. B, the peak SI values of peptide 13-induced PBMC proliferation and the day 5 
absolute values of peptide 13-induced cytokine production detected in the healthy 
subjects. 
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A) 
ID 
Peptide 14-induced PBMC responses 
3HTdR incorporation 
SI value (peak) 
Cytokine production (day 5) 
IL-10 IL-17 IL-4 IL-6 TNF-α IFN-γ 
RA 5.11 3.3 0 0 0 603 0 0 
RA 5.12 1.1 0 0 0 3 7 104 
RA 5.13 1.2 - - - - - - 
RA 5.14 1.3 0 24 0 254 0 0 
RA 5.15 1.1 0 0 0 0 0 0 
RA 5.16 1.4 0 0 0 0 0 0 
RA 5.17 0.7 0 7 0 0 0 0 
RA 5.18 1.1 17 13 7 516 2107 0 
RA 5.19 0.9 0 0 0 0 0 0 
 
B) 
ID 
Peptide 15-induced PBMC responses 
3HTdR incorporation 
SI value (peak) 
Cytokine production (day 5) 
IL-10 IL-17 IL-4 IL-6 TNF-α IFN-γ 
RA 5.11 1.3 0 52 0 90 0 0 
RA 5.12 1.2 0 0 0 0 0 104 
RA 5.13 1.4 - - - - - - 
RA 5.14 1.1 0 145 3 3685 10 0 
RA 5.15 1.2 0 0 0 0 0 0 
RA 5.16 1.3 0 0 0 0 0 0 
RA 5.17 1.1 0 0 0 0 0 12 
RA 5.18 1.1 31 0 17 832 2925 0 
RA 5.19 0.9 4 26 4 0 0 0 
 
Table 5.16. Peptide 14-induced and peptide 15-induced PBMC proliferation and 
cytokine production detected in RA patients. A, the peak SI values of peptide 14-
induced PBMC proliferation and the day 5 absolute values of peptide 14-induced 
cytokine production detected in the RA patients. B, the peak SI values of peptide 15-
induced PBMC proliferation and the day 5 absolute values of peptide 15-induced 
cytokine production detected in the RA patients. In both tables, a dash (-) represents an 
untested value. 
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A) 
ID 
Peptide 14-induced PBMC responses 
3HTdR incorporation 
SI value (peak) 
Cytokine production (day 5) 
IL-10 IL-17 IL-4 IL-6 TNF-α IFN-γ 
HS 5.11 1.3 0 0 0 0 0 0 
HS 5.12 1.2 0 2 0 0 0 0 
HS 5.13 3.0 0 0 0 0 0 0 
HS 5.14 3.3 7 612 0 98 10 0 
HS 5.15 0.9 0 0 0 0 0 0 
HS 5.16 1.1 6 33 3 2670 33 0 
HS 5.17 1.5 0 2 0 0 0 7 
HS 5.18 1.8 9 0 0 0 0 0 
HS 5.19 2.3 0 0 0 144 13 38 
 
B) 
ID 
Peptide 15-induced PBMC responses 
3HTdR incorporation 
SI value (peak) 
Cytokine production (day 5) 
IL-10 IL-17 IL-4 IL-6 TNF-α IFN-γ 
HS 5.11 1.1 0 0 0 424 0 0 
HS 5.12 1.0 2 13 0 341 30 0 
HS 5.13 1.5 0 0 0 0 0 0 
HS 5.14 2.3 0 0 0 12 6 0 
HS 5.15 0.9 0 0 0 10 0 0 
HS 5.16 1.1 5 16 0 780 11 0 
HS 5.17 2.3 0 18 0 0 0 6 
HS 5.18 0.9 0 0 0 0 0 0 
HS 5.19 1.5 0 0 0 0 0 0 
 
Table 5.17. Peptide 14-induced and peptide 15-induced PBMC proliferation and 
cytokine production detected in healthy subjects. A, the peak SI values of peptide 
14-induced PBMC proliferation and the day 5 absolute values of peptide 14-induced 
cytokine production detected in the healthy subjects. B, the peak SI values of peptide 
15-induced PBMC proliferation and the day 5 absolute values of peptide 15-induced 
cytokine production detected in the healthy subjects. 
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ID 
Positive PBMC proliferative and/or cytokine production response (Yes/No) 
Peptide 
8 
Peptide 
9 
Peptide 
10 
Peptide 
11 
Peptide 
12 
Peptide 
13 
Peptide 
14 
Peptide 
15 
RA 
5.11 
Yes Yes Yes Yes Yes No Yes Yes 
RA 
5.12 
Yes Yes Yes Yes Yes Yes Yes Yes 
RA 
5.13 
No No No No No No No No 
RA 
5.14 
Yes Yes Yes Yes - - Yes Yes 
RA 
5.15 
- Yes - No - No No No 
RA 
5.16 
- Yes - No - No No No 
RA 
5.17 
- Yes - Yes - - Yes Yes 
RA 
5.18 
- Yes - Yes - Yes Yes Yes 
RA 
5.19 
- Yes - Yes - Yes No Yes 
 
Table 5.18. RA patient responders and non-responders; peptide panel #2. How 
each of the RA patients responded to the peptides. A dash (-) represents an untested 
value. 
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ID 
Positive PBMC proliferative and/or cytokine production response (Yes/No) 
Peptide 
8 
Peptide 
9 
Peptide 
10 
Peptide 
11 
Peptide 
12 
Peptide 
13 
Peptide 
14 
Peptide 
15 
HS 
5.11 
No No No No Yes Yes No Yes 
HS 
5.12 
No Yes Yes Yes Yes Yes Yes Yes 
HS 
5.13 
Yes No No Yes Yes Yes Yes No 
HS 
5.14 
Yes Yes Yes Yes Yes Yes Yes Yes 
HS 
5.15 
Yes No No No No No No Yes 
HS 
5.16 
No Yes Yes Yes Yes Yes Yes Yes 
HS 
5.17 
- Yes - Yes - Yes Yes Yes 
HS 
5.18 
- Yes - No - Yes Yes No 
HS 
5.19 
- No - No - No Yes No 
 
Table 5.19. Healthy subject responders and non-responders; peptide panel #2. How 
each of the healthy subjects responded to the peptides. A dash (-) represents an untested 
value. 
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RA patients Healthy subjects Disease controls 
ID 
3HTdR 
incorporation 
SI value (peak) 
ID 
3HTdR 
incorporation 
SI value (peak) 
ID 
3HTdR 
incorporation 
SI value (peak) 
REP-1 CEP-1 REP-1 CEP-1 REP-1 CEP-1 
RA5.20 2.8 35.2 HS5.20 1.1 0.6 DC5.1 1.5 13.0 
RA5.21 1.1 8.4 HS5.21 1.5 1.0 DC5.2 2.8 6.0 
RA5.22 1.1 26.1 HS5.22 4.4 4.3 DC5.3 2.3 10.1 
RA5.23 3.9 4.8 HS5.23 3.4 5.7 DC5.4 2.2 27.0 
RA5.24 1.8 5.8 HS5.24 1.6 1.0 DC5.5 1.3 17.8 
RA5.25 2.1 13.3 HS5.25 2.0 5.7 DC5.6 2.6 42.4 
RA5.26 0.9 11.7 HS5.26 3.2 9.5 DC5.7 1.1 35.4 
RA5.27 0.9 1.4 HS5.27 1.6 6.1 DC5.8 2.0 33.7 
RA5.28 1.6 16.7 HS5.28 6.4 9.8 DC5.9 3.8 7.3 
RA5.29 5.4 3.2    DC5.10 1.8 32.9 
RA5.30 5.1 2.7    DC5.11 1.3 9.6 
RA5.31 1.5 9.5       
RA5.32 1.8 11.0       
RA5.33 0.8 13.2       
RA5.34 0.8 3.2       
RA5.35 1.5 2.0       
RA5.36 3.1 5.8       
RA5.37 1.2 9.8       
RA5.38 - 4.6       
RA5.39 - 15.3       
 
Table 5.20. REP-1-induced and CEP-1-induced PBMC responses detected in RA 
patients, healthy subjects and disease controls. PBMC from 20 RA patients, 9 
healthy subjects and 11 disease controls were cultured in triplicate with either medium 
alone, 5µg/ml PHA, 1µg/ml PPD, 10µg/ml REP-1 or 10µg/ml CEP-1. Proliferation was 
assessed after 3, 5, 7, 9 & 11 days via 3HTdR incorporation and cytokine levels in cell 
culture supernatant samples harvested at day 5 were assessed via ECL multiplex and 
ELISA. The table shows the peak SI values of both REP-1-induced and CEP-1-induced 
PBMC proliferation detected in the RA patients, healthy subjects and disease controls. 
A dash (-) represents an untested value. 
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A) 
ID 
‘LPS-free’ REP-1-induced PBMC responses 
3HTdR incorporation 
SI value (peak) 
Cytokine production (day 5) 
IL-10 IL-17 IL-4 IL-6 TNF-α IFN-γ 
RA 5.40 1.5 0 0 0 0 0 0 
RA 5.41 3.2 0 0 0 0 0 0 
RA 5.42 1.5 0 9 0 756 50 0 
RA 5.43 1.2 0 0 0 0 0 0 
RA 5.44 1.4 0 0 0 0 0 0 
RA 5.45 0.8 0 0 0 0 0 0 
RA 5.46 1.2 0 0 0 277 0 0 
RA 5.47 1.1 0 0 0 0 0 0 
 
B) 
ID 
‘LPS-free’ CEP-1-induced PBMC responses 
3HTdR incorporation 
SI value (peak) 
Cytokine production (day 5) 
IL-10 IL-17 IL-4 IL-6 TNF-α IFN-γ 
RA 5.40 1.3 0 0 0 0 0 0 
RA 5.41 2.1 0 0 0 0 0 0 
RA 5.42 1.2 0 0 0 24 3 0 
RA 5.43 1.2 0 0 0 0 0 0 
RA 5.44 1.2 0 0 0 0 0 0 
RA 5.45 0.7 0 5 0 8 0 0 
RA 5.46 1.2 23 29 7 403 3022 0 
RA 5.47 1.0 0 0 0 22 0 0 
 
Table 5.21. ‘LPS-free’ REP-1-induced and ‘LPS-free’ CEP-1-induced PBMC 
proliferation and cytokine production detected in RA patients. PBMC from 8 RA 
patients were cultured in triplicate with either medium alone, 5µg/ml PHA, 1µg/ml 
PPD, 10µg/ml LPS-free REP-1 or 10µg/ml LPS-free CEP-1. Proliferation was assessed 
after 3, 5, 7, 9 & 11 days via 3HTdR incorporation and cytokine levels in cell culture 
supernatant samples harvested at day 5 were assessed via ECL multiplex and ELISA. A, 
the peak SI values of LPS-free REP-1-induced PBMC proliferation and the day 5 
absolute values of LPS-free REP-1-induced cytokine production. B, the peak SI values 
of LPS-free CEP-1-induced PBMC proliferation and the day 5 absolute values of LPS-
free CEP-1-induced cytokine production. 
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A) 
ID 
‘LPS-free’ REP-1-induced PBMC responses 
3HTdR incorporation 
SI value (peak) 
Cytokine production (day 5) 
IL-10 IL-17 IL-4 IL-6 TNF-α IFN-γ 
HS 5.29 1.5 0 0 0 0 0 0 
HS 5.30 2.9 0 16 0 52 0 0 
HS 5.31 1.7 0 0 0 0 0 0 
HS 5.32 1.2 0 0 0 13 0 0 
HS 5.33 1.1 0 0 0 0 0 0 
HS 5.34 1.3 0 0 0 0 0 0 
 
B) 
ID 
‘LPS-free’ CEP-1-induced PBMC responses 
3HTdR incorporation 
SI value (peak) 
Cytokine production (day 5) 
IL-10 IL-17 IL-4 IL-6 TNF-α IFN-γ 
HS 5.29 1.2 0 0 0 0 0 0 
HS 5.30 2.8 0 0 0 0 0 0 
HS 5.31 1.5 0 0 0 9 3 0 
HS 5.32 1.1 0 3 0 135 10 0 
HS 5.33 1.2 0 0 0 0 0 0 
HS 5.34 1.0 0 0 0 8 0 0 
 
Table 5.22. ‘LPS-free’ REP-1-induced and ‘LPS-free’ CEP-1-induced PBMC 
proliferation and cytokine production detected in healthy subjects. PBMC from 6 
healthy subjects were cultured in triplicate with either medium alone, 5µg/ml PHA, 
1µg/ml PPD, 10µg/ml LPS-free REP-1 or 10µg/ml LPS-free CEP-1. Proliferation was 
assessed after 3, 5, 7, 9 & 11 days via 3HTdR incorporation and cytokine levels in cell 
culture supernatant samples harvested at day 5 were assessed via ECL multiplex and 
ELISA. A, the peak SI values of LPS-free REP-1-induced PBMC proliferation and the 
day 5 absolute values of LPS-free REP-1-induced cytokine production. B, the peak SI 
values of LPS-free CEP-1-induced PBMC proliferation and the day 5 absolute values of 
LPS-free CEP-1-induced cytokine production. 
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ID 
Background cytokine production in pg/ml (day 5) 
IL-10 IL-17 IL-4 IL-6 TNF-α IFN-γ 
RA 5.1 0 0 0 198 4 0 
RA 5.2 0 0 0 0 2 0 
RA 5.3 0 0 0 675 6 0 
RA 5.4 0 0 0 48 0 0 
RA 5.5 0 0 0 342 32 0 
RA 5.6 0 0 0 234 16 0 
RA 5.7 8 47 15 186 76 0 
RA 5.8 0 0 0 5896 89 0 
RA 5.9 0 0 0 18 23 9 
RA 5.10 0 0 0 27 8 0 
RA 5.11 0 0 0 56 0 0 
RA 5.12 0 0 0 34 12 0 
RA 5.13 0 0 6 8954 103 12 
RA 5.14 3 0 0 47 28 0 
RA 5.15 0 0 0 23 6 0 
RA 5.16 4 23 11 5 0 0 
RA 5.17 0 0 0 56 34 0 
RA 5.18 0 0 0 4524 57 0 
RA 5.19 0 6 0 18 10 0 
RA 5.40 0 0 0 2145 43 0 
RA 5.41 3 0 0 9 15 0 
RA 5.42 0 0 0 0 0 0 
RA 5.43 0 0 0 41 8 0 
RA 5.44 0 0 0 867 97 6 
RA 5.45 0 0 0 54 36 0 
RA 5.46 0 0 0 24 29 0 
RA 5.47 0 0 0 38 17 0 
 
Table 5.23. Background cytokine production detected in the RA patients tested for 
candidate RA autoantigen-derived peptide-induced cytokine production in the 
experiments described in chapter 5. 
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ID 
Background cytokine production in pg/ml (day 5) 
IL-10 IL-17 IL-4 IL-6 TNF-α IFN-γ 
HS 5.1 0 0 0 0 0 0 
HS 5.2 0 0 0 29 12 0 
HS 5.3 0 0 0 43 65 0 
HS 5.4 0 0 0 214 29 0 
HS 5.5 15 10 21 3245 56 18 
HS 5.6 0 0 0 21 6 0 
HS 5.7 0 0 8 153 17 0 
HS 5.8 0 0 0 44 8 0 
HS 5.9 0 0 0 387 32 0 
HS 5.10 0 0 0 24 24 0 
HS 5.11 0 0 0 27 52 0 
HS 5.12 3 5 0 324 28 7 
HS 5.13 0 0 0 0 0 0 
HS 5.14 0 0 13 2879 43 0 
HS 5.15 6 0 0 43 58 0 
HS 5.16 0 0 0 62 87 0 
HS 5.17 0 0 0 0 0 0 
HS 5.18 0 0 0 27 9 0 
HS 5.19 0 0 0 434 35 0 
HS 5.29 9 6 32 5132 62 9 
HS 5.30 0 0 0 76 94 0 
HS 5.31 0 0 0 0 0 0 
HS 5.32 0 0 0 32 84 0 
HS 5.33 0 0 0 254 26 0 
HS 5.34 0 0 0 120 10 0 
 
Table 5.24. Background cytokine production detected in the healthy subjects tested 
for candidate RA autoantigen-derived peptide-induced cytokine production in the 
experiments described in chapter 5. 
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Figure 5.1. Proportions of positive responses to peptides 1-7 in RA patients versus 
healthy subjects. PBMC from 10 RA patients and 10 healthy subjects were cultured in 
triplicate with either medium alone, 5µg/ml PHA, 1µg/ml PPD or 10µg/ml each of 
peptides 1, 2, 3, 4, 5, 6 or 7. Proliferation was assessed after 3, 5, 7, 9 & 11 days via 
3HTdR incorporation and cytokine levels in cell culture supernatant samples harvested 
at day 5 were assessed via ECL multiplex and ELISA. Graph shows the proportions of 
RA patients and healthy subjects showing positive PBMC proliferative and/or cytokine 
production responses to each of the 7 peptides comprising peptide panel #1. 
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Figure 5.2. Proportions of positive responses to peptides 8-15 in RA patients versus 
healthy subjects. PBMC from 9 RA patients and 9 healthy subjects were cultured in 
triplicate with either medium alone, 5µg/ml PHA, 1µg/ml PPD or 10µg/ml each of 
peptides 8, 9, 10, 11, 12, 13, 14 or 15. Proliferation was assessed after 3, 5, 7, 9 & 11 
days via 3HTdR incorporation and cytokine levels in cell culture supernatant samples 
harvested at day 5 were assessed via ECL multiplex and ELISA. Graph shows the 
proportions of RA patients and healthy subjects showing SI value-based positive PBMC 
proliferative and/or cytokine production responses to each of the 8 peptides comprising 
peptide panel #2. 
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Figure 5.3. Comparing REP-1-induced PBMC proliferation with CEP-1-induced 
PBMC proliferation in RA patients, healthy subjects and disease controls. The peak 
SI values of REP-1-induced PBMC proliferation compared with those of CEP-1-
induced PBMC proliferation in A) RA patients, B) healthy subjects and C) disease 
controls. In all graphs, the dotted horizontal line represents the threshold level for a 
positive response, while the bold horizontal line with error bars in each data set 
represents the mean value and SEM. 
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Figure 5.4. Comparing REP-1-induced PBMC proliferation and CEP-1-induced 
PBMC proliferation in RA patients (RA), healthy subjects (HS) and disease 
controls (DisC). A compares the peak SI values of REP-1-induced PBMC proliferation 
detected in each of the 3 subject groups. B compares the peak SI values of CEP-1-
induced PBMC proliferation detected in each of the 3 subject groups. In each graph, the 
dotted horizontal line represents the threshold level for a positive response, while the 
bold horizontal line in each data set represents the median value. 
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Figure 5.5. Kinetics of the REP-1-induced and CEP-1-induced proliferative 
responses. The kinetics of the REP-1-induced and CEP-1-induced PBMC proliferative 
responses detected in the RA patients are shown in A & B respectively. The kinetics of 
the REP-1-induced and CEP-1-induced PBMC proliferative responses detected in the 
healthy subjects are shown in C & D respectively. The kinetics of the REP-1-induced 
and CEP-1-induced PBMC proliferative responses detected in the disease controls are 
shown in E & F respectively. In each graph, the dotted horizontal line represents the 
threshold level for a positive response, and each data point represents an individual SI 
value. 
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Figure 5.6. Comparing REP-1-induced cytokine production with CEP-1-induced 
cytokine production in RA patients. A, B, C, D, E & F show the day 5 absolute 
values of both REP-1-induced and CEP-1-induced IL-10, IL-17, IL-4, IL-6, TNF-α & 
IFN-γ production respectively that were detected within the RA patient group. In all 
graphs, the bold horizontal line with error bars in each data set represents the mean 
value and SEM. 
C) 
A) B) 
D) 
E) F) 
 182 
 
 
Figure 5.7. Comparing REP-1-induced cytokine production with CEP-1-induced 
cytokine production in healthy subjects. A, B, C, D, E & F show the day 5 absolute 
values of both REP-1-induced and CEP-1-induced IL-10, IL-17, IL-4, IL-6, TNF-α & 
IFN-γ production respectively that were detected within the healthy control group. In all 
graphs, the bold horizontal line with error bars in each data set represents the mean 
value and SEM. 
A) B) 
C) D) 
E) F) 
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Figure 5.8. Comparing REP-1-induced cytokine production with CEP-1-induced 
cytokine production in disease controls. A, B, C, D, E & F show the day 5 absolute 
values of both REP-1-induced and CEP-1-induced IL-10, IL-17, IL-4, IL-6, TNF-α & 
IFN-γ production respectively that were detected within the disease control group. In all 
graphs, the bold horizontal line with error bars in each data set represents the mean 
value and SEM. 
A) B) 
C) D) 
E) F) 
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Figure 5.9. Comparing REP-1-induced cytokine production in RA patients (RA), 
healthy subjects (HS) and disease controls (DisC). A, B, C, D, E & F show the day 5 
absolute values of REP-1-induced IL-10, IL-17, IL-4, IL-6, TNF-α & IFN-γ production 
respectively that were detected in each of the 3 subject groups. In all graphs, the bold 
horizontal line in each data set represents the median value. 
A) B) 
C) D) 
E) F) 
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Figure 5.10. Comparing CEP-1-induced cytokine production in RA patients (RA), 
healthy subjects (HS) and disease controls (DisC). A, B, C, D, E & F show the day 5 
absolute values of CEP-1-induced IL-10, IL-17, IL-4, IL-6, TNF-α & IFN-γ production 
respectively that were detected in each of the 3 subject groups. In all graphs, the bold 
horizontal line in each data set represents the median value. 
F) E) 
A) B) 
C) D) 
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Figure 5.11. LPS-induced PBMC proliferation. PBMC from 3 healthy subjects were 
cultured in triplicate with either medium alone, 5µg/ml PHA, 1µg/ml PPD or a range of 
concentrations of LPS, and proliferation was assessed after 3, 5, 7, 9 & 11 days via 
3HTdR incorporation. The graph shows representative data from a single subject 
showing the peak SI values of PBMC proliferation detected in response to the varying 
concentrations of LPS. The dotted horizontal line represents the threshold level for a 
positive response. 
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Figure 5.12. The effect of polymyxin B on the CEP-1 response. PBMC from a 
healthy subject were cultured in triplicate with either medium alone or 10µg/ml CEP-1, 
with or without the presence of PMB (+PMB or –PMB respectively). Proliferation was 
assessed after 3, 5, 7, 9 & 11 days via 3HTdR incorporation and cytokine levels in cell 
culture supernatant samples harvested at day 5 were assessed via ECL multiplex and 
ELISA. A, the peak SI values of CEP-1-induced PBMC proliferation detected with and 
without the presence of PMB. The dotted horizontal line represents the threshold level 
for a positive response. B, the day 5 absolute values of CEP-1-induced cytokine 
production detected with and without the presence of PMB. 
A) 
B) 
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Figure 5.13. Comparing the immunogenicities of original CEP-1 and *clean* CEP-
1. PBMC from 2 healthy subjects were cultured in triplicate with either medium alone, 
10µg/ml original CEP-1 or 10µg/ml *clean* CEP-1. Proliferation was assessed after 3, 
5, 7, 9 & 11 days via 3HTdR incorporation and cytokine levels in cell culture 
supernatant samples harvested at day 5 were assessed via ECL multiplex and ELISA. A, 
the peak SI values of PBMC proliferation detected in response to original CEP-1 and 
*clean* CEP-1 in each subject. The dotted horizontal line represents the threshold level 
for a positive response. B, the mean day 5 absolute values of cytokine production 
detected in response to original CEP-1 and *clean* CEP-1 (the vertical bars in each data 
set represent SEM). 
A) 
B) 
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Chapter 6. Discussion 
 
6.1. Introduction 
At the start of this study, I had three main aims, the first of which was to optimise an 
experimental system suitable for detecting candidate RA autoantigen-specific 
proliferative and cytokine production responses. In the experiments described in chapter 
3, I showed that the use of 5% AS-supplemented culture medium enabled the most 
sensitive detection of antigen-specific proliferative and cytokine production T-cell 
responses. The use of 10% FBS-supplemented culture medium was associated with high 
levels of background proliferation and cytokine production that could interfere with 
detection of antigen-specific T-cell responses and to a lesser extent even mitogenic 
responses. 5% HABS-supplemented culture medium was not capable of supporting cells 
for the prolonged culture periods that are necessary for antigen-specific T-cell responses 
to be manifested. These experiments also demonstrated that using the 3HTdR 
incorporation assay to measure proliferation within populations of un-separated PBMC 
gives an accurate assessment of T-cell proliferation within the PBMC. 
 
6.1.1. Qualitative and quantitative comparisons of candidate RA autoantigen-specific 
T-cell responses in RA patients and healthy subjects 
My second aim was to compare, both in terms of quality and quantity, candidate RA 
autoantigen-specific T-cell responses in RA patients and healthy subjects in order to 
determine whether such responses are heightened in the former. My postulates were as 
follows: 
 
i) Candidate RA autoantigen-specific T-cell responses are more prevalent in 
RA patients than in healthy subjects. 
ii) Candidate RA autoantigen-specific T-cell responses of RA patients are 
qualitatively different from those of healthy subjects, the former being pro-
inflammatory in nature and the latter being immunosuppressive. 
 
In the experiments described in chapters 4 and 5, I measured proliferation and cytokine 
production in response to several whole protein and peptide candidate RA autoantigens 
in RA patient, healthy subject and disease control groups. The experiments described in 
chapter 4 showed that T-cell responses to the whole protein of the candidate RA 
autoantigens HCgp39, CII, GlyAgg and DeglyAgg were detected in similar proportions 
 190 
of RA patients and healthy subjects. In addition, the magnitudes of the proliferative and 
cytokine production responses detected in response to the candidate RA autoantigens 
were comparable between both groups. Furthermore, the kinetics of the candidate 
autoantigen-induced proliferative responses were similar in both RA patients and 
healthy subjects, with peak proliferation being observed mostly at later time-points. 
Overall, both the quantity and the quality of T-cell responses against these whole 
autoantigen proteins were similar between RA patients and healthy subjects. The 
experiments described in chapter 5 showed that T-cell responses to peptides derived 
from the candidate RA autoantigens HCgp39, aggrecan, α-enolase, fibrinogen, filaggrin 
and vimentin were also detected in comparable proportions of RA patients as healthy 
subjects. As was observed in the experiments with the whole protein autoantigens, the 
magnitudes of the responses detected in the RA patients were similar to those detected 
in the healthy subjects and there was no difference in the quality and quantity of the T-
cell responses against these peptides between RA patients and healthy subjects. 
Ultimately, with both whole protein and peptide forms of the candidate autoantigens, 
proliferative responses to these stimuli were generally very weak. Taken together, the 
weak magnitudes and delayed manifestations of the candidate RA autoantigen-induced 
proliferative responses are suggestive of primary responses of naïve T-cells (Berard & 
Tough, 2002 and Davies et al, 2002). 
 
6.1.2. Exploring the role of citrullinated candidate RA autoantigens 
My third aim was to explore whether the citrullination of candidate autoantigens 
enhances their immunogenicity in RA patients. My initial postulates regarding T-cell 
responses to citrullinated candidate RA autoantigens in RA patients and healthy subjects 
were as follows: 
 
i) T-cell responses to citrullinated candidate RA autoantigens are more 
frequent than T-cell responses to uncitrullinated candidate RA autoantigens, 
but only in RA patients and not in healthy subjects. 
ii) The T-cell responses elicited by citrullinated candidate RA autoantigens are 
qualitatively different from those elicited by their uncitrullinated 
counterparts, with the former being more pro-inflammatory in nature than 
the latter. 
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In the experiments described in chapter 5 I measured proliferative and cytokine 
production responses of PBMC from RA patients, healthy subjects and disease controls 
to the citrullinated and uncitrullinated analogues of a panel of candidate RA 
autoantigen-derived peptides. The experiments described in 5.2.1 and 5.2.2 showed that 
citrullinated candidate RA autoantigen-derived peptides were no more immunogenic 
than their uncitrullinated counterparts in either RA patients or healthy subjects. Both 
citrullinated and uncitrullinated versions of the same peptides induced similar 
proportions of positive responses in both groups. Furthermore, the magnitudes and 
cytokine profiles of the responses were also comparable between those induced by 
citrullinated and uncitrullinated peptide analogues in both groups. This differs from 
what was shown in studies by von Delwig et al (2010) and more recently Law et al 
(2012), where phenotypically distinct, citrulline-specific responses were observed in RA 
patients but not healthy subjects. The former study showed that while the native form of 
aggrecan84-103 failed to induce proliferation in both RA patients and healthy subjects, N 
citrullinated aggrecan84-103 induced PBMC proliferation detectable in ~60% of the RA 
patients but none of the healthy subjects. In addition, in the RA patients but not the 
healthy subjects, the magnitudes of the proliferative responses induced by the 
citrullinated peptide were significantly greater than those induced by the native peptide. 
Furthermore, the citrulline-specific response observed in the RA patients was 
accompanied by IL-17 production and an induction of IL-17
+
 CD4
+
 T-cells (von Delwig 
et al, 2010). While the very low SI values of PBMC proliferation in response to both 
native and citrullinated forms of several candidate RA autoantigen-derived peptides in 
both RA patients and healthy subjects that were reported by Law et al may support my 
observations described in 5.2.1 and 5.2.3, the group showed that in RA patients but not 
healthy subjects, the magnitudes of the proliferative responses induced by a citrullinated 
aggrecan peptide were significantly greater than those induced by its native counterpart. 
In addition, the group showed that the citrullinated form of the aggrecan peptide 
induced significantly greater levels of IL-10 and TNF-α in the RA patients than in the 
healthy subjects, while a similar trend for IL-17 production in response to the 
citrullinated peptides of aggrecan and fibrinogen was also observed (Law et al, 2012). 
 
The results from the experiments described in 5.2.3 however were more consistent with 
my hypotheses. Firstly, the citrullinated form of the α-enolase5-21 peptide with terminal 
cysteines (CEP-1) elicited a significantly greater proportion of positive proliferative 
responses than its uncitrullinated counterpart (REP-1) in the RA patient group but not in 
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either of the control groups. Secondly, in the RA patient group, the levels of 
proliferation and of IL-17, IL-4, IL-6, TNF-α and IFN-γ production detected in response 
to the citrullinated peptide were significantly greater than those detected in response to 
the uncitrullinated peptide, and while a similar observation was made in the disease 
control group, this was not the case in the healthy subject group. In addition, the levels 
of production of the pro-inflammatory cytokines IL-6 and TNF-α detected in response 
to the citrullinated form of the peptide were significantly greater in the RA patient group 
than in either of the control groups. Furthermore, the levels of production of the 
immunosuppressive cytokine IL-10 detected in response to the citrullinated form of the 
peptide were significantly greater than in the healthy subject group. Ultimately 
however, the experiments described in 5.2.4 suggested that the responses to the 
citrullinated form of the enolase peptide were potentially being influenced by 
contaminating LPS within the CEP-1 preparations. Indeed the experiments with LPS-
free preparations of the peptide described in 5.2.5 showed that the citrullinated form of 
the peptide induced similar proportions of T-cell proliferation and cytokine production 
responses as its uncitrullinated counterpart in both the RA patient group and the healthy 
subject group and the T-cell responses against these peptides were similar in the RA 
patient and healthy control groups. 
 
However, it is debatable whether the responses to the initial, LPS-contaminated batch of 
CEP-1 are simply indirect, bystander responses to LPS, as there were substantial 
differences in the T-cell responses to ‘LPS-contaminated CEP-1’ from the three study 
groups. As mentioned in the discussion section of chapter 5, it is possible that the 
macrophages of RA patients, because of increased expression of TLR4 compared to 
those of controls (Huang et al, 2007), are more sensitive to LPS than control 
macrophages. Thus LPS may induce secretion of greater levels of cytokines and 
expression of greater numbers of T-cell co-stimulatory molecules in RA patients than in 
controls which may account for the increased cytokine profiles and proliferative 
responses of the former. Alternatively, the LPS could simply have been acting as an 
adjuvant, amplifying/enhancing responses to the CEP-1 by inducing the expression of 
co-stimulatory molecules and cytokines by antigen-presenting cells so that they were 
capable of activating T-cells recognising MHC class II:CEP-1 peptide complexes that 
the former expressed on their surfaces. LPS contamination may potentially explain 
some of the discrepant data on autoantigen-specific T-cell responses in RA reported in 
the literature. The underlying mechanisms of LPS-‘induced’ amplification of the T-cell 
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responses against autoantigens in my experimental system require further investigation. 
Furthermore, whether LPS contamination also amplifies T-cell responses against non-
self antigens is an interesting question to be pursued in future experiments. 
 
6.2. Limitations of the study 
I initially set out hoping only to recruit early RA patients with no prior history of 
immunomodulatory therapy, anticipating that autoantigen-specific T-cell responses, if 
present, would be more readily detected in such patients. However, as the tables of 
clinical details show (Tables 2.1-2.6 in chapter 2), the majority of the RA patients tested 
in this study have long-standing RA and/or a history of immunomodulatory therapy. 
Indeed, two thirds of the RA patients had been diagnosed with RA for at least 2 years at 
the time of recruitment, many of these had much longer disease duration, and all of 
these patients were receiving immunomodulatory therapy. Furthermore, of those RA 
patients only recently diagnosed at the time of recruitment (i.e. within 2 years of the 
time of recruitment), only 16% were not receiving immunomodulatory therapy. As 
previously mentioned, it is possible that measuring autoantigen-specific T-cell 
responses in RA patients with established disease and/or a history of 
immunomodulatory therapy may bias against the detection of such responses. In 
addition, information on whether the RA patients tested were using glucocorticoids was 
unavailable and it is possible that the use of corticosteroids may influence T-cell 
responses in vitro. 
 
It is possible that the AS used as a culture medium supplement in the experiments 
described in this thesis may have contained significant levels of certain cytokines which 
could have influenced the data obtained from cytokine production assays performed on 
candidate autoantigen-stimulated PBMC cultured in AS-supplemented medium. While I 
measured cytokine production in cultures of un-stimulated PBMC that were cultured in 
AS-supplemented medium, I did not determine whether the AS itself contained 
substantial levels of any of the cytokines that I assayed for. 
 
In the experiments described in chapter 3, I did not measure the sensitivities of the 
3HTdR incorporation and CFSE dilution assays, and thus the frequencies of antigen-
specific T-cells that may have been detectable with each of the assays were not 
determined. Although this would have been a difficult task, it could perhaps have been 
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achieved by spiking T-cell populations with differing proportions of T-cells from a 
clone of a known specificity. 
 
Whenever possible I tested subjects with more than one candidate autoantigen but 
sometimes this was not feasible because of the large numbers of PBMC required and 
the numbers of PBMC obtained from some of the clinical samples were low. As a 
result, 27 of the RA patients studied were only screened for T-cell responses to a single 
autoantigen. Since it is possible that different autoantigens are involved in disease 
pathogenesis in different patients or at different stages of the disease, then if patients 
were tested with only a single candidate autoantigen, this may also have biased against 
the successful detection of autoantigen-specific T-cell responses in these patients. 
 
While cell culture supernatant samples had been collected from the bulk culture 
experiments described in 4.2.2, these supernatants were not analysed for cytokine 
production therefore I only have proliferation data from these experiments. As 
mentioned in chapter 4, I only measured cytokine production in supernatant samples 
from the triplicate culture experiments as proliferative responses detected in these 
experiments were generally more frequent and more potent when using this approach as 
opposed to the bulk culture approach. It is possible that cytokine data from the bulk 
culture experiments may be more informative, although there is no obvious theoretical 
argument to suggest that this will be the case. 
 
In the vast majority of cases, I did not see statistical differences between the 
autoantigen-specific T-cell responses of the RA groups and those of the control groups. 
While it is possible that the qualities and quantities of autoantigen-specific T-cell 
responses do not differ between RA patients and healthy subjects in vivo, it is also 
possible that I did not observe any significant differences between the different groups 
due to small sample size. With the levels of intra-group variability, it is possible that 
using a larger sample size may have revealed statistically significant differences in 
autoantigen-specific T-cell responses between RA patients and healthy subjects. 
However, if that is the case, it would suggest that such differences in T-cell responses 
are likely to be small and the clinical significance of such small differences is uncertain. 
Furthermore, to repeat the experiments with a substantially bigger sample size is beyond 
the scope of my PhD study due to time and financial constraints. 
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Another potential limitation is that the HLA genotypes of the subjects used in this study 
were not known. While SE-positive HLA-DR molecules are prevalent amongst 
seropositive RA patients, it is possible that some of the patients tested in this study were 
SE-negative. Furthermore, the proportion of healthy controls that carry the SE genotype 
is unclear but it is expected to be lower than in RA groups. Several of the peptides 
tested in the experiments described in chapter 5 were selected because previous studies 
had shown them to bind certain RA-associated HLA-DR molecules with high affinity. 
For example, the citrullinated form of the 65-77 peptide of vimentin was reported by 
Hill et al (2003) to bind only the SE-positive HLA-DR molecules DR1(DRB1*0101), 
DR4(DRB1*0401) and DR4(DRB1*0404), while the 201-213 and 299-311 peptides of 
aggrecan were shown to bind well to DR4(DRB1*0401) molecules but not to 
DR4(DRB1*0404) molecules (Boots et al, 1997). Therefore it could have been the case 
that these peptides were not being presented in vitro because the antigen-presenting 
cells lacked the correct subtype(s) of HLA-DR molecules. This could explain the lack of 
T-cell responses against these peptides. 
 
For the experiments described in 5.2.5 in which subjects were tested for responses to 
LPS-free preparations of REP-1 and CEP-1, new groups of RA patients and healthy 
subjects were recruited who were not tested for reactivity to the original preparations of 
the peptides. Therefore this was not an optimal comparison of these two peptide 
preparations. 
 
Because my experimental system involved measuring autoantigen-induced proliferation 
in cultures of whole PBMC, it is important to consider the effect that the autologous 
mixed lymphocyte reaction (AMLR) may have had on the interpretation of these 
proliferative responses. The AMLR is a phenomenon observed in vitro in which T-cells, 
predominantly of the CD4
+
 subset, proliferate during culture with autologous non-T-
cells as a result of TCAR stimulation by MHC-encoded molecules expressed on the 
surfaces of the latter (Smolen et al, 1981). The AMLR has been shown to demonstrate 
both immunological memory and specificity (Weksler & Kozak, 1977), and is thought 
to reflect the in vivo interactions of T-cells and non-T-cells that may be involved in the 
regulation of immune responses (Scheinecker et al, 1998). Indeed, abnormal AMLRs 
have been reported in RA and other autoimmune diseases (Pope et al, 1984; Miyasaka 
et al, 1980 and Takada et al, 1985). When measuring proliferation in unstimulated 
cultures of PBMC, I was effectively measuring the AMLR, and these cpm readings 
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were used to calculate the SI values of proliferation observed in autoantigen-stimulated 
PBMC cultures. Because the autoantigen-induced proliferative responses detected in 
this study were generally very weak, they would therefore have been more susceptible 
to influence by the AMLR. 
 
6.3. Strengths of the study 
Despite the aforementioned, the study has a number of strengths. For example, multiple 
candidate RA autoantigens in both whole protein and peptide forms were tested, and I 
measured both proliferation and the production of a range of selected cytokines (six in 
total) in response to these stimuli. In the majority of cases, proliferation was measured 
in conjunction with cytokine production. In addition, a variety of different approaches 
(un-separated PBMC in both bulk and triplicate cultures and mo-DC:T-cell co-cultures) 
and different assays (both CFSE dilution and 3HTdR incorporation assays to measure 
proliferation) were studied. Furthermore, large numbers of subjects within both RA 
patient and control groups were studied, and in many cases each subject was tested with 
several different autoantigens. 
 
In the experiments described in chapter 4, I measured T-cell responses to whole protein 
candidate RA autoantigens; HCgp39, CII, GlyAgg and DeglyAgg. Table 6.1 
summarises the approaches and assays used and the numbers of subjects tested with 
each of the four autoantigens in the experiments described in the various sections of 
chapter 4. In the experiments described in 4.2.3, substantial proportions of subjects from 
both the RA patient group (50%) and the healthy subject group (69%) were tested with 
two or more of the autoantigens. Table 6.2 shows the numbers of subjects tested with 
various combinations of the four autoantigens. Overall, in the experiments described in 
chapter 4, a total of fifty RA patients and twenty seven healthy subjects were tested with 
various candidate RA autoantigens. 
In the experiments described in chapter 5, I measured T-cell responses to candidate 
autoantigen-derived peptides, and tested both non-citrullinated and citrullinated peptides 
of HCgp39, aggrecan, vimentin, fibrinogen, filaggrin and enolase. All experiments 
utilised triplicate culture approach. Table 6.3 shows the numbers of subjects tested with 
the various candidate autoantigen-derived peptides in the experiments described in the 
various sections of chapter 5. Overall, in the experiments described in chapter 5, a total 
of forty seven RA patients, thirty four healthy subjects and eleven disease controls were 
tested with various candidate RA autoantigen-derived peptides. 
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Thus, in the entire study, I tested a total of ninety seven RA patients, sixty one healthy 
subjects and eleven disease controls for candidate RA autoantigen-specific T-cell 
responses. Considering the range of candidate RA autoantigens tested and 
assays/readouts used to detect the T-cell responses, I believe that this body of work has 
made a substantial contribution to the existing literature on the role of candidate RA 
autoantigen-specific T-cell responses in RA. 
 
6.4. Future work 
 To obtain further samples from the subjects studied in order to determine their 
HLA-DR genotypes. 
 Instead of assessing T-cell responses to individual candidate autoantigens, it 
may be more efficient to screen for the presence of autoantigen-specific T-cell 
responses using pooled autoantigen approaches. Alternatively, addition of an 
adjuvant (such as cytokines or co-stimulation) in the cell culture may enable the 
detection of autoantigen-specific T-cell responses that are otherwise 
undetectable when using the experimental approaches described in this study. 
 To dissect the underlying mechanisms of LPS-induced amplification of 
autoantigen-stimulated T-cell responses. 
 T-cells from the inflamed joints or draining lymph nodes could also be used 
instead of peripheral blood T-cells, as auto-reactive T-cells involved in RA 
pathogenesis may be selectively recruited to the disease sites and therefore not 
detected in the peripheral blood. However, obtaining sufficient numbers of T-
cells from synovial tissues or draining lymph nodes can be challenging, 
especially with the improved medical treatments available for RA patients. 
 Multimeric, MHC class II:autoantigen-derived peptide ‘tetramers/multimers’ 
could be used to identify the presence of autoantigen-specific CD4
+
 T-cells, as 
has been previously described (Kotzin et al, 2000; Huang et al, 2004; Svendsen 
et al, 2004; Davis et al, 2011 and Massilamany et al, 2011). However, different 
MHC class II:autoantigen-derived peptide tetramers are needed for RA patients 
with different HLA-DR genotypes and also for different peptides being studied. 
Therefore, such an approach is expensive and unless there are dominant 
autoantigenic peptides involved, its usefulness in studying autoantigen-specific 
T-cell responses is likely to be limited. 
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6.5. Conclusions 
In conclusion, the whole protein candidate RA autoantigens or their peptide derivatives 
(with or without citrullination) elicited similar T-cell responses in RA patients, healthy 
subjects and disease controls. Furthermore, I found no evidence of an RA-specific 
increase in T-cell responses against citrullinated autoantigens. Finally, LPS 
contamination, even at low concentrations, could amplify autoantigen-specific T-cell 
responses. Therefore, until the underlying mechanisms of how LPS augments 
autoantigen-specific T-cell responses are clarified, preparations of antigenic stimuli for 
use in assessing T-cell responses should be checked for potential LPS contamination. 
Future experiments to assess autoantigen-specific T-cell responses should focus on 
further optimisation of experimental protocol. 
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Total 
number 
of 
subjects 
tested 
Culture 
approach 
Assay(s) 
used 
Autoantigens 
(numbers of subjects tested) 
HCgp39 CII GlyAgg DeglyAgg 
4
.2
.1
 
15xRA 
Bulk 
culture 
CFSE 
dilution 
proliferation 
assay 
15xRA - - - 
4
.2
.2
 
9xRA 
8xHS 
Bulk 
culture 
3HTdR 
incorporation 
proliferation 
assay 
9xRA 
8xHS 
4xRA 
4xHS 
- 
4
.2
.3
 
24xRA 
16xHS 
Triplicate 
culture 
3HTdR 
incorporation 
proliferation 
assay 
10xRA 
8xHS 
7xRA 
8xHS 
9xRA 
10xHS 
12xRA 
13xHS 
ECL 
multiplex & 
ELISA 
cytokine 
production 
assays 
6xRA 
6xHS 
4xRA 
6xHS 
5xRA 
8xHS 
8xRA 
8xHS 
4
.2
.4
 
2xRA 
3xHS 
T-cell & 
mo-DC 
co-culture 
3HTdR 
incorporation 
proliferation 
assay 
2xRA 
3xHS 
 
Table 6.1. Numbers of subjects tested with each of the four whole protein 
candidate autoantigens and the approaches and assays used in the experiments 
described in the various sections of Chapter 4. A dash (-) signifies untested. 
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Combinations of 2 or 
more autoantigens tested 
in 4.2.3 
Number of RA patients 
tested (out of 24) 
Number of healthy 
subjects tested (out of 16) 
HCgp39 + CII 4 1 
HCgp39 + GlyAgg 2 - 
HCgp39 + DeglyAgg - - 
CII + GlyAgg - - 
CII + DeglyAgg - - 
GlyAgg + DeglyAgg 4 3 
HCgp39 + CII + GlyAgg - - 
HCgp39 + CII + DeglyAgg 1 2 
HCgp39 + GlyAgg + 
DeglyAgg 
- - 
CII + GlyAgg + DeglyAgg 1 - 
HCgp39 + CII + GlyAgg + 
DeglyAgg 
- 5 
Proportion & percentage 
of total subjects tested in 
4.2.3 that were tested with 
2 or more autoantigens 
12 out of 24 = 50% 11 out of 16 = 69% 
 
Table 6.2. Numbers of subjects tested with the various combinations of 2 or more 
of the four whole protein candidate autoantigens in the experiments described in 
4.2.3. A dash (-) signifies untested. 
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Total 
number 
of 
subjects 
tested 
Assay(s) 
used 
Autoantigens (numbers of subjects tested) 
Peptide 
panel 
#1 
Peptide 
panel 
#2 
REP-1 CEP-1 
LPS-
free 
REP-
1 
LPS-
free 
CEP-
1 
5
.2
.1
 
10xRA 
10xHS 
3HTdR 
incorporation 
assay 
10xRA 
10xHS 
- - - - - 
ECL 
multiplex & 
ELISA 
cytokine 
production 
assays 
- - - - - 
5
.2
.2
 
9xRA 
9xHS 
3HTdR 
incorporation 
assay 
- 
9xRA 
9xHS 
- - - - 
ECL 
multiplex & 
ELISA 
cytokine 
production 
assays 
- 
8xRA 
9xHS 
- - - - 
5
.2
.3
 20xRA 
9xHS 
11x 
DisC 
3HTdR 
incorporation 
assay 
- - 
18xRA 
9xHS 
11x 
DisC 
20xRA 
9xHS 
11x 
DisC 
- - 
ECL 
multiplex & 
ELISA 
cytokine 
production 
assays 
- - - - 
5
.2
.5
 
8xRA 
6xHS 
3HTdR 
incorporation 
assay 
- - - - 
8xRA 
6xHS 
ECL 
multiplex & 
ELISA 
cytokine 
production 
assays 
- - - - 
 
Table 6.3. Numbers of subjects tested with each of the various candidate 
autoantigen-derived peptides in the experiments described in the various sections 
of Chapter 5. A dash (-) signifies untested. 
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